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Abstract 
Salivary biomarkers not only reflect the current status of periodontal diseases but 
may predict their progression and response to treatment. This study aimed to identify 
and characterize novel salivary biomarkers for periodontal diseases as a biomarker 
paradigm for an oral inflammatory disease.   
Proteome profiler arrays were used to study the protein profile of whole saliva from 
12 patients with chronic periodontitis and 12 healthy subjects, and to identify novel 
salivary biomarkers for periodontal diseases. Results revealed that there were 
differences in the whole saliva protein profile between health and disease status. 
Salivary urokinase (uPA), urokinase receptor (uPAR), and vitamin D binding protein 
(VDBP) were among the highly expressed proteins in periodontitis. These proteins 
were identified as candidate salivary biomarkers for periodontal diseases. 
ELISA assays were used to quantify the candidate salivary biomarkers in 158 
patients with periodontal diseases as compared to 103 healthy controls and were 
found to be significantly elevated in the patients (p<0.001). Salivary uPA levels but 
not uPAR and VDBP, were significantly downregulated following treatment of the 
patients (p<0.01). The uPA enzymatic activity was investigated in saliva of the 
patients and was found to be significantly elevated as compared to the controls 
(p<0.001). Salivary uPA, uPAR and VDBP levels and uPA activity were positively 
correlated with periodontal disease measures such as pocket depth. 
The in vitro stimulation of human gingival fibroblasts with P.gingivalis 
lipopolysaccharide induced the cells to produce higher levels of uPA and uPAR along 
with uPA activity as compared to unstimulated cells (p<0.01). 
In conclusion, salivary uPA, uPAR and VDBP in addition to uPA activity are 
suggested as biomarkers that may be useful in the diagnosis of periodontal diseases 
and can indicate their severity. Salivary uPA is a potential biomarker that can assess 
the response of periodontitis to treatment and may predict the disease progression.  
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Chapter 1 Introduction 
A biomarker is a biological substance which can be measured objectively and used 
as an indicator for a number of activities in the human body which could be a 
homeostatic, pathogenic, or pharmacological response to therapy (Taba et al. 2005; 
Strimbu and Tavel 2010). As they both contain locally and systemically derived 
biomarkers, saliva and gingival crevicular fluid (GCF) can provide the basis for the 
diagnosis and monitoring of many oral and systemic diseases such as periodontitis, 
oral squamous cell carcinoma, oral lichen planus, and cardiovascular diseases (Taba 
et al. 2005; Ng et al. 2007; Ghallab et al. 2010; Sorsa et al. 2011; Rathnayake et al. 
2013; Cheng et al. 2014; Taylor 2014). Since the 1990s, several studies on reliable 
salivary biomarkers for oral squamous cell carcinoma (OSCC) have been published, 
revealing that there are more than 100 different salivary components suggested to be 
potential OSCC salivary biomarkers such as interleukins (IL-1β, IL-6, and IL-8), 
defensin-1, α-amylase, tumour necrosis factor-α (TNF-α), matrix metalloproteinases 
(MMP-2,and 9) and many others (Cheng et al. 2014). Salivary interferon gamma 
(IFN-γ), TNF-α, and TNF receptor-2 have been found in detectable levels in patients 
with erosive oral lichen planus and were significantly decreased after treatment 
(Ghallab et al. 2010). Interleukins (IL-1β, IL-6, and IL-8), MMP- 8, tissue inhibitors of 
MMPs (TIMPs), TNF-α, lysozymes, peroxidases and other salivary biomarkers have 
been identified as potential biomarkers for periodontal diseases (Rathnayake et al. 
2013; Taylor 2014). Periodontal diseases, especially chronic periodontitis and 
gingivitis are the most common oral inflammatory diseases affecting wide range of 
population in the UK, Europe, and worldwide. The early diagnosis, prevention, and 
management of periodontal diseases are among the priorities for any dental health 
care system, as the consequences of the delayed diagnosis will be an extensive loss 
in the supporting connective tissue and alveolar bone ending with the loss of teeth 
and expensive and complicated restorative treatments (Borrell and Papapanou 2005; 
Pihlstrom et al. 2005; Corbet and Leung 2011; Dye 2012; Petersen and Ogawa 2012; 
White et al. 2012; Slots 2013; Leong et al. 2014). In comparison to periodontally 
healthy individuals, periodontitis patients have significantly poorer oral health related 
quality of life with functional, psychological and social effects (Durham et al. 2013). 
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1.1 Periodontal diseases 
Periodontal diseases are group of diverse multifactorial diseases with an 
inflammatory and destructive nature affecting the surrounding and supporting tissues 
of the teeth (Kornman 2008). Pihlstrom et al. (2005), defined periodontal disease as 
“any inherited or acquired disorder of the tissues surrounding and supporting the 
teeth (periodontium)”. Commonly, the term periodontal disease refers to the 
inflammation of the gingiva (gingivitis) and the surrounding periodontal tissues 
(periodontitis), mostly initiated as a host response to the bacteria present in the 
dental plaque which accumulate on the surfaces of the adjacent teeth (Pihlstrom et 
al. 2005). 
1.1.1 Classification of periodontal diseases  
Despite the fact that gingivitis and chronic periodontitis are the most common, 
periodontal diseases comprise a wider range of entities that requires a proper 
recognition and diagnosis (Highfield 2009). The need for a classification of 
periodontal diseases is necessary not only for the clinicians to develop the basis for a 
precise diagnosis and efficient management of the patients, but it is a requisite 
framework for the researchers in order to classify subjects into groups based on the 
presence or absence of the disease. The latest classification of periodontal diseases 
was set by the American Academy of Periodontology (AAP), and modified by an 
international classification workshop held at 1999 (Armitage 1999; Highfield 2009), 
which represents a consensus view of experts within the field of periodontology 
(Table 1.1).  
  Gingival diseases 
With reference to the1999 classification, the gingival diseases or conditions can be 
classified into 2 main groups, the plaque and non-plaque induced (Highfield 2009). 
The most common form of gingival conditions is the plaque induced gingival 
inflammation known as gingivitis or chronic gingivitis, which is the mildest and highly 
prevalent form of periodontal diseases that affects 50–90% of adults worldwide 
depending on its precise definition (Armitage 1999; Albandar and Rams 2002; 
Highfield 2009). In comparison to other forms of periodontal diseases, plaque 
induced gingivitis is readily reversible by simple and effective oral hygiene measures. 
Though it is caused by dental plaque, gingivitis could be modified by local factors, 
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which may include teeth anatomical factors, fractures, and dental restorations. 
Furthermore, chronic gingivitis can be modified or exacerbated to an acute form by 
systemic factors such as endocrine factors, pregnancy, menstruation, puberty, 
hematologic dyscrasias, medications, and malnutrition. Typically, gingivitis is 
confined to the periodontal soft tissue ‘gingiva’, the junctional epithelium remains on 
the root surface with intact alveolar bone without loss of attachment; however, 
gingivitis may occur with a reduced but stable attachment level with no progressive 
loss of attachment (Offenbacher 1996; Armitage 1999; Albandar 2005; Page and Eke 
2007; Highfield 2009).  
The non-plaque induced gingival conditions comprise groups of lesions caused by 
specific bacteria (such as Neisseria gonorrhoea, and Streptococci species), viruses 
(such as Herpes virus infections), and fungi (such as Candida species infections and 
linear gingival erythema). Other gingival conditions could be genetic (such as 
hereditary gingival fibromatosis), as manifestations of systemic conditions such as 
mucocutaneous diseases (lichen planus, and pemphigus vulgaris), or allergic 
reactions to medications, dental restorations and food additives. Gingival traumatic 
lesions, which could be iatrogenic or accidental lesions due to chemical, physical, 
and thermal injuries. Gingival lesion as a reaction to a foreign body and other non-
specified conditions (Highfield 2009). 
  Periodontitis 
Subjects with gingivitis are more prone to have periodontal attachment loss than 
those with no signs of gingival inflammation. Hence, gingivitis always predates the 
appearance of periodontitis, with the exception of aggressive periodontitis no case of 
periodontitis without an antecedent gingival inflammation has been reported 
(Albandar et al. 1998b; Albandar and Rams 2002). When the inflammation extends 
from the gingiva deep into the surrounding connective tissue and alveolar bone 
leading to loss of these supporting structures this is known as periodontitis (Pihlstrom 
et al. 2005). Periodontitis is usually associated with sub-gingival pockets which may 
extend deeply forming crevices between the gingiva and tooth root. If left untreated, 
the inflammation will progress to advanced or severe periodontitis resulting in 
loosening of the teeth, discomfort and pain, impaired mastication, and subsequently 
loss of teeth (Pihlstrom et al. 2005). According to the 1999 classification, there are 
various forms of periodontitis including chronic periodontitis, aggressive periodontitis, 
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periodontitis as a manifestation of systemic diseases, necrotizing periodontal 
diseases, and other periodontal lesions such as abscesses of the periodontium, 
periodontal-endodontic lesions, and developmental or acquired conditions (Highfield 
2009). 
  Chronic periodontitis 
Chronic periodontitis is the most common form of destructive periodontal diseases 
(Albandar 2005), defined by Lindhe et al. (1999) as “an infectious disease resulting in 
inflammation within the supporting tissues of the teeth, with a progressive attachment 
and bone loss, characterized by pocket formation and/or gingival recession, its onset 
may be at any age, but is most commonly detected in adults, its prevalence and 
severity increases with age, and it may affect a variable number of teeth and has 
variable rates of progression’’. Though it is more common in adults, cases have been 
reported in adolescents and occasionally in children, that’s why the term adult 
periodontitis was replaced by the term chronic periodontitis in the 1999 classification. 
It was found that the term chronic is more representative for the disease as such a 
term is nonspecific, non-age dependent, and less restrictive (Highfield 2009). 
The international workshop of 1999, listed the clinical features of chronic periodontitis 
(Lindhe et al. 1999; Highfield 2009), to be: 
 Most prevalent in adults but can occur in children and adolescents. 
 The amount of destruction is consistent with the presence of local factors. 
 Sub-gingival calculus is a frequent finding. 
 Associated with a variable microbial pattern. 
 Slow to moderate rate of progression but may have periods of rapid 
progression. 
 Can be further classified on the basis of extent and severity. 
 Can be associated with local predisposing factors (such as tooth-related or 
iatrogenic factors). 
 May be modified by and/or associated with systemic diseases (such as 
diabetes mellitus, HIV infection). 
 Can be modified by factors other than systemic disease such as cigarette 
smoking and emotional stress. 
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Depending on the number of teeth sites affected, chronic periodontitis can be either 
localized or generalized. The case is defined as localized when the sites affected are 
30% or less, and as generalized when more than 30% of sites are affected (Lindhe et 
al. 1999; Highfield 2009). Conventionally, the severity of the disease has been 
described as being slight or early when the bone loss is confined to the coronal third 
of the root, moderate when bone loss extends to the middle third of the root, and 
advanced when the bone loss extends to the apical third of the root. Moreover, the 
1999 workshop categorized a further general guide for the disease severity based on 
the clinical attachment loss (CAL) as follows: slight = 1–2 mm CAL, moderate = 3 to 4 
mm CAL, and severe = ≥ 5 mm CAL (Lindhe et al. 1999; Pihlstrom et al. 2005; 
Highfield 2009). A further periodontitis case definition was set by the 5th European 
Workshop in Periodontology which includes measuring the CAL at the proximal sites 
of non-adjacent teeth (Tonetti and Claffey 2005), (Table 1.2). The AAP case 
definition suggests measuring both the CAL and the probing depth (PD) at the 
interproximal sites of more than one tooth as criteria for case definition (Page and 
Eke 2007), (Table 1.2). Considering the possible mistakes that may happen while 
measuring the CAL, which may exclude cases with periodontitis or include cases 
without periodontitis, a threshold for the CAL was set at ≥5 mm by (Tonetti and 
Claffey 2005) and ≥6 mm by (Page and Eke 2007). 
Severe periodontitis is defined by the AAP as a minimum of two teeth with 6 mm CAL 
and one tooth with a probing depth of 5 mm present (Page and Eke 2007). According 
to this case definition, a patient or a subject included in a study might be diagnosed 
with severe periodontitis by the presence of only minimal levels of attachment loss 
which might be due to overhanging restorations or on the distal aspect of second 
molars where a third molar has been extracted. Therefore, in order to generate more 
reliable data from which conclusions can be drawn, it is necessary to include cases 
which have sufficient levels of the disease. In comparison to the AAP case definition, 
the 5th European Workshop in Periodontology have more comprehensive inclusion 
criteria with respect to the extent and severity of the disease, requiring an 
interproximal attachment loss of ≥ 5 mm in ≥ 30% of teeth present to define the 
subject with severe periodontitis (Tonetti and Claffey 2005). 
For an improved description of the total prevalence of periodontitis in populations, 
there was an update on the periodontitis case definition by the Centres for Disease 
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Control and Prevention (CDC) in partnership with AAP (Eke et al. 2012), (Table 1.3). 
The criteria for defining both the moderate and severe periodontitis remained same 
as previously described by Page and Eke (2007), the update was the inclusion of the 
case definition criteria for mild periodontitis. The previous case definitions by the 5th 
European Workshop and the AAP did not define mild periodontitis as they set their 
case definition criteria for surveying moderate and severe periodontitis only. 
Therefore, the moderate and severe periodontitis case definitions were not enough to 
determine the overall prevalence of periodontitis in populations as they missed the 
mild periodontitis (Eke et al. 2012). In their survey, Eke et al. (2012) found that the 
incorporation of the mild periodontitis criteria increased the total prevalence of 
periodontitis about 31% when compared to the surveys involving the moderate and 
severe periodontitis only. Therefore, neglecting mild periodontitis while carrying out a 
survey will underestimate the overall prevalence and burden of the disease. This 
could be more evident in populations with young adults who are more likely to have 
mild periodontitis which is more responsive to oral health measures and preventive 
dental care, but if not detected will remain at risk of progressing to the moderate and 
severe periodontitis that are more difficult and expensive to treat (Eke et al. 2012). 
All the above-mentioned case definitions used the CAL as the primary criteria; 
however, there is a perception that the definition of periodontitis cannot be restricted 
to a single variable such as CAL. Though it represents a measure of the cumulative 
lifetime experience of periodontitis, CAL presents brief information about the current 
inflammatory status of the periodontal tissues. Hence, clinicians and researchers 
considered the incorporation of other measures such as the PD, bleeding on probing 
(BOP), recession, periodontal epithelial surface area (PESA), and periodontal 
inflamed surface area (PISA), along with the CAL for a more precise case definition 
(Hujoel et al. 2001; Page and Eke 2007; Nesse et al. 2008; Nesse et al. 2009). 
Furthermore, there are concerns expressed by the clinicians that the CAL 
measurement might be challenging, time consuming and difficult especially when the 
gingival margin is located coronal to the cemento-enamel junction (CEJ) as the CAL 
measurement in this case may be a kind of guesswork or estimation. Reports stated 
that clinicians are excluding the CAL measurements in favour of PD alone or PD with 
recession measures at the mid-facial or mid-buccal or mid-lingual aspects of the 
teeth, only when the recession is actually present (AAP-TF 2015; Lopez and Baelum 
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2015). On the other hand, the half and full mouth examination were considered in the 
case definition and prevalence of periodontitis, for instance the accuracy of the 
periodontitis prevalence determined by the National Health and Nutrition Examination 
Survey (NHANES) using partial mouth periodontal examinations, was compared to 
the full mouth ‘gold standard’ periodontal examinations. This comparison found that 
the partial examinations substantially underestimated the prevalence of periodontitis 
by 50% or more depending on the periodontitis case definition used, which generated 
high levels of misclassification of periodontitis cases (Eke et al. 2010). 
1.1.2 Pathogenesis of periodontal diseases 
The proper diagnosis and treatment, as well as the prevention of periodontal 
diseases, require a comprehensive understanding of the disease aetiology and 
pathogenesis. It is well known that the dental plaque with all its inhabitant species of 
bacteria and their products is the main cause of periodontal diseases. This dental 
plaque induces the inflammatory process of periodontal diseases through the 
disruption of normal homeostasis, and this is modified by many environmental and 
genetic factors (Pihlstrom et al. 2005; Zee 2009; Darveau 2010). Typically, the 
inflammatory process will start first in the gingiva leading to gingivitis which is 
reversible with the improvement of oral hygiene. If left untreated, the inflammation of 
the gingiva will progress to periodontitis which is a substantially irreversible damaging 
inflammatory process affecting the surrounding tissue (gingiva and periodontal 
ligament) and the supporting alveolar bone. This destructive process will lead to 
tissue injuries including loss of collagen fibres and attachment with cementum 
surface, apical migration of junctional epithelium resulting in deepened periodontal 
pockets and alveolar bone loss. If left untreated, periodontitis will continue with 
further bone destruction resulting in teeth mobility, pain, impaired function and finally 
teeth loss (Pihlstrom et al. 2005; Taba et al. 2005; Kornman 2008), (Figure 1.1). 
  Dental plaque and periodontal pathogens 
Like any other surface in the body, the oral cavity, possesses a substantial microflora 
living in harmony with the surrounding host environment. The oral microflora 
encompasses hundreds of species of aerobic and anaerobic, or Gram-positive and 
Gram-negative bacteria which live and grow within biofilms (Pihlstrom et al. 2005). 
Clinically, the biofilm may be defined as a bacterial deposit which cannot be easily 
rinsed away and it may form on any surface within the oral cavity such as teeth, 
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mucosa or other solid surfaces (Hasan and Palmer 2014). The biofilm represents an 
organized community or communities of bacteria (comprises about 15-20% of the 
biofilm volume), nested in a glycocalyx matrix (comprises about 75-80% of the biofilm 
volume), these bacterial populations are attached to each other and to a solid 
surface. The major advantage of the biofilm is the protection that it provides for the 
colonizing bacteria from other competing microorganisms, from the surrounding 
environment effects such as host defence mechanisms, and from potentially toxic 
substances in the environment such as antibiotics, this protection allows the bacteria 
to stick to and to multiply on the solid surface (Socransky and Haffajee 2002). The 
biofilm which forms and grows on solid surfaces including teeth or restorative 
materials (the metal, ceramics or acrylic in appliances), is known as the dental plaque 
or dental biofilm. As it is formed on solid and non-shedding surfaces, the dental 
plaque is a stable community and it differs from other biofilms formed on shedding or 
desquamating mucosal surfaces (Hasan and Palmer 2014). 
Loe et al. (1965), were the first to describe the role of dental plaque in the initiation 
and development of periodontal diseases, when they found that gingivitis will develop 
within four days following the build-up of the dental plaque in an experimental 
gingivitis model. In the primary stages, the bacterial populations in the dental plaque 
consist of aerobic and facultative anaerobes such as Gram-positive cocci 
(Streptococci species). Later on, Gram-positive rods appear, increase in number and 
finally predominate over the cocci. Subsequently, Gram-positive filaments such as 
Actinomyces species will predominate. The Gram-positive bacteria (cocci and rods) 
have specific surface receptors that allow the adherence of Gram-negative bacteria, 
which otherwise lack the ability to attach directly to the biofilm. If the dental biofilm 
remains, and as time goes on, there will be a shift in the microflora from Gram-
positive to Gram-negative microorganisms with more diversity in the inhabitant 
microbial species (Hasan and Palmer 2014). 
Hasan and Palmer (2014), indicated that despite the fact that the dental plaque plays 
a major role in the pathogenesis of periodontal diseases, whether the bacteria in the 
dental plaque induce periodontal diseases specifically or non-specifically, this is still a 
debate. Hasan and Palmer (2014), reported three hypotheses about the role of the 
bacteria in the periodontal diseases pathogenesis, though, these hypotheses ignored 
the role of the host factors and responses. The first hypothesis is the “non-specific 
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plaque” hypothesis, which proposes that periodontal diseases occurs due to the 
accumulation of bacteria regardless to their species. According to this hypothesis, 
preservation of standard oral hygiene will prevent periodontal diseases. Thus, the 
dental plaque amounts may correlate positively with the severity of periodontal 
diseases in cross-sectional studies; however, this correlation may be poor in 
longitudinal studies, this was explained by the variations in the dental plaque bacteria 
or even the host responses which were both ignored by this hypothesis (Marsh 2003; 
Marsh 2006; Hasan and Palmer 2014). 
The second hypothesis is the “specific plaque” hypothesis, which proposes that a 
periodontal disease results from an infection with specific bacteria. This may explain 
why not all patients who have high amounts of dental plaque suffer from severe 
destructive periodontitis, which means that specific bacteria cause this form of 
periodontitis. This hypothesis implies that one should be concerned about the 
specific bacteria responsible for periodontal disease; therefore, there is a need to 
focus on the oral hygiene measures and treatment that eliminate the specific 
pathogen. According to this, it may be unnecessary to remove all the dental plaque 
and it may be sufficient either to remove the anaerobic bacteria or to disrupt their 
growth and survival which could be achieved by the root surface debridement. 
Moreover, when a specific pathogen is identified the treatment could be targeted at 
this specific pathogen using a specific antibiotic to which it is sensitive. However, 
despite the fact that the bacteria Aggregatibacter actinomycetemcomitans is specific 
for aggressive periodontitis; no single pathogen has been specifically associated with 
chronic gingivitis or periodontitis (Marsh 2003; Marsh 2006; Hasan and Palmer 
2014). 
The third hypothesis is the “multiple pathogen” hypothesis, which proposes that 
periodontal disease results from an infection with a relatively small number of 
interacting bacterial species. One of the major difficulties with this hypothesis lies in 
the identification of the most important bacterial combination. Among these bacteria, 
Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, Treponema 
denticola, Fusobacterium nucleatum, and Campylobacter species, are found in 
diseased periodontal sites and have been involved in the progression of periodontitis. 
However, the presence of these bacteria does not prove that they are responsible for 
tissue damage, and some clinicians or researchers may argue that these bacteria are 
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more likely to be detected in deeper periodontal pockets and at the sites with more 
inflammation simply because they flourish in such environments (Hasan and Palmer 
2014). 
The previously mentioned hypotheses (non-specific plaque, specific plaque, and 
multiple pathogen hypotheses), outlined the theoretical role of the dental plaque 
bacteria in the pathogenesis of periodontal diseases, yet they ignored the role of the 
host response and/or the environmental effects on the dental plaque bacteria. 
Consequently, the “ecological plaque hypothesis” has been proposed as a result of 
research that investigated the dynamic relationship between the plaque bacteria and 
the host environment during health and disease. This hypothesis proposes that 
ecological or environmental changes affect the bacterial flora in plaque resulting in a 
shift towards a pathogenic sub-gingival microflora and progression to periodontal 
disease (Marsh 1991; Marsh 1994). Hence, disease can be prevented not only by 
directly removing the putative pathogens, but also by interfering with the host 
environmental factors which influence the selection and enrichment of plaque 
bacteria. Therefore, more holistic approaches might be considered in disease control 
and management (Marsh 1994; Marsh 2003; Marsh 2006). The local host 
environmental changes do shift the dental plaque microflora during disease, for 
instance during inflammatory response to sub-gingival plaque, the pH rises to 
become slightly alkaline and the GCF flow increases delivering potentially novel 
substrates for the proteolytic bacteria in the dental plaque (Marsh 1994; Marsh 2003; 
Marsh 2006; Marsh et al. 2011). Moreover, conventional pure culture investigations 
found that such environmental changes might affect the gene expression and 
virulence factors of dental plaque bacteria (Marsh 2006). 
Studies have reported that 500-600 or even more distinct species were identified in 
the dental plaque from periodontal pockets of humans and about 30-100 species 
may be found in a single site (Moore and Moore 1994; Pihlstrom et al. 2005; Hasan 
and Palmer 2014). However, number of studies indicated that it is still not easy to 
define which microorganisms are more important than the others due to some 
difficulties, such as: The host may determine what species can grow as a 
consequence of the host’s own environment. Contamination with other species may 
make it difficult to obtain representative bacterial samples from periodontal pockets. 
The time of collecting the bacterial samples may be critical as the periodontal 
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disease progresses and there is a shift in the microflora from Gram-positive and 
aerobic to more Gram-negative and anaerobic bacteria. The presence of 
opportunistic infections or infections from other sites in the oral cavity may also 
confound the identification of bacteria. In addition to the inter-individual variations in 
the host immune responses to the bacteria (Tanner et al. 1996; Tanner et al. 1998; 
Kroes et al. 1999; Ximenez-Fyvie et al. 2000; Ramberg et al. 2003; Lepp et al. 2004; 
Pihlstrom et al. 2005; Hasan and Palmer 2014). The major periodontal pathogens 
implicated in periodontal diseases include: Porphyromonas gingivalis (P. gingivalis), 
Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) (previously 
known as Actinobacillus actinomycetemcomitans), Tannerella forsythia (T. forsythia) 
(previously known as Bacteroides forsythus), Treponema denticola (T. denticola), 
Prevotella intermedia (P. intermedia), Prevotella nigrescens (P. nigrescens), 
Fusobacterium nucleatum (F. nucleatum), and Campylobacter species (Zambon 
1996; Pihlstrom et al. 2005; Teles et al. 2006; Hasan and Palmer 2014). It has been 
demonstrated by molecular techniques and cluster analysis of sub-gingival plaque 
that certain bacterial species frequently co-exist in ‘complexes’ These analyses 
confirmed a strong association of P. gingivalis (which is one of the red complex 
microorganisms) with deep periodontal pockets and increased bleeding on probing in 
periodontal diseases (Socransky et al. 1998). Another study, reported that plaque 
samples from patients with periodontitis demonstrated an increased proportion of red 
and orange complex bacterial species as compared to plaque samples from 
periodontally healthy subjects (Ximenez-Fyvie et al. 2000). Furthermore, the 
relationships of orange and red complex bacterial species with the clinical measures 
of periodontitis is also mirrored for supra-gingival plaque samples (Haffajee et al. 
2008). However, other studies reported the detection of the same periodontal 
pathogens in periodontally healthy subjects (Loomer 2004; Sanz and Quirynen 
2005), highlighting the complex interplay between the bacterial challenge and the 
host response that is involved in periodontal disease. Though they are less common, 
Herpes viruses as well as Candida albicans and other fungi were implicated in the 
pathogenesis of periodontal diseases especially in immunocompromised patients 
(Michalowicz et al. 2000b; Robinson 2002; Kubar et al. 2004; Slots 2004; Albandar 
2005; Kubar et al. 2005; Pihlstrom et al. 2005; Saygun et al. 2005; Darveau 2010; 
Nickles et al. 2016). 
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Several studies indicated the importance of human microbiome in both host health 
and disease; however, there is a great interest in the mechanisms by which the host-
microbial homeostasis is maintained at the mucosal surfaces, the mechanisms that 
disturb this homeostasis, how the microbiome mediates diseases, and protection 
against it (Artis 2008; Darveau 2010; Littman and Pamer 2011; Hajishengallis et al. 
2012). On this basis the, “keystone pathogen” hypothesis has been developed, this 
hypothesis implies that certain low-abundance microbial pathogens have the ability to 
orchestrate an inflammatory disease by remodelling normally benign microbiota into 
a dysbiotic one (Hajishengallis et al. 2012). Differences in the composition of 
periodontal microbiota (plaque) during health and disease have been demonstrated 
in early bacteriological studies (Socransky 1977; Moore et al. 1982). These 
differences in the dental plaque bacterial community might be explained by two ways 
(Hajishengallis et al. 2012). Firstly, these differences could be considered as an 
indication that specific bacteria are implicated in the aetiology of periodontitis, and 
that the disease associated microbiota contained novel periodontal pathogens that 
were either not present or barely detected during health status (Hajishengallis et al. 
2012). Secondly, the differences might suggest that periodontitis is due to the 
dysbiosis of the dental plaque microbiota, which means there is a shift in the relative 
abundance of the dental plaque bacteria as compared to their abundance during 
health, leading to alterations in the host-microbial crosstalk (signal-transduction) 
sufficient to initiate periodontitis (Hajishengallis et al. 2012). 
Research has led to the identification of candidate gram-negative anaerobic bacteria 
known as “the red complex” including P. gingivalis, T. denticola and Tannerella 
forsythia (Socransky et al. 1998; Haffajee et al. 2008). Research has been carried 
out on these three bacteria to understand the pathogenic mechanisms, virulence 
factors, and their interaction with the host (Holt and Ebersole 2005). In support to the 
“keystone pathogen hypothesis”, studies indicated that P. gingivalis has developed 
strategies to evade the host immune components (such as toll-like receptors and 
complement) rather than acting directly as a pro-inflammatory bacterium (Darveau 
2009; Darveau 2010; Hajishengallis and Lambris 2011). Therefore, it was proposed 
that P. gingivalis impairs the innate immunity in ways leading to alteration in the 
growth and development of the entire dental biofilm, affecting the host-microbial 
balance and initiating a destructive changes in the periodontium. Accordingly, P. 
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gingivalis could be a keystone pathogen of periodontitis (Hajishengallis et al. 2012). 
Despite its high prevalence and association with progressive bone loss in 
periodontitis patients (Moore et al. 1991; Chaves et al. 2000), P. gingivalis being a 
quantitatively minor constituent of human periodontitis-associated biofilms (Moore et 
al. 1982; Doungudomdacha et al. 2000; Kumar et al. 2006; Hajishengallis et al. 
2011), is consistent with the keystone hypothesis (Hajishengallis et al. 2012). 
Moreover, the specific removal of P. gingivalis from the periodontal biofilm (such as 
using complement component 5a receptor antagonist) reverses the dysbiotic 
changes (Hajishengallis et al. 2011), indicating that dysbiotic diseases could be 
treated by targeting the keystone pathogens (Hajishengallis et al. 2012). 
The periodontal bacteria present in the dental plaque have many antigens to which 
the host immune system will react. In addition to their antigenicity, different bacterial 
macromolecules play serious roles in the inflammatory process of periodontitis. 
Among these are: leukotoxin, lipoteichoic acid, peptidoglycan, lipopolysaccharides 
(LPS), proteases, fimbriae and extracellular enzymes (Travis et al. 1997; Fives-
Taylor et al. 1999; Guo et al. 2010; Zia et al. 2011; Hasan and Palmer 2014). These 
bacterial products are the bacterial virulence factors, which will destroy the host 
tissues either directly or indirectly by stimulating the host immune system to respond 
and produce inflammatory mediators, and enzymes that will damage the supporting 
periodontal tissues. For instance, P. gingivalis LPS has a direct toxic effect on the 
periodontal tissues and stimulates the host immune reaction via specific host 
receptors, and the P. gingivalis gingipains facilitate bacterial invasion into the tissues 
and contribute to periodontal tissue destruction (Genco et al. 1999; Imamura 2003; 
Andrian et al. 2004; Dixon et al. 2004; Gupta 2013; Wara-aswapati et al. 2013; 
Hasan and Palmer 2014; Kang et al. 2016). 
  Host response 
Though bacteria and dental plaque are necessary to initiate periodontal diseases, a 
susceptible host is a prerequisite. The host will react to the chronic presence of 
dental plaque bacteria by immune-inflammatory responses that develop in the 
gingiva and periodontium and result in the inflammation and destruction of these 
periodontal tissues leading to the clinical signs of periodontal diseases (Pihlstrom et 
al. 2005). However, not all the classical signs of inflammation are present in 
periodontal diseases, for instance pain and loss of function are not present in chronic 
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gingivitis and at the early stages of chronic periodontitis (Hasan and Palmer 2014). 
Clinically, gingivitis which is a reversible inflammatory reaction of the marginal gingiva 
to the dental plaque biofilm, differs from chronic periodontitis which is a non-
reversible and destructive host inflammatory reaction, by demonstrating the 
inflammatory signs of redness, oedema, higher tendency for bleeding, and 
tenderness (Offenbacher 1996; Kinney et al. 2007).  
The histopathology of the inflammatory events during periodontal diseases was 
identified in the 1970s (Page and Schroeder 1976). The presence of the dental 
plaque biofilm initiates host inflammatory response in the periodontal tissues which is 
characterized by an increase in the blood flow and dilatation of the blood vessels with 
enhanced permeability, this will lead to influx of fluid and inflammatory cells 
especially the polymorphonuclear leukocytes (PMNs) and monocytes (macrophages) 
into the tissues at the site of infection in order to remove the invading bacteria (Page 
and Schroeder 1976; Page and Kornman 1997; Page et al. 1997; Kinney et al. 2007). 
Therefore, both the host and the virulent bacteria in the plaque biofilm, act together to 
destroy the periodontal tissues. Both release proteolytic enzymes which damage the 
periodontal tissues directly, in addition to chemotactic factors that recruit the PMNs 
and other inflammatory cells into the infection site. These cells which infiltrate the 
junctional epithelium down to the periodontal pocket following the bacteria, will also 
release enzymes and other products that will damage the supporting connective 
tissue and alveolar bone (Pihlstrom et al. 2005; Bartold and Narayanan 2006). The 
periodontal tissue destruction by the basically protective host immune response may 
be termed as ‘collateral damage’ (Preshaw and Taylor 2011). 
Neutrophils are among the important components of the innate immune system, they 
represent the first line of host defence and play a crucial role in maintaining the 
periodontal tissues health especially when they are threatened by bacterial challenge 
from the plaque biofilm. Neutrophils protect the host via their capability to 
phagocytize and kill microorganisms. Therefore, the severity of periodontal diseases 
is raised in patients with diseases such as leukocyte adhesion deficiency, lazy 
leukocyte disease and Papillon-Lefèvre, Chediak-Higashi and Down’s syndromes, as 
well as diabetes mellitus, which impair the functional responses of the neutrophils, 
and may cause neutropenia and agranulocytosis leading to recurrent microbial 
infections (Lekstrom-Himes and Gallin 2000; Fredriksson et al. 2003; Van Dyke and 
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Serhan 2003; Bascones-Martinez et al. 2009; Jain and Darveau 2010; Hasan and 
Palmer 2014). Aside from their protective role, neutrophils mediate the tissue 
destruction in the pathogenesis of inflammatory diseases. In spite of the intent of the 
active neutrophils to engulf invading bacteria, some virulent periodontal bacteria have 
the ability to avoid neutrophils that may lead to continuous accumulation of the 
activated neutrophils in the gingival sulcus and periodontal pocket (Van Dyke and 
Serhan 2003; Bascones-Martinez et al. 2009). These activated neutrophils release 
potent lysosomal and proteolytic enzymes, cytokines, and reactive oxygen species or 
radicals (ROS), all can cause direct destruction of the periodontal tissues (Van Dyke 
and Vaikuntam 1994; Johnstone et al. 2007; Aboodi et al. 2011). Therefore, the 
overproduction of all the antimicrobial proteins and ROS along with the neutrophils 
hyperactivity, explain the destructive role of activated neutrophils in periodontal 
diseases (Fredriksson et al. 2003; Johnstone et al. 2007; Aboodi et al. 2011). 
The innate immunity is responsible for the earlier responses, and helps to focus the 
later adaptive immune responses. The bacteria present in the dental plaque biofilms 
represent hundreds or even thousands of antigens that have the ability to stimulate 
the adaptive immunity by arousing both the humoral antibody-mediated and cell-
mediated immune responses. Once the microbial antigens have been identified by 
the appropriate receptors on the innate immunity cells such as neutrophils or 
macrophages or dendritic cells, then interleukins and cytokines are released which 
attract more cells and activate the T and B cells, thereby engaging cell-mediated and 
humoral immune responses, consequently the host is able to orchestrate an immune-
inflammatory response that reflects the bacterial challenge (Pihlstrom et al. 2005; 
Hasan and Palmer 2014). The antigens expressed by the bacteria are termed as 
microbe-associated molecular patterns (MAMPs), these MAMPs are recognized by a 
collection of specific receptors on the host innate immune system cells known as the 
pattern recognition receptors (PRRs). Among the important MAMPs in periodontal 
diseases pathogenesis, are bacterial LPS and fimbriae which are recognised via 
receptors such as soluble LPS binding protein, membrane-associated CD14 and toll-
like receptors (TLRs) (Dixon and Darveau 2005; Pathirana et al. 2010; Taylor 2010). 
Numerous studies reported that the MAMPs stimulate the host cells to secrete wide 
range of pro-inflammatory cytokines such as IL-1 α, IL-1β, IL-6, IL-8, IL-12, TNF-α 
and IFN-γ, and prostanoids such as prostaglandin E2 (PGE2), which attract more 
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inflammatory cells and mediate periodontal tissue destruction, in addition to the 
secretion of enzymes such as matrix metalloproteinases (MMPs) which directly 
degrade the extracellular matrix and lead to attachment loss (Okada and Murakami 
1998; Sandros et al. 2000; Jotwani et al. 2003; Dixon et al. 2004; Kusumoto et al. 
2004; Eskan et al. 2007; Eskan et al. 2008; Preshaw 2008; Liu et al. 2010; Hans and 
Hans 2011). All these studies highlight the vital role of host cell receptors in the 
inflammatory immune response during the pathogenesis of periodontal diseases. 
Hence, the activation of specific receptors by specific bacterial MAMPs directs an 
inflammatory immune response that is relevant to the bacterial challenge present 
within the dental plaque biofilm. 
The cytokines and chemokines released by the innate immune cells lead the host 
response toward a robust cell mediated adaptive immunity. Therefore, in the early or 
non-progressive periodontal lesion, the inflammatory cell infiltrate comprises 
predominantly of T-lymphocytes and macrophages, indicating that the cell mediated 
response can control the disease process (Gemmell et al. 2002; Yamazaki et al. 
2003; Pihlstrom et al. 2005; Gemmell et al. 2007; Kinane and Bartold 2007; Ohlrich 
et al. 2009). However, in the more destructive lesions, where the T-cell response 
cannot supress or limit the bacterial challenge, the cell infiltrate will be dominated by 
the B lymphocytes and plasma cells (Gemmell et al. 2002; Yamazaki et al. 2003; 
Pihlstrom et al. 2005; Gemmell et al. 2007; Kinane and Bartold 2007; Ohlrich et al. 
2009). The B and plasma cells produce antibodies which are either protective and 
therefore control the bacterial infection, or non-protective resulting in connective 
tissue destruction and bone loss (Gemmell et al. 2002; Yamazaki et al. 2003; 
Gemmell et al. 2007; Kinane and Bartold 2007; Ohlrich et al. 2009). 
The types of the antibodies produced by the B cells relies on the appropriate 
adaptive immune response to the chronic bacterial challenge, which in turn depends 
on a balanced production of different subsets of T cells by the host tissues (Th1 and 
Th2 cells) which release diverse but overlapping sets of cytokines (Gemmell and 
Seymour 1994; Bartova et al. 2000; Ohlrich et al. 2009). When the Th1 cells are 
produced, this will lead to cell mediated immune response, which activates both the 
macrophages to kill the invading bacteria and the B cells to produce the opsonising 
protective antibodies which facilitates bacterial killing, this happens in more stable 
periodontal lesions. Whereas, the production of Th2 cells results in humoral immunity 
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response, with the activation of B cells to produce non-protecting antibodies, which is 
associated with more progressive periodontal lesions (Gemmell and Seymour 1994; 
Bartova et al. 2000; Ohlrich et al. 2009). 
However, there are studies that reported the predominance of Th1 cells responses or 
reduced Th2 cell responses in periodontal disease (Ebersole and Taubman 1994; 
Salvi et al. 1998; Takeichi et al. 2000). Other studies reported the involvement of 
both the Th1 and Th2 cells in periodontal diseases (Gemmell et al. 1999; Nakajima et 
al. 1999; Berglundh et al. 2002). Despite the fact that the Th1 and Th2 cells patterns 
provide indications about the possible mechanism by which the periodontal lesions 
become progressive or remain stable, a question may arise, which is: what causes 
some lesions to show Th1 characteristics while others show Th2 characteristics? The 
answer may lie in the nature of the bacterial challenge as well as the particular 
genetic and environmental susceptibility factors (some of these factors may be 
clinically identifiable and modifiable) (Ohlrich et al. 2009). Moreover, the balance of 
the cytokines produced by the innate and adaptive immune responses within the 
inflamed periodontal tissues, is an essential factor that determines whether the 
periodontal disease remains stable or progresses to a more destructive form (Okada 
and Murakami 1998). 
Interestingly, chronic inflammatory reactions within local tissues lead to dysregulation 
or imbalance in the bone remodelling homeostasis of the adjacent bone which results 
in osteolytic lesion (bone loss). This may explain the enhanced bone loss and 
resorption during chronic periodontitis (Liu et al. 2010). During periodontitis the 
infiltrating inflammatory cells in addition to the resident fibroblasts within the 
periodontal tissues, release a number of inflammatory cytokines, of which there are 
stimulatory and inhibitory cytokines that influence the osteoclasts formation and 
activity in the inflammatory induced periodontal bone loss lesion (Liu et al. 2010). 
  Cytokines in periodontal diseases 
The pro-inflammatory cytokines play a significant role in the pathogenesis of 
periodontal diseases as they are involved in the destruction of both the periodontal 
connective tissues and alveolar bone, mainly via the stimulation of the host MMPs 
(Taylor 2010; Preshaw and Taylor 2011). During the innate host response, the 
bacterial LPS and other antigens stimulate the monocytes, PMNs, macrophages, and 
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the resident periodontal cells such as fibroblasts and other cells to release the 
cytokines IL-1β, TNF-α and PGE2 (Kinney et al. 2007). IL-6 is also released by the 
same cells and they are all involved in the stimulation of bone resorption (Ishimi et al. 
1990; Okada and Murakami 1998; Palmqvist et al. 2002; Buduneli and Kinane 2011). 
Furthermore, the 7th European Workshop on Periodontal Diseases confirmed in a 
consensus paper that IL-1β, TNF-α, IL-6 and the receptor activator of nuclear factor 
kappa-B ligand (RANKL) as the most important cytokines to play role in the 
pathogenesis of periodontal diseases (Kinane et al. 2011). 
IL-1β is the key inflammatory cytokine in various inflammatory diseases 
characterized by destruction of bone and connective tissue, for instance IL-1β is the 
central mediator of inflammation and connective tissue destruction in rheumatoid 
arthritis (Raymond et al. 2006). IL-1β is produced by the inflammatory cells infiltrate 
as well as the local periodontal cells in response to the bacterial challenge from the 
dental biofilm, and it plays essential roles in the innate and adaptive host immune 
events during the pathogenesis of periodontal diseases (Barksby et al. 2007). 
Usually, IL-1β, TNF-α, and PGE2 act synergistically to induce many inflammatory 
changes and govern the neutrophils chemotaxis and emigration from the nearby 
circulation into the periodontium. During the adaptive immune response, IL-1β 
stimulates the presentation of bacterial antigens by the antigen presenting cells 
(APCs) thereby influencing the T-cells development and phenotype (Assuma et al. 
1998; Barksby et al. 2007). 
PGE2, which is an arachidonic acid metabolite of the cyclooxygenase (COX) 
pathway, is a potent vasodilator and increases the capillaries’ permeability which 
results in the inflammation signs of redness and oedema. Moreover, PGE2 is a potent 
mediator of alveolar bone loss in periodontitis, and it stimulates the fibroblasts and 
osteoclasts to produce IL-1β and other cytokines, as well as the MMPs that destroy 
the supporting periodontal tissues (Offenbacher et al. 1984; Offenbacher et al. 1993; 
Kinney et al. 2007; Buduneli and Kinane 2011). Though it is a less potent stimulator 
for PGE2 production when compared to IL-1β, but TNF-α and IL-1β act synergistically 
to enhance PGE2 production (Yucel-Lindberg et al. 1999; Buduneli and Kinane 
2011). Hence, the synergism of IL-1β, TNF-α, and PGE2, ultimately stimulates the 
fibroblasts and osteoclasts to secrete MMPs, as well as, activates the osteoclastic 
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activity which will destroy supporting connective tissues and alveolar bone in 
periodontitis (Kinney et al. 2007; Taylor 2014). 
In a similar manner to IL-1β, TNF-α, and other cytokines, IL-6 is secreted by different 
inflammatory cells and local periodontal cells such as gingival fibroblasts, it is 
believed that the IL-1β and TNF-α may stimulate the production of IL-6 (Taylor 2014). 
This interaction among IL-6, IL-1β and TNF-α was illustrated by a cell culture study of 
primary gingival fibroblasts which revealed mRNA expression of IL-6, and a dose-
dependent up-regulation of IL-6 mRNA and IL-6 protein levels in response to 
stimulation by IL-1β and TNF-α (Palmqvist et al. 2008). On the contrary, it has been 
shown that IL-6 induces IL-1 receptor antagonist (Tilg et al. 1994), which may provide 
a sort of control over the upregulated inflammatory responses. As a pro-inflammatory 
cytokine, IL-6 plays an important role in the pathogenesis of periodontal diseases via 
its effects in the regulation, development, proliferation, and activation of the immune 
cells (B and T-cells), as well as, its ability to stimulate bone resorption by the 
activation of osteoclasts (Palmqvist et al. 2002; Bartold and Narayanan 2006; 
Preshaw and Taylor 2011). Moreover, IL-6 stimulates the fibroblasts to secrete 
MMPs, therefore, IL-6 along with IL-1β and TNF-α, are considered as the key 
cytokines that propagate the destructive host inflammatory response to the plaque 
bacterial challenge at different levels, which may explain the increased 
concentrations of these cytokines found in the inflamed periodontal tissues (Irwin and 
Myrillas 1998; Graves and Cochran 2003). 
The destruction of the alveolar bone which is one of the main characteristic features 
of periodontitis, led to the investigation of the importance of regulatory interactions 
between bone metabolism and inflammation (Nagasawa et al. 2007; Buduneli and 
Kinane 2011; Graves et al. 2011). Several cytokines such as IL-1β and IL-6 stimulate 
and upregulate the RANKL expression which enhances bone resorption, the 
cytokines also regulate the ratio of RANKL and its natural antagonist osteoprotegerin 
(OPG), and this upregulation is important in determining bone resorption and 
turnover (Lerner 2006; Nagasawa et al. 2007; Koide et al. 2010), and this ratio is 
elevated in periodontitis (Buduneli and Kinane 2011; Preshaw and Taylor 2011). 
Additionally, cytokines such as IL-1β and TNF-α also enhance the COX-2-mediated 
PGE2 production by osteoblasts (Lerner 2006; Coon et al. 2007). In turn, PGE2 
efficiently stimulates RANKL pathway and expression in osteoblasts (Li et al. 2002), 
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as well as osteoclast progenitor cells (Ono et al. 2005). Therefore, at persistently 
high levels, PGE2 stimulates the master osteoclast activator (RANKL) expression in 
osteoblasts, subsequently enhances the bone resorption which occurs in destructive 
inflammatory diseases such as periodontitis (Buduneli and Kinane 2011). 
All the activities regulated by the cytokines indicate that, periodontal disease 
progression depends on the balance between pro-inflammatory and anti-
inflammatory responses maintained by a network of cytokines (Graves and Cochran 
2003). 
  Matrix Metalloproteinases in periodontal diseases 
MMPs are a family of zinc-dependent proteases, their main function is to degrade the 
components of the extracellular matrix (ECM) and basement membrane components, 
and they may also play other roles related to cell growth/proliferation, and 
inflammation. In humans the MMPs family comprise 23 structurally related but 
genetically distinct proteases (Jackson et al. 2010). Though they are classified 
according to their main substrate, but the MMPs enzymatic activities are complex and 
overlapping and they may digest a wide range of peptide sequences found in a 
number of protein substrates and some of which are targets to specific MMPs 
(Birkedal-Hansen 1993; Sorsa et al. 2006; Hannas et al. 2007). 
In a similar manner to the cytokines, MMPs are produced by inflammatory cells such 
neutrophils and macrophages, and by the cells of the periodontium such as 
fibroblasts, keratinocytes, endothelial cells, and osteoclasts, in response to 
stimulation by pro-inflammatory cytokines, as well as bacterial challenge from the 
dental plaque (Birkedal-Hansen 1993). In addition to their proteolytic function, MMPs 
play roles in the tissue development, homeostasis, repair, and cell apoptosis, as well 
as having roles in the host immune responses including antigen processing and 
presentation, cells migration, processing and activating a variety of proteins such as 
antimicrobial peptides, chemokines, cytokines, and growth factors, thereby mediating 
pro- and anti-inflammatory processes (Sorsa et al. 2006; Hannas et al. 2007; 
Giannobile 2008; Hernandez et al. 2011; Butler and Overall 2013). The MMPs 
activities are regulated at multiple levels including: transcription, 
secretion/degranulation, activation of the zymogen, inhibition of activity, extracellular 
inhibitors, localization whether inside or outside the cell, as well as internalization and 
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clearance. Different transcription factors, co-activators and co-suppressor proteins 
regulate the MMPs expression. The transcriptional activation of MMPs is stimulated 
by a variety of pro-inflammatory cytokines, hormones and growth factors, such as IL-
1β, IL-6, TNF-α, epidermal growth factor, platelet-derived growth factor and fibroblast 
growth factor (Sorsa et al. 2006; Hannas et al. 2007). The active MMPs are inhibited 
by two main inhibitors, first, the tissue inhibitors of matrix metalloproteases (TIMPs) 
which form bimolecular complexes with the active forms of MMPs and sometimes 
even with the latent MMP precursors. The second inhibitor molecule is the α2-
Macroglobulin which captures active MMPs by a unique trap mechanism. The 
balance between the levels of MMPs and their inhibitors is the determinant and 
regulator of the MMP activity, and this balance is crucial for the maintenance of 
tissue integrity, otherwise any imbalance or excessive production of either the MMPs 
or their inhibitors may lead to increased tissue degradation (Birkedal-Hansen 1993; 
Sorsa et al. 2004; Jacqueminet et al. 2006; Sorsa et al. 2006; Hannas et al. 2007). 
It is well known that MMPs play a serious role in the pathogenesis of periodontal 
diseases through the regulation of periodontal tissue turnover (Uitto et al. 2003; 
Sorsa et al. 2004; Sorsa et al. 2006; Li et al. 2012). During periodontal diseases, the 
balance between MMPs and their inhibitors especially TIMPs is influenced by the 
dysregulation in the synthesis and secretion of MMPs due to the bacterial and host 
stimulation. The periodontal tissue infected with dental biofilm bacteria will be 
invaded by neutrophils in an attempt to remove the bacterial threat, which may 
explain the high levels of the neutrophils MMPs (especially MMP-8 and -9) found in 
the inflamed periodontal tissues and GCF (Uitto et al. 1990; Uitto et al. 2003). Sorsa 
et al. (1995), reported that the main collagenase in periodontitis is MMP-8 followed 
by MMP-9. For instance, MMP-8 levels in GCF correlate positively with the severity of 
periodontal disease and reduce significantly in response to periodontal treatment 
(Golub et al. 1990; Kinane et al. 2003; Kinney et al. 2007). In addition to the 
conventional non-surgical periodontal treatment, tetracyclines, especially 
doxycycline, which further to their antimicrobial activity, are able to inhibit the MMPs, 
an effect which is independent of their antimicrobial activity (Sorsa et al. 1994; Golub 
et al. 1998; Preshaw et al. 2004). The sub-antimicrobial dose of doxycycline 
approach became a successful adjunctive therapy in the management of 
periodontitis, which has the ability to inhibit the MMPs at many levels especially their 
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activities and gene expression, and this indeed confirms the importance of the MMPs 
in the periodontal diseases pathogenesis (Ciancio and Ashley 1998; Golub et al. 
1998; Sorsa et al. 2006; Giannobile 2008). 
  Risk and modifying factors 
Further to the plaque biofilm bacteria and their products which are the main factors 
that initiate the host response in periodontal diseases, as multifactorial diseases 
there are several local and systemic factors which may increase the risk or 
susceptibility for periodontal diseases and modify the host response. However, the 
significance of these factors in the pathogenesis of periodontal diseases may vary 
from one periodontal disease to another and from patient to patient. Several studies 
investigated the risk factors, some of which were found to have real risk modifying 
effects, whereas others may barely modify the host response or the disease 
pathogenesis (Nunn 2003; Albandar 2005; Kornman 2008). For instance, some local 
factors such as tooth anatomy, dental caries, and dental restorations may enhance 
the dental plaque accumulation or even influence the composition of the dental 
plaque biofilm, therefore they may potentiate the harmful effects of the plaque biofilm 
and its bacteria (Albandar et al. 1995a; Kinane 2001; Albandar 2002a; Nunn 2003). 
However, the inflammatory response to plaque accumulation may vary substantially 
among individuals (Tatakis and Trombelli 2004). 
In addition to the local factors that facilitate plaque accumulation, poor oral hygiene 
has been typically associated with the high prevalence of periodontal diseases 
(Albandar 2002b; Hyman and Reid 2003). It is well known that thorough oral hygiene 
measures are efficient in preventing or reducing the level of gingival inflammation 
thereby reducing the risk for chronic periodontitis (Albandar 2005), nevertheless, oral 
hygiene practice may not be useful in preventing aggressive periodontitis as it is not 
related to the amount of dental plaque (Albandar et al. 1995b; Highfield 2009; Clark 
et al. 2017). Various studies investigated the relationship between the oral hygiene 
measures and periodontitis, for example a longitudinal study carried out on a Sri 
Lankan population revealed that the attachment loss was significantly associated 
with dental calculus (Neely et al. 2001). Consequently, it is obvious that poor oral 
hygiene will lead to chronic periodontitis as there is evidence that patients with 
gingival inflammation have a higher risk for progression of attachment loss and loss 
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of teeth than periodontally healthy subjects (Albandar et al. 1998b; Schatzle et al. 
2003; Schatzle et al. 2004). 
One of the most important and common risk factors for periodontal diseases is 
smoking. Numerous studies reported that smokers have a higher risk for loss of 
attachment, periodontal destruction and loss of teeth in comparison to non-smokers 
(Albandar et al. 2000; Tomar and Asma 2000; Albandar 2002a; Albandar 2005; 
Pihlstrom et al. 2005; Zee 2009; Genco and Borgnakke 2013). Studies demonstrated 
that the risk of having attachment loss is increased by 2-7 folds in cigarette smokers 
as compared to non-smokers, with a higher risk in young smokers (Grossi et al. 
1994; Linden and Mullally 1994; Grossi et al. 1995; Gelskey 1999; Bergstrom et al. 
2000; Bergstrom 2003). Furthermore, evidence indicated a positive dose-effect 
relationship between smoking and periodontal diseases and that the attachment loss 
and severity of periodontitis are higher in heavy smokers with long history of smoking 
than the light smokers or those with brief history of smoking (Grossi et al. 1995; 
McGuire and Nunn 1999; Bergstrom et al. 2000; Tomar and Asma 2000; Bergstrom 
2003; Albandar 2005; Genco and Borgnakke 2013). The risk of smoking in relation to 
periodontitis has been investigated in population surveys, for example the third 
National Health and Nutrition Examination survey in the USA population found that 
41.9% of periodontitis cases were attributed to current smoking and 10.9% of cases 
were due to former cigarette smoking (Tomar and Asma 2000). Another survey from 
Brazil estimated that about 12% of periodontitis cases might be due to smoking 
(Susin et al. 2004). In a similar manner to cigarette smoking, cigar and pipe smoking 
have been shown to have risk effects on the periodontal health as they were 
significantly related to both teeth and alveolar bone loss (Krall et al. 1999; Albandar 
et al. 2000; Johnson and Slach 2001). 
Different studies investigated the mechanisms by which smoking affects the 
periodontal health, Heasman et al. (2006) reported that the smoking effects on the 
periodontal health falls in the categories of plaque biofilm bacteria, gingival blood 
supply, neutrophils and PMNs phagocytosis, cytokine production (such as IL-1), the 
CD4 and CD8+ T-cell subsets, and periodontal healing. Studies reported evidence 
that smoking leads to peripheral vasoconstriction, which is probably due to nicotine 
and that this vasoconstriction results in reduced gingival bleeding which may explain 
why smokers have less gingivitis and reduced gingival bleeding as compared to non-
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smokers. This nicotine vasoconstriction effect may also explain the impaired gingival 
circulation in smokers, which might lead to decreased oxygen tension in the 
periodontal pocket which favours the overgrowth of anaerobic bacteria, such as P. 
gingivalis and T. denticola (Loesche 1994; Bergstrom and Bostrom 2001; Dietrich et 
al. 2004; Morozumi et al. 2004). Smoking can affect neutrophil function especially 
their migration and chemotaxis, these effects might be attributed to nicotine. 
Moreover, nicotine enhances the degranulation of the neutrophils making these cells 
more sensitive to bacterial challenge (Seow et al. 1994; Soder et al. 1999; Soder et 
al. 2002). The periodontal connective tissues and bone destruction in smokers with 
periodontitis were attributed to the increased levels of macrophage/neutrophil-derived 
TNF-α in response to nicotine (Fredriksson et al. 2002; Genco and Borgnakke 2013). 
Nicotine also inhibits the proliferation, chemotaxis, and attachment of the fibroblasts 
within the periodontal ligament, an effect that is enhanced by the nicotine binding to 
the root surface which consequently inhibits the periodontal regeneration, and 
healing (Cuff et al. 1989; James et al. 1999). Smoking increases the number of the 
CD4 and CD8+ T-cell subsets in the periodontal tissues leading to an extensive 
periodontal tissue destruction (Loos et al. 2004). However, some studies reported 
that the levels of IL-1β is reduced in the GCF of smokers with periodontitis, which is 
raised in periodontally healthy smokers. This may indicate the possibility of an 
imbalance in the pro-inflammatory cytokines production that may affect the 
periodontal diseases pathogenesis in smokers (Petropoulos et al. 2004). 
In addition to oral hygiene and smoking, age is another important risk factor in the 
periodontal diseases pathogenesis, various epidemiological studies reported that the 
prevalence and severity of attachment loss increase with age (Burt 1994; Corbet et 
al. 2001; Albandar 2002b; Albandar and Rams 2002; Steele and O’Sullivan 2011; 
White et al. 2012); however, the increased risk of periodontitis associated tissue 
destruction in older individuals might be related to the time cumulative effect of the 
disease (Nunn 2003; White et al. 2012). Along with age, it has been reported that 
there is an association between the gender and attachment loss, and that men have 
higher prevalence and severity of periodontal diseases than women (Albandar 
2002b; Steele and O’Sullivan 2011; White et al. 2012). The prevalence of periodontal 
destruction and loss of attachment in males might be related to gender-dependent 
genetic predisposing factors (Reichert et al. 2002). For instance, it has been found 
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that oestrogen plays a protective role against periodontal inflammation, experimental 
studies showed that postmenopausal women receiving oestrogen supplement have 
less gingival inflammation and bleeding, reduced attachment loss and bone 
destruction than postmenopausal women without oestrogen supplementation, which 
may explain why periodontal diseases are less prevalent in females as compared 
males (Norderyd et al. 1993; Payne et al. 1999; Reinhardt et al. 1999). 
Socioeconomic status is also a considerable risk factor and indicator for the 
prevalence and severity of periodontal diseases, high measures of attachment loss 
and probing depth have been reported in low socioeconomic groups in comparison to 
high socioeconomic groups (Steele and O’Sullivan 2011; White et al. 2012; Eke et al. 
2015). Though its exact role is not clear, studies reported that race or ethnicity might 
also influence the severity and prevalence of periodontal diseases. For instance, 
studies in the USA demonstrated that certain race-ethnicity groups particularly those 
of African and Hispanic American background, have a higher risk of developing 
periodontal diseases than other groups (Albandar et al. 1999; Albandar and Rams 
2002). However, the race-ethnicity factors may be negligible when other factors are 
considered such as smoking or socioeconomic status (Poulton et al. 2002; Hyman 
and Reid 2003). 
Numerous studies have demonstrated the association of many systemic diseases 
with different periodontal diseases. Diabetes mellitus is the most common systemic 
disease associated with periodontal diseases, studies reported that there is a strong 
evidence for direct relation between diabetes and periodontitis and that there is a 
positive correlation between diabetes mellitus with each of attachment loss, severity 
and extent  of periodontitis (Nunn 2003; Albandar 2005; Kornman 2008; Chapple and 
Genco 2013). Results obtained from cross-sectional, longitudinal and prospective 
cohort studies indicated that patients with type 1 diabetes at all ages and adult 
patients with type 2 diabetes have more severe and prevalent periodontal disease 
than subjects without diabetes (Nelson et al. 1990; Shlossman et al. 1990; Emrich et 
al. 1991; Taylor et al. 1998; Soskolne and Klinger 2001; Taylor 2001; Chavarry et al. 
2009; Fernandes et al. 2009; Taylor et al. 2009; Hodge et al. 2012), additionally, 
uncontrolled or poorly controlled diabetic patients are at high risk for periodontitis with 
progressive bone loss (Taylor 2001; Pihlstrom et al. 2005). The impaired wound 
healing, exaggerated monocyte response to dental biofilm antigens, and the impaired 
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neutrophil functions and chemotactic responses, all might explain the severe 
periodontal tissue and alveolar bone destruction in diabetic patients with periodontitis 
(Salvi et al. 1997; Gustke et al. 1998). 
The relationship of other systemic diseases and conditions with periodontal diseases 
pathogenesis were also investigated. HIV/AIDS may have some effects on the 
progression of chronic periodontitis. Moreover, the HIV-positive and immune-
suppressed patients may develop severe forms of periodontal diseases such as 
necrotizing ulcerative gingivitis/periodontitis which represents an indication for the 
reduced count of CD4+ cells to less than 200 cells/µl (Glick et al. 1994; Robinson et 
al. 2002; Mulligan et al. 2004; Albandar 2005; Pihlstrom et al. 2005). Studies reported 
the association of poor maternal periodontal health and risk for preterm birth, low 
birthweight, and pre-eclampsia (Offenbacher et al. 1996; Dasanayake 1998; Jeffcoat 
et al. 2001; Lopez et al. 2002; Sanz and Kornman 2013). However, such an 
associations were not found in the UK (Davenport et al. 2002; Moore et al. 2004), 
and it is worthy of note that some of the studies which reported the positive 
association of maternal periodontal diseases and the adverse pregnancy outcomes 
were carried out on African-American or Hispanic-American women who were at 
higher risk for such outcomes than other race-ethnicity groups (Pihlstrom et al. 2005). 
In respect to the relationship between periodontal diseases and cardiovascular 
disorders, the European Federation of Periodontology (EFP) and AAP Workshop on 
periodontitis and systemic diseases reported that “there is consistent and strong 
epidemiologic evidence that periodontitis imparts increased risk for future 
cardiovascular disease” (Tonetti and Van Dyke 2013). Despite the fact that 
malnutrition was historically associated with periodontal diseases especially vitamin 
C deficiency and scurvy, various epidemiological studies didn’t find any relation 
between minor vitamin deficiencies and periodontal diseases especially in Europe 
and the USA; however, in countries and areas such as sub-Saharan Africa were 
malnutrition and poverty are common, Noma (cancrum oris) which usually starts as 
acute necrotising ulcerative gingivitis is still prevalent in malnourished (especially 
kwashiorkor) individuals (Enwonwu et al. 2000; Pihlstrom et al. 2005). 
In addition to the systemic diseases and conditions, the association between genetic 
factors and periodontal diseases were also heavily investigated. Severe periodontal 
manifestations associated with some of the rare genetic disorders which have 
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serious effects on the phagocytes, epithelia, connective tissue, and teeth (Albandar 
2005; Pihlstrom et al. 2005). For example, Haim-Munk and Papillon-Lefèvre 
syndromes, which are rare autosomal recessive disorders, are associated with 
periodontitis onset at childhood and early loss of both deciduous and permanent 
teeth (Hart et al. 1999; Toomes et al. 1999; Hart et al. 2000). Evidence obtained from 
studies carried out on twins suggested that nearly half the population variance in 
periodontitis might be related to genetic disorders (Michalowicz et al. 1991b; 
Michalowicz et al. 1991a; Michalowicz et al. 2000a). Furthermore, different studies 
indicated that variations and polymorphisms in or near some cytokine genes such as 
the IL-1 and TNF-α genes, might affect the inflammatory response in patients with 
periodontitis (Kornman et al. 1997; D'Aiuto et al. 2004; Taylor et al. 2004). 
1.2 Saliva and gingival crevicular fluid in periodontal diagnostics 
The diagnosis of periodontal diseases is based on clinical diagnostic parameters that 
were introduced about 4-5 decades ago and used continuously as the basic model 
for periodontal diagnosis in daily clinical practice. These parameters include 
measuring the gingival inflammation, periodontal pocket depth, bleeding on probing, 
clinical attachment loss, plaque and calculus indices, as well as the interpretation of 
radiographs to quantify the alveolar bone level (Armitage 1996; Armitage 2004a). 
Despite the fact that these clinical parameters are common, easy to use and cost 
effective for the clinicians; all these conventional parameters only reflect the history 
of the disease rather than the current status and are not able to predict the future 
outcome of the disease. These limitations led the researchers to seek a new 
diagnostic paradigm that is able to identify susceptible subjects who are at risk to 
have the disease, reflect the current status of the disease, predict the clinical course 
of the disease and asses its response to treatment. Therefore, the use of oral fluids 
including saliva and GCF gained attention in the diagnosis and monitoring of 
periodontal diseases. In the last 2-3 decades, significant improvements have been 
achieved in the analysis of saliva and GCF samples for the diagnosis of periodontal 
and different oral and systemic diseases (Streckfus and Bigler 2002; Taba et al. 
2005; Ng et al. 2006; Kinney et al. 2007; Ng et al. 2007; Taylor 2014). 
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1.2.1 Gingival crevicular fluid 
The gingival crevice (sulcus) is bathed with a fluid known as the gingival crevicular 
fluid (GCF). GCF can be either a physiological (gingival interstitial) fluid or an 
inflammatory serum exudate that originates from the blood supply of the highly 
vascularized connective tissue adjacent to the epithelial lining of the gingival sulcus. 
As a serum exudate, GCF contains the same normal and inflammatory components 
of the serum such as proteins, enzymes, pro-inflammatory cytokines, prostanoids, 
complement components, antibodies and inflammatory cells such as PMNs and 
plasma cells (Griffiths 2003; Kinney et al. 2007; Gupta 2013; Barros et al. 2016; 
Perunovic et al. 2016; Taylor and Preshaw 2016; Wassall and Preshaw 2016). 
During normal physiological conditions (healthy gingiva) the volumes of the GCF are 
very low, but both the volumes and the inflammatory components of the GCF 
increase during the inflammation of the gingiva and periodontal tissues, where the 
GCF traverses with all its contents into the gingival crevice to overcome the microbial 
challenge of the plaque biofilm (Taylor and Preshaw 2016; Wassall and Preshaw 
2016). Hence, GCF plays a protective role in the host-bacterial interactions by two 
means: First, physical via the dilution of bacteria and their products, as well as, its 
outflow in an attempt to wash out these bacteria and their products. Secondly, 
delivering all the anti-inflammatory and antibacterial components into the site of 
infection within the gingival crevice and periodontal pocket (Armitage 2004b; Lamster 
and Ahlo 2007). 
GCF was discovered accidentally in the late 1950s while investigating the sub-
gingival biofilm from the gingival pockets of a dog (Brill and Krasse 1958; Krasse 
1996), the interest in studying this oral fluid began in the early 1960s (Egelberg 
1963), which evolved rapidly during the 1970s and the first detailed study concerning 
the GCF was published in 1974 (Cimasoni 1974). As its contents reflects the 
inflammatory status of the gingiva and periodontium, along with the non-invasive 
collection procedure and the improvement in the analytical technologies for the very 
small volumes of biological fluids, the analysis of GCF gained the attention of both 
the clinicians and researchers and became a popular tool for the diagnosis of 
periodontal diseases and improved the understanding of their pathogenesis (Lin et al. 
2005; Loos and Tjoa 2005; Bostanci et al. 2007; Fine et al. 2014; Barros et al. 2016; 
Wassall and Preshaw 2016). In addition to its non-invasive collection and the ability 
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to collect more than one sample simultaneously, the major advantage of the GCF 
analysis is that it provides site-specific information about the inflammatory status at 
any particular periodontal site. However, as it is site-specific, GCF analysis may not 
provide comprehensive diagnostic information about the periodontal disease at full 
mouth level unless samples are collected from numerous or all periodontal sites, 
which is indeed costly, time consuming and clinically impractical (Taylor 2014; 
Wassall and Preshaw 2016). 
1.2.2 Saliva 
The oral cavity is bathed with a complex biological fluid known as saliva, comprised 
mainly of water as well as various organic and inorganic components (Chiappin et al. 
2007; Hassona and Scully 2016). Saliva is produced by three pairs of major salivary 
glands (parotid, submandibular, and sublingual), and hundreds of minor salivary 
glands scattered throughout the oral cavity on the buccal, labial and palatal mucosa 
(Veerman et al. 1996; Korte and Kinney 2016). Most of the salivary constituents are 
produced by the major and minor salivary glands; however, there are also non-
salivary components that may pass to saliva from the nearby oral/periodontal tissues 
and circulation through diffusion, active transport and ultrafiltration (Miller et al. 2010). 
Water constitutes about 99% of the total salivary composition. Minerals and ions are 
the inorganic components of saliva. Whereas, the organic part of saliva consists of 
salivary and non-salivary components including mucin, GCF, serum, blood traces, 
proteins, antibodies, enzymes, peptides, desquamated cells, various local and 
systemic body secretions such as nasopharyngeal discharge, extraneous debris, 
bacteria and bacterial by-products and many other constituents (Schenkels et al. 
1995; Zimmermann et al. 2007; Miller et al. 2010; Hassona and Scully 2016; Korte 
and Kinney 2016). 
Saliva performs a number of important physiological functions which are crucial to 
maintain oral health. Besides protecting, lubricating and hydrating the oral mucosa, 
saliva facilitates speech and swallowing, wash out substances from the mouth, 
buffers pH, maintains teeth mineralization, aids in wound healing, digest 
carbohydrates via amylase and neutralizes some harmful dietary components, 
influences the oral flora, and protects against infections by its antimicrobial and 
inflammatory contents (Proctor 2016). The typical salivary flow rate in healthy adults 
ranges between 800-1500 ml/day, which means that saliva is a readily available and 
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abundant biological fluid. Indeed this makes the collection of saliva easy, non-
invasive, painless, inexpensive, and do not require sophisticated techniques and 
highly trained or specialized personnel. However, variations in salivary production 
and flow rate may occur due to factors such as time of day or circadian rhythm, 
duration of collection, temperature, hydration status, individual oral and systemic 
health as well as the emotional status. Saliva can be collected either as unstimulated 
(resting) or stimulated following chewing paraffin wax or applying 2% citric acid onto 
the tongue (Navazesh 1993; Wu et al. 1995; Vissink et al. 1996; Kavanagh et al. 
1998; Ship 2002; Burlage et al. 2005; Kariyawasam and Dawes 2005; Baum et al. 
2011; Hassona and Scully 2016). 
Within the last 2-3 decades the use of saliva as a clinical diagnostic fluid gained 
growing attention and became popular in the diagnosis of different periodontal, oral 
and systemic diseases (Lee and Wong 2009; Zhang et al. 2010a; Pfaffe et al. 2011; 
Liu and Duan 2012; Hassona and Scully 2016). However, some points should be 
considered when using saliva as a diagnostic fluid. For instance, inhibitors and 
enzymes present in saliva may affect or obscure some of the immunologically 
important proteins. Proteases are the most common, they are found to be elevated in 
saliva of periodontitis patients, and may reduce the levels of some proteins and 
biomarkers (Ingman et al. 1993; Ng et al. 2007). Salivary flow rate, oral hygiene 
status, inflammatory conditions such as gingivitis and salivary gland diseases may 
also affect saliva composition and complicate the measurement of some biomarkers. 
Even the method of saliva collection may alter the efficacy of different salivary assays 
(Baum et al. 2011; Genco 2012; Slowey 2013). However, the analysis of salivary 
biomarkers is still common and of great importance in both medicine and dentistry 
(Korte and Kinney 2016). Moreover, the advances in the technologies such as 
proteomics, genomics, metabolomics, and nanotechnology have improved the 
sensitivity and reliability of saliva analysis in the diagnosis and monitoring of oral and 
periodontal diseases and their response to treatment (Denny et al. 2008; Lee et al. 
2009; Al-Tarawneh et al. 2011; Al Kawas et al. 2012; Zhang et al. 2012; Zhang et al. 
2013a). 
In the diagnosis of periodontal diseases, the GCF analysis provides a site specific 
information, but there are limitations to the use of GCF including: the need for trained 
personnel, the time consumed in collection and processing the filter paper stripes 
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used for collection, contamination by gingival bleeding, as well as the limited volumes 
of GCF obtained, all may limit the usefulness of GCF (Taba et al. 2005; Ng et al. 
2007; Buduneli and Kinane 2011; Taylor 2014). In addition to the GCF limitations, the 
advantages of saliva collection especially the non-invasive methods that makes 
saliva sampling convenient for both the patients and clinicians/researchers, and the 
large volumes obtained, favoured saliva sampling over GCF sampling. Furthermore, 
as a biologically rich fluid, whole saliva mostly contains the same biomarkers found in 
GCF, and represents a fluid that contains pooled samples from all periodontal sites. 
Therefore, the analysis of whole saliva provides an overall assessment of the 
periodontal disease status rather than site limited information provided by GCF 
analysis (Miller et al. 2006; Ng et al. 2007; Buduneli and Kinane 2011; Taylor 2014). 
1.3 Biomarkers of periodontal diseases 
Numerous clinical cross-sectional and longitudinal studies, in addition to in vitro and 
in vivo experimental studies, investigated and identified a wide range of pro- and anti-
inflammatory cytokines, chemokines, enzymes, bone metabolic by-products, bacterial 
products, and various other proteins and inflammatory mediators as biomarkers for 
periodontal diseases in periodontal cells, GCF and saliva obtained from patients with 
different periodontal diseases, as well as experimental animals. The identified 
biomarkers were useful in the diagnosis and differentiation of the disease from 
healthy status, evaluation of the disease severity, progression and response to 
treatment by studying the correlations of these biomarkers with the clinical 
periodontal measures. The following sections present salivary and GCF biomarkers 
for periodontal diseases. 
1.3.1 Periodontal diseases biomarkers in GCF 
Various studies utilized GCF as a diagnostic tool for periodontal diseases, thus, 
numerous inflammatory mediators and biomarkers were identified in the GCF. 
Inflammatory cytokines are released from the cells of the junctional epithelium, 
gingival fibroblasts, and the inflammatory cells such as neutrophils, dendritic cells 
and macrophages. Moreover, during the destructive process of periodontitis, 
enzymes such matrix metalloproteinases are released by the fibroblasts, neutrophils 
and osteoclasts (Barros et al. 2016). According to Armitage (2004b), more than 65 
GCF components have been evaluated as diagnostic biomarkers for the progression 
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of periodontitis, and that these biomarkers fall into three categories: host-derived 
enzymes and their inhibitors, inflammatory mediators and host-response modifiers, 
and the tissue breakdown products. Whereas, Loos and Tjoa (2005) reported that 
almost 100 components in the GCF have been evaluated as biomarkers for the 
diagnosis and classification of periodontal diseases, and that these components can 
be serum proteins, antibodies, enzymes, cytokines and different proteins and 
mediators. In their analysis of proteins in human GCF using mass spectrometry, Kido 
et al. (2012) detected 104 proteins in the GCF of healthy and periodontitis sites, 
these proteins were serum, cytoskeleton, immunity, inflammation and lipid-related 
proteins and enzymes, with 63 proteins to be higher in the GCF of periodontitis sites. 
Other study reported that, up 432 different human proteins and 30 bacterial have 
been identified in the GCF of both healthy subjects and chronic periodontitis patients. 
Among these proteins, 120 novel human proteins were identified. Neutrophil 
defensin-1, carbonic anhydrase-1 and elongation factor-1 gamma were among the 
proteins identified in the GCF of periodontitis patients (Baliban et al. 2012). Silva-
Boghossian et al. (2013), identified 214 proteins in the GCF of periodontitis sites and 
154 proteins in the GCF of gingivitis sites obtained from patients with chronic 
periodontitis. 
In their review of host derived periodontal biomarkers, Buduneli and Kinane (2011), 
reported that cytokines and other inflammatory components are detected in the oral 
fluids such as GCF. Early studies by Offenbacher et al. (1984); (Offenbacher et al. 
1986), reported that high levels of PGE2 were detected in GCF of patients with 
chronic and aggressive periodontitis, and that these high PGE2 levels were 
associated with the increased attachment loss, severity and aggressiveness of the 
periodontitis, indicating that PGE2 is biomarker for tissue destruction in periodontal 
diseases. Nakashima et al. (1994), measured the PGE2, alkaline phosphatase (ALP), 
and osteocalcin (OC) levels in the GCF of healthy, gingivitis and periodontitis 
patients. OC is a major component of bone matrix produced by the osteoblasts and 
could be considered as an indicator for alveolar bone degradation. High levels of 
PGE2, ALP and OC were detected in the GCF of the periodontitis patients as 
compared to the gingivitis and healthy subjects, as well as, OC, PGE2 and ALP were 
positively correlated with each other. Nakashima et al. (1994) results suggested 
GCF-PGE2, ALP and OC as potential markers of periodontitis. PGE2 has been 
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detected in higher levels in gingival tissue and GCF proportional to the severity of 
periodontal disease. 
Studies reported that there is a positive correlation between increased GCF levels of 
IL-1β and periodontitis (Engebretson et al. 2002; Barksby et al. 2007; Buduneli and 
Kinane 2011; Chaudhari et al. 2011). Significantly higher concentration of IL-1β, IL-6, 
and β2-microglobulin were found in the GCF of patients with severe periodontitis as 
compared to healthy controls (Mogi et al. 1999). High levels of IL-1β and neutrophil 
elastase (NE) in GCF have been associated with increased levels of gingival 
inflammation in experimental gingivitis studies, which suggested NE as a good 
marker for gingival inflammation (Gonzales et al. 2001; Herrmann et al. 2001). TNF-
α, IL-1β, -6, -8 and -18, were heavily expressed in human gingiva, and high levels 
have been detected in GCF of periodontitis patients (Preiss and Meyle 1994; Boch et 
al. 2001; Graves and Cochran 2003; Toker et al. 2008; Pradeep et al. 2009; 
Fitzsimmons et al. 2010; Teles et al. 2010). High levels of IL-6 and oncostatin M 
(OSM), were detected in GCF of chronic periodontitis patients, and the total amounts 
of IL-6 and OSM were positively correlated with the severity of periodontitis (Lin et al. 
2005). In their study, Silva et al. (2008) followed the progression of periodontal 
destruction in 56 moderate to severe chronic periodontitis patients, and they detected 
significantly higher GCF levels of RANKL, IL-1β, and MMP-13 activity in active sites 
than the inactive sites. IL-11 and IL-17 levels were investigated in GCF of 40 chronic 
periodontitis patients and 20 healthy controls. The IL-11/IL-17 ratio was significantly 
higher in the healthy subjects than the periodontitis patients, whereas shallow 
pockets in the periodontitis patients demonstrated higher ratios than the deep 
pockets in the same patients. These results suggested that, periodontal destruction 
in periodontitis may be attributed to an imbalance in the pro- and anti-inflammatory 
cytokines (Yetkin Ay et al. 2009). A cross-sectional study carried out on 20 chronic 
periodontitis patients, 17 generalized aggressive periodontitis patients and 10 
gingivitis patients. The study revealed that the GCF IL-1β levels and elastase activity 
were higher in the deep pockets as compared to the shallow pockets in the 
periodontitis patients. The results suggested that these two biomarkers might be 
helpful to indicate the periodontal tissue destruction (Rescala et al. 2010). 
Growth factors were among the biomarkers detected in GCF of patients with different 
periodontal diseases. Growth factors, have various activities which may overlap and 
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participate in the immune responses (Taylor 2014). High levels of growth factors such 
as transforming growth factor –alpha and -beta (TGF-α, -β), epidermal growth factor 
(EGF), hepatocyte growth factor (HGF) and vascular endothelial growth factor 
(VEGF) were found in GCF of patients with periodontal diseases (Chang et al. 1996; 
Uematsu et al. 1996; Skaleric et al. 1997; Booth et al. 1998; Mogi et al. 1999; 
Kakimoto et al. 2002; Ohshima et al. 2002; Ohnishi and Daikuhara 2003). 
Different types of matrix metalloproteases and their inhibitors have been detected in 
the GCF of patients with periodontal diseases (Golub et al. 1997; Kinane et al. 2003; 
Buduneli and Kinane 2011; Kinney et al. 2014). Higher levels of MMP-8 and MMP-9 
were detected in the GCF of chronic periodontitis patients as compared to localized 
aggressive periodontitis (LAgP) patients and healthy controls. Whilst, significantly 
elevated levels of MMP-1 and tissue inhibitor of MMP-1 (TIMP-1) were detected in 
the GCF of the LAgP patients as compared to the chronic periodontitis patients and 
healthy controls. Moreover, no difference was found in the GCF MMP-3 levels among 
the three groups (Ingman et al. 1996). In addition to MMP-8, Golub et al. (1997) 
found high levels of MMP-13 in GCF samples of periodontitis patients. Chen et al. 
(2000), detected high levels of MMP-8 and neutrophil elastase in the GCF of 
periodontitis patients, and that the MMP-8 levels reduced significantly following 
treatment. High levels of GCF MMP-3, and TIMP-1 were found in periodontitis sites 
as compared to healthy sites in 40 subjects monitored over a 6 month period, which 
indicated the high risk for periodontal disease progression at the diseased sites 
(Alpagot et al. 2001). The GCF MMP-8 can be used to differentiate periodontitis from 
gingivitis and healthy sites, as well as, to monitor the response to treatment in 
chronic periodontitis patients (Mantyla et al. 2003). Additionally, Kinane et al. (2003) 
reported that the GCF MMP-8 levels were significantly reduced in chronic 
periodontitis patients following non-surgical periodontal treatment. The GCF MMP-8 
and -9 activities were positively correlated with the periodontal disease severity which 
was negatively correlated with TIMP-1, -2 levels (Pozo et al. 2005). 
High levels of MMP-7, TIMP-1, and extracellular matrix metalloproteinase inducer 
(EMMPRIN) were detected in GCF of patients with different periodontal diseases, 
indicating that these proteins are engaged in the progression of periodontal diseases 
(Emingil et al. 2006b). In another study, Emingil et al. (2006a) demonstrated higher 
levels and activities of both MMP-25 and -26 in the GCF of chronic and generalised 
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aggressive periodontitis (GAgP) patients as compared to gingivitis and healthy 
subjects, and that these MMP-25/-26 levels and activities were associated with the 
severity of periodontal inflammation, indicating that these novel MMPs may play a 
role in the progression of periodontal diseases, and suggesting them as 
diagnostically useful biomarkers. Significantly high GCF levels and activity of MMP-
13 were reported in active sites of periodontitis patients, suggesting that MMP-13 
could serve as a biomarker for the disease progression (Hernandez et al. 2006). In 
their study, Beklen et al. (2006) reported that the GCF MMP-8 and -9 levels were 
positively correlated with the disease activity in chronic periodontitis patients. Though 
the mean levels were reduced following treatment, persistently high levels of GCF 
MMP-8 were detected in sites with progressive periodontitis among smokers and 
non-smoking periodontitis patients, indicating the sites at high risk, as well as, the 
patients with poor response to non-surgical periodontal treatment, suggesting MMP-8 
as a useful biomarker to follow the response to treatment in periodontal diseases 
(Mantyla et al. 2006). 
A statistically significant association was found between the GCF MMP-8 
concentrations from shallow gingival crevices and the extent of attachment loss, an 
association which suggested the GCF MMP-8 as a prognostic biomarker for 
attachment loss in periodontal diseases (Passoja et al. 2008). High levels and activity 
of MMP-13 were detected in GCF samples obtained from active periodontitis sites of 
patients with moderate and advanced periodontitis (Silva et al. 2008). Rai et al. 
(2008), reported that higher levels of MMP-9 were found in GCF of periodontitis 
patients in comparison to gingivitis and healthy subjects, as well as, higher levels of 
GCF MMP-2 were detected in the gingivitis patients in comparison to the periodontitis 
and healthy subjects, Rai et al. (2008) also found that the GCF MMP-2 and -9 were 
positively correlated with both the probing depth and gingival bleeding suggesting 
these 2 GCF MMPs as biomarkers for periodontal diseases and that they may aid in 
the early detection of periodontitis and gingivitis. The high GCF levels of MMP-9 and 
-13 found within the active sites of moderate and advanced chronic periodontitis 
patients, led Hernandez Rios et al. (2009) to suggest these proteases as useful 
biomarkers for the progression of tissue destruction in periodontitis. By the end of a 6 
months monitoring phase, high levels of MMP-8, MMP-9, OPG and IL-1β were 
detected in GCF samples of patients with progressive periodontitis as compared to 
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more stable patients, suggesting this panel of biomarkers as a sensitive tool to 
distinguish patients with risk of progressive periodontitis from those who are more 
stable or responding positively to treatment (Kinney et al. 2014). 
In addition to the MMPs, other inflammatory mediators, cells, proteins and enzymes 
were also investigated in the GCF of patients with different periodontal diseases. 
Neutrophil elastase (NE) is one of the most destructive proteolytic enzymes which 
has the ability to degrade almost all extracellular matrix components as well as 
plasma proteins, activates pro-MMPs and inactivates TIMP-1. High levels of this 
elastase was detected in the GCF of patients and subjects with different periodontal 
conditions (Meyle et al. 1992; Eley and Cox 1996; Sorsa et al. 2006; Geraghty et al. 
2007). In a longitudinal study, Eley and Cox (1996) showed that the increased levels 
and activity of elastase in the GCF of periodontitis patients was predictive for 
attachment loss. Furthermore, the long term follow up of the patients undergoing 
supportive periodontal treatment by Eley and Cox (1996), revealed that the GCF 
elastase was positively correlated with the attachment loss. Elastase and other 
enzymes were also investigated in the GCF of patients with periodontal diseases. In 
their study, Cox and Eley (1992) analysed cathepsin B/L, elastase, tryptase, trypsin, 
and dipeptidyl peptidase (DPP) IV-like activities in GCF samples obtained from 20 
chronic periodontitis patients before and after non-surgical treatment. They found that 
the levels and activities of these enzymes were significantly higher in the pre-
treatment status as compared to the post-treatment status, and that the enzymes 
levels and activities were positively and significantly correlated with the periodontal 
parameters of the patients. Therefore, Cox and Eley (1992) suggested these GCF 
proteases as useful markers to reflect the clinical status of periodontal lesions and 
may be beneficial in monitoring the disease activity. Another study by Eley and Cox 
(1995), reported that the significantly high levels of DPP II/IV, total activity and 
concentration found in the GCF obtained from 120 sites with rapid and gradual 
attachment loss in 48 periodontitis patients may be predictors for periodontal 
attachment loss. 
β-Glucuronidase is a proteolytic enzyme released from neutrophils lysosomes, and 
its’ action is the degradation of proteoglycans and the ground substance (Lamster et 
al. 2003). Number of studies investigated the β-glucuronidase levels and activity in 
the GCF of patients with different periodontal diseases especially chronic and 
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aggressive periodontitis. The studies revealed that the levels and activity of this 
enzyme were significantly increased in the GCF of periodontal diseases patients, and 
were positively correlated with the clinical periodontal parameters. Therefore, the 
results of these studies suggested β-glucuronidase as a useful biomarker for the 
PMNs activity, loss of attachment, detection of active periodontitis sites and the 
progression of the disease (Lamster et al. 1988; Lamster et al. 1994; Lamster et al. 
1995; Lamster et al. 1996; Albandar et al. 1998a; Layik et al. 2000; Lamster et al. 
2003). 
The degradation of the collagen matrix in the ECM and ground substance by the 
action of proteolytic enzymes such as MMPs, will result in the release of collagen 
fragments or peptides into the circulation, these substances were assayed as 
diagnostic markers for bone turnover in periodontitis (Giannobile 1997; Giannobile et 
al. 2003). One of these markers is the C-telopeptide pyridinoline cross-links of type-1 
collagen (ICTP), several experimental and clinical studies investigated the levels of 
this marker in the GCF of patients with periodontitis. High levels of GCF ICTP were 
detected in periodontitis patients, and these high levels were positively correlated 
with the clinical parameters of periodontal tissues destruction (Talonpoika and 
Hamalainen 1994; Giannobile et al. 1995; Golub et al. 1997; Shibutani et al. 1997; 
Palys et al. 1998). 
1.3.2 Salivary biomarkers for periodontal diseases 
Saliva contains constituents from the salivary glands, GCF and dental plaque from all 
periodontal sites, as well as it is readily available, easily collected and abundant 
when compared to GCF. Hence, the interest in saliva analysis for the diagnosis and 
monitoring of periodontal diseases is growing and gaining popularity. Numerous 
studies investigated and identified several biomarkers and inflammatory mediators in 
saliva of patients with different periodontal diseases (Kaufman and Lamster 2000; 
Kinane and Chestnutt 2000; Lamster et al. 2003; Kinney et al. 2007; Buduneli and 
Kinane 2011; Taylor 2014; Korte and Kinney 2016; Taylor and Preshaw 2016). The 
proper diagnosis, differentiation, prediction and follow up of periodontal diseases in 
response to treatment, require the consideration of the disease complex 
pathogenesis and progression. Therefore, Korte and Kinney (2016), suggested that 
the host-derived biomarkers can be divided according to the three phases of 
periodontal diseases: inflammation, connective tissue degradation, and bone 
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turnover. In addition to the periodontal bacteria and their products. Hence, the 
identified biomarker or mediator may offer an indication about the current status and 
what stage of the disease pathogenesis the patient is experiencing. However, some 
of the biomarkers may play roles in both inflammation and tissue degradation, others 
may be associated with both inflammation and bone resorption (Korte and Kinney 
2016). 
In respect to the biomarkers of inflammation, numerous studies investigated the 
relations of several cytokines such as interleukins with the periodontal diseases 
pathogenesis. In particular, it has been shown that IL-1β demonstrated high levels in 
saliva of patients with periodontal diseases especially periodontitis (Tobon-Arroyave 
et al. 2008; Fine et al. 2009; Gursoy et al. 2009; Mirrielees et al. 2010; Ebersole et al. 
2013; Taylor 2014; Jaedicke et al. 2016; Korte and Kinney 2016). Evidence derived 
from several studies, strongly correlated salivary IL-1β with the progression of 
periodontal diseases suggesting this interleukin as a good biomarker for periodontitis 
and can be useful to discriminate periodontitis patients from healthy subjects as well 
as active periodontal sites from healthy or inactive sites (Miller et al. 2006; Tobon-
Arroyave et al. 2008; Gursoy et al. 2009; Gursoy et al. 2011; Kaushik et al. 2011; 
Ebersole et al. 2013; Rathnayake et al. 2013). For instance, several studies revealed 
that there were significantly positive correlations between the high levels of salivary 
IL-1β and the clinical periodontal measures of periodontal diseases including: 
bleeding on probing, gingival and plaque indices, and clinical attachment loss (Miller 
et al. 2006; Kaushik et al. 2011; Kinney et al. 2011; Sexton et al. 2011; Yoon et al. 
2012; Rathnayake et al. 2013; Salminen et al. 2014). Longitudinal studies revealed 
that the IL-1β levels in saliva of periodontitis patients reduced significantly in 
response to periodontal treatment (Kaushik et al. 2011; Kinney et al. 2011; Sexton et 
al. 2011). Moreover, studies also demonstrated that salivary IL-1β levels were 
positively associated with the extent of alveolar bone loss (Ng et al. 2007; 
Scannapieco et al. 2007; Fine et al. 2009). Nevertheless, some studies reported that, 
though IL-1β was detected in saliva of periodontitis patients, but there was no 
significant difference in its levels as compared to control groups (Christodoulides et 
al. 2007; Ramseier et al. 2009; Teles et al. 2009). For example,Teles et al. (2009) 
found that the mean salivary levels of IL-1β were not able to discriminate between 
periodontitis and healthy status. 
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Most of the available studies revealed that, there was no statistically significant 
difference in the salivary IL-6 levels between periodontitis patients and healthy 
controls and that the salivary IL-6 levels were not associated with the periodontitis 
clinical measures or the alveolar bone loss (Ng et al. 2007; Scannapieco et al. 2007; 
Gursoy et al. 2009; Ramseier et al. 2009; Teles et al. 2009; Rathnayake et al. 2013). 
However, other studies reported high levels of salivary IL-6 in periodontitis patients 
(Costa et al. 2010; Ebersole et al. 2013; Prakasam and Srinivasan 2014). Other 
interleukins were also investigated in saliva of patients with periodontal diseases. 
Three studies found that IL-4, -17A, -17E, IL-17A/E ratio and IL-18 were significantly 
elevated in saliva of periodontitis patients and were positively correlated with the 
clinical parameters of periodontitis (Ozcaka et al. 2011b; Awang et al. 2014; 
Prakasam and Srinivasan 2014). Other studies reported that IL-2, -3, -4, -8, -9, -10, -
12, -13, -17, and -33 were detected in saliva of periodontitis patients but their levels 
were either lower than the control subjects or the difference was not statistically 
significant, and that they were not associated with the alveolar bone loss and the 
periodontal measures, on the other hand, some interleukins such as IL-5 were not 
detected by some studies (Vastardis et al. 2003; Scannapieco et al. 2007; Fine et al. 
2009; Ramseier et al. 2009; Teles et al. 2009; Ozcaka et al. 2011b; Sexton et al. 
2011; Buduneli et al. 2012; Rathnayake et al. 2013; Prakasam and Srinivasan 2014). 
Though some studies reported the detection of TNF-α in saliva of patients with 
periodontal diseases, the TNF-α levels were either lower than the control subjects or 
the difference between them was not statistically significant, and no association was 
found between the salivary TNF-α levels and any periodontitis parameter. Whereas, 
other studies were not able to detect TNF-α in saliva of periodontitis patients. 
Subsequently, the studies’ results indicated that the salivary TNF-α may not be useful 
as a biomarker for periodontitis (Gursoy et al. 2009; Ramseier et al. 2009; Teles et al. 
2009; Mirrielees et al. 2010; Ebersole et al. 2013; Rathnayake et al. 2013). However, 
one study reported significantly higher levels of TNF-α in saliva of periodontitis 
patients in comparison to control subjects (Frodge et al. 2008). Another study which 
was longitudinal, revealed that the salivary TNF-α levels were significantly reduced in 
periodontitis patients following periodontal treatment (Sexton et al. 2011). 
Though interferon gamma (IFN-γ) was detected in saliva of HIV patients with 
periodontitis, but their levels were not statistically different in comparison to healthy 
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controls (Vastardis et al. 2003). It has been reported that the salivary levels of IFN-γ 
were not associated with the amount of alveolar bone loss (Scannapieco et al. 2007). 
On the other hand, Ramseier et al. (2009) were not able to detect IFN-γ in saliva of 
periodontitis and gingivitis patients. Further to IL-1β, -2, -4, -5, -6, -8, -10, and TNF-α, 
the salivary levels of granulocyte-macrophage colony-stimulating factor (GM-CSF), 
and IFN-γ in periodontitis patients were not statistically different when compared to 
healthy control subjects (Teles et al. 2009). In their longitudinal study of children who 
were at risk of LAgP, Fine et al. (2009) also detected GM-CSF and IFN-γ in saliva of 
children who developed lesions with bone loss but the difference was not statistically 
significant in comparison to those who remain healthy. 
Macrophage inflammatory protein-1α (MIP-1α) was also investigated in saliva of 
patients with periodontal diseases. The salivary MIP-1α levels were elevated in 
children who were at risk of LAgP and developed lesions with bone loss in 
comparison to healthy controls (Fine et al. 2009). The association of MIP-1α with the 
bone loss in periodontitis was confirmed again in another longitudinal study by Fine 
et al. (2014) when they detected high levels of MIP-1α in saliva of adolescents who 
were at risk of aggressive periodontitis and developed lesions with bone loss. 
Another longitudinal study carried out by Sexton et al. (2011), reported that the 
salivary MIP-1α levels reflected the severity of periodontitis and they were reduced in 
response to periodontal treatment, suggesting the salivary MIP-1α as a potential 
biomarker for periodontitis. Al-Sabbagh et al. (2012), reported high levels of MIP-1α 
in saliva of periodontitis patients in comparison to healthy controls, and the salivary 
MIP-1α levels were positively correlated with the periodontitis clinical measures. A 
longitudinal study investigated the levels and the role of the inflammatory chemokine 
monocyte chemoattractant protein-1 (MCP-1) in chronic periodontitis, it was found 
that the salivary MCP-1 levels were significantly higher in the periodontitis patients in 
comparison to the healthy controls, and the levels were positively correlated with the 
periodontitis clinical measures. Furthermore, the salivary MCP-1 levels were 
significantly reduced in response to treatment (Gupta et al. 2013). 
Though high levels of the growth factors TGF-β, EGF and VEGF were detected in 
GCF of periodontitis patients, there are limited studies which investigated the same 
growth factors in saliva of periodontitis patients (Taylor 2014; Jaedicke et al. 2016). 
VEGF is known to play a role in the angiogenesis of both healthy and diseased 
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tissues, it has been shown that the VEGF levels were significantly elevated in saliva 
of periodontitis patients as compared to healthy controls, which suggested that the 
periodontal disease status influence the salivary VEGF levels (Booth et al. 1998). It 
has been shown that HGF is secreted by human gingival fibroblasts and this 
production is in response to, and regulated by the inflammatory cytokines and 
bacterial products (Sugiyama et al. 1996; Sugiyama et al. 2000; Ohshima et al. 
2001). Studies reported that HGF may enhance the production of the MMPs, and 
stimulates the wound healing through vascularization and keratinocyte proliferation, 
additionally it has been hypothesized that HGF may drive the apical migration of 
epithelial cells in periodontitis (Dunsmore et al. 1996; Sugiyama et al. 1996; 
Matsumoto and Nakamura 1997; Ohshima et al. 2001; Kakimoto et al. 2002; Ohnishi 
and Daikuhara 2003). Moreover, a recent study reported that HGF play roles as a 
regulator of inflammation and autoimmunity (Molnarfi et al. 2015). Salivary HGF 
levels were investigated in four independent studies. Significantly higher levels of 
salivary HGF were detected in periodontitis patients as compared to healthy control 
subjects, and the salivary HGF levels were positively correlated with the gingival, 
plaque, and papillary bleeding indices, suggesting salivary HGF as a potential 
biomarker for periodontitis (Wilczynska-Borawska et al. 2006). A longitudinal study of 
5-year time period, reported a positive association between the salivary HGF levels 
and the extent of bone loss in periodontitis (Scannapieco et al. 2007). The salivary 
HGF levels were significantly elevated in patients with moderate and severe 
periodontitis in comparison to healthy controls (Rudrakshi et al. 2011). Once again, 
Wilczynska-Borawska et al. (2012), reported that significantly higher levels of salivary 
HGF were found in periodontitis patients as compared to healthy control subjects, 
and that the salivary HGF levels were positively correlated with the gingival, plaque, 
and papillary bleeding indices, which confirmed the results of their previous study 
(Wilczynska-Borawska et al. 2006). 
Several studies investigated the biomarkers of connective tissue destruction in saliva 
of patients with periodontal diseases. The MMPs are the most important enzymes 
associated with the destruction of the supporting periodontal tissues. In agreement 
with the GCF studies, the salivary neutrophil collagenase (MMP-8) was the target of 
several studies. Data derived from studies reported significantly elevated levels and 
activity of MMP-8 in saliva of periodontitis patients, as well as positive correlations of 
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the salivary MMP-8 with increased bleeding on probing, clinical attachment loss and 
periodontal pocket depth (Iijima et al. 1983; Gangbar et al. 1990; Hayakawa et al. 
1994; Makela et al. 1994; Ingman et al. 1996; Matsuki et al. 1996; Miller et al. 2006; 
Herr et al. 2007a; Rai et al. 2008; Ramseier et al. 2009; Costa et al. 2010; Gursoy et 
al. 2010; Mirrielees et al. 2010; Kinney et al. 2011; Ebersole et al. 2013; Rathnayake 
et al. 2013; Miricescu et al. 2014). The salivary MMP-2 (gelatinase-A) and MMP-9 
(gelatinase-B) and elastase were also investigated in relation to periodontal 
diseases, studies reported that their levels were significantly higher in periodontitis 
patients as compared to healthy subjects (Makela et al. 1994; Pederson et al. 1995; 
Shetty and Pattabiraman 1998; Ramseier et al. 2009; Isaza-Guzman et al. 2011; 
Kinney et al. 2011). However, some studies found that there were no differences in 
the salivary MMP-9 and elastase levels between periodontitis patients and healthy 
controls (Ingman et al. 1996; Gursoy et al. 2009). In respect to MMP-1 (fibroblast or 
interstitial collagenase) and MMP-3 (stromelysin-1), and MMP-14 (a membrane type 
MMP), no evidence has been reported about the association of these MMPs with 
periodontitis (Ingman et al. 1996; Gursoy et al. 2010; Taylor 2014). 
A study of the collagenase activity in whole saliva of both healthy subjects and 
periodontitis patients revealed that, the total activity in saliva of the healthy controls 
was in the form of the inactive pro-collagenase, whereas the activity in the whole 
saliva of periodontitis patients was mainly in the form of the active collagenase 
(Hayakawa et al. 1994). Moreover, the TIMP-1 levels were higher in the healthy 
controls as compared to the periodontitis patients, which indicates the higher 
collagenase activity and low inhibition activity in periodontitis (Hayakawa et al. 1994). 
Two other studies also reported that the TIMP-1 levels were significantly higher in 
saliva of healthy subjects in comparison to periodontitis patients (Gursoy et al. 2010; 
Isaza-Guzman et al. 2011). Nevertheless, one study reported that there were no 
statistically significant differences in the levels of both TIMP-1 and MMP-1 in saliva of 
chronic and LAgP periodontitis patients in comparison to healthy controls (Ingman et 
al. 1996). 
In comparison to GCF, there are limited longitudinal studies that measured the levels 
of MMPs in saliva of periodontitis patients following the natural progression of the 
disease and in response to treatment. In their longitudinal study carried out on 66 
chronic periodontitis patients who received 2 modes of treatment, Gorska and Nedzi-
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Gora (2006), reported high levels of salivary MMP-8, MMP-9, TIMP-1, as well as 
MMP-8/TIMP-1 and MMP-9/TIMP-1 ratios in the patients prior to treatment. After 
treatment, only the salivary MMP-9/TIMP-1 ratio was significantly reduced in the 33 
patients who received the periostat treatment (scaling and root planning + 20 mg 
doxycycline twice daily) as compared to the pre-treatment status. Whereas the other 
33 patients who received the conventional treatment (scaling and root planning only) 
demonstrated significantly reduced levels of both the salivary MMP-8 and salivary 
MMP-8/TIMP-1 ratio as compared to the pre-treatment levels (Gorska and Nedzi-
Gora 2006). The salivary MMP-9 levels were also reduced in the patients who 
received the conventional treatment more than those who received the periostat 
treatment; however, the difference was not significant as compared to the pre-
treatment levels. In contrast to the MMPs, the salivary TIMP-1 levels were 
significantly elevated following the periostat treatment as compared to the pre-
treatment levels, but not after the conventional treatment (Gorska and Nedzi-Gora 
2006). 
A cohort study monitored periodontitis in 219 subjects over a 4-year period, during 
which time they didn’t receive any dental treatment (Kibayashi et al. 2007). The study 
used a multiple logistic model to follow the periodontitis progression in relation to 
smoking, the model involved measuring the changes in periodontal pocket probing 
depth as compared to levels of salivary biomarkers and other lifestyle factors. This 
logistic model revealed that among the lifestyle factors the smoking habit exerted the 
greatest influence on periodontitis risk, and the disease progression was related to 
smoking habit but not to the levels of any of the 9 proteins biomarkers combination 
(IL-1β, MMP-8, MMP-9, lactoferrin, IgA, albumin, aspartate aminotransferase AST, 
lactate dehydrogenase LDH, and alkaline phosphatase ALP) (Kibayashi et al. 2007). 
The levels of salivary lactoferrin, AST, and LDH were significantly reduced in 
smokers, a finding concordant with the well-known immunosuppressive effects of 
smoking on the host-defence system, which may promote periodontitis progression 
(Nishida et al. 2006; Kibayashi et al. 2007). 
A case-controlled longitudinal study carried out on 68 adult patients with chronic 
periodontitis, in which 33 patients received oral hygiene instructions (OHI) alone and 
35 treated with scaling and root planning (SRP) combined with OHI (Sexton et al. 
2011). The salivary levels of MMP-8 and OPG (along with the previously mentioned 
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IL-1β, IL-8, MIP-1α, and TNF-α) were measured before treatment and after treatment 
at weeks 16 and 28. The periodontal health was improved in both treatment groups, 
and the salivary levels of MMP-8 and OPG (as well as the other biomarkers) were 
significantly reduced following treatment in the SRP treated patients as compared to 
the OHI group. The study revealed that the salivary levels of all the biomarkers 
especially MMP-8 (excluding IL-8) reflected the periodontitis severity and response to 
treatment, suggesting them as useful biomarkers for monitoring periodontitis status 
(Sexton et al. 2011). 
Another longitudinal study investigated the role of a panel of potential salivary 
biomarkers and periodontal pathogens in the progression of periodontitis in a cohort 
of 100 participants during 1 year (Kinney et al. 2011). First, there was a 6 month-
monitoring phase, during which the participants received no treatment. As compared 
to baseline, during the monitoring phase neither the periodontal status nor the 
salivary biomarkers levels in the participants were significantly changed. By the end 
of the monitoring phase, the participants received appropriate treatment, followed by 
a 6-month “disease-recovery” phase during which the disease recovery and 
progression were monitored. By the end of the 12 months, the study revealed that 
the levels of salivary MMP-8, MMP-9, OPG, as well as IL-1β were significantly 
reduced following treatment in participants with moderate to severe periodontitis 
(Kinney et al. 2011). Two studies reported the significant reduction of active 
collagenase in saliva of both localized juvenile (aggressive) periodontitis and adult 
(chronic) periodontitis in response to surgical and non- surgical periodontal treatment 
(Gangbar et al. 1990; Uitto et al. 1990). 
In regard to the ability of salivary MMPs to differentiate periodontitis patients from 
gingivitis and healthy subjects, to determine the severity and extent of periodontitis, 
and to evaluate the response to periodontal treatment, it looks like the salivary MMP-
8 to be the best among the other MMPs, as well as a better biomarker for 
periodontitis than other mediators such as IL-1β (Rathnayake et al. 2013). A previous 
study reported that the combined elevated salivary levels of MMP-8 and IL-1β were 
positively correlated with the clinical periodontitis measures and increased the risk for 
experiencing periodontal disease 45-fold (Miller et al. 2006). As compared to IL-1β, 
MIP-1α, OPG and TNF-α, the receiver operating characteristic curve (ROC) analysis 
revealed that the salivary MMP-8 had the highest area under the curve value (0.7, 
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p=0.01) and was the best to discriminate patients who responded to treatment from 
those who didn’t (Sexton et al. 2011). Using the ROC analysis, it was found that a 
combination of salivary biomarkers and periodontal pathogens augmented the 
prediction of disease category. The combination of salivary MMP-8, -9 and OPG 
analysis along with the anaerobic periodontal bacteria P. gingivalis and T. denticola 
analysis, provided more precise predictions of periodontal disease category, and the 
combination of the elevated salivary MMP-8 and T. denticola biofilm levels was the 
best in predicting periodontal disease severity (Ramseier et al. 2009). The ROC 
analyses of the combination (IL-1β, IL-6 and MMP-8) demonstrated high areas under 
the curves (0.963-0.984) indicating good discrimination of periodontitis from health 
status, these results indicated that the biomarker panel comprising IL-1β, MMP-8 and 
IL-6 have a particular diagnostic potential (Ebersole et al. 2013). A recent study 
reported that salivary MMP-8 can be used alone or together with IL-1β and P. 
gingivalis to calculate the cumulative risk score of periodontitis at the subject level as 
an efficient diagnostic tool, which can be useful in large-scale public health surveys 
when a full periodontal examination is inapplicable (Sorsa et al. 2016). 
During the active phase of periodontitis which is associated with death of cells, a 
number of enzymes, proteins and other molecules will be released into the 
surrounding tissues making these molecules viable markers of disease activity, one 
of these enzymes is the soluble cytoplasmic enzyme aspartate aminotransferase 
(AST) (Page 1992). A number of studies investigated the relation between the 
elevated levels of salivary AST and periodontitis, results of such studies linked the 
progression of periodontitis as defined by gingival bleeding, pocket depth, and 
suppuration with the elevated levels of salivary AST (Todorovic et al. 2006; Totan et 
al. 2006). Other studies investigated the effects of periodontal treatment on the 
salivary AST levels, the studies reported that the salivary AST levels decreased 
significantly in response to non-surgical periodontal treatment (Nomura et al. 2006; 
Miller et al. 2010; Nomura et al. 2012). In addition to AST, other host derived 
enzymes related to cellular damage and inflammation such as alkaline phosphatase 
(ALP), lactate dehydrogenase (LDH), and alanine transferase (ALT), have been 
studied as salivary biomarkers for the detection and progression of periodontitis. 
Studies reported evidence for the association of elevated salivary levels of these 
enzymes with the progression of periodontitis and its clinical measures such as 
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periodontal pocket depth, and gingival bleeding (Cesco Rde et al. 2003; Nomura et 
al. 2006; Totan et al. 2006; Zappacosta et al. 2007; Gursoy et al. 2008; Kugahara et 
al. 2008; Miller et al. 2010; Nomura et al. 2012). However, one study reported no 
association between the salivary ALP, AST, and ALT with periodontitis (Nomura et al. 
2006), another study didn’t find a relation between salivary LDH and periodontitis 
(Gursoy et al. 2009). 
Biomarkers of alveolar bone turnover/resorption such as the cytokines RANKL, OPG, 
osteocalcin, and calprotectin have been investigated in saliva of patients with 
periodontal diseases (Giannobile et al. 2003; Miller et al. 2006; Buduneli and Kinane 
2011; Korte and Kinney 2016). A number of cross-sectional studies reported 
significantly elevated levels of RANKL in saliva of periodontitis patients as compared 
to healthy controls (Buduneli et al. 2008; Tobon-Arroyave et al. 2012; Tabari et al. 
2013). However, one study was not able to find significant differences in the salivary 
RANKL levels between periodontitis patients and healthy controls (Frodge et al. 
2008). Other studies investigated OPG which plays a role in preventing bone 
resorption and acts as a neutralizing receptor for RANKL (Cappellen et al. 2002). The 
ratio of RANKL/OPG plays a crucial role in the bone resorption and reconstruction 
(Cappellen et al. 2002; Jin et al. 2007). Significantly lower levels of OPG have been 
found in saliva of periodontitis patients as compared to healthy controls (Ramseier et 
al. 2009; Tobon-Arroyave et al. 2012). Other studies didn’t find significant differences 
in the salivary OPG levels between periodontitis patients and healthy controls (Miller 
et al. 2006; Frodge et al. 2008; Costa et al. 2010; Kinney et al. 2011; Tabari et al. 
2013). Few longitudinal studies demonstrated that the salivary OPG levels declined 
significantly in response to periodontal treatment (Kinney et al. 2011; Sexton et al. 
2011). 
In regard to the other bone regulating cytokines and molecules such as the neutrophil 
protein calprotectin, it was found that the salivary levels of this marker to be 
increased in periodontitis patients (Ramseier et al. 2009). Whereas, Kinney et al. 
(2011), found that both the healthy controls and the periodontitis patients 
demonstrated significantly elevated salivary calprotectin levels by the end of their 12 
month-period longitudinal study as compared to baseline. Studies reported 
inconsistent evidence regarding the association of both salivary osteonectin and 
osteocalcin with periodontitis (Bullon et al. 2005; Bullon et al. 2007; Burton 2007; 
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Ozcaka et al. 2011a; Miricescu et al. 2014). Moreover, a 5-year period longitudinal 
study demonstrated a negative association between the salivary osteonectin levels 
and the extent of alveolar bone loss (Scannapieco et al. 2007). 
Peptides represent other markers for bone turnover, they are released as a result of 
alveolar bone and collagen destruction. Among these peptides is the ICTP, which is 
a specific marker for alveolar bone deterioration and considered as a potentially 
useful indicator to discriminate periodontitis from gingivitis patients (Taylor 2014; 
Korte and Kinney 2016). Some studies reported elevated salivary levels of ICTP in 
periodontitis patients as compared to healthy controls and that these elevated ICTP 
levels were positively correlated with the clinical measures of periodontitis (Gursoy et 
al. 2010; Ozcaka et al. 2011a; Gursoy et al. 2013). However, other studies were not 
able to detect ICTP in saliva of periodontitis patients (Ng et al. 2007; Frodge et al. 
2008; Ramseier et al. 2009; Al-Sabbagh et al. 2012). 
1.4 Proteomics and biomarkers identification 
1.4.1 Proteomics in the diagnosis of periodontal diseases 
The majority of the published literature on salivary and GCF biomarkers for 
periodontal diseases indicate that these biomarkers were selected for investigation 
on the basis of their previously known roles in immunity and inflammation, and they 
were identified by techniques such as ELISA, western blot, polymerase chain 
reaction techniques (PCR), immunohistochemistry, microbiological techniques and 
others. Despite the fact that they are well-known, verified, reliable, and improvements 
are continually introduced to these techniques, they always need candidate 
biomarkers and they can detect a limited number of proteins or cytokines in saliva 
and GCF samples. Hence, there is a need for more open and unbiased approaches 
to identify biomarkers for diseases with complex pathogenesis such as periodontal 
diseases (Haigh et al. 2010; Taylor 2014). There is a growing interest to use 
alternative techniques such as genomics, proteomics and other advanced 
approaches that are able to identify changes in genes, and proteins. These advanced 
techniques do not require candidate proteins and can concurrently identify wide 
range of proteins in one sample (Haigh et al. 2010). Therefore, proteomics offers the 
potential to identify numerous disease associated proteins (Xie et al. 2011; Zhang et 
al. 2013a; Taylor 2014). Proteomics can be defined as “the study of protein 
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properties on a large scale to achieve more extensive vision about diseases 
processes, cellular processes and networks at the protein level” (Blackstock and Weir 
1999), or as “the large-scale study of proteins, especially their structures and 
functions”  (Zhang et al. 2010b). The term proteome is an admixture of protein and 
genome, the concept of proteome was first coined by the PhD student Marc Wilkins 
in 1994 (Wilkins et al. 1996). Whereas, the term proteomics was first introduced in 
1997 to make an analogy with genomics which studies the genome (James 1997). 
Diverse proteomic techniques have been used to analyse the protein content of 
saliva both qualitatively and quantitatively (Xiao and Wong 2010). Denny et al. 
(2008), reported that the identified salivary proteome comprises the sum of 1166 
proteins. However, substantial improvements and modifications have been and are 
always introduced to the proteomic analysis of saliva such as using a combination of 
advanced techniques for protein separation, as well as advances in the spectrometry 
technologies using liquid chromatography-mass spectrometry (LC-MS) quantitative 
protocols (Xiao and Wong 2010; Xie et al. 2011), therefore, it is expected to identify 
more salivary proteins in the future. In the last 2 decades, various studies used 
proteomics to identify and investigate salivary and GCF protein biomarkers for 
periodontal diseases (Haigh et al. 2010; Taylor 2014). Salivary proteomic studies 
might reveal high quality diagnostic and prognostic protein biomarker signatures, 
such biomarkers may help in the diagnosis, personalizing treatment paths and 
monitoring patients with high susceptibility for periodontitis in their young adulthood 
before the clinical onset of tissue destruction associated with periodontitis 
(Giannobile et al. 2009; Kornman and Duff 2012; Salazar et al. 2013). 
One of the earliest studies that used proteomics in the diagnosis of periodontal 
diseases identified two of the S100 family of calcium binding proteins in GCF and 
saliva of periodontitis patients, the S100 proteins are known to have regulatory roles 
in inflammation. Using two-dimensional-gel electrophoresis (2-D PAGE) with peptide 
mass fingerprinting and matrix-assisted laser desorption ionization time of flight mass 
spectrometry (MALDI-TOF-MS), Kojima et al. (2000) identified the S100A8 (MRP8) 
and S100A9 (MRP14) proteins in GCF and saliva of periodontitis patients, the results 
were then confirmed by western blot. The two proteins were highly expressed in both 
the GCF and saliva of periodontitis patients as compared to healthy and edentulous 
controls, and they were more abundant in GCF. The study results suggested these 
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two S100 proteins in GCF as biomarkers for periodontitis and introduced proteomics 
as a new diagnostic approach for periodontal diseases (Kojima et al. 2000). Another 
proteomic study analysed GCF samples obtained from periodontitis patients and 
healthy controls. Using 1-D PAGE and LC-MS/MS, the study detected the protein 
azurocidin which was highly expressed in the GCF of periodontitis patients in 
comparison to healthy controls. Azurocidin is one of the antibacterial proteins 
produced by neutrophils, it is also known to have chemotactic effects, and it was 
found that azurocidin inhibits the differentiation of bone marrow-derived 
macrophages to osteoclasts suggesting a protective role against alveolar bone loss 
during the early stages of periodontitis. The increased expression of azurocidin 
during periodontitis was verified by ELISA assay of the periodontitis patients GCF 
samples compared to those of the healthy individuals. The study results suggested 
azurocidin as a potential biomarker for the early detection of inflammatory periodontal 
destruction in periodontitis (Choi et al. 2011). 
The 2-D PAGE and LC techniques were used to identify changes in α-amylase, Ig 
heavy chain, and albumin along with cystatin levels in saliva of patients with gingivitis 
and chronic periodontitis. These approaches provided information about the salivary 
proteome profile during gingival and periodontal inflammation, and considered as 
contribution to the improvement in the salivary diagnostics of periodontal diseases 
(Goncalves Lda et al. 2010; Goncalves Lda et al. 2011). In their study, Salazar et al. 
(2013) used highly sensitive LC-MS approaches to identify 20 salivary human 
proteins. Salivary MMP-8, MMP-9, α2-macroglobulin, S100-P protein and 
complement C3 were among the identified proteins, they demonstrated more than 
1.5-fold difference in their abundance and they were higher in periodontitis patients 
as compared to healthy controls. This finding confirmed previous studies which used 
proteomics and approaches other than proteomics to identify the same proteins as 
potential salivary biomarkers for periodontitis (Kojima et al. 2000; Zhang et al. 2009; 
Haigh et al. 2010; Choi et al. 2011; Heo et al. 2011). Using gene ontology analysis, 
and Ingenuity pathway analysis, Salazar et al. (2013) demonstrated that the identified 
salivary proteins were mostly related to the acute phase signalling pathway and 
regulation of inflammatory response in periodontitis. With an exception for the S100-
P protein which demonstrated the highest abundance and strongest difference (fold 
change 2.4), Salazar et al. (2013) found that only small differences in the levels of 
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the identified salivary proteins, were enough to differentiate periodontitis patients 
from healthy subjects, a finding that was in agreement with other studies which used  
2-D PAGE and MS techniques (Wu et al. 2009; Haigh et al. 2010; Chan et al. 2012; 
Range et al. 2012). 
However, despite the fact that various proteomic techniques are able to detect wide 
range of proteins and biomarkers in saliva and GCF samples, issues such as 
sensitivity, recovery and reproducibility have been reported and thought to be 
limitations to obtain reliable data. To overcome such challenges, new protocols and 
advanced alternative technologies have been used and are always improving. It is 
believed that these new protocols and technologies will optimize the biomarkers 
detection and the generated data (Vitorino et al. 2012; Juncker et al. 2014). 
1.4.2 Advances in saliva proteomics 
The salivary proteomic studies generated a huge amount of data, and dealing with 
this data was indeed a challenge for most of the researchers as they encountered 
difficulties such as the inability to interface and cross-reference data obtained from 
saliva proteomics with that derived from other studies including transcriptomics, 
genomics and metabolic studies (Ai et al. 2012). Bioinformatics is one of the key 
advances in the field of proteomics that may play a significant role in the 
investigation, exploration, and utilization of data obtained from proteomics and 
related studies, which will eventually help in the identification of novel salivary 
biomarkers (Ai et al. 2012; Rosa et al. 2012; Taylor 2014). Furthermore, the 
emergence and development of what is known as salivomics knowledge database 
(SKB), enabled the researchers to overcome challenges in data exchange and 
interpretation (Hu et al. 2006; Ng et al. 2006; Huang and Zhu 2009; Takeda et al. 
2009; Ai et al. 2012; Wong 2012). SKB can be defined as “a data management 
system and web resource constructed to support saliva diagnostics research” (Ai et 
al. 2012). Which means that SKB is enriched with data derived from saliva 
proteomics, transcriptomics, metabolomics and other approaches. Therefore, 
bioinformatics and SKB provide information about salivary proteins which may 
encourage the invention and development of individualized diagnostic approaches 
which could be used in the dental clinics as well as domestically (Ai et al. 2012; 
Wong 2012). 
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New systems such as microfluidics, micro-electromechanical and nano-electro-fluidic 
systems (MEMS and NEMS) have been introduced in the last decade and are under 
continuous development, these systems raised the sensitivity and specificity of 
salivary diagnostics and offer the chance for pre-symptomatic diagnosis (Wong 
2006). These advanced systems have been introduced in various biosensors, the 
MEMS-NEMS based biosensors are supplied with multiple probes for various 
proteins and nucleic acid targets which enable simultaneous and rapid detection of 
multiple salivary components (Wong 2006). One of the major advantages of these 
sensors is that they enable the use of minute amount of saliva sample with an easy 
and rapid measurement of salivary components (Wong 2006; Herr et al. 2007a). 
These advanced technologies encouraged the invention of miniaturized “lab-on-a-
chip” chairside and handheld devices suitable for both clinical and domestic use such 
as point-of-care (POC) devices (Wong 2006; Herr et al. 2007a; Fuentes et al. 2014; 
Taylor 2014). The invention of POC devices is one the novel advances in saliva 
diagnostics, these devices hold the promise for rapid and simultaneous 
measurement of multiple salivary biomarkers with the ability for data storage, 
exchange and transmission. Hence, POC devices enable both the clinicians and the 
patients to assess the status and progression of periodontal diseases as well as the 
efficacy and response to treatment (Wong 2006; Christodoulides et al. 2007; Herr et 
al. 2007b; Taylor 2014). In addition to their clinical and domestic use, POC devices 
can be used in epidemiological surveys especially in remote and impoverished areas 
where laboratories, sample storage and transport facilities may not be available or 
accessible (Taylor 2014). 
However, any advanced technology or device such as POC devices must be 
commercially attractive (Urdea et al. 2011). Therefore, these developed technologies 
and devices must be ultrasensitive and ultra-specific in detecting and measuring 
multiple diseases biomarkers, rapid, high throughput, automated, portable, 
miniaturized, easy to use especially by patients, and most importantly with 
reasonable cost (Herr et al. 2007a; Taylor 2014). 
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1.5 Aims and objectives 
1.5.1 Aims of the study 
1. To identify novel salivary biomarkers that may predict the onset of periodontal 
disease. 
2. To investigate salivary biomarkers that can be used to indicate the severity of 
chronic periodontitis. 
3. To characterize novel salivary biomarkers that may predict the clinical course 
of periodontitis in response to non-surgical treatment. 
4. To compare biomarkers in saliva and gingival crevicular fluid of periodontitis 
patients 
1.5.2 Objectives 
1. Identify novel salivary biomarkers by proteomic analysis of saliva from 
periodontitis patients using antibody arrays, along with the interrogation of the 
existing data from previous transcriptomic and proteomic studies. 
2. Characterization of these novel biomarkers in saliva of periodontitis and 
gingivitis patients using ELISA. 
3. Correlate the levels of the identified salivary biomarkers with the clinical 
parameters of gingivitis and periodontitis utilizing study databases. 
4. Measure the biological activity of one of the identified biomarkers in saliva 
using fluorescent peptide digestion assay. 
5. Assay biomarkers in GCF samples from periodontitis and gingivitis patients. 
6. In vitro study of the identified biomarkers production by human gingival 
fibroblasts.  
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I. Gingival diseases 
A. Dental plaque induced gingival diseases 
1. Gingivitis associated with dental plaque only 
2. Gingival diseases modified by systemic factors 
a. Associated with the endocrine system 
b. Associated with blood dyscrasias  
3. Gingival diseases modified by medications 
4. Gingival diseases modified by malnutrition 
B. Non-plaque induced gingival lesions 
1. Gingival diseases of specific bacterial origin 
2. Gingival diseases of viral origin 
3. Gingival diseases of fungal origin 
4. Gingival lesions of genetic origin 
5. Gingival manifestations of systemic conditions 
a. Mucocutaneus disorders 
b. Allergic reactions 
6. Traumatic lesions 
a. Chemical injury 
b. Physical injury 
c. Thermal injury 
7. Foreign body reactions 
8. Not otherwise specified (NOS) 
II. Chronic periodontitis 
A. Localized 
B. Generalized 
III. Aggressive periodontitis 
A. Localized 
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B. Generalized 
IV. Periodontitis as a manifestation of systemic diseases 
A. Associated with haematological disorders 
B. Associated with genetic disorders 
C. NOS 
V. Necrotizing periodontal diseases 
A. Necrotizing ulcerative gingivitis (NUG) 
B. Necrotizing ulcerative periodontitis (NUP) 
VI. Abscesses of the periodontium 
A. Gingival abscess 
B. Periodontal abscess 
C. Pericoronal abscess 
VII. Periodontitis associated with endodontic lesions 
VIII. Developmental or acquired deformities and conditions 
A. Localized tooth-related factors that modify or predispose to plaque-induced 
gingival diseases or periodontitis 
B. Mucogingival deformities and conditions around teeth 
C. Mucogingival deformities and conditions on edentulous ridges 
D. Occlusal trauma 
Table 1.1: Classification of periodontal diseases. 
Demonstrating the classification of periodontal diseases and conditions by the International Workshop for the Classification of Periodontal 
Diseases and Conditions (1999) and the American academy of periodontology. As a general guide, the extent of the disease can be 
characterized as localized when ≤ 30% of sites involved and generalized when >30% of sites involved. The severity of periodontitis can 
be characterized on the basis of the CAL into: slight or mild = 1 or 2 mm CAL, moderate = 3 or 4 mm CAL, and severe = ≥5 mm CAL, 
(Armitage 1999; Highfield 2009). 
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Case definition 5th European Workshop 
in Periodontology 
criteria 
AAP criteria 
Incipient or moderate 
periodontitis 
Presence of proximal 
attachment loss of ≥ 3 
mm in ≥ 2 non-adjacent 
teeth. 
Presence of ≥2 
interproximal sites with 
CAL of ≥4 mm (not on 
same tooth) or ≥2 
interproximal sites with 
PD ≥5 mm (not on same 
tooth). 
Substantial or severe 
periodontitis 
Presence of proximal 
attachment loss of ≥5 mm 
in ≥30% of teeth present. 
Presence of ≥2 
interproximal sites with 
CAL of ≥6 mm (not on 
same tooth) and ≥1 
interproximal site with PD 
≥5 mm. 
Table 1.2: Periodontitis case definition.  
Demonstrating the periodontitis case definition by 2 studies. The first study presents 
the periodontitis case definition by the 5th European Workshop in Periodontology 
(Tonetti and Claffey 2005), measuring the CAL at the proximal sites of non-adjacent 
teeth. The second study (Page and Eke 2007), presents the periodontitis case 
definition by the AAP, measuring the CAL and the PD at the interproximal sites of 
more than 1 tooth. 
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Case  Definition 
No periodontitis No evidence of mild, moderate, or 
severe periodontitis 
Mild periodontitis ≥2 interproximal sites with CAL ≥3 mm, 
and ≥2 interproximal sites with PD ≥4 
mm (not on same tooth) or one site with 
PD ≥5 mm 
Moderate periodontitis ≥2 interproximal sites with CAL ≥4 mm 
(not on same tooth), or ≥2 interproximal 
sites with PD ≥5 mm (not on same 
tooth) 
Severe periodontitis ≥2 interproximal sites with CAL ≥6 mm 
(not on same tooth) and ≥1 
interproximal site with PD ≥5 mm 
Table 1.3: Update on the periodontitis case definition. 
Demonstrating the update on the periodontitis case definition by the CDC-AAP. The 
criteria for the moderate and severe periodontitis remain same as the previous case 
definitions, this updated case definition also measures the CAL and the PD at the 
interproximal sites of more than 1 tooth for the definition of mild periodontitis, and the 
third molars were excluded (Eke et al. 2012). 
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Figure 1.1: The pathogenesis of periodontal diseases. 
As multi-factorial diseases, many factors contribute to the pathogenesis of 
periodontal diseases. The dental biofilm bacterial antigens and products such as LPS 
and other virulence factors represent the microbial challenge that stimulates and 
initiates the host inflammatory response. The PMNs which is the first line of defence 
as well as the macrophages and dendritic cells try to remove this bacterial challenge, 
these innate immunity cells carry receptors that recognize the bacterial antigens 
(adaptive immune response) present them to the immune system and release 
cytokines which stimulates the T cells (cell mediated response) and the B cells 
(humoral response to produce antibodies that attack bacteria). Furthermore, the 
bacterial challenge stimulates the inflammatory and local periodontal cells produce 
pro-inflammatory mediators such as cytokines and prostanoids which regulate the 
inflammatory process, attract more inflammatory cells, stimulate the production of 
enzymes such as matrix metalloproteinases and activate the osteoclastic activity 
which all lead to the destruction of both the periodontal connective tissue and 
alveolar bone. These responses are presented clinically by bleeding, periodontal 
pockets, loss of attachment, and finally loss of teeth.  Moreover, the sequence of 
these events are affected by risk factors which may modify or exaggerate the host 
immune response and periodontal disease pathogenesis, these factors may be local 
environmental, systemic diseases, or genetic factors (Page and Kornman 1997; 
Kornman 2008). 
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Chapter 2 Materials and Methods 
2.1 Clinical studies 
Saliva and gingival crevicular fluid (GCF) samples assayed in this research were 
obtained from three independent clinical studies carried out as part of previous 
projects by the periodontology research group at the School of Dental Sciences/ 
Newcastle University. Details of these studies are described below. 
2.1.1 Ethical approval 
Each clinical study included in this research was ethically approved. Clinical study A 
was ethically approved by the Newcastle and North Tyneside 1 Research Ethics 
Committee (REC) reference (12/NE/0396). Clinical study B was ethically approved by 
the Newcastle and North Tyneside 1 REC reference (09/H0905/49). Clinical study C 
was ethically approved by the Sunderland Local REC reference (06/Q0904/8). The 
application to the ethics committees enclosed a protocol for each study, which 
highlighted the possible ethical concerns related to the study. The saliva and GCF 
samples were collected purely for research purposes and would otherwise not be 
collected. The purpose and reason for collecting samples was made clear to the 
prospective participants in the information sheet. The periodontal examination and 
treatment provided as part of the study, constituted routine clinical care. Furthermore, 
all participants in the study were given information and instructions on how to better 
maintain their oral health. All data recorded and samples collected were stored 
securely and anonymously, using a coding system. The information that was 
generated as part of this research study did not have an impact on the patients’ 
clinical care and treatment other than that relating to any required periodontal clinical 
management. 
2.1.2 Consent  
At the first visit of each clinical study, written informed consent was obtained from all 
patients and healthy control volunteers. Here, the clinician confirmed that the patient 
had understood the written information sheet they had received about the study. 
Subsequently, the background and aims of the study were verbally confirmed by the 
clinician, moreover, all potential benefits and risks that the participants may 
60 
 
encounter by their involvement in the study were explained by the clinician. All 
participants were offered the chance to ask any question related to the study, as well 
as, the option to refuse the participation or withdraw from the study at any time. 
Participants who verbally accepted to participate in the study were asked to sign two 
copies of the consent form, one of which was kept in the patients’/volunteer case 
report form and the other copy was given to the patient. 
2.1.3 Study groups 
The studies were carried out and participants recruited at the Dental Hospital, School 
of Dental Sciences/Newcastle University (Figure 2.1, Figure 2.2 & Figure 2.3). All 
participants met the criteria of being adult males or females of 18-65 years of age, 
had a minimum of 20 natural teeth (excluding 3rd molars), were non-smokers and 
were not pregnant or nursing females. Subjects were excluded if they had crown, 
bridge, or rampant caries. Subjects with dentures (except the edentulous group in 
study B), who had a history of oral or systemic disease (such as xerostomia, 
Sjögren’s syndrome, mucocutaneous and vesicobullous disorders, diabetes, 
systemic infectious disease), patients on treatment that my interfere with study (such 
as head and neck radiotherapy, systemic corticosteroids, long term use of phenytoin, 
cyclosporine, coumarin, warfarin, and heparin), who had extensive dental/orthodontic 
treatment, who had dental implants, cardiac pacemakers or automatic implanted 
cardiac defibrillators were also excluded. The edentulous group included in study B, 
were edentulous for more than 1 year with healthy oral tissues. 
  Clinical study A 
This study was carried out on patients with chronic periodontitis and healthy control 
volunteers. During the visit 1 (the “baseline” assessment, one month before start of 
the study proper) the consent form, medical/dental history, and saliva samples were 
obtained for all participants. Oral/dental examination, and periodontal screening were 
carried out at this visit. At visit 2 (month 0), medical/dental history updated, saliva 
sampling, and periodontal assessment, were carried out for all participants. After 
sampling and periodontal assessment, non-surgical treatment was offered for 
periodontitis patients, whereas, healthy subjects had scaling and polishing and they 
then exited the study. Visits 3 (month 1), 4 (month 2), 5 (month 3), 6 (month 6) for all 
periodontitis patients, involved the previous steps with non-surgical treatment as 
maintenance. The study was ended at visit 6. Saliva samples involved in the present 
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research, were obtained at visits 1 (Baseline), 2, and 6. Healthy saliva samples 
comprised 2 sets. The first set comprised 34 saliva samples obtained at visit 1 
(Baseline): some of these samples were used in proteome profiler arrays (PPA) 
assays and all were analysed for uPAR levels using ELISA. The second set 
comprised 40 saliva samples obtained at visit 2 of the study and were analysed for: 
uPAR, uPA, and VDBP levels using ELISA, as well as, uPA activity using activity 
assay. Saliva samples from periodontitis patients included 3 sets. The first set 
comprised 30 saliva samples from patients with untreated chronic periodontitis 
obtained at visit 1 (Baseline): some were used in the PPA assays and all were 
analysed for uPAR levels using ELISA. The second set comprised 45 pre-treatment 
saliva samples from 45 periodontitis patients obtained at visit 2 of the study and were 
analysed for: uPAR, uPA, and VDBP levels using ELISA, as well as, uPA activity 
using activity assay. The third set comprised 45 post-treatment saliva samples 
obtained from the same 45 periodontitis patients at visit 6 of the study which were 
analysed for uPAR, uPA, and VDBP levels using ELISA. (Figure 2.1). 
  Clinical study B 
This study involved edentulous subjects, healthy volunteers, gingivitis patients, and 
periodontitis patients. The study started at visit 1 (day 0) for all participants. In this 
visit the informed consent form, the medical/dental history, and saliva samples were 
obtained. An oral/dental examination and periodontal screening were also carried out 
at this visit. At visit 2 (5-30 days from day 0) the same procedures as visit 1 were 
repeated and it was the last visit for the edentulous, healthy, and gingivitis 
participants. Visit 2 was followed by 1-2 non-surgical treatment visits (within 2 weeks 
of visit 2), and follow up/recall visits (3, 6, and 9 weeks after treatment), for the 
periodontitis patients. Finally, visit 3 (12±2 weeks after treatment) at which same 
steps as visit 1 and 2 were repeated again, and the study was completed. Five 
groups of saliva samples obtained at visit 2 and two groups obtained at visit 3 of 
study B, were assayed for uPA levels and uPA activity. The groups included: 26 
samples from edentulous subjects, 29 samples from dentulous healthy subjects, and 
25 samples from gingivitis patients, all obtained at visit 2 of the study. Saliva samples 
from mild/moderate periodontitis patients comprised 31 pre-treatment samples 
obtained at visit 2, and 31 post-treatment samples obtained at visit 3. Lastly, saliva 
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samples from advanced periodontitis patients comprised 27 pre-treatment samples 
obtained at visit 2, and 27 post-treatment samples obtained at visit 3. (Figure 2.2). 
  Clinical study C 
The study involved investigations carried out on 2 groups of participants. The first 
group comprised periodontally healthy volunteers, gingivitis patients, and 
periodontitis patients all with type-2 diabetes mellitus. The second group comprised 
periodontally healthy volunteers, gingivitis patients, and periodontitis patients all were 
systemically healthy. The clinical protocol of the study included 7 visits. All 
participants were assessed at a pre-treatment screening visit (visit 1), in which the 
informed consent form, medical/dental history, and samples (saliva, GCF, and 
serum) were obtained. Furthermore, oral, dental, and periodontal examinations were 
carried out at this visit. At the end of pre-treatment visit, the healthy and gingivitis 
participants in both groups were not seen again. Two months after the pre-treatment 
screening (visit 1), non-surgical periodontal treatment was offered for the 
periodontitis patients at visit 2 which was the start of the study proper (month 0 time 
point). Visit 3 (week 3), and visit 4 (week 6), both involved only oral examination and 
prophylaxis. At visit 5 (month 3), and visit 6 (month 6) the same steps as visit 1 were 
repeated with prophylaxis and additional treatment if required. The same steps as 
visits 5 and 6 were followed at visit 7 (month 12), which was the end of the study. 
From clinical study C, only GCF samples obtained from the systemically healthy 
group (not from the type-2 diabetes group) were assayed for uPA levels in the 
present research. The samples were divided into 2 sets. The first set of samples 
comprised 3 groups: 7 healthy GCF samples, 13 gingivitis GCF samples, and 9 pre-
treatment periodontitis GCF samples, all obtained at the pre-treatment screening 
(visit 1) of the study. The second set comprised 2 groups of post-treatment GCF 
samples obtained from the same periodontitis patients, including: 9 post-treatment 
samples at visit 5, and 9 post-treatment samples at visit 6 of the study. (Figure 2.3). 
2.1.4 Clinical assessment 
At the pre-treatment or first visit of each study, all patients and subjects received a 
full-mouth periodontal screening, which included recording periodontal disease 
indices at 6 sites per tooth. When clinically indicated, radiographs were taken for 
participants and, thereafter, clinical and radiographic data were used to confirm the 
periodontal diagnosis based on the diagnostic criteria (Table 2.1). Following the 
63 
 
confirmation of diagnosis at this visit, patients were screened again on treatment and 
post-treatment visits. 
  Periodontal disease indices 
A number of periodontal indices were used in the three clinical studies for the clinical 
assessment of participants at the first visit and to monitor the disease progression 
and response to treatment in the following visits. These periodontal indices used 
were: modified gingival index (MGI), probing or pocket depths (PD), bleeding on 
probing (%BOP), and clinical attachment loss (CAL). The University of North Carolina 
(UNC) 15 probe (Dentsply, Addlestone, UK) was used for the indices measurements. 
Modified gingival index: The modified gingival index by (Lobene et al. 1986), was 
used for the clinical assessment of gingival inflammation as follows: 
0 Absence of inflammation 
1 Presence of mild inflammation: slight change in colour, little change in texture of 
any portion but not the entire gingival margin or papillary gingival unit. 
2 Mild inflammation: criteria as above but involving the entire marginal or papillary 
gingival unit. 
3 Moderate inflammation: glazing, redness, oedema and/or hypertrophy of the 
marginal or papillary gingival unit. 
4 Severe inflammation: marked redness, oedema and/or hypertrophy of the marginal 
or papillary gingival unit, spontaneous bleeding, congestion or ulceration. 
In both clinical studies A and B, the above scores were recorded by visual 
examination for 6 sites per tooth, the mean of the scores for each tooth was 
calculated, and then the mean of the mean scores was calculated for all teeth 
examined. In clinical study C, the scores were also recorded by visual examination 
for 6 sites per tooth, the mean of the scores for each tooth was calculated, and then 
the mean of the mean scores was calculated for the four target teeth from which GCF 
samples were obtained. 
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Probing depth: Using the UNC periodontal probe, probing depths or periodontal 
pockets for the three clinical studies were measured at 6 sites per tooth for all 
standing teeth except 3rd molars. The periodontal pocket represents the distance 
from the gingival margin to the base of the pocket measured by millimetres (mm). 
The probe was inserted into the gingival sulcus and advanced apically, along the 
long axis of the tooth, until resistance of the tissue was felt at the base of the gingival 
sulcus or pocket. The PD measurements were recorded by direct visualisation of the 
markings on the probe. The PD final score was calculated in a similar manner to 
MGI. 
Bleeding on probing: Following the measurement of periodontal pockets in one 
aspect of a quadrant (such as buccal aspect of lower left quadrant), the probing 
depth sites (periodontal pockets) were re-examined to determine whether post-
probing bleeding occurred. In a similar manner to probing depth, bleeding status was 
recorded at 6 sites per tooth depending on the presence (score 1) or absence of 
bleeding (score 0) from the base of the pocket following probing. The final score was 
presented as percentage of the bleeding sites for all teeth examined (%BOP), for 
example if there were 75 bleeding sites for 20 teeth then the final score will be as 
following: 
6 sites × 20 teeth=180,      75/180= 0.417 × 100= 41.7 %BOP  
Clinical attachment loss (CAL): This is the sum of probing depth and recession, 
hence, it represents the distance from the cemento-enamel-junction (CEJ) to the 
base of the periodontal pocket measured in mm. Again, CAL was measured at 6 
sites per tooth for all teeth present, excluding 3rd molars. Then the total score for 
each patient or subject was used in the study. 
Before calculating the CAL, recession was measured using the UNC probe. 
Recession represents the distance from the CEJ to the gingival margin measured by 
mm. It was recorded during PD measurement whilst the probe was inserted into the 
gingival sulcus. When the CEJ was located above the gingival margin, recession was 
recorded by direct visualisation of the probe markings. When the CEJ was located 
below the gingival margin (such as in case of false pocketing), the position of the 
CEJ was estimated in relation to the gingival margin and a negative recording was 
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made. Recession was recorded at 6 sites per tooth for all standing teeth excluding 
the 3rd molars. 
2.1.5 Saliva and GCF sampling  
  Saliva samples 
In clinical study A, whole unstimulated saliva samples were obtained from study 
participants at least one hour after their last food or drink intake and, at least one 
hour after their last oral hygiene measure (tooth brushing, flossing, and/or mouth 
rinse). The participants were seated in the dental chair, avoiding any noise or 
distraction. Neither stimulation nor examination of the oral tissues and mouth were 
carried out during sample collection. A pre-labelled, sterile, 50 ml polypropylene tube 
was given to each participant and the participant was instructed to simply drool saliva 
into the tube until approximately 5-10 ml of saliva were collected. The estimated 
collection time was 5-10 minutes, time and date of collection were recorded. The 
samples were placed on ice and taken to the lab for processing. Saliva samples were 
centrifuged (at 1500g, 15 minutes, 4°C), the supernatant was pipetted into aliquots 
(to avoid multiple freeze-thaw cycles), snap frozen in liquid nitrogen and then stored 
at -80°C till use in different assays. 
In clinical study B: The same steps of saliva sampling as in study A were followed in 
regard to participants seating, time of collection, processing and storage of samples. 
The only difference was that the samples were stimulated, each participant was 
instructed to place a sterile marble into the mouth and asked to roll it gently around 
the moth to stimulate the oral musculature, promote mixing of GCF and saliva, and 
stimulate salivary flow. 
  GCF samples 
GCF samples were collected using Periopaper strips (Oraflow Inc., New York) and 
the volume quantified using a calibrated Periotron 6000 (Preshaw et al. 1996; 
Wassall and Preshaw 2016). As recommended by the manufacturer, the Periotron 
was allowed to ‘warm up’ before use, and then zeroed with a blank (dry) Periopaper. 
The reading dial was adjusted until the digital display indicated zero. To minimise 
contamination by blood, GCF samples were collected prior to periodontal pockets 
probing.  At the first visit (pre-treatment screening visit), 4 samples were collected 
from each participant, from the mesio-buccal aspects of the four 1st molars. If the 1st 
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molar was absent in a quadrant, the 2nd molar was used, then the 2nd premolar, then 
the 1st premolar, then the canine or incisor teeth (the sampled teeth were designated 
target teeth). To collect a sample, first the site was isolated with cotton rolls and a 
saliva ejector, then dried by a gentle stream of air. If present, supra-gingival plaque 
was carefully removed with a curette prior to sampling. A Periopaper was placed 
carefully into the gingival sulcus till mild resistance was felt and was held in place for 
30 seconds. After collection of GCF, Periopapers were transferred immediately to the 
Periotron jaws to minimise evaporation. Periopapers were carefully positioned in a 
standardised position between the jaws, so that the black line on the paper was at 
the outer rim of the jaw plate. The GCF volume (in Periotron units) was recorded 
when ‘mode II’ illuminated on the Periotron display. The Periopaper was then placed 
into a sterile plastic 0.5 ml micro-tube (Sarstedt, Leicester, UK) containing 150μl 
autoclaved and filtered PBS (Dulbecco’s phosphate buffered saline). The GCF 
samples were kept on ice at the chair side and transferred, within 20 minutes of 
sampling, to the laboratory and frozen at -80°C (Cutler et al. 1999) till subsequent 
elution & analysis. For longitudinal study of periodontitis patients, the same steps 
were followed to collect GCF samples from the same 4 sites at months 3, 6 and 12. 
GCF samples from the Periopaper required elution, which was executed by thawing 
the 4 sites samples on ice for 15 minutes and then 50μl of 1% bovine serum albumin 
(BSA) was added. GCF samples were centrifuged (using Sigma 3K10 centrifuge) at 
300 rpm for 60 minutes at 4 °C and then at 12000 rpm for 2 minutes at 4 °C. The 
Periopapers were then removed with college tweezers, with the ends of the tweezers 
being rinsed with PBS between samples. The final 4 sites GCF samples for each 
participant were stored at -80°C till use in different assays. In the present research 
due to the minimum volumes left from the previous projects in the periodontology 
group, the 4 sites GCF samples were pooled into one sample for each participant. 
2.2 Laboratory investigations 
2.2.1 Materials, reagents, and equipment 
The plastic-ware used in all assays was supplied by Greiner Bio One (Stonehouse, 
UK). All ELISA kits (Quantikine and DuoSet), PPA kits, and reagents were purchased 
from R & D Systems (Abingdon, UK). uPA activity fluorometric assay kits, in addition 
to cell culture reagents and media, were purchased from Sigma-Aldrich (Dorset, UK). 
For PPA assays, 3D rocking platform shaker STR (from Stuart Scientific, 
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Staffordshire, UK) was used in incubations and washing steps. An autoradiography 
film cassette, and highly sensitive autoradiography film (from Amersham Hyperfilm 
ECL, Buckinghamshire, UK), was used to take radiographs of the array membranes. 
Image analysis software (Gene Tools software Syngene, Cambridge, UK), was used 
for the analysis of the pixel intensity (PI) of the radiographic images. 
In ELISA assays, phosphate buffered saline (PBS), reagent diluent (RD), and 
calibrator diluent (CD) (R & D systems) were used for the dilution of the standards 
and antibodies. Wash buffer (0.05%Tween in PBS) (R & D systems) was diluted by 
1:25 in distilled water, and an auto-washer from BioTek Instruments Ltd (Swindon, 
UK) were used to wash the plates as required. A horizontal orbital microplate shaker 
(from IKA-Labortechnik, Staufen im Breisgau, Germany) set at 500±50 rpm, was 
used during the incubations of Quantikine ELISA plates. Optical density for each 
assay was determined using Synergy HT microplate reader from BioTek Ltd. The 
plate reader was set to 450 nm with wavelength correction set to 540 or 570 nm. 
Standard curves were generated and results were calculated using Software Gen5 
1.11 from BioTek Ltd. For uPA activity assay, same plate reader was used to read 
the fluorescence of the activity assay. 96 well flat-bottom black plates from Greiner 
Bio One were used for the uPA activity assay. 
The recombinant proteins used in cell culture included: human recombinant IL-1β 
(R&D Systems) which was prepared at 25 μg/ml in 0.1% w/v endotoxin-free bovine 
serum albumin (BSA) in Dulbecco’s phosphate buffered saline (PBS). IL-1β stock 
aliquots stored at -80 °C, further dilutions prepared as needed using serum-free 
medium (SFM) “SFM was Dulbecco’s modified Eagle’s medium nutrient mixture F-12 
Ham (DMEM) from Sigma-Aldrich, added to it L-glutamine (2 mM), penicillin (200 
U/ml), and streptomycin (200 μg/ml), without foetal bovine serum (FBS)”. 
Lipopolysaccharides (LPS) used for the stimulation of human gingival fibroblasts 
(hGFs) were: Escherichia coli (E. coli) LPS strain 0111:B4 (Invivogen, Nottingham, 
UK ) which was prepared as a 5 mg/ml stock solution in sterile filtered water, and 
Porphyromonas gingivalis (P.gingivalis) ultrapure TLR4 agonist LPS (Invivogen) 
prepared as a 1 mg/ml stock solution in sterile filtered water. LPS stocks were stored 
as 20 µl aliquots at -20 °C, further dilutions were prepared with sterile filtered water 
and SFM as required. 
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2.2.2 Cell culture 
A Class II hood (laminar flow unit-BioAir, Biological Instrumentation Services, 
Manchester, UK), was used for all cell culture procedures. Sterile CELLSTAR 
(Greiner Bio One) cell culture plastic-ware including: T75 and/orT25 flasks were used 
for cell growth, and 6-multi-well plates were used for cells stimulation. All reagents 
used were sterile and endotoxin-free. Cells were incubated in a 5% CO2 atmosphere 
at 37 °C unless otherwise indicated. DMEM+ medium (SFM supplemented with 10% 
v/v FBS) was used for cell growth. For cells stimulation the SFM medium was used. 
A Ca2+/Mg2+ free Dulbecco’s phosphate buffer saline (PBS) was used for wash of 
cells. Trypsin ethylene diamine tetra acetic acid (EDTA) solution (supplied as a bottle 
of 500 ml of 1x solution of 0.5g porcrine trypsin and 0.2g EDTA. 4Na per litre of 
Hanks’ balanced salt solution with phenol red, from Sigma-Aldrich) was used to 
detach cells from the bottom of growth flasks and/or multi-well plates. Dimethyl 
Sulfoxide (DMSO) (Sigma-Aldrich) 99.5% pure “cryo-protectant agent for the 
preservation of cells” was used in cell freezing media to protect cells from ice crystal 
induced injury. 
The cells used in the cell culture experiments were primary hGFs cells previously 
prepared by Dr Rachel Williams from gingival tissue obtained from separate patients 
undergoing canine tooth exposure surgery at Newcastle Dental Hospital (Williams et 
al. 2016), this was approved by the National Research Ethics Service Committee 
North East (Newcastle and North Tyneside 2, REF: 07/Q1003/41). The cells were 
stored in cryo-vials in liquid nitrogen till use. 
2.3 Assays methods 
2.3.1 Proteome profiler arrays 
The PPA works on the principle of two-site sandwich immunoassay, in which 
samples are incubated with membranes in an overnight procedure, and any captured 
analyte is detected by a cocktail of biotinylated antibodies specific for each array 
(Figure 2.4). A chemiluminescent substrate mix is used to demonstrate the positive 
spots on the membranes, to view these positive spots multiple radiographs are 
needed. Human proteome profiler protease array kits (ARY021, R & D systems) and 
human proteome profiler cytokine array kits (ARY022, R & D systems), were used to 
identify candidate biomarkers in whole unstimulated saliva of periodontitis patients. 
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The protease array membranes contain 34 capture antibodies in duplicate for a 
range of human proteases, whereas, the cytokines array membranes contain 102 
capture antibodies in duplicate for human cytokines. Each PPA membrane has three 
pairs of positive reference spots on three corners, and a pair of negative reference 
spots next to the last protease on the protease detection membrane and on the lower 
right hand corner of the cytokine detection membrane (Figure 2.5). The reference 
spots are used for three reasons: firstly, as a positive control for the performance of 
the array as the positive reference spots will have signals while the negative 
reference spots will be blank, secondly, to help in the alignment of the overlay 
template, and finally to be used as a reference for the calculation of the relative 
density of the proteins spots. 
  The human protease PPA assay 
 Aliquots of saliva samples previously obtained from healthy subjects and chronic 
periodontitis patients from the baseline visit of study A, stored at -80°C, were 
analysed in the protease PPA assays. Each sample aliquot used once only to avoid 
repeated freeze-thaw cycles. All samples and reagents were prepared at room 
temperature (RT). Using flat-tip tweezers each protease PPA membrane with the 
identification number faced upward, was placed in a separate well of a 4-well multi-
dish (supplied with each kit, R & D systems) in which 2 ml of array buffer 6 were 
pipetted per well. Array buffer 6 served as a block buffer. The membranes were 
incubated in the blocking buffer for 1 hour on the platform shaker at RT. While the 
membranes were blocking, the samples were prepared and adjusted with array 
buffers to a volume of 1.5 ml; thus, 
 0.5 ml of array buffer 4 + 300 µl of the sample + 700 µl of array buffer 6 were 
combined. According to the manufacturer, the sample volume should not be less 
than 100µl, adjusted to 1.5 ml with the 2 array buffers. Then, 15 µl of the specific 
biotinylated detection antibody cocktail (DAC) were added up to each prepared 
sample, mixed and incubated for 1 hour at RT. 
By the end of blocking, the blocking buffer was aspirated, then the prepared 
sample/antibody mixtures were added, and incubated overnight on the platform 
shaker at 2-8°C in a refrigerator. According to the manufacturer’s recommendations, 
overnight incubation is necessary for optimal sensitivity of the assay. After the 
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overnight incubation, the membranes were carefully removed and each membrane 
placed into an individual plastic container (such as sterile Petri dish) containing 20 ml 
of 1X wash buffer. Each membrane was washed at RT for 10 minutes on the platform 
shaker, for a total of 3 washes. After washing, the membranes were carefully 
removed from the washing containers, allowed to drain by blotting onto dry paper 
towels, then the membranes were placed into the multi-well dish containing 2 ml of 
streptavidin-HRP/well (diluted by 1:2000 in array buffer 6 immediately before use), 
protected from light by covering the multi-well dish with aluminium foil, and incubated 
for 30 minutes at RT on the shaker. The membranes were washed again, and 
allowed to drain carefully on paper towels. Each membrane was placed on a plastic 
sheet with the identification number facing up. 1 ml of the chemiluminescent reagent 
mix (CRM, prepared by mixing equal volumes of reagents 1 and 2 immediately 
before use), was added on each membrane ensuring complete coverage, and 
carefully covered by a top plastic sheet protector. Any air bubbles generated were 
gently smoothed out to ensure an even spread of the CRM on all corners of each 
membrane. The covered membranes were incubated for 1 minute protected from 
light with aluminium foil. Using paper towels, any excess of CRM was squeezed out. 
The top plastic sheet was removed then the remaining liquid was carefully wiped off 
using absorbent paper. Thereafter, radiographs were taken for the protease PPA 
membranes. 
  The human cytokines PPA assay 
 Aliquots of saliva samples previously obtained from healthy subjects and chronic 
periodontitis patients from the baseline visit of study A, stored at -80°C, were 
analysed in the cytokine PPA assays. Each sample aliquot used once only to avoid 
repeated freeze-thaw cycles. All samples and reagents were prepared at RT. Using 
flat-tip tweezers each cytokine PPA membrane with the identification number faced 
upward, was placed in a separate well of the 4-well multi-dish in which 2 ml of array 
buffer 6 were pipetted per well. Array buffer 6 served as a block buffer. The 
membranes were incubated in the blocking buffer for 1 hour on the platform shaker at 
RT. While the membranes were blocking, the samples were prepared and adjusted 
with array buffer 6 to a volume of 1.5 ml; thus, 
200 µl of the sample + 1300 µl of array buffer 6 were combined. 
71 
 
The blocking buffer was aspirated, then the prepared samples were added to each 
well, and incubated overnight on the platform shaker at 2-8°C in refrigerator. 
According to the manufacturer’s recommendations, overnight incubation is necessary 
for optimal sensitivity of the assay. After the overnight protection, the membranes 
were carefully removed and each membrane placed into an individual plastic 
container containing 20 ml of 1X wash buffer. Each membrane was washed at RT for 
10 minutes on the platform shaker, for a total of 3 washes. After washing, the 
membranes were carefully removed from the washing containers, allowed to drain by 
blotting onto dry paper towels, and placed into the multi-well dish containing 1.5 ml of 
DAC/array buffers mixture per well which was prepared immediately before use as 
following: 
First, for 4 wells, 6 ml of array buffer 4/6 mixture was prepared in 1:2 ratio                  
2 ml of array buffer 4 + 4 ml of array buffer 6= 6 ml array buffer 4/6 mixture  
Then, 30 µl of DAC needed for each 1.5 ml of the array buffer mixture, therefore 120 
µl of DAC were added up to the 6 ml of array buffer mixture. 
The membranes were incubated for 1 hour at RT on the platform shaker. Then, the 
membranes were washed as described before. After washing, and blotting onto 
paper towels to drain, the cytokine membranes were placed into the multi-well dish 
containing 2 ml of streptavidin-HRP/well (diluted by 1:2000 in array buffer 6 
immediately before use), protected from light and incubated for 30 minutes at RT on 
the shaker. The membranes were washed again, allowed to drain carefully on paper 
towels. Each membrane was placed on a plastic sheet with the identification number 
facing up. 1 ml of the CRM mix (prepared by mixing equal volumes of reagents 1 and 
2 immediately before use), was added on each membrane ensuring complete 
coverage, and carefully covered by a top plastic sheet protector. Any air bubbles 
generated were gently smoothed out to ensure an even spread of the CRM on all 
corners of each membrane. The covered membranes were incubated for 1 minute 
protected from light. Using paper towels, any excess of CRM was squeezed out. The 
top plastic sheet was removed then the remaining liquid was carefully wiped off using 
absorbent paper. Thereafter, radiographs were taken for the cytokine PPAs 
membranes, except the first cytokine PPA assay in which images were captured for 
the membranes. 
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  PPA assay imaging  
In the first cytokine PPA experiment, after incubation with the CRM, images for both 
the healthy control sample and the periodontitis sample membranes were captured 
using G:BOX Chemi XL viewer (Syngene, UK), at the Institute for Cell and Molecular 
Biosciences, Newcastle University. The pixel intensity (PI) of the resultant spots were 
quantified by the image analysis software. 
  Radiography of PPAs 
In the majority of experiments, PPA assay membranes were analysed using 
radiography. Thus, after incubation with the CRM, the protease and cytokine 
membranes were wrapped carefully with plastic protective sheets with the 
identification numbers facing up, placed in autoradiography film cassette, to be 
exposed to a highly sensitive autoradiography film for 1-10 minutes (the radiography 
procedure was carried out in a dark X-ray room at the Institute for Cell and Molecular 
Biosciences, Newcastle University). It was found that 4-5 minutes exposure time was 
the best time to develop clear signals on the radiographs. These signals were 
identified by placing transparency overlay template on the radiograph, aligning it with 
pairs of positive reference spots on three corners of each array. Finally, the 
radiographs were scanned, and the PI of each spot on the resultant images was 
quantified using the image analysis software (section 2.2.1). 
  Quantification of hybridisation on PPA membranes  
The PI values of the resultant spots on the images were exported to an excel 
spreadsheet file for calculation. The mean PI of each doubled spot was subtracted 
from the mean PI of the duplicate negative control spot of each array membrane 
(background correction). The resultant PI values from the protease and cytokine 
PPAs from each sample and control array membranes, were compared to each other 
to determine the relative changes in the analytes, this was achieved by the means of 
PI values fold change, p-value of the logarithm-fold change, and bar graphs 
demonstrating the high and low protein expression. 
2.3.2 Enzyme linked immunosorbent assay (ELISA) 
Following the identification of the candidate biomarkers and to confirm the results of 
PPAs, human urokinase receptor (uPAR) (DuoSet kits DY807, R & D systems), 
human urokinase (uPA) (Quantikine kits DUPA00, R & D systems) and human 
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vitamin D binding protein (VDBP) (Quantikine kits DVDBP0, R & D systems) were 
used to measure the levels of these mediators in saliva and GCF samples obtained 
from the three clinical studies. For assays of cell culture supernatants, the following 
assays were used: uPAR DuoSet, human uPA DuoSet (DY1310, R & D systems), 
and human total matrix metalloproteinase 1 (MMP-1) DuoSet (DY901, R & D 
systems). All assays were performed at room temperature. For each assay, new 
aliquots of saliva or GCF samples were used to avoid repeated freeze-thaw cycles. 
Along with the standards, saliva and GCF samples were diluted as appropriate using 
reagent diluent (RD) for DuoSet ELISAs, or in calibrator diluent (CD) for Quantikine 
ELISAs. 
DuoSet ELISA assays were carried out according to the manufacturer’s protocol on 
benchtop. Briefly, plates were coated with 100 µl/well of capture antibody (Cab) 
diluted in PBS (concentrations were: 4 µg/ml for uPAR, 1 µg/ml for uPA, and 2 µg/ml 
for MMP-1), incubated overnight, washed next day with 400 µl/well of wash buffer 
(section 2.2.1) for a total of 3 washes using auto-washer (BioTek) to remove any 
unbound antibodies. The plates were blocked with 300 µl/well of RD for 1 hour. After 
washing, 100 µl/well of standards and samples were dispensed into the plates and 
incubated for 2 hours (samples and standards were diluted in RD as required, 
standards dilution series were: 2000-31.3 pg/ml for uPAR, 4000-62.5 pg/ml for uPA, 
and 10000-156.3 pg/ml for MMP-1). During incubation, any uPAR or uPA or MMP-1 
in the samples is bound by the Cab. The plates were washed again to remove any 
unbound proteins, and then 100 µl of biotinylated detection antibody (Dab) diluted in 
RD (concentrations were: 200 ng/ml for uPAR, 400 ng/ml for uPA, and 100 ng/ml for 
MMP-1) were added per well, and incubated for 2 hours. Following another washing 
step to remove any unbound antibodies, 100 µl/well of streptavidin-horseradish 
peroxidase (HRP) solution (1:200 in RD, prepared immediately before use) were 
added to the plates, which were protected from light using aluminium foil and 
incubated for 20-30 minutes. During incubation, streptavidin-HRP bound to the 
biotinylated Dab. Any unbound streptavidin-HRP was removed by a further washing 
step, then 100 µl of substrate solution were pipetted per well (prepared immediately 
before use by mixing colour reagents A and B in a 1:1 ratio), protected from light and 
incubated for 20-30 minutes depending on the analyte. To stop the reaction, 50 
µl/well of stop solution (2N Sulphuric acid, R & D systems) was added to the plates, 
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the colour of the substrate solution in the wells changed immediately from blue to 
yellow, when the colour change was not uniform or delayed or appeared green it was 
hastened by gentle tapping of the plates to ensure thorough mixing of the acid stop 
and substrate solutions in the wells (R & D systems). Once the colour changed, the 
plates were immediately read by the microplate reader to generate the standard 
curve (Figure 2.6, Figure 2.7, & Figure 2.8) and calculate the desired biomarkers 
concentrations in the samples (section 2.2.1). 
Quantikine ELISA assays for both uPA and VDBP were also carried out according to 
the manufacturer’s protocol. Briefly, the Quantikine assay plates are supplied with 
pre-coated antibodies to which 100 µl/well of assay diluent were added, followed by 
50 µl of standards or samples (diluted as required in CD) and incubated on the 
microplate shaker (section 2.2.1) for 1 hour, during this time any uPA or VDBP 
present is bound by the specific immobilized antibody. The standard concentration 
ranges were: 2000-31.25 pg/ml for uPA, and 250-15.6 ng/ml for VDBP. The plates 
were washed with 400 µl/well of wash buffer (section 2.2.1) for a total of 4 washes 
using auto-washer (BioTek) to remove any unbound samples, then 200 µl/well of 
conjugate (HRP-linked antibody specific for each biomarker), were added to the 
plates and incubated for 2 hours on the shaker. After washing the plates to remove 
any unbound antibody, 200 µl of substrate solution were added per well (prepared 
immediately before use by mixing colour reagents A and B in a 1:1 ratio), plates 
incubated for 30 minutes on the benchtop protected from light with aluminium foil. 
The colour development was stopped by adding 50 µl per well of stop solution (2N 
Sulphuric acid, R & D systems), the colour of the substrate solution in the wells 
changed immediately from blue to yellow, when the colour change was not uniform or 
delayed or appeared green it was hastened by gentle tapping of the plates to ensure 
thorough mixing of the acid stop and substrate solutions in the wells (R & D systems). 
The intensity of the resultant colour was measured immediately by microplate reader 
to generate the standard curve (Figure 2.9 & Figure 2.10) and calculate the desired 
biomarkers concentrations in the samples (section 2.2.1). 
  ELISA validation assays  
The aim of these assays is to validate an ELISA kit for samples other than specified 
by the manufacturer in order to secure the most accurate, reliable, and reproducible 
data (Jaedicke et al. 2012). Before carrying out an ELISA assay on the invaluable 
75 
 
saliva samples obtained from patients, it is necessary to perform these validation or 
quality control assays to certify the use of the assay with saliva samples. Even if the 
ELISA kit was verified by the manufacturer for the use on saliva, there is still a need 
to perform at least one of the validation assays before risking the study samples, 
such as testing volunteer samples to set a dilution factor at which the desired protein 
falls within the standard curve range and is possible to be detected by the assay. 
ELISA validation assays include: determination of optimal dilution, recovery and 
linearity measurements, intra- and inter-assay variations, and assay sensitivity. 
Validation assays were carried out on the uPA DuoSet, uPAR DuoSet, uPA 
Quantikine, and VDBP Quantikine kits. 
 
Determination of optimal dilution: The concentrations of the desired mediators to be 
expected in saliva samples were completely unknown (i.e. not measured before), so 
samples were assayed in different dilutions (neat, 1:10, 1:100, and 1:500) in order to 
determine the optimal dilution factor. This gave a first indication if the assay will work 
with different samples, as well as important information relating to the most 
appropriate sample dilution for the rest of the validation assays. 
 
Recovery and linearity measurements: Recovery works on the principle that whatever 
known amount added into the assay is what should be measured (i.e. recovered) in 
return as the result of the assay. The design of recovery assay was to test the 
recovery of a spiked saliva sample and a spiked control. The control was the reagent 
diluent in DuoSet ELISA and the calibrator diluent in Quantikine ELISA. 
Linearity follows the same principle; however, uses different dilutions to assess 
recovery. The design of linearity assay was to test spiked, and unspiked samples 
along with spiked control, in four different dilutions 1:2, 1:4, 1:8 and 1:16 for each. 
In both recovery and linearity, the control and sample were spiked with the same 
amount of the provided ELISA standard selected from or near to the middle range of 
the standard curve. Linearity was useful to investigate whether or not dilutions of 
samples yielded readings in the assay which were parallel to the standard curve. 
Linearity was also used to assess whether saliva samples have to be diluted 
differently because some might have high and some might have low concentrations 
of the protein of interest, that the dilution itself does not affect recovery in the assay. 
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A recovery between 80 and 120% is generally acceptable, which is an indication that 
the assay was suitable for the tested sample and will work properly with the study 
samples (R & D systems), (Jaedicke et al. 2012). All dilution factors should be 
considered when conducting the calculations. 
The following formulas were used to calculate the recovery % for recovery assay: 
For spiked sample: [(assay result for spiked sample - assay result for neat sample)/ 
(amount spiked)] ×100                                             neat sample=unspiked sample 
 
For spiked control: (assay result for spiked control/ amount spiked) ×100 
 
The following formulas were used to calculate the recovery % for the linearity assay: 
For 1:2 spiked sample: (assay result for spiked sample/ assay result for 1:2 spiked 
sample) ×100 
So on for 1:4, 1:8, and 1:16 dilutions. 
 
For 1:2 unspiked sample: (assay result for unspiked sample/ assay result for 1:2 
unspiked sample) ×100 
So on for 1:4, 1:8, and 1:16 dilutions. 
For 1:2 spiked control: (assay result for spiked control/ assay result for 1:2 spiked 
control) ×100 
And so on for 1:4, 1:8, and 1:16 dilutions. 
 
Intra-and Inter-assay variation: 
Intra- and inter-assay variation measurements are often quoted in papers and give 
an indication of how reproducible data is within one assay and between assays 
performed on different days, respectively. Intra-assay variation employs the analysis 
of three different samples, assayed in triplicate on the same plate. Whereas, inter-
assay variation employs the analysis of three different samples in three different 
assays (preferably on three separate days, if this is not possible, at least with three 
separate preparations of antibodies, samples and standards). 
The intra- and inter-assay coefficient of variation (CV), calculated by the formula: 
 (standard deviation of assay results/ mean of assay results) ×100 
CV value less than 10-15 is generally acceptable (Hanneman et al. 2011). 
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Assay sensitivity: 
Values of for assay sensitivity are usually included in the ELISA kits datasheet and 
indicates the smallest concentration of the protein of interest the assay can detect in 
the type of sample used (e.g. saliva). Twenty replicates of the ELISA reagent diluent 
were assayed for the sensitivity step. 
Assay sensitivity is defined as “the mean of assay results for the 20 zero standard 
replicates + 2 standard deviations of the mean” (Jaedicke et al. 2012). The resultant 
value represents an optical density value to be used in the standard curve equation 
to calculate the minimum concentration of the desired protein that can be detected by 
the ELISA. 
2.3.3 Cell culture experiments 
Cell culture experiments were performed to investigate the expression of both uPAR 
and uPA in the supernatants of hGFs stimulated with IL-1β, E. coli LPS, and P. 
gingivalis LPS. uPA biological activity was also measured in response to the 
mentioned stimulants. All cell culture experiments were carried out independently on 
cells obtained from each of 8 donors in total, and the cells were always used in 
passage 5-10. One preliminary IL-1β stimulation experiment was carried out on cells 
obtained from one donor as one replicate (T25 flask) for each of the stimulating 
concentrations and control. Three independent IL-1β stimulation experiments were 
carried out on cells obtained from 3 donors in a total of 10 replicates (wells) for each 
of the stimulating concentrations and control. Two independent E. coli LPS 
stimulation experiments were carried out on cells obtained from 2 donors in a total of 
6 replicates (wells) for each of the stimulating concentration and control. Two 
independent P. gingivalis LPS stimulation experiments were carried out on cells 
obtained from 2 donors in a total of 6 replicates (wells) for each of the stimulating 
concentration and control. The donor variability of hGFs with respect to response to 
pro-inflammatory stimuli has been investigated in detail in our laboratory previously 
(Williams et al. 2016) and has been found to be minimal. All cell culture procedures 
and stimulating experiments were carried out as previously described by Williams 
(2015) and Williams et al. (2016). The concentrations used in the stimulating 
experiments were selected near to those used by the same two studies or in other 
dilutions to investigate the stimulatory effects of different concentrations, including 
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100 ng/ml of LPS instead of 10 ng/ml, and 5 ng/ml along with 0.05 ng/ml 
concentrations for IL-1β. 
  Primary hGF culture procedure 
Cell culture procedures were carried out aseptically in a class II hood (section 2.2.1) 
in the cell culture lab within the oral biology lab, at level 7/school of dental sciences, 
Newcastle University. All cells were incubated in a 5% CO2 atmosphere at 37 °C. The 
hGF cells were taken out of liquid nitrogen, thawed in a water bath at 37°C, then 
slowly pipetted into T75 flask containing 15 ml DMEM+ medium (section 2.2.1). The 
hGFs were incubated at 37°C to grow to confluence as a monolayer adherent to the 
bottom of tissue culture flask with DMEM+. During growth, hGFs exhibited the 
characteristic spindle-shaped morphology (Figure 2.11). While on confluent growth, 
the cells appear aligned in the same orientation (Figure 2.12). The hGFs growth was 
monitored daily by visual inspection using a light microscope (DM IL, Leica 
Microsystems, Milton Keynes, UK) and the medium was changed every two days 
until the cells were ≥80% confluent (this may take 7-10 days depending on the cells 
growth). To passage the cells, 10 ml of PBS was used to wash the cells in the flasks 
(to washout any unattached or floating cells), then the cells were covered with 3-5 ml 
of 1x trypsin-EDTA solution (section 2.2.1) and incubated at 37°C for 3 minutes until 
detached. 5 ml of DMEM+ were added to the cell suspension to neutralize the 
trypsin. The cells were pelleted by centrifugation (168g, 5 minutes, 20°C) using CR3i 
multifunction centrifuge (Thermo Fisher Scientific, Loughborough, UK) and re-
suspended with 1 ml of DMEM+. At this stage, the cells were counted and sub-
cultured using a new flask or seeded into multi well plates for stimulation 
experiments, or cryopreserved for future use. The hGFs could be used up to passage 
13 as they were found to stop dividing at this passage (Williams 2015). 
  Counting and viability assessment of cells 
The hGFs cells were counted on haemocytometer under a light microscope using 
trypan blue (0.4%) stain. Equal volumes of cell suspension and trypan blue (10 µl of 
each) were mixed in an Eppendorf tube and incubated at room temperature for 30 
seconds, then 10 µl of the mixture was loaded onto a haemocytometer. Trypan blue 
was used to count the cells and assess their viability, cells that uptake the stain were 
considered dead. The Bright-Line Haemocytometer (Hausser Scientific, VWR, 
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Lutterworth, UK) used has a Neubauer ruling pattern and therefore the number of 
cells/ml was determined using the formula: 
Cells/ml = number of cells counted in 1 mm2 (4 squares at the corners of the 
Neubauer pattern) x 2 (dilution factor in trypan blue) x 104  
Morphology and adherence of the cells to culture surfaces were considered. Hence, 
when the cells’ viability was <90% or they were poorly adherent, they were excluded 
from stimulation experiments. 
  Cryopreservation of hGFs 
Following centrifugation, cell pellets were re-suspended with 1ml of DMEM+ 
containing 10% v/v DMSO to give a cell density of ≥ 1x106 cells/ml. Each 1 ml aliquot 
was dispensed into a cryovial which was then placed in a freezing unit (containing 
propan-2-ol) in a -80°C freezer overnight. The cryovials were transferred to liquid 
nitrogen for long-term storage. To revive the hGF cells from cryo-preservation, they 
were thawed by warming to 37°C. Thereafter, the hGFs cells were slowly seeded into 
a T75 cell culture flask containing 15 ml DMEM+ medium. The flask was incubated 
overnight at 37°C, next day and after checking the cells were adherent to the bottom 
of the flask, the medium was changed to remove any residual cryopreservant or non-
viable cells and DMSO. The cells were then sub-cultured to be used in an 
experiment. 
  In vitro IL-1β stimulation of hGFs 
Depending on the experiment and plastic-ware format to be used, hGF cells were 
slowly seeded at two densities in DMEM+ (2-4x105 cells/flask in T25 flask, and 1-
2x105 cells/well in 6-multi-well plate). The hGFs, whether in 6-multi-well plate or T25 
flask, were incubated at 37°C until 80-90% confluent and at this point the cells were 
serum-starved. To serum-starve the cells, the DMEM+ medium was carefully pipetted 
out avoid touching the bottom of the well or flask then, replaced with SFM (2 ml per 
well or 5 ml per flask) for 24 hours at 37°C. Then, the SFM was carefully pipetted out 
avoid touching the bottom of the well or flask then, the cells were stimulated for 24 
hours at 37°C with IL-1β (2 ml per well or 5 ml per flask of SFM containing two 
concentrations of IL-1β). hGFs used in IL-1β stimulation experiments were between 
passages 5 and 10. 
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A preliminary stimulating experiment was carried out using three T25 cell culture 
flasks, in which hGFs were stimulated with 5 ml/flask of two concentrations of IL-1β in 
SFM (5 ng/ml and 0.05 ng/ml, one flask/concentration) and the third flask with control 
(0 ng/ml of SFM), all incubated at 37°C for 24 hours. The aim of this experiment was 
to check if the IL-1β will stimulate the hGFs to produce MMP-1 (fibroblast 
collagenase), which is a measure of pro-inflammatory response by such cells (Eren 
et al. 2015; Williams et al. 2016). Following the preliminary experiment, a number of 
further stimulating experiments were carried out using 6-multi-well plates, in which 
hGFs were stimulated with 2 ml/well of two concentrations of IL-1β in SFM (5 ng/ml, 
0.05 ng/ml) and control (0 ng/ml of SFM), all incubated at 37°C for 24 hours. The aim 
of these experiments, was to investigate if the hGFs are able to produce the desired 
candidate biomarkers (uPA and uPAR) when stimulated with IL-1β, by assaying the 
cell culture supernatants using DuoSet ELISAs, as well as, assaying uPA activity in 
the supernatants by uPA activity assay. Following the 24 hours stimulation with IL-1β, 
the hGFs supernatants were pipetted out from each well, placed into cryovials, and 
stored at -80°C till use. 
  In vitro LPS stimulation of hGFs 
In a similar manner to IL-1β stimulating experiments, hGFs cells were slowly seeded 
into DMEM+ containing 6-multi-well plates at the density of 1-2x105 cells/well, 
incubated at 37°C to confluency of 80-90%, serum-starved with SFM at 37°C for 24 
hours, and stimulated for 24 hours at 37°C with bacterial lipopolysaccharide (LPS). In 
cell culture stimulating experiments, P. gingivalis and E. coli LPS were found to 
stimulate the production of pro-inflammatory cytokines (such as IL-1β, and IL-6), 
chemokines and MMPs in gingival fibroblasts and other cells (Kraus et al. 2012; Kuo 
et al. 2012; Williams 2015). hGFs used in LPS stimulation experiments were between 
passages 4 and 9. 
The stimulating experiments were carried out on the hGFs seeded into the 6-multi-
well-plates, using E. coli and P. gingivalis LPS in a concentration of 100 ng/ml and 
control (0 ng/ml of SFM), all incubated at 37°C for 24 hours. Same as the IL-1β 
experiments, the hGFs supernatants were assayed first to check if the E. coli and P. 
gingivalis LPS were able to stimulate the cells to produce MMP-1 as a measure of 
pro-inflammatory response. The aim of the stimulation experiments was to 
investigate if the hGFs cells will secrete the candidate biomarkers (uPA and uPAR) in 
response to the LPS, by assaying the cell culture supernatants using DuoSet ELISA 
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kits, as well as, assaying uPA activity in the supernatants by uPA activity assay. 
Following the 24 hours stimulation with LPS, the cell culture supernatants were 
pipetted out from each well, placed into cryovials, and then stored at -80°C till use. 
2.3.4 uPA activity fluorometric assay 
The uPA activity fluorometric assay kit measures urokinase activity ranging from 
0.01-0.5 IU/well in a variety of samples. uPA activity in saliva and cell culture 
supernatants, was determined using the enzymatic cleavage of an AMC (amido-
methyl-coumarin) based peptide substrate, which results in the generation of AMC (λ 
excitation= 350/λ emission= 450 nm) proportional to the enzymatic activity present, 
measured by fluorometric multi well microplate reader (BioTek Instruments Ltd). 
The assay was carried out at room temperature. 50 µl of standards and samples 
were pipetted per well in duplicates. Saliva samples were not listed among the 
samples to be assayed with this kit, therefore, multiple dilutions assays were 
performed to ensure that saliva samples readings are within linear range of the 
standard curve. All samples were diluted in 50 µl of uPA assay buffer or filtered PBS. 
Cell culture supernatants were used as neat samples. Inherent fluorescence in 
samples might result in sample background. To correct for the background, sample 
blanks were included for the samples. The sample blank was only uPA assay buffer 
or filtered PBS without uPA substrate. The sample blanks readings were subtracted 
from the samples readings for the background correction. 
Fifty µl of appropriate reaction mix were added per well, to ensure mixing with 
standards and samples, the plate was placed immediately on horizontal shaker on 
low speed. The reaction mix was prepared within 10 minutes and kept protected from 
light till use. For standards and samples the reaction mix was 48 µl of uPA assay 
buffer + 2 µl of uPA substrate, whereas, only 50 µl of assay buffer were added to 
sample blanks. Initial readings were taken after 2-3 minutes of incubation with the 
reaction mix on the microplate shaker with protection from light. The initial 
fluorescence intensity (FLU initial) was measured at (λ ex = 350/λ em = 450 nm) at the 
initial time (T initial). The plate was incubated again at room temperature protected 
from light and measurements (FLU) were taken every 5 minutes. The total incubation 
time varies with the activity of the sample. Samples with low uPA activity occasionally 
needed a longer incubation in order to detect enough fluorescence within the range 
of the standard curve. In order to obtain accurate measurements, the ΔFLU (FLU final 
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- FLU initial) must be in the linear range of the corrected fluorescence values used to 
create the standard curve. Therefore, readings were taken until the ΔFLU for saliva 
or cell culture supernatants samples fall within the standard curve range. For saliva 
samples 30-35 minutes incubation time with 6-7 readings were enough to fall within 
the standard curve range. 
To calculate the results, first the changes in the fluorescence measurements were 
calculated from initial time (T initial) to the final time (T final) for all standards and 
samples to obtain the corrected fluorescence readings 
                              ΔFLU = FLU final - FLU initial 
The background of the readings for the standards were corrected by subtracting the 
corrected fluorescence reading of the 0 blank standard (ΔFLU Blank Standard) from each 
standard 
                     ΔFLU - FLU Blank Standard  
The values obtained were used to plot the standard curve (Figure 2.13). A new 
standard curve was generated for each assay. 
Following the determination of the standard curve, the background of the final 
readings for samples were corrected by subtracting the corrected fluorescence 
reading of the 0 blank sample (ΔFLU Blank Sample) from each sample 
                        ΔFLU - FLU Blank Sample 
The corrected readings were used in the standard curve equation to determine the 
uPA values for the samples. The values obtained from the equation were used to 
determine the uPA activity taking in consideration the dilution factor 
uPA Activity (IU/ml) = Sa / Sv 
                     Sa = Amount of uPA for each sample from the standard curve.  
                     Sv = Sample volume (ml) added to well. 
2.4 Statistical Analysis 
Statistical analysis was performed using SPSS 23.0 software (IBM, Portsmouth, UK), 
and Minitab 17 statistical software (Minitab Inc. Coventry, UK). Box and scatter plot 
graphs were created in SPSS. Bar graphs were created in Microsoft Excel 2013. All 
data were assessed for normality and homogeneity of variance using Shapiro-Wilk 
test for normal distribution and Levene's test for homogeneity of variance. When data 
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were normally distributed, means, standard errors of the means (SEM) and standard 
deviations (SD) of the means were calculated and presented, and parametric 
statistical tests were performed on the data. Parametric statistical tests included: 
paired samples t-test for related samples and independent samples t-test for non-
related samples, whereas, for more than one group one-way ANOVA test was used. 
When the normal distribution of data was rejected, medians and interquartile ranges 
(IQR) were calculated and presented, and non-parametric statistical tests were 
performed on the data. Non-parametric statistical tests included: Wilcoxon signed 
rank test for dependent samples and Mann-Whitney U test for independent samples. 
Friedman test was used for more than 2 groups with dependent samples. When 
more than 2 independent samples groups with not-normally distributed data were 
presented, Kruskal-Wallis test was used. One sample t-test was used to determine 
the significance (p-value) for the logarithms of fold change in the PPA assays. 
A p-value of <0.05 was considered significant. The p-values were corrected for 
multiple comparisons with the post hoc or Bonferroni correction tests.  Spearman’s 
coefficient correlation analysis was used to determine possible associations between 
pairs of parameters including: salivary ELISA results with periodontal indices scores, 
GCF ELISA results with periodontal indices scores, uPA activity assay results with 
uPA levels, and uPA activity assay results with periodontal indices scores. 
Spearman’s correlations were considered to be significant when p<0.05. Using 
Sigma Plot 12.5 software (from Sigma Plot, Hounslow, London, UK), receiver 
operating characteristic curve analysis (ROC), was carried out to study the ability of 
the candidate biomarkers to discriminate between healthy and diseased status. The 
ROC curve, is a statistical test used to study the ability of a biomarker, assay or 
clinical procedure to differentiate between healthy and diseased status by the means 
of sensitivity (true positive rate) and 1-specificity (false positive rate) as measures of 
accuracy of the test or biomarker, results were presented as the area under the curve 
(AUC) value ranging between 0-1 (Fawcett 2006; Hajian-Tilaki 2013).  
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Figure 2.1: Clinical study A timetable. 
The visits of clinical study A at which saliva samples were obtained. Saliva samples 
were obtained from healthy subjects at the Baseline month -1 visit (visit 1), and 
month 0 visit (visit 2). Saliva samples were obtained from periodontitis patients at the 
Baseline month -1 visit (visit 1), at the pre-treatment month 0 visit (visit 2) which was 
followed by a number of non-surgical periodontal treatment visits, and finally at the 
post-treatment month 6 visit (visit 6). 
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Figure 2.2: Clinical study B timetable. 
The visits of clinical study B at which saliva samples were obtained. Saliva samples 
were obtained from edentulous subjects, dentulous healthy subjects and gingivitis 
patients at the visit 2 (which was 5-30 days from visit 1). Saliva samples were 
obtained from mild/moderate and advanced periodontitis patients at the visit 2 (pre-
treatment), followed by a number of non-surgical periodontal treatment visits, and 
finally at the visit 3 (post-treatment) which was12 ± 2 weeks after treatment. 
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Figure 2.3: Clinical study C timetable. 
The visits of clinical study C at which the GCF samples were obtained. GCF samples 
were obtained from healthy subjects, gingivitis patients and periodontitis patients at 
the pre-treatment screening visit (2 months before treatment). Non-surgical 
periodontal treatment was offered for the periodontitis patients at the treatment visit 
(month 0). GCF samples were obtained again from the same periodontitis patients at 
the post-treatment month 3 visit, and at the post-treatment month 6 visit. 
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Periodontal 
diagnosis 
Criteria 
Healthy BOP≤15% 
No PD sites >4mm 
No LOA (Disregard any recession due to tooth brushing) 
No bone loss 
Gingivitis BOP≥15% 
No sites with PD >4 mm, except for sites at the distal surface of last standing 
molars (up to 5 sites with 5 mm PD accepted) 
No LOA (Disregard any recession due to tooth brushing) 
Periodontitis ≥6 sites with PD of ≥5 mm  
LOA and/ or bone loss present. 
Table 2.1: Periodontal diagnostic criteria. 
Firm diagnostic criteria for periodontal status were used to classify the patients from 
healthy volunteers. To avoid any misdiagnosis of a difficult case for a patient or 
subject, decision was made by discussion between the clinicians involved. 
  
88 
 
 
Figure 2.4: Assay principle of the proteome profiler arrays. 
The two-site sandwich assay principle of proteome profiler arrays. The target analyte 
binds to the specific capture antibody on the array membrane on one site, and the 
biotinylated detection antibody on the other site, to be detected and visualised by 
Streptavidin-HRP and substrate. (R & D systems). 
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Figure 2.5: Proteome profiler arrays templates. 
The transparency overlay templates for the protease and cytokine arrays, illustrating 
the positions of the reference spots. The arrows represent the three duplicate spot 
positive control references on three corners of each template. The stars represent 
the duplicate spot of the negative control reference on each template. Each protein 
identified by its precise duplicate spot on the template for instance the duplicate spot 
(C13, C14) on the protease template represent the MMP-1. The duplicate spot (D3, 
D4) on the cytokine template represent the growth hormone. 
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Figure 2.6: uPAR DuoSet ELISA standard curve. 
Despite of the ideal standard curve detection range, an individual uPAR DuoSet 
ELISA standard curve was generated for each individual assay with little bit higher or 
lower ranges. The ΔOD values of the different uPAR concentrations were plotted 
against the uPAR concentration. A 4-parameter curve fit was created to produce the 
7-point standard curve for the uPAR ELISA. ΔOD: OD 450 nm – OD 550 nm. 
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Figure 2.7: uPA DuoSet ELISA standard curve. 
In spite of the ideal standard curve detection range, an individual uPA DuoSet ELISA 
standard curve was generated for each individual assay with little bit higher or lower 
ranges. The ΔOD values of the different uPA concentrations were plotted against the 
uPA concentration. A 4-parameter curve fit was created to produce the 7-point 
standard curve for the uPA ELISA. ΔOD: OD 450 nm – OD 550 nm. 
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Figure 2.8: Human total MMP-1 DuoSet ELISA standard curve. 
Regardless to the ideal standard curve detection range, an individual MMP-1 DuoSet 
ELISA standard curve was generated for each individual assay with little bit higher or 
lower ranges. The ΔOD values of the different MMP-1 concentrations were plotted 
against the MMP-1 concentration. A 4-parameter curve fit was created to produce the 
7-point standard curve for the MMP-1 ELISA. ΔOD: OD 450 nm – OD 550 nm. 
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Figure 2.9: uPA Quantikine ELISA standard curve. 
Aside from the ideal standard curve detection range, an individual uPA Quantikine 
standard curve was generated for each single assay. The ΔOD values of the different 
uPA concentrations were plotted against the uPA concentration. A 4-parameter curve 
fit was created to produce the 7-point standard curve for the uPA ELISA. ΔOD: OD 
450 nm – OD 550 nm. 
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Figure 2.10: VDBP Quantikine ELISA standard curve. 
In spite of the ideal standard curve detection range, an individual VDBP Quantikine 
ELISA standard curve was generated for each single assay. The ΔOD values of the 
different VDBP concentrations were plotted against the VDBP concertation. A 4-
parameter curve fit was created to produce the 5-point standard curve for the VDBP 
ELISA. ΔOD: OD 450 nm – OD 550 nm. 
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Figure 2.11: hGF cells during growth. 
Spindle-shaped morphology of viable hGF cells under microscope. At low confluency 
during growth in DMEM+ medium the cells were attached to the bottom of plastic-
ware cell culture flask.100x magnification. 
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Figure 2.12: hGF cells on confluent growth. 
The hGF cells in confluent growth under microscope. As the cells’ growth reach 80 % 
confluency and above, they will appear aligned in the same orientation at the bottom 
of plastic-ware cell culture flask containing DMEM+ medium.100x magnification. 
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Figure 2.13: uPA activity fluorometric assay standard curve. 
The corrected FLU values of the uPA standards were plotted against their known 
activity values (IU/ml). A 4-parameter curve fit was created to produce the 6-point 
standard curve of the uPA activity assay. The resultant equation was used to 
calculate the uPA activity for the samples.
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Chapter 3 Identification of candidate salivary biomarkers 
3.1 Introduction 
Several clinical studies identified a number of biomarkers and inflammatory 
mediators associated with periodontitis. These biomarkers were correlated with the 
clinical measurements of the disease, and their levels were changed in parallel with 
the clinical course of the disease and in response to treatment (Buduneli and Kinane 
2011; Taylor 2014). Salivary IL-1β has been suggested as a good biomarker for 
periodontitis in a number of studies as the measurement of IL-1β can discriminate 
periodontitis patients from healthy volunteers (Miller et al. 2006; Tobon-Arroyave et 
al. 2008; Gursoy et al. 2009; Mirrielees et al. 2010; Kaushik et al. 2011; Ebersole et 
al. 2013; Rathnayake et al. 2013; Javed et al. 2014). Numerous studies 
demonstrated that salivary matrix metallo-proteinase 8 (MMP-8) activity was elevated 
in periodontitis patients in comparison to healthy volunteers, and it was correlated 
with the clinical measures of periodontitis (Miller et al. 2006; Ramseier et al. 2009; 
Costa et al. 2010; Gursoy et al. 2010; Mirrielees et al. 2010; Ebersole et al. 2013; 
Rathnayake et al. 2013; Miricescu et al. 2014). MMP-8 appears to be the best 
biomarker in comparison to others such as IL-1β, as it not only identifies the 
presence of periodontal inflammation but also has the ability to determine the extent 
of tissue destruction (Rathnayake et al. 2013). Other salivary MMPs such as MMP-1, 
salivary gelatinases (MMP-2 and MMP-9) and elastase were significantly elevated in 
periodontitis patients as compared to healthy controls (Pietruska et al. 2009; 
Ramseier et al. 2009; Isaza-Guzman et al. 2011; Morelli et al. 2014). Significant 
association of salivary hepatocyte growth factor (HGF) with periodontitis was 
demonstrated in independent studies (Wilczynska-Borawska et al. 2006; 
Scannapieco et al. 2007; Rudrakshi et al. 2011; Wilczynska-Borawska et al. 2012). 
Though IL-1β, MMPs, and HGF are good biomarkers for periodontitis, for an efficient 
diagnosis of a disease such as periodontitis with its complex pathogenesis, 
progression, and inter-individual variation, there is a need for multiple biomarkers 
(Giannobile et al. 2009; Kinney et al. 2011). This notion known as “biomarker 
signature” which was defined by Lagani et al. (2013) as “a minimal subset of 
molecular quantities that are maximally informative for a given task when considered 
jointly”. Therefore, investigation of the proteome profile of human saliva, with 
comprehensive analysis of salivary proteins, may help to understand oral diseases 
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pathogenesis and identify novel salivary biomarkers for human diseases such as 
periodontitis (Hu et al. 2007). On this basis, the first aim of the present study to be 
discussed in this chapter, is to identify novel salivary biomarkers for periodontitis. 
In the diagnosis of periodontitis, proteomics is considered as a novel approach to 
identify salivary biomarkers associated with the disease. Proteomics can provide 
information about different proteins that cannot be obtained by ELISAs or western 
blot techniques (Haigh et al. 2010). One of the proteomic techniques is the proteome 
profiler array (PPA) system (R & D systems), which was employed for the first time in 
this study to identify candidate salivary biomarkers for periodontal diseases. Two 
types of arrays were used: a human protease array and a human cytokine array. The 
PPAs offer a wide panel of target antibodies per array membrane for sample 
screening. 34 and 102 specific capture antibodies are spotted in duplicate onto 
protease and cytokine PPAs respectively. The PPA procedure involved: an overnight 
incubation of the samples with the membranes at 2-8°C, followed by multiple steps of 
washing and incubation at room temperature with specific detection antibodies, and 
streptavidin. Finally, a chemiluminescent substrate mix was added to demonstrate 
the positive spots on the arrays, and to view these positive spots multiple 
radiographs were taken. 
3.2 Results 
In the present study, 6 PPA assays for salivary proteases and 6 assays for salivary 
cytokines, were performed on whole unstimulated saliva samples from the baseline 
visit of clinical study A, according to the previously described method (see chapter 2, 
section 2.3.1). 4-5 minutes was found to be the optimum exposure time to develop 
positive signals of the array membranes by autoradiography. Image analysis of the 
radiographs revealed that, the arrays identified a number of proteases and cytokines 
in saliva samples obtained from patients with untreated chronic periodontitis and 
healthy control volunteers. The relative expression of the proteins were measured by 
the means of pixel intensity (PI), the PI values were calculated by subtracting the 
mean of each protein duplicate spot from the mean of the negative reference 
duplicate spot on the PPA membrane for background correction as described by R & 
D systems. The changes in the relative expression of the proteases and cytokines 
were compared in periodontitis and control samples. These changes were illustrated 
by the means of bar graphs representing the means of the PI values as described by 
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R & D systems and (Westman et al. 2015; Tsuboki et al. 2016). Furthermore, the 
difference in the mean PI values for the relative expression of the detected proteases 
and cytokines, were compared by the means of fold change and p-value of the 
logarithm-fold change obtained by performing the one sample t-test on the logarithms 
of the fold change to test the null hypothesis H0: log (fold change) equal to 0 against 
the alternative H1: log (fold change) not equal to 0 (McCarthy and Smyth 2009). 
The proteins described in the following sections were examples of proteases and 
cytokines selected according to their known roles in extra cellular proteolysis, bone 
metabolism and degradation, cellular signalling, and chemotaxis of inflammatory 
cells, or inflammatory events, which may take place in the pathogenesis of 
periodontitis. The remaining PPA data from both the protease and cytokine PPA 
arrays are presented in the Appendix tables (Appendix A. Table 1, Appendix A. Table 
2, Appendix A. Table 3, & Appendix A. Table 4). 
3.2.1 Salivary protease analysis 
Twelve study samples obtained from untreated chronic periodontitis patients and 12 
control samples obtained from healthy subjects, were assayed in 6 protease PPA 
assays. Three independent single sample protease PPA assays were performed on 
6 samples (2 samples for each assay, one chronic periodontitis sample and one 
healthy sample). Also, 3 independent protease PPA assays were performed on 6 
pooled samples (2 samples for each assay, each pooled sample consisted of 3 
periodontitis or 3 healthy samples mixed in equal ratios). 
  Single sample assays 
The overall analysis of the three assays in which individual saliva samples (rather 
than pooled samples) were analysed revealed that all the 34 proteases were 
expressed in both the periodontitis and healthy samples. The relative expression of 
15 proteases were numerically higher in the periodontitis samples as compared to 
the expression in the periodontally healthy volunteers, but only 2 of these were 
statistically significant (Figure 3.1, Table 3.1 & Appendix A. Table 1). The 2 proteins, 
which were significantly elevated, were ADAM8 and uPA (Figure 3.1 & Table 3.1). In 
contrast, the relative expression of some 19 proteases was numerically higher in the 
healthy samples as compared to the periodontitis samples but in only one case was 
this difference statistically significant (Table 3.1 & Appendix A. Table 1). The protein, 
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which was significantly elevated in healthy samples, was MMP-9 (Figure 3.1 & Table 
3.1). 
  Pooled sample assays 
The overall analysis of the in which pooled saliva samples (rather than individual 
samples) were analysed demonstrated that all the 34 proteases on the array were 
expressed in saliva samples of both the periodontitis patients and healthy volunteers. 
The relative expression of 33 proteases (including ADAM8 and uPA) were 
numerically higher in the periodontitis samples as compared to the expression in the 
periodontally healthy volunteers and 17 of these differences were statistically 
significant (Figure 3.2, Table 3.2 & Appendix A. Table 2). In contrast to the data from 
the analysis of the single sample assays, the levels of MMP-9 were not significantly 
different between health and periodontitis. From the 3 pooled sample assays, only 
proteinase 3 was more highly expressed in the healthy samples in comparison to the 
periodontitis samples, but this difference was not statistically significant (Figure 3.2 & 
Table 3.2). 
  Summary of protease expression analysis 
The results analysis of both the single and pooled sample protease assays revealed 
that, there was a difference in the protease profile for the whole unstimulated saliva 
obtained from the periodontitis patients and the healthy subjects. In the periodontitis 
samples, the relative expression for the salivary proteases was higher in the pooled 
sample assays in comparison to the single sample assays. Both the single and 
pooled sample assays were able to detect all the 34 listed proteases in both the 
healthy and periodontitis saliva samples. It is interesting that in both the single and 
pooled sample protease PPA assays, there was a statistically significantly higher 
expression of salivary uPA as well as ADAM8 in the periodontitis patients in 
comparison to the healthy subjects (Figure 3.3). 
3.2.2 Salivary cytokine analysis 
In a similar manner to the salivary protease PPA assays, 6 cytokine PPA assays 
were performed on 12 study samples obtained from untreated chronic periodontitis 
patients and 12 control samples obtained from healthy subjects. Three independent 
single sample cytokine PPA assays were performed on 6 samples (2 samples for 
each assay, one chronic periodontitis sample and one healthy sample). Also, 3 
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independent cytokine PPA assays were performed on 6 pooled samples (2 samples 
for each assay, each pooled sample consisted of 3 periodontitis or 3 healthy samples 
mixed in equal ratios). 
  Single sample assays 
The assays in which individual saliva samples (rather than pooled samples) were 
analysed revealed that, from the total of 102 cytokines, 90 were detected by the 
arrays specific capture antibodies in the periodontitis samples, whereas only 30 
cytokines were expressed in the healthy samples (Table 3.3 & Appendix A. Table 3). 
Among the detected cytokines, the relative expression of 26 cytokines were 
numerically higher in the periodontitis samples in comparison to the healthy samples, 
but these differences were only statistically significantly different in 4 cases: 
adiponectin, complement factor D, uPAR and retinol binding protein 4 (RBP4) (Figure 
3.4, Table 3.3 & Appendix A. Table 3). In contrast, there were only 4 proteins 
numerically more highly expressed in the healthy samples in comparison to the 
periodontitis samples, but none of these differences were statistically significant 
(Table 3.3 & Appendix A. Table 3). The majority of proteins (n=60) detected in 
periodontitis samples, in addition to 12 other proteins (total 72) were not detected at 
all in saliva from healthy volunteers (Appendix A. Table 3). 
  Pooled sample assays 
The results of assays in which pooled saliva samples (rather than individual samples) 
were analysed showed that, from the total of 102 cytokines, 95 were expressed in the 
periodontitis samples, and 93 cytokines were expressed in the healthy samples 
(Table 3.4 & Appendix A. Table 4). Among the 95 cytokines detected in the 
periodontitis samples, 55 were relatively more highly expressed in comparison to the 
healthy samples in numerical terms, but these differences were only significant with 
respect to 6 proteins (EGF, IL-8, resistin, uPAR, VEGF and IL-1Ra) (Figure 3.5, 
Table 3.4 & Appendix A. Table 4). The elevated expression of uPAR in periodontitis 
is in agreement with the data from the single sample protease PPA assays. In 
contrast, there were some 34 proteins numerically more highly expressed in the 
healthy samples in comparison to the periodontitis samples, but none of these 
differences were statistically significant (Figure 3.5, Table 3.4 & Appendix A. Table 
4). The expression of 9 proteins was not detected in the pooled healthy saliva 
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samples and 7 proteins were not detected in the pooled periodontitis samples (Table 
3.4 & Appendix A. Table 4). 
  Summary of cytokine expression analysis 
The single and pooled sample cytokine PPA assays revealed that, there were 
differences in the cytokine profile for the whole unstimulated saliva obtained from the 
periodontitis patients and healthy subjects. The relative expression of the cytokines in 
both the healthy and periodontitis samples was higher in the pooled sample assays 
than the single sample assays. In contrast to the protease assays which detected all 
the 34 listed salivary proteases, a number of the 102 listed proteins were not 
detected at all by the cytokine arrays in both the periodontitis and healthy samples. . 
Significantly, both the single and pooled sample cytokine PPAs indicated that there 
was significantly higher expression of the salivary uPAR in the periodontitis patients 
in comparison to the healthy subjects (Figure 3.6). 
3.3 Discussion 
3.3.1 Proteome profiler arrays and proteomics 
The diverse and powerful technologies of proteomics have opened the door for the 
identification of new biomarkers that will improve the diagnosis and monitoring of 
several oral and systemic diseases (Zhang et al. 2013a). Therefore, PPA assays 
were selected to be used for their ability to detect wide range of proteins in saliva 
samples and thus to identify candidate salivary biomarkers for chronic periodontitis. 
The results revealed that there was a difference in the proteome profile of the whole 
unstimulated saliva obtained from the periodontitis patients as compared to that of 
the healthy subjects. 
Despite the fact that proteomics offers advantages when compared to other 
techniques that identify single or limited number of proteins, there are some problems 
or weakness points associated with proteomics. The global analysis of saliva using 
proteomics may represent a challenge to the researchers due to the wide range of 
abundances for the proteins of interest. For instance, though proteomics are able to 
detect the salivary protein profile; some proteomic approaches are only sensitive 
when the proteins are highly abundant, whereas other proteins with low abundance 
such as some cytokines and MMPs may not be detected, therefore, many studies 
working on expanding the range of proteome profile coverage and salivary protein 
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catalogue by combining different techniques together such as 2D & 3D gel 
electrophoresis, protein/peptide fractioning, and liquid chromatography-mass 
spectrometry / mass spectrometry (LC-MS/MS) (Xie et al. 2005; Guo et al. 2006; 
Bandhakavi et al. 2009; Wu et al. 2009; Goncalves Lda et al. 2010; Haigh et al. 2010; 
Salazar et al. 2013). 
Although some salivary proteins such as MMP-8 and IL-1β are well known 
biomarkers for periodontal diseases (Kaushik et al. 2011; Ebersole et al. 2013; 
Rathnayake et al. 2013; Miricescu et al. 2014); there is a controversy about the 
detection of these proteins in proteomic studies. Haigh et al. (2010) reported that 
though the 2 dimensional sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (2D SDS-PAGE) can accurately quantify a wide range of proteins in 
one sample; proteins of less than 1 µg/ml concentration, and smaller than 10 kDa in 
size or of high hydrophobicity, are either poorly resolved or not detected. Some 
proteins such as cytokines and MMPs, are only presented in ng/ml concentrations in 
saliva, hence these proteins were not quantified by the 2D SDS-PAGE (Haigh et al. 
2010). The use of other sensitive approaches such as more sensitive fluorescent 
stain, instead of Coomassie blue, may have increased the technique ability to detect 
these low abundance proteins (Haigh et al. 2010). This finding by Haigh et al. (2010) 
may explain why some proteases such as MMP-8 and MMP-9 were variably or not 
highly expressed by the protease PPA membranes, and cytokines namely IL-1β was 
either not detected by the single sample cytokine PPA assays or detected in low 
expression by the pooled sample PPA assays in saliva of periodontitis patients in the 
present study. However, in contrast to Haigh et al. (2010), using LC-MS/MS 
approaches enabled Salazar et al. (2013) to find that MMP-8 and MMP-9 were 
among the proteins detected in saliva of periodontitis patients that showed ≥1.5 fold 
change difference in abundance with p<0.05 significance as compared to healthy 
controls. Whereas, the present study protease PPA assays results revealed that the 
MMP-8 was numerically but not significantly highly expressed in saliva of the 
periodontitis patients as compared to the healthy controls. The MMP-9 was both 
numerically and significantly highly expressed by the single sample protease PPA 
assays in the healthy subjects as compared to the patients, but it was only 
numerically highly expressed in the periodontitis patients as compared to the healthy 
controls by the pooled sample PPA assays. In addition to their ng/ml concentrations 
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in saliva (Haigh et al. 2010), this inconstancy in the MMPs expression especially the 
MMP-9, may be due to inter-individual variation. Hence, regardless to the health or 
disease status, the expression of salivary MMPs and IL-1β in the PPA assays found 
by the present study indicates that these proteomic antibody membranes may be 
more sensitive to proteins presented in high concentrations in human saliva than to 
those of relatively low concentrations. 
Vitorino et al. (2012), reported issues including sensitivity and reproducibility 
associated with proteomic techniques such as two-dimensional gel electrophoresis 
(2-DE), which may represent limitations to obtain reliable data. However, to bypass 
these challenges new approaches and alternative techniques are developing. For 
instance, for reasons of reproducibility, Vitorino et al. (2012) used proteomics 
analysis with iTRAQ (isobaric tags for relative and absolute quantification reagents) 
which identified higher number of various peptides and discrete quantities of many 
proteins in saliva samples (Vitorino et al. 2012). Reagent driven and protein driven 
cross reactivity in antibody microarrays and multiplexed sandwich assays with 
reagent mixing have been reported, such as the cross reactivity that occurs between 
the capture and detective antibodies of the assays, or between these antibodies and 
proteins other than the targets, the possibility of such cross reactivity might increase 
proportionally with the number of targets (Pla-Roca et al. 2012; Juncker et al. 2014).  
All these issues were considered when conducting the present study. Though, 34 
specific antibodies for proteases and 102 specific antibodies for cytokines spotted in 
duplicate on each PPA membrane, cross reactivity may occur. This cross reactivity 
may be due to the antibodies spots are closely located to each other with no barrier 
or separation between them. As well as, some proteins may be genetically or 
structurally related. In addition to that, each reagent/sample was loaded on each 
membrane to be exposed to all the capture antibodies spots at the same time and 
the membranes were rocked on a platform shaker during the incubations, which may 
increase the chance for cross reactivity. Differences in the abundance of salivary 
proteins and inter/intra-individual variations may affect the detection of some proteins 
such as MMPs and interleukins. Also there is the possibility of immune complexes 
being formed in mixed saliva samples, which may compromise detection. Hence, to 
overcome cross reactivity and for the purposes of sensitivity, and reproducibility, the 
assays were repeated 6 times for each array. Three PPA assays were carried out 
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using individual healthy and individual periodontitis samples. As well as three assays 
with saliva samples, which comprised a pool of 3 individual healthy or 3 individual 
periodontitis samples. It is interesting to note that the relative expression of the 
proteins was higher in the pooled sample protease assays than the single sample 
assays for the periodontitis samples, and for both the healthy and periodontitis 
samples in the pooled cytokine assays than the single sample assays. It is not clear 
whether these differences are explained by technical artefact (and hence ‘false 
positive’ differences), variation between samples and/or genuine increased sensitivity 
to differences between health and disease when pooled samples are employed. 
Also, there were many instances of substantial numerical differences in proteins 
expression between health and disease but which were not statistically significantly 
different; these findings cannot be confirmed until further samples have been 
analysed (e.g. by ELISA). It is important to emphasise; however, that there was 
substantial consistency between analysis of individual saliva samples and pooled 
samples in as much as the majority of statistically significant differences detected by 
analysis of 3 individual saliva samples were confirmed by analysis of pooled 
samples. Thus, 2 of these markers (UPA and uPAR) were selected for further, 
detailed, analysis (see below). 
PPA assays were used for the first time in this study for saliva proteome profiling in 
periodontitis. Previously published studies have used different proteomic techniques 
to identify candidate biomarkers in saliva or GCF for periodontal diseases. Using 
different techniques including: two-dimensional polyacrylamide gel electrophoresis 
(2-D PAGE), n-terminal amino acid sequencing, MS, and immunostaining (western 
blot), Kojima et al. (2000) detected 2 members of calcium binding proteins of the 
s100 family in saliva and GCF of 10 periodontitis patients. The detection of high 
levels of both MRP8 (S100A8) and MRP14 (S100A9), led to the hypothesis that 
these two S100 proteins may play an important role in pathogenesis of periodontal 
diseases (Kojima et al. 2000). In agreement with (Kojima et al. 2000), the same S100 
proteins were detected in whole unstimulated saliva of five patients with generalized 
aggressive periodontitis (GAgP) using 2-D PAGE and electrospray tandem MS (Wu 
et al. 2009). Third study identified the S100A9 protein in saliva of chronic 
periodontitis patients (Goncalves Lda et al. 2010). In addition to S100A8/A9 another 
S100 protein (A6) were identified in high abundance in saliva of periodontitis patients 
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(Haigh et al. 2010). The detection of S100 proteins, were confirmed by a fifth study 
using MS analysis of whole saliva from twenty periodontitis patients (Salazar et al. 
2013). 
MMPs, Kalllikreins and cystain C were among the salivary proteins identified by the 
PPA assays in the present study as potential biomarkers, which was in agreement 
with previous non-proteomic studies (Kathariya 2010). Besides VDBP (which was 
identified in the present study) and S100 proteins, 9 other proteins were identified in 
the proteome profile of saliva from GAgP patients, such as albumin, Igγ2 chain C 
region, Igα2 chain C region, α-amylase, zinc-α2 glycoprotein and lactoferrin (Wu et 
al. 2009). In agreement with the Wu et al. (2009) study, Goncalves Lda et al. (2010) 
also used 2-D gel electrophoresis but with LC techniques to identify a number of 
proteins in whole unstimulated saliva of 10 chronic periodontitis patients, including 
along with S100A, other proteins such as serum albumin, haemoglobin, α-amylase, 
cystatins, and transferrin, these findings gave a novel perception about the salivary 
proteins alterations in periodontal diseases (Goncalves Lda et al. 2010). Haigh et al. 
(2010), used quantitative proteomics (2-D PAGE and MS) to investigate the salivary 
proteome profile in samples of 9 patients with severe periodontitis before and after 
treatment, the study demonstrated that among 128 proteins identified, 15 proteins 
were significantly altered after treatment including S100 proteins, haptoglobin, 
prolactin inducible protein and parotid secretory protein. The results were in 
agreement with previous studies regarding the involvement of S100 proteins in the 
pathogenesis of periodontitis, as well as, led to the identification of new potential 
biomarkers to be used in monitoring the disease progression (Haigh et al. 2010). 
In their search for biomarkers that have the ability to predict periodontal diseases, 
Bostanci et al. (2010) used the quantitative proteomic approach LC-MS to investigate 
the GCF proteome profile in 5 patients with aggressive periodontitis in comparison to 
healthy controls. The results revealed that the GCF proteins cystatin-B and alpha 
defensin-1 were detected only in the healthy subjects and the annexin-1 was 5 fold 
higher in the healthy subjects’ samples as compared to the patients. Whereas the 
actin bundling protein L-plastin was only detected in the GCF of the patients 
(Bostanci et al. 2010). L-plastin, which is exclusively expressed by leukocytes, plays 
a crucial role in immune-mediated events (Ozturk et al. 2015). A recent study used 
quantitative real-time PCR and ELISA approaches, identified high levels of L-plastin 
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in GCF samples of chronic and generalized aggressive periodontitis patients (Ozturk 
et al. 2015). 
Pursuing studies to analyse salivary proteome using 2-D PAGE, LC and MS 
techniques, one study found that there was a difference in the salivary proteome 
profile of 10 patients with gingivitis in comparison to 10 healthy controls (Goncalves 
Lda et al. 2011). High levels of proteins such as α-amylase, albumin, haemoglobin, 
immunoglobulin peptides and keratins were detected in saliva of the gingivitis 
patients, whereas salivary cystatins were higher in the controls, the study results 
highlighted a new salivary proteome profile which may aid in the diagnosis and 
monitoring of gingivitis (Goncalves Lda et al. 2011). MS proteome analysis of whole 
saliva from obese patients with and without periodontitis detected 8 candidate 
biomarkers such as albumin, α and β haemoglobin chains and α-defensins (Range et 
al. 2012). The study concluded that periodontal inflammation may modify the whole 
saliva proteome profile in obese patients, and that α-defensins may be associated 
with gingival inflammation, therefore, might explain the high susceptibility of obese 
patients to periodontitis (Range et al. 2012). A study was carried out to investigate 
the salivary proteome profile in type 2 diabetes mellitus (T2DM) patients with and 
without periodontitis (Chan et al. 2012). The authors used 2-D PAGE and LC-MS/MS 
techniques to investigate the changes in the salivary proteome profile of the patients 
and found that seven proteins, including polymeric immunoglobulin receptor, plastin-
2, actin related protein 3, leukocyte elastase inhibitor, carbonic anhydrases 6, 
immunoglobulin J and interleukin-1 receptor antagonist, to be differentially and 
significantly expressed (p<0.01) in the T2DM patients with periodontitis as compared 
to the periodontally healthy patients. The study suggested that these proteins may 
have the potential to be used as biomarkers for the prediction of T2DM patients who 
are at risk of periodontitis (Chan et al. 2012). Using LC-MS/MS analysis of whole 
unstimulated saliva from 20 patients with periodontitis in comparison to 20 healthy 
controls demonstrated that, including the previously mentioned S100 proteins, a total 
of 344 proteins were detected in both groups, with 152 proteins identified with more 
than one unique peptide, of which 20 proteins were significantly higher in the 
periodontitis patients such as lacto-peroxidase, catalase, MMP-9, neutrophil 
collagenase, neutrophil defensin, complement C3 and others (Salazar et al. 2013). 
The study concluded that the proteome profile analysis of whole unstimulated saliva 
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is an efficacious means to characterize and differentiate between periodontitis 
patients (during acute phase of the disease) and healthy subjects (Salazar et al. 
2013). 
Gel free and gel-based electrophoresis along with LC-MS/MS techniques were used 
in the proteomic analysis of GCF for discovery of novel periodontal disease 
biomarkers (Tsuchida et al. 2012). A total of 327 proteins were identified in GCF of 
healthy subjects as compared to supra-gingival saliva. Among these proteins, some 
of which were found to be significantly expressed in GCF especially superoxide 
dismutase 1 (SOD1), apolipoprotein A-I (ApoA-I), and dermcidin (DCD). Suggesting 
future proteomic studies for these proteins as potential GCF biomarkers for 
periodontal diseases (Tsuchida et al. 2012). Baliban et al. (2013), used high-
performance LC, tandem MS, and the pilot protein algorithm, with a mixed-integer 
linear optimization (MILP) model to identify GCF biomarker combinations of which 
can distinguish a blind subject sample as healthy or diseased. Glyceraldehyde 3-
phosphate dehydrogenase, thymidine phosphorylase and Ig kappa chain V-I region 
AG, were identified as protein biomarkers for periodontally healthy status. The study 
reported that this novel biomarkers combination have greater than 95% predictive 
accuracy in the diagnosis of periodontal status; however, the authors recommended 
further investigations regarding the roles of these proteins (Baliban et al. 2013). 
In respect to the protein ADAM8 (A disintegrin and metalloproteinase domain-
containing protein 8), the present study was the first to detect this protein in saliva of 
periodontitis patients. The single and pooled sample protease PPA assays revealed 
that this protein was both numerically and significantly highly expressed in saliva of 
periodontitis patients as compared to healthy volunteers, this finding was in harmony 
with 3 recent studies which investigated this protein in relation to periodontal 
diseases. Though these 3 studies used techniques other than PPA assays, all of 
them reported high levels of ADAM8 in patients with periodontal diseases. Using 
sodium dodecyl sulphate polyacrylamide gel electrophoresis with immunoblotting and 
ELISA assays, Khongkhunthian et al. (2013) detected significantly high levels of 
ADAM8 in GCF of patients with gingivitis, chronic and aggressive periodontitis as 
compared to healthy control subjects and these high levels of ADAM8 were positively 
correlated with the clinical periodontal measures. The second study used ELISA 
assay to detect significantly elevated levels of ADAM8 in GCF samples of patients 
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with chronic periodontitis in comparison to healthy controls, and these high GCF 
ADAM8 levels were positively associated with the clinical parameters of periodontitis 
(Elavarasu et al. 2015). Finally, ADAM8 expression was investigated in gingival 
epithelial cells obtained from 33 patients with chronic periodontitis in comparison to 
23 healthy subjects (Aung et al. 2017). The real time PCR, immunoblotting, 
immunohistochemistry and flow cytometry investigations of the epithelial cells 
reported significantly elevated mRNA and protein expression of ADAM8 in the 
periodontitis patients as compared to the healthy volunteers. Moreover, the study 
reported consistent upregulation of ADAM8 expression in the gingival epithelial cells 
but not gingival fibroblasts in response to stimulation with F. nucleatum bacteria 
(Aung et al. 2017). Therefore, these studies may justify the detection and the 
significantly high expression of ADAM8 in saliva of periodontitis patients by the 
present study. 
Many of the proteins detected in the previously mentioned salivary proteomic studies 
were also identified in the present study, which may justify the use of the PPA assays 
to identify candidate biomarkers in saliva of chronic periodontitis patients. 
Furthermore, the difference in the proteome profile of whole unstimulated saliva from 
the periodontitis patients and healthy controls found by the present study, was in 
agreement with many of the above studies in regard to the ability of periodontal 
inflammation to alter the salivary proteins profile. However, with an exception for 
Salazar et al. (2013) who identified MMP-8 and MMP-9, and the present study which 
detected the same MMPs (though they were variably expressed) as well as MMP-2, -
3, & -12, and number of interleukins (such as IL-8), up to the time conducting the 
present study, no other proteomic study was able to detect MMPs and IL-1β in saliva 
and GCF of patients with periodontal diseases (Haigh et al. 2010; Amado et al. 
2013). 
3.3.2 Identified salivary biomarkers and periodontitis 
Based on the results of the protease and cytokine PPA assays and in a review of the 
previous clinical and experimental studies, three candidate salivary biomarkers for 
periodontitis were identified including: uPA, uPAR and VDBP. uPA and uPAR were 
consistently elevated in periodontitis samples as compared to healthy samples and 
these differences were statistically significantly different. VDBP was also selected as 
good analysis reagents were available for this protein and there were substantial 
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numerical differences between the patients and healthy samples although these were 
not statistically significantly different. 
Gustafsson et al. (2011), carried out the only published study on salivary uPAR and 
they have reported the analysis of soluble uPAR (suPAR) in saliva and plasma of 
healthy non-smoking adults. Their detection of uPAR in saliva was in agreement with 
the present study for the identification of uPAR in human saliva by PPAs; however, 
Gustafsson et al. (2011) results were not correlated with any oral or systemic 
disease. The present study was the first that identified uPA in saliva of periodontitis 
patients and investigated both its levels and enzymatic activity. There was a single 
study carried out by Virtanen et al. (2006) who investigated uPA activity along with 
other plasminogen activators (PAs) and inhibitors (PAIs) in human saliva and salivary 
gland tissues, but their study had no relation with any periodontal disease. However, 
the presence of an active uPA and other PA activators in human saliva found by 
Virtanen et al. (2006), might explain the identification of salivary uPA by the PPA 
protease assays in the present study. 
Though they were not identified or measured in saliva of chronic periodontitis 
patients, uPA/uPAR and other components of the PA system were investigated in 
GCF and gingival epithelium of patients with different forms of periodontal diseases 
(Ogura et al. 1995; Kinnby et al. 1996; Ogura et al. 1999; Ogura et al. 2001; Buduneli 
et al. 2004; Buduneli et al. 2005; Smith and Martinez 2006; Sulniute et al. 2011; 
Fleetwood et al. 2015). These studies related uPA/uPAR and other PA system 
components to gingivitis and periodontitis, and studied those PA system proteins in 
response to inflammatory or periodontal bacterial stimuli. Therefore, as whole 
unstimulated saliva contains traces of GCF, and inflammatory exudate from all sites 
of periodontal disease, this might explain the identification of uPA and uPAR in saliva 
of chronic periodontitis patients by the present study. 
In regard to the identification of salivary VDBP, few studies investigated this protein 
in oral fluids (saliva and GCF) of patients with periodontal diseases. In agreement 
with the present study, a clinical study carried out in 1987 detected VDBP in saliva 
samples of periodontitis patients; however, the study didn’t measure the protein 
levels following treatment (Krayer et al. 1987). Though it was carried out on GAgP 
patients, using techniques other than PPA assays including 2D gel electrophoresis 
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and electrospray ionization tandem mass spectrometry, the protein profile analysis of 
whole unstimulated saliva carried out by Wu et al. (2009), revealed that, VDBP was 
one of 11 proteins identified in the GAgP patients in significantly elevated levels as 
compared to healthy controls (the VDBP was 1.7 folds higher in the GAgP patients), 
this finding is in agreement with the present study for the identification of VDBP in 
saliva of chronic periodontitis patients. 
All the studies focusing on the identified biomarkers and their possible roles in 
periodontitis will be discussed in details in their related chapters. 
3.3.3 Summary of findings 
The PPA assays demonstrated that: the proteome profile of whole unstimulated 
saliva obtained from patients with untreated chronic periodontitis, differs from that of 
healthy control subjects, this finding suggested that periodontitis may affect the 
proteome profile of saliva. Referring to the PPA assays and in review of previous 
studies, three candidate salivary biomarkers for periodontitis were identified 
including: uPA, uPAR and VDBP, though the latter was identified in 1987, it was not 
studied following periodontal treatment. The PPA assays, are simple, readily usable, 
with reasonable costs (i.e. do not need expensive or sophisticated equipment when 
compared to other proteomic techniques), able to detect wide range of proteins and 
to investigate the proteome profile of saliva. However, it is recommended to perform 
multiple assays for the reasons of reproducibility and to over-come cross reactivity 
and sensitivity issues. 
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Figure 3.1: The analysis of three single saliva samples using proteome profiler 
arrays for salivary proteases. 
Three independent single sample protease arrays were performed on 6 whole 
unstimulated saliva samples obtained from 3 untreated chronic periodontitis patients 
and 3 healthy volunteers. Two samples were analysed in each assay, one of 
periodontitis patient and one of healthy subject. The bars represent the mean pixel 
intensity values for the relative expression of 11 proteins obtained from the analysis 
of the three single sample assays. Statistics: One sample t-test was used to 
determine the p-value of the log-fold change (*=p<0.05). 
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Figure 3.2: The analysis of three pooled saliva samples using proteome profiler 
arrays for salivary proteases. 
Three independent pooled sample protease arrays were performed on pooled saliva 
samples. Two pooled samples were analysed in each assay (and the assay repeated 
twice further using the same pools), each pooled sampled consisted of 3 periodontitis 
or 3 healthy samples mixed in equal volumes. The bars represent the mean pixel 
intensity values for the relative expression of 11 proteins obtained from the analysis 
of the three pooled sample assays. Statistics: One sample t-test was used to 
determine the p-value of the log-fold change (*=p<0.05, and **=p<0.01 as indicated). 
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Salivary proteases 
Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
ADAM8 6177 ±1266 14659 ±4958 + 2.37 <0.05 
MMP-1 16586 ±4263 6894 ±1572 - 2.41 NS 
MMP-2 2805 ±2116 1750 ±260 - 1.6 NS 
MMP-3 2699 ±1106 10656 ±5540 + 3.95 NS 
MMP-7 14219 ±12614 8881 ±5481 - 1.6 NS 
MMP-8 36296 ±9667 37598 ±11532 + 1.03 NS 
MMP-9 20909 ±10961 9619 ±4173 - 2.17 <0.05 
MMP-12 15781 ±7305 20775 ±9153 + 1.32 NS 
Neprilysin 1742 ±722 5959 ±3361 + 3.42 NS 
Proteinase 3 10059 ±7727 3262 ±1282 - 3.08 NS 
Urokinase uPA  11350 ±4723 24370 ±6599 + 2.15 <0.05 
Table 3.1: Relative expression of salivary proteases in periodontitis samples as compared to healthy samples. 
The relative expression of 11 salivary proteases were identified in 3 single sample protease PPA assays. Data are presented as mean 
and standard error of the mean (SEM) of the pixel intensity (PI) values. Proteins were compared by the means of fold change and p-
value of the logarithm-fold change (Statistics: One sample t-test, NS= non-significant).  
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Salivary proteases 
Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
  (periodontitis vs health) 
p-value of the log-fold change 
ADAM8 830 ±36 12059 ±945 + 14.52 <0.01 
MMP-1 8809 ±3045 14609 ±1755 + 1.66 NS 
MMP-2 808 ±24 3618 ±925 + 4.48 <0.05 
MMP-3 1679 ±495 6831 ±1822 + 4.07 <0.01 
MMP-7 4183 ±2134 4967 ±914 + 1.19 NS 
MMP-8 12659 ±2399 19843 ±1289  + 1.57 NS 
MMP-9 11411 ±893 12487 ±1633 + 1.09 NS 
MMP-12 1463 ±176 6823 ±770 + 4.66 <0.01 
Neprilysin 798 ±272 9739 ±801 + 12.19 <0.05 
Proteinase 3 8846 ±1036 5295 ±999 - 1.67 NS 
Urokinase uPA  1363 ±364 9102 ±563 + 6.68 <0.05 
Table 3.2: Relative expression of salivary proteases in periodontitis samples as compared to healthy samples. 
The relative expression of 11 salivary proteases identified in 3 pooled sample protease PPA assays. Data are presented as mean ±SEM 
of the PI values. Proteins compared by the means of fold change and p-value of the logarithm-fold change (Statistics: One sample t-test, 
NS= non-significant). 
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Figure 3.3: Radiography for protease proteome profiler arrays. 
Following the radiography of the protease PPA assays, the radiographs were 
scanned for image analysis. These are scanned images of the radiographs for one of 
the single sample protease PPA assays for periodontitis and healthy samples. On 
each image, each duplicate spot represents a precise protein, and there are 3 
duplicate spot positive control references on the 3 corners of the image with one 
duplicate spot negative control reference located near to the last protein. The marks 
represent the positions of the identified candidate salivary biomarker urokinase 
(uPA), the well-known biomarkers MMP-8 and MMP-9, and other proteases such as 
ADAM8, MMP-3, and MMP-12. The expression of the labelled proteins in this assay 
was relatively higher in the periodontitis samples as compared to the healthy sample. 
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Figure 3.4: The analysis of three single saliva samples using proteome profiler 
arrays for salivary cytokines. 
Three independent single sample cytokine arrays were performed on 6 whole 
unstimulated saliva samples obtained from 3 untreated chronic periodontitis patients 
and 3 healthy volunteers. Two samples were analysed in each assay, one of 
periodontitis patient and one of healthy subject. The bars represent the mean pixel 
intensity values for the relative expression of 10 proteins obtained from the analysis 
of the three single sample assays. Statistics: One sample t-test was used to 
determine the p-value of the log-fold change (*=p<0.05). 
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Figure 3.5: The analysis of three pooled saliva samples using proteome profiler 
arrays for salivary cytokines. 
Three independent pooled sample cytokine arrays were performed on pooled saliva 
samples. Two pooled samples were analysed in each assay (and the assay repeated 
twice further using the same pools), each pooled sampled consisted of 3 periodontitis 
or 3 healthy samples mixed in equal volumes. The bars represent the mean pixel 
intensity values for the relative expression of 11 proteins obtained from the analysis 
of the three pooled sample assays. Statistics: One sample t-test was used to 
determine the p-value of the log-fold change (*=p<0.05). 
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Salivary cytokines 
Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
  (periodontitis vs health) 
p-value of the log-fold change 
Adiponectin 1455 ±348 16358 ±9770 + 11.24 <0.05 
Cystatin C 14711 ±6523 16338 ±8525 + 1.11 NS 
EGF 4553 ±2066 11868 ±9000 + 2.61 NS 
EMMPRIN 2071 ±1665 10009 ±8962 + 4.83 NS 
IL-8 4434 ±4197 8917 ±7184 + 2.01 NS 
Myeloperoxidase 2631 ±2788 5866 ±4943 + 2.23 NS 
Resistin 9039 ±8517 13996 ±8541 + 1.55 NS 
uPAR 1962 ±1543 9811 ±7743 + 5 <0.05 
VEGF 7321 ±6861 16900 ±15147 + 2.31 NS 
VDBP 4898 ±786 13290 ±7078 + 2.71 NS 
Table 3.3: Relative expression of salivary cytokines in periodontitis samples as compared to healthy samples. 
The relative expression of 10 salivary cytokines identified in 3 single sample cytokine PPA assays. Data are presented as mean ±SEM of 
the PI values. Proteins compared by the means of fold change and p-value of the logarithm-fold change (Statistics: One sample t-test, 
NS= non-significant).  
122 
 
Salivary cytokines 
Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
  (periodontitis vs health) 
p-value of the log-fold change 
Adiponectin 14406 ±13661 54877 ±46998 + 3.81 NS 
Cystatin C 14533 ±9730 30613 ±22256 + 2.11 NS 
EGF 13569 ±11214 31755 ±25132 + 2.34 <0.05 
EMMPRIN 12093 ±11661 23814 ±20195 + 1.97 NS 
IL-1α 7044 ±6673 18526 ±15308 + 2.6 NS 
IL-1β 6722 ±6825 6395 ±5766 - 1.05 NS 
IL-8 4650 ±3622 25759 ±20951 + 5.54 <0.05 
Resistin 3921 ±2796 38600 ±28020 + 9.84 <0.05 
uPAR 3844 ±3117 21691 ±17627 + 5.64 <0.05 
VEGF 8623 ±7651 51721 ±47079 + 6 <0.05 
VDBP -2891 ±7659 37974 ±28669 NA NA 
Table 3.4: Relative expression of salivary cytokines in periodontitis samples as compared to healthy samples. 
The relative expression of 11 salivary cytokines identified in 3 pooled sample cytokine PPA assays. Data presented as mean ±SEM of 
the PI values. Proteins compared by the means of fold change and p-value of the logarithm-fold change (Statistics: One sample t-test, 
NS= non-significant). NA not applicable. 
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Figure 3.6: Radiography for cytokine proteome profiler arrays. 
The radiographs of the cytokine PPA assays were scanned for image analysis. 
These are scanned images of the radiographs for one of the pooled sample cytokine 
PPA assays for periodontitis and healthy samples. On each image, each duplicate 
spot represents a precise cytokine, and there are 3 duplicate spot positive control 
references on the 3 corners of the image with one duplicate spot negative control 
reference located on the lower right corner of the image. The marks represent the 
positions of the identified candidate salivary biomarkers urokinase receptor (uPAR) 
and vitamin D binding protein (VDBP), the well-known biomarker IL-1β, and other 
cytokines such as IL-1ra, IL-8, resistin, and VEGF. In this assay, the labelled 
cytokines’ expressions were relatively higher in the periodontitis sample as compared 
to the healthy sample. 
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Chapter 4 Investigation of the association of salivary and GCF uPA 
and uPAR with periodontitis 
4.1 Introduction 
As the results of experiments described in the previous chapter, a number of proteins 
have been identified by the protease and cytokine PPA assays in saliva of patients 
with untreated chronic periodontitis. Among the identified proteins were the urokinase 
plasminogen activator (uPA) and its receptor (uPAR). Both the uPA and uPAR 
belong to the plasminogen activating (PA) system. In the presence of a stimulus 
(host-derived or bacterial), uPA binds to its receptor uPAR, this binding activates and 
localizes uPA on the cell surface, and in turn uPA converts plasminogen (the key 
component of the PA system) into active plasmin, thereby initiating the activities of 
the PA system (Crippa 2007; Blasi and Sidenius 2010; Smith and Marshall 2010). 
Once the PA system has been activated, the system will carry out a number of 
functions including, inflammatory cells chemotaxis, activation of matrix-
metalloproteases and subsequently activation of extra-cellular matrix proteolysis 
(Ogura et al. 1999; Ogura et al. 2001; Buduneli et al. 2004; Buduneli et al. 2005; 
Crippa 2007; Blasi and Sidenius 2010; Smith and Marshall 2010). These pro-
inflammatory activities take place during the pathogenesis of periodontitis. Therefore, 
on this basis, uPA and uPAR have been selected as candidate salivary biomarkers 
for periodontitis. The PA system proteins were investigated by a number of studies 
which detected the tissue plasminogen activator (tPA), plasminogen inhibitors (PAI-1 
& PAI-2) and uPA in the GCF of patients with periodontal diseases (Kinnby et al. 
1991; Kinnby et al. 1996; Yin et al. 2000; Buduneli et al. 2005). Positive correlations 
were found between these GCF PA proteins and different periodontal clinical 
measures. However, salivary uPA has not been investigated in periodontal diseases 
with the exception of a single study which investigated the uPA and tPA activities 
along with PAI-1 and 2 in the saliva and salivary gland tissues of patients with 
neurological conditions but the results were not related to any periodontal, oral or 
systemic disease (Virtanen et al. 2006). In a similar manner to uPA, a single study 
detected uPAR in saliva of healthy young adults (Gustafsson et al. 2011). The 
research presented in this chapter aimed to investigate whether uPA and uPAR 
levels elevated in saliva of patients with periodontal diseases and whether or not 
there is a relationship between these two salivary proteins levels and periodontitis. 
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4.2 Results 
Following the identification of uPA and uPAR as candidate salivary biomarkers for 
periodontitis, ELISA assays were carried out to confirm the results of the PPA assays 
and to quantify the biomarkers in saliva and GCF samples of patients with 
periodontal diseases. Experiments were carried out on saliva samples obtained from 
2 clinical studies (study A and study B, see Chapter 2, section 2.1.3), and on GCF 
samples obtained from the clinical study C (see Chapter 2, section 2.1.3). Human 
uPAR DuoSet ELISA, and human uPA Quantikine ELISA kits were used to measure 
the biomarkers levels in saliva and GCF samples obtained from the 3 studies. ELISA 
validation assays were carried out on each ELISA assay prior to use on the study 
samples in order to confirm the efficacy of these assays in measuring the desired 
mediators in saliva. The ELISA results were compared between the patients and 
control groups, and in the patients groups before and after non-surgical treatment. 
The results were correlated with the periodontal indices used for the clinical 
assessment of the patients and control subjects. Finally, the salivary uPA enzymatic 
activity was investigated using uPA activity fluorometric assay kits (Sigma-Aldrich), 
and the relationship of salivary uPA activity with both the salivary uPA levels and the 
periodontal disease indices was determined. 
The results of the ELISA assays (concentrations pg/ml) and the uPA enzymatic 
activity assays (IU/ml), are presented either as median and interquartile ranges (IQR) 
[median (upper quartile-lower quartile)] when data were not normally distributed, or 
as mean and standard error of the mean SEM (mean ±SEM) when data were 
normally distributed.  
All GCF samples were obtained from a previous project of the periodontal research 
group/School of Dental Sciences/Newcastle University, which may explain the limited 
number of GCF samples and volumes as compared to saliva samples. 
4.2.1 ELISA validation assays 
As saliva was not listed by the manufacturer among the samples that can be assayed 
by the uPAR DuoSet, the uPA DuoSet, and the uPA Quantikine ELISA assays and 
for the most precise quantification of the biomarkers, validation assays were carried 
out prior to use on the study samples. The validation assays included: determination 
of optimal dilution, recovery and linearity measurements, intra- and inter-assay 
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variations, and sensitivity of the assay (see Chapter 2, section 2.3.2, ELISA 
validation assays). 
  Determination of optimal dilution 
Three saliva samples obtained from 3 healthy volunteers were used for each ELISA 
assay. For the uPA and uPAR DuoSet ELISA kits, the samples were assayed in 4 
dilutions for each sample (neat, 1:10, 1:100, and 1:500). Whereas, for the uPA 
Quantikine ELISA, samples were assayed as neat, 1:2, and 1:3 dilutions. For each 
ELISA, the assay gave an indication for which dilution to be used in the next steps of 
the validation assays, and at which the desired biomarker falls within the range of the 
standard curve. The assay results revealed that the optimal dilutions for the ELISA 
assays were 1:100 for uPAR DuoSet ELISA, neat (no dilution) for uPA DuoSet 
ELISA, and 1:2 for uPA Quantikine ELISA. 
  Recovery and linearity measurements  
For each ELISA assay, one saliva sample was used as the neat sample to be spiked 
in the recovery and linearity assays. The sample to be spiked was diluted according 
to the optimal dilution factor for each ELISA. In addition to the saliva sample, a 
control was also used in both recovery and linearity assays, and the control was 
reagent or calibrator diluent only. Both assays were carried out on the same plate. 
Recovery was useful to check the ability of each ELISA assay to measure the 
desired biomarker in saliva samples.  Recovery was carried out by spiking both the 
sample and control with the same known amount of the standard recombinant protein 
supplied with each assay kit selected from or near to the middle of the standard 
curve, and the resultant concentrations were expected to be same as or near to that 
used for spiking. In the uPA DuoSet ELISA, both the sample and control were spiked 
with 1000 pg/ml of the uPA standard. In the uPAR DuoSet ELISA, both the sample 
and control were spiked with 500 pg/ml of the uPAR standard. In the uPA Quantikine 
ELISA, both the sample and control were spiked with 500 pg/ml of the uPA standard. 
Recovery values between 80 and 120% generally acceptable (Jaedicke et al. 2012), 
results presented in Table 4.1. 
For each ELISA assay, linearity was determined in the same saliva sample (as neat 
and spiked) along with the spiked control in different dilutions. In both the uPA and 
uPAR DuoSet ELISAs: the neat, spiked sample and spiked control were assayed in 4 
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dilutions (1:2, 1:4, 1:8, and 1:16). Whereas in the Quantikine uPA ELISA: the neat, 
spiked sample and spiked control were assayed in 2 dilutions only (1:2 and 1:4). 
Same as recovery, linearity values between 80 and 120% were considered to be 
acceptable, results are presented in Table 4.1. 
  Intra- and inter-assay variations  
Usually, the intra- and inter-assay variations (precision) are listed by the 
manufacturer, if not they should be determined along with the validation assays. The 
intra- and inter-assay variations values determined with the coefficient of variation 
CV%, values less than 10-15% generally acceptable (R & D systems) and 
(Hanneman et al. 2011). For the uPAR DuoSet ELISA assay, the intra-assay 
variation was carried out on three different saliva samples obtained from three 
healthy volunteers, assayed in triplicates on the same plate. The values were: 7.2, 
2.4, and 5.3 CV% respectively (Table 4.2).  Whereas, the inter-assay variations 
analysed three different saliva samples in three different plates on three separate 
days. The values were: 3.9, 4.4, and 2.8 CV% respectively (Table 4.3). For the uPA 
Quantikine ELISA the values were obtained from the manufacturer (R & D systems), 
the intra-assay variation values were: 2.1, 1.4, and 2.4 CV% respectively, and the 
inter-assay variation values were: 7.1, 6.5, and 6.9 CV% respectively. The assays 
were not carried out on the uPA DuoSet ELISA. These variation assays gave an 
indication about the reproducibility of the data within one assay and between assays 
performed on different days. 
  Assay sensitivity 
ELISA manufacturers usually list information about the assay sensitivity in their kits 
leaflets, which indicates the smallest concentration of the desired protein the precise 
assay can measure in a sample. The assay was carried out on the uPAR DuoSet 
ELISA by assaying 20 replicates of reagent diluent in one plate. For the uPA 
Quantikine ELISA, the sensitivity values were obtained from R & D systems. The 
assay was not performed for the uPA DuoSet ELISA. Assay sensitivity values 
obtained as “the mean of assay results for 20 zero standard replicates + 2 standard 
deviations of the mean”. The resultant value presented as optical density (OD), which 
was used in the standard curve equation to calculate the minimum concentration of 
the desired protein to be detected by the precise ELISA assay. 
129 
 
For the uPAR DuoSet ELISA, the sensitivity was: 
0.175+ (2 × 0.00831) = 0.192 this value represents the OD value at which the ELISA 
assay can detect minimum concentration of uPAR (1 pg/ml). 
 
For the uPA Quantikine ELISA, values obtained from R & D systems: sensitivity was 
0.931, and the minimum detectable concentration was 1.61 pg/ml. 
  Summary of ELISA validation assays 
The results of ELISA validation assays revealed that the uPA DuoSet ELISA assay 
was not able to measure uPA in saliva samples, therefore, the assay was excluded 
and replaced by the uPA Quantikine ELISA assay. The results of the validation 
assays carried out on the uPA Quantikine ELISA along with the values obtained from 
R & D systems, revealed that the assay can measure uPA in saliva samples. For the 
uPAR DouSet ELISA, the validation assays revealed that the assay can measure 
uPAR in saliva samples. Hence, uPAR DuoSet ELISA and uPA Quantikine ELISA 
were used to measure the uPAR and uPA levels respectively in saliva samples of the 
present study. Validation assays were not performed on the GCF samples as they 
are treated same as cell culture supernatants and serum samples which are already 
validated by the manufacturer. 
4.2.2 Investigations of salivary uPAR levels and relationship with periodontitis 
The uPAR DuoSet ELISA kits were used to measure the uPAR levels in saliva 
samples obtained from the clinical study A. Investigations were then carried out to 
study the relationships of the uPAR levels in saliva samples with the periodontal 
disease indices used for the clinical assessment of periodontitis. 
  Salivary uPAR levels in untreated periodontitis patients  
Experiments were carried out to measure the uPAR levels in saliva of 30 patients 
with untreated chronic periodontitis and 34 healthy control subjects (cross-sectional 
investigation). All samples were obtained at the baseline visit (visit 1) of the clinical 
study A (see Chapter 2, section 2.1.3, study A). Salivary uPAR levels were higher in 
the periodontitis patients [10672 (6918-22133) pg/ml], than in the healthy subjects 
[5296 (3528-9028) pg/ml] and the difference was highly significant (Mann-Whitney U 
test, p<0.001), (Figure 4.1). 
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  Salivary uPAR levels in pre- and post-treatment samples of periodontitis 
patients 
The uPAR levels were measured in saliva of 45 pre-treatment periodontitis patients 
and 40 healthy control subjects (cross-sectional investigation). All samples were 
obtained at visit 2 of the clinical study A (see Chapter 2, section 2.1.3, study A). 
Salivary uPAR levels were measured again in the same 45 periodontitis patients 
following non-surgical periodontal treatment (longitudinal investigation), the post 
treatment periodontitis samples were obtained at visit 6 which was 6 months after 
visit 2 of the clinical study A (see Chapter 2, section 2.1.3, study A). Salivary uPAR 
levels in the pre-treatment periodontitis patients [9540 (4482-16814) pg/ml] were 
higher than in the healthy subjects [4058 (1870-6651) pg/ml] and the difference was 
highly significant (Mann-Whitney U test, p<0.001), (Figure 4.2). However, the 
difference in the salivary uPAR levels of the periodontitis patients at the pre-
treatment visit [9540 (4482-16814) pg/ml] and the post-treatment visit [8842 (6805-
14269) pg/ml], was not statistically significant (Wilcoxon signed rank test, p>0.05). 
  Salivary uPAR correlations with periodontal disease indices  
Determination of Spearman’s rank correlation coefficient (rho) was used to 
investigate the relationships of the salivary uPAR levels in 45 pre-treatment 
periodontitis patients and 40 healthy controls with the periodontal disease indices 
used for the clinical assessment of periodontitis in the clinical study A. These 
correlations gave information about the potential of salivary uPAR as a biomarker 
that can indicate the severity of chronic periodontitis. The statistical analysis of the 
salivary uPAR correlations revealed that there was a significant positive correlation 
between the salivary uPAR levels and each of: modified gingival index (MGI) 
(rho=0.316, p<0.01), probing depth (PD) (rho=0.294, p<0.01), percentage of bleeding 
on probing (%BOP) (rho=0.380, p<0.001), and clinical attachment loss (CAL) 
(rho=0.361, p<0.01), (Figure 4.3, Figure 4.4, Figure 4.5 & Figure 4.6). 
  Summary of the investigation of salivary uPAR  
The salivary uPAR investigations revealed that the uPAR levels were significantly 
higher in the whole unstimulated saliva of patients with untreated chronic 
periodontitis as compared to the healthy control subjects, and these elevated levels 
were positively correlated with the periodontal disease indices of periodontitis. 
Though the uPAR levels in the whole unstimulated saliva of the periodontitis patients 
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were reduced following treatment, the difference was not statistically significant as 
compared to the pre-treatment status. 
4.2.3 Investigations of the uPA levels in saliva and GCF and relationship with 
periodontitis 
The uPA Quantikine ELISA kits were used to measure the uPA levels in saliva 
samples obtained from the clinical studies A and B, as well as to measure the uPA 
levels in GCF samples obtained from the clinical study C. Investigations were then 
carried out to study the relationships of the uPA levels in both saliva and GCF 
samples with the periodontal disease indices used for the clinical assessment of 
periodontitis. 
  Salivary uPA levels in pre- and post-treatment samples of periodontitis 
patients in study A 
ELISA assays were carried out to measure the uPA levels in saliva samples of 45 
pre-treatment periodontitis patients and 40 healthy control subjects (cross-sectional 
investigation), the samples were obtained at visit 2 of the clinical study A (see 
Chapter 2, section 2.1.3, study A). Assays were also carried out to measure the 
salivary uPA levels in the same 45 periodontitis patients following non-surgical 
treatment (longitudinal investigation), the post treatment periodontitis samples were 
obtained at visit 6 which was 6 months after visit 2 of the clinical study A (see 
Chapter 2, section 2.1.3, study A). Salivary uPA levels were higher in the pre-
treatment periodontitis patients [910 (615-1866) pg/ml] as compared to the healthy 
subjects [206 (129-356) pg/ml] and the difference was highly significant (Mann-
Whitney U test, p<0.001), (Figure 4.7). Salivary uPA levels were significantly reduced 
from [910 (615-1866) pg/ml] at the pre-treatment visit to [609 (461-1346) pg/ml] 
following non-surgical treatment (Wilcoxon signed rank test, p<0.05), (Figure 4.8). 
  Salivary uPA correlations with periodontal disease indices in study A 
Determination of the Spearman’s rank correlation coefficient was used to investigate 
the relationships of the salivary uPA levels in 45 pre-treatment periodontitis patients 
and 40 healthy control subjects with the periodontal disease indices used for the 
clinical assessment of periodontitis in the clinical study A. These correlations gave 
information about potential of salivary uPA as a biomarker that can indicate the 
severity of chronic periodontitis. The statistical analysis of the salivary uPA 
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correlations revealed that, there was a highly significant positive correlation between 
the salivary uPA levels and each of the indices: MGI (rho=0.716, p<0.001), PD 
(rho=0.770, p<0.001), %BOP (rho=0.781, p<0.001), and CAL (rho=0.724, p<0.001), 
(Figure 4.9, Figure 4.10, Figure 4.11, & Figure 4.12). 
  Salivary uPA levels in pre- and post-treatment samples of periodontitis 
patients in study B  
Salivary uPA levels were measured in 5 groups of samples (cross-sectional 
investigation) obtained at visit 2 of the clinical study B (see Chapter 2, section 2.1.3, 
study B). The groups comprised samples from: 26 edentulous subjects, 29 dentulous 
healthy subjects, 25 gingivitis patients, 31 pre-treatment mild/moderate periodontitis 
patients, and 27 pre-treatment advanced periodontitis patients. The uPA levels were 
also measured in post-treatment saliva samples obtained from the same periodontitis 
patients at visit 3 of the clinical study B which was12±2 weeks after treatment (see 
Chapter 2, section 2.1.3, study B), (longitudinal investigation). The post-treatment 
samples comprised 31 saliva samples obtained from the mild/moderate periodontitis 
patients, and 27 saliva samples obtained from the advanced periodontitis patients. 
Salivary uPA levels were higher in all the groups [healthy 139 (55-238) pg/ml, 
gingivitis 318 (172-636) pg/ml, pre-treatment mild/moderate periodontitis 395±36 
pg/ml, and pre-treatment advanced periodontitis 495 (430-948) pg/ml] as compared 
to the edentulous subjects [0.9 (0-60) pg/ml] and the difference was highly significant 
(Kruskal-Wallis with Mann-Whitney U test and Bonferroni correction, p<0.001), 
(Figure 4.13). Salivary uPA levels were higher in the gingivitis and the both pre-
treatment periodontitis groups [318 (172-636) pg/ml, 395±36 pg/ml, and 495 (430-
948) pg/ml respectively] as compared to the healthy subjects [139 (55-238) pg/ml] 
and the difference was highly significant (Kruskal-Wallis with Mann-Whitney U test 
and Bonferroni correction, p<0.001), (Figure 4.13). Salivary uPA levels were 
significantly higher in the pre-treatment advanced periodontitis patients [495 (430-
948) pg/ml] than in the pre-treatment mild/moderate periodontitis patients (395±36 
pg/ml) (Mann-Whitney U test, p<0.01), (Figure 4.13). There was no statistically 
significant difference in the salivary uPA levels between the gingivitis patients [318 
(172-636) pg/ml] and the pre-treatment mild/moderate periodontitis patients (395±36 
pg/ml) (Mann-Whitney U test, p>0.05), (Figure 4.13). Whereas, the uPA levels were 
higher in saliva of the pre-treatment advanced periodontitis patients [495 (430-948) 
pg/ml] than in saliva of the gingivitis patients [318 (172-636) pg/ml] and the difference 
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was statistically significant (Mann-Whitney U test, p<0.01), (Figure 4.13). Salivary 
uPA levels were significantly reduced in the post-treatment samples of the 
mild/moderate periodontitis patients (280±31 pg/ml) as compared to their pre-
treatment levels (395±36 pg/ml) (Paired samples t-test, p<0.01), (Figure 4.14). The 
advanced periodontitis patients demonstrated significantly reduced levels of salivary 
uPA following non-surgical treatment [344 (221-609) pg/ml] as compared to their pre-
treatment levels [495 (430-948) pg/ml] (Wilcoxon signed rank test, p<0.01), (Figure 
4.15). 
  Salivary uPA correlations with periodontal disease indices in study B 
Determination of the Spearman’s rank correlation coefficient was used to investigate 
the relationships of salivary uPA levels in 31 pre-treatment mild/moderate 
periodontitis patients, 27 pre-treatment advanced periodontitis patients, and 29 
healthy control subjects with the periodontal disease indices used for the clinical 
assessment of periodontitis in the clinical study B. These correlations gave 
information about the potential of salivary uPA as a biomarker that can indicate the 
severity of mild/moderate and advanced periodontitis. The statistical analysis of the 
salivary uPA correlations revealed that, there was a highly significant positive 
correlation between the salivary uPA levels in the pre-treatment mild/moderate 
periodontitis patients and each of the indices: MGI (rho=0.524, p<0.001), PD 
(rho=0.574, p<0.001), %BOP (rho=0.510, p<0.001), and CAL (rho=0.578, p<0.001), 
(Figure 4.16, Figure 4.17, Figure 4.18, & Figure 4.19). There was a highly significant 
positive correlation between the salivary uPA levels in the pre-treatment advanced 
periodontitis patients and each of the indices: MGI (rho=0.675, p<0.001), PD 
(rho=0.711, p<0.001), %BOP (rho=0.719, p<0.001), and CAL (rho=0.689, p<0.001), 
(Figure 4.20, Figure 4.21, Figure 4.22, & Figure 4.23). 
  The uPA levels in pre- and post-treatment GCF samples of periodontitis 
patients  
The uPA levels were measured in 3 groups of GCF samples obtained at visit 1 of the 
clinical study C (see Chapter 2, section 2.1.3, study C), (cross-sectional 
investigation). The groups were:  the healthy subjects’ group which comprised 7 GCF 
samples, the gingivitis patients’ group which comprised 13 GCF samples, and the 
chronic periodontitis patients’ group which comprised 9 pre-treatment GCF samples. 
The uPA levels were measured again in post-treatment GCF samples obtained from 
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the same periodontitis patients (longitudinal investigation) including: 9 post-treatment 
GCF samples obtained at visit 5 (3 months after treatment), and 9 post-treatment 
GCF samples obtained at visit 6 (6 months after treatment), (see Chapter 2, section 
2.1.3, study C). There was a statistically significant difference in the GCF uPA levels 
among the healthy, gingivitis and pre-treatment periodontitis groups (Kruskal-Wallis 
test with Mann-Whitney U test and Bonferroni correction, p<0.001), (Figure 4.24). 
The GCF uPA levels were higher in the pre-treatment periodontitis patients [257 
(199-265) pg/ml] than in both the healthy subjects (0 pg/ml) and gingivitis patients (0 
pg/ml), and the difference was highly significant (Mann-Whitney U test, p<0.01 and 
p<0.001 respectively), (Figure 4.24). There was no statistically significant difference 
in the GCF uPA levels between the healthy and gingivitis groups (Man-Whitney U 
test, p>0.05), (Figure 4.24). The GCF uPA levels were significantly decreased in the 
periodontitis patients following non-surgical treatment at the both post-treatment 
visits 5 and 6 [61 (0-201) pg/ml and 0 (0-46) pg/ml respectively] as compared to their 
pre-treatment levels [257 (199-265) pg/ml] (Friedman test with Wilcoxon signed rank 
test and Bonferroni correction, p<0.05), (Figure 4.25). Though the GCF uPA levels 
were lower in the post-treatment visit 6 [0 (0-46) pg/ml] in comparison to the post-
treatment visit 5 [61 (0-201) pg/ml], the difference was not statistically significant 
(Wilcoxon signed rank test, p>0.05), (Figure 4.25). 
  The GCF uPA correlations with periodontal disease indices 
Determination of the Spearman’s rank correlation coefficient was used to study the 
relationships of the uPA levels in GCF samples of 9 pre-treatment periodontitis 
patients and 7 healthy subjects with the periodontal disease indices used for the 
clinical assessment of periodontal health status in the clinical study C. These 
correlations gave information about the potential of GCF uPA as a biomarker that can 
indicate the severity of periodontitis. The statistical analysis of the GCF uPA 
correlations revealed that there was a significant positive correlation between the 
GCF uPA levels and each of the indices: MGI (rho=0.862, p<0.001), PD (rho=0.690, 
p<0.01), %BOP (rho=0.704, p<0.01), and CAL (rho=0.743, p<0.01), (Figure 4.26, 
Figure 4.27, Figure 4.28, & Figure 4.29). 
  Summary of the investigation of uPA levels  
The investigations of the uPA levels in studies A, B, and C revealed that the uPA 
levels were significantly higher in the whole unstimulated saliva, whole stimulated 
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saliva and GCF samples of the pre-treatment chronic, mild/moderate, and advanced 
periodontitis patients in comparison to both gingivitis patients and healthy control 
subjects. The uPA levels were higher in the whole stimulated saliva of the gingivitis 
patients as compared to the healthy controls in study B. However, there was no 
statistically significant difference in the GCF uPA levels between the gingivitis 
patients and healthy controls in study C. The uPA levels were significantly reduced in 
the whole unstimulated saliva, whole stimulated saliva, and GCF samples of all 
periodontitis patients following non-surgical periodontal treatment. In conclusion, the 
uPA levels were elevated in both the whole unstimulated and stimulated saliva and in 
the GCF of the periodontitis patients and reduced after treatment. 
4.2.4 Investigation of the relationship of salivary uPA activity with periodontitis 
The uPA activity fluorometric assay kits were used to measure the uPA enzymatic 
activity in saliva samples obtained from the clinical studies A and B (see Chapter 2, 
section 2.1.3, study A & study B). Correlations of the uPA activity with both its levels 
in saliva and the periodontal disease indices used for the clinical assessment of 
periodontal health status were also determined. The uPA activity assay was validated 
prior to use on study samples, validation was carried out by assaying three volunteer 
samples in different dilutions (neat, 10:100, 10:500, and 10:1000) using three diluting 
agents (the kit assay buffer, reagent diluent, and PBS). The validation revealed that, 
10:1000 was the dilution factor at which the uPA activity in saliva samples falls within 
the range of the assay standard curve, and that PBS was the suitable diluting agent 
to replace the limited volume of the assay buffer supplied by the manufacturer. It was 
not possible to investigate the uPA activity in the GCF samples due to the limited 
volumes of GCF available. 
  Salivary uPA activity in the periodontitis patients of study A 
The salivary uPA activity was assayed in 45 samples of pre-treatment periodontitis 
patients and 40 samples of healthy control subjects, all samples were obtained at 
visit 2 of the clinical study A (see Chapter 2, section 2.1.3, study A). Salivary uPA 
activity was higher in the pre-treatment periodontitis patients [242 (142-337) IU/ml] as 
compared to the healthy subjects [117 (76-205) IU/ml] and the difference was highly 
significant (Mann-Whitney U test, p<0.001), (Figure 4.30). 
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  Salivary uPA activity correlations with periodontal disease indices in study A 
Determination of the Spearman’s rank correlation coefficient was used to study the 
relationships of the uPA activity with both its levels in saliva samples of 45 pre-
treatment periodontitis patients and 40 healthy control subjects, and with the 
periodontal disease indices used for the clinical assessment of periodontitis in the 
clinical study A. These correlations gave information about the relationship of salivary 
uPA activity with salivary uPA levels as measured by ELISA, and the severity of 
periodontitis. The statistical analysis of the salivary uPA activity correlations revealed 
that, there was a significant positive correlation between the uPA activity and the uPA 
levels in saliva (rho=0.497, p<0.001), (Figure 4.31). Also, there was a significant 
positive correlation between salivary uPA activity and each of the indices: MGI 
(rho=0.247, p<0.05), PD (rho=0.366, p<0.01), %BOP (rho=0.298, p<0.01), and CAL 
(rho=0.367, p<0.01), (Figure 4.32, Figure 4.33, Figure 4.34, & Figure 4.35). 
  Salivary uPA activity in the periodontitis patients of study B 
Experiments were carried out to measure the uPA activity in 4 groups of saliva 
samples obtained at visit 2 of the clinical study B (see Chapter 2, section 2.1.3, study 
B). The groups comprised: 31 pre-treatment mild/moderate periodontitis patients, 27 
pre-treatment advanced periodontitis patients, 25 gingivitis patients and 29 healthy 
control subjects. There was a statistically significant difference in the salivary uPA 
activity among the groups (Kruskal-Wallis test with Mann-Whitney U test and 
Bonferroni correction, p<0.001), (Figure 4.36). Salivary uPA activity was higher in the 
pre-treatment mild/moderate periodontitis patients [75 (56-141) IU/ml] than in both 
the gingivitis patients [24 (14-48) IU/ml] and healthy subjects [41 (8-63) IU/ml] and 
the difference was highly significant (Mann-Whitney U test, p<0.001 respectively), 
(Figure 4.36). Salivary uPA activity was higher in the pre-treatment advanced 
periodontitis patients [57 (31-123) IU/ml] as compared to both the healthy subjects 
[41 (8-63) IU/ml] and the gingivitis patients [24 (14-48) IU/ml] and the difference was 
statistically significant (Mann-Whitney U test, p<0.05, and p<0.001 respectively), 
(Figure 4.36). Though the salivary uPA activity appeared to be higher in the pre-
treatment mild/moderate periodontitis patients [75 (56-141) IU/ml] than in the pre-
treatment advanced periodontitis patients [57 (31-123) IU/ml], the difference was not 
statistically significant (Mann-Whitney U test, p>0.05), (Figure 4.36). There was no 
statistically significant difference in the salivary uPA activity between the healthy 
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subjects [41 (8-63) IU/ml] and gingivitis patients [24 (14-48) IU/ml] (Mann-Whitney U 
test, p>0.05), (Figure 4.36). 
  Salivary uPA activity correlations with periodontal disease indices in study B 
Determination of the Spearman’s rank correlation coefficient was used to study the 
relationships of the uPA activity with both its levels in saliva samples of the pre-
treatment periodontitis patients and the healthy subjects, and with the periodontal 
disease indices used for the assessment of periodontitis in the clinical study B. These 
correlations gave information about the relationship of salivary uPA activity with 
salivary uPA levels as measured by ELISA, and the severity of periodontitis. The 
statistical analysis of the salivary uPA activity correlations demonstrated that there 
was a significantly positive correlation between the uPA activity and its high levels in 
saliva of the mild/moderate periodontitis patients (rho=0.467, p<0.001), (Figure 4.37). 
Also, there was a significant positive correlation between the salivary uPA activity in 
the mild/moderate periodontitis patients and each of the indices: MGI (rho=0.525, 
p<0.001), PD (rho=0.480, p<0.001), %BOP (rho=0.482, p<0.001), and CAL 
(rho=0.512, p<0.001), (Figure 4.38, Figure 4.39, Figure 4.40, & Figure 4.41). The 
salivary uPA activity was positively correlated with its high levels in saliva of the 
advanced periodontitis patients (rho=0.295, p<0.05), (Figure 4.42). Furthermore, 
there was a significant positive correlation between the salivary uPA activity in the 
advanced periodontitis patients and each of the indices: MGI (rho=0.409, p<0.01), 
PD (rho=0.333, p<0.05), %BOP (rho=0.424, p<0.01), and CAL (rho=0.365, p<0.01), 
(Figure 4.43, Figure 4.44, Figure 4.45, & Figure 4.46). 
  Summary of salivary uPA activity investigations 
The investigations of uPA activity in saliva samples of studies A and B revealed that, 
the uPA activity was significantly higher in the whole unstimulated saliva of the pre-
treatment periodontitis patients in comparison to the healthy controls in study A, and 
in the whole stimulated saliva of the pre-treatment mild/moderate and advanced 
periodontitis patients as compared to both gingivitis patients and healthy control 
subjects in study B. The uPA activity in the whole stimulated saliva of the gingivitis 
patients was not statistically different in comparison to the healthy controls in study B. 
There were significant positive correlations for the salivary uPA activity with both the 
salivary uPA levels and the periodontal disease indices in both studies. In conclusion, 
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the uPA activity was elevated in both the whole stimulated and whole unstimulated 
saliva of periodontitis patients but not in gingivitis patients. 
4.3 Discussion 
4.3.1 Salivary uPAR levels and relationship with periodontitis 
The present study was the first to detect and investigate uPAR in saliva of chronic 
periodontitis patients in comparison to healthy control subjects. The present study 
was in agreement with Gustafsson et al. (2011) in regard to detecting considerable 
amounts of uPAR in human saliva, using ELISA they detected soluble uPAR with the 
median value of 17100 pg/ml (17.1 ng/ml) in saliva of 20 healthy young adults, and 
they found that uPAR levels in saliva were higher than serum/plasma levels. 
However, Gustafsson et al. (2011) did not relate the high levels of salivary uPAR to 
any oral or systemic disease, and they explained that these high levels may be as a 
consequence of periodontal inflammation, therefore, they suggested that salivary 
uPAR should be studied in relation to periodontal diseases which was carried out and 
investigated by the present study. Another explanation for the high levels of salivary 
uPAR by Gustafsson et al. (2011) was, that the uPAR molecules could be actively 
transported into saliva from the nearby blood supply. These authors also suggested 
that, the elevated levels of salivary uPAR might be attributed to local production by 
the gingival tissues or the salivary glands. These explanations may also clarify the 
high levels of salivary uPAR in the periodontitis patients found by the present study. 
Despite the fact that uPAR levels in saliva of periodontitis patients have not been 
previously analysed, some studies investigated different components of the PA 
system in GCF samples from patients with different forms of periodontal diseases. 
Kinnby et al. (1991), investigated the PA system proteins including the tissue 
plasminogen activator (tPA), uPA, and the plasminogen activator inhibitors PAI-1, 
PAI-2 in GCF samples of gingivitis patients before and after treatment. The same 
components of the PA system were detected again in GCF samples of pregnant 
women with symptoms of gingival inflammation (Kinnby et al. 1996). Buduneli et al. 
(2005), detected high levels of the same PA system proteins in GCF samples of 
smokers and non-smoking adults with chronic gingivitis and chronic periodontitis as 
compared to healthy subjects. Hence, as uPAR is one of the essential components of 
the PA system and it is responsible for binding and localizing the activity of uPA that 
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will initiate proteolysis (Ploug and Ellis 1994; Crippa 2007; Blasi and Sidenius 2010; 
Smith and Marshall 2010; Fleetwood et al. 2014), and as saliva contains traces of 
GCF, these GCF studies and their findings may explain the high levels of uPAR 
found in saliva of patients with untreated chronic periodontitis by the present study. 
These studies will be discussed in further details in the next section (4.3.2). 
Using the Spearman’s correlation coefficient, positive correlations were found 
between the high levels of salivary uPAR in the periodontitis patients and the 
periodontal indices used for the clinical assessment of periodontitis. These positive 
correlations suggested that an increase in the salivary uPAR levels can be 
associated with an increase in the severity of periodontitis and vice versa. Once 
again, the aforementioned studies regarding the PA system components in GCF, 
were all carried out on patients and all their results were related to periodontal 
diseases, which may justify the positive relationship between salivary uPAR levels 
and periodontitis found by the present study. Therefore, the high levels of salivary 
uPAR in the periodontitis patients and their positive correlations with the periodontal 
disease indices, suggested that the salivary uPAR is a good biomarker for the 
diagnosis of chronic periodontitis and can indicate the severity of the disease. 
Following non-surgical treatment of the periodontitis patients, the salivary uPAR 
levels were reduced at the post-treatment visit as compared to the pre-treatment visit, 
but the difference was not statistically significant. The presence of considerable 
levels of salivary uPAR in the periodontitis patients following treatment may be 
explained by the fact that, though the periodontal health status was improved 
clinically after treatment which was obvious by the reduction in the mean values of 
the periodontal disease indices (such as PD from 3.6 mm to 2.9 mm, and MGI from 
2.8 to 1.1); unlike gingivitis, once they are destroyed and pockets formed, periodontal 
supporting tissues in chronic periodontitis will never return back to the normal healthy 
status (Pihlstrom et al. 2005), but their conditions can be improved and controlled to 
retain teeth in position, this means that sites of mild inflammation may still exist in the 
periodontium from which uPAR may be expressed into saliva. On the other hand, the 
improvement in the periodontal health status of the periodontitis patients was 
associated with significant reduction in the salivary uPA levels in response to non-
surgical treatment, whereas the salivary uPAR retained considerable levels in the 
same patients. Refer to the biology and function of uPA/uPAR, during inflammation 
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uPAR binds and localizes the uPA activity initiating proteolysis, which is proposed to 
occur during periodontitis, by the end of proteolysis the PA inhibitor (PAI-1) will 
inactivate the uPA-uPAR active complex and block the uPA activity. In cooperation 
with members of the low density lipoprotein receptor family (LDL), uPAR will mediate 
the internalization of this inactive complex (uPA-uPAR-PAI-1) which will finally result 
in the degradation of uPA by the PAI-1 inhibitor and the release of uPAR to be 
available again for another proteolysis activation (Conese and Blasi 1995; Ghosh et 
al. 2000; Preissner et al. 2000; Crippa 2007; Blasi and Sidenius 2010; Smith and 
Marshall 2010), this may explain why the salivary uPAR levels were not reduced after 
treatment and the significant reduction in the salivary uPA levels of the patients 
following treatment and improvement in their periodontal health status. Therefore, the 
persistence of considerable levels of uPAR in saliva of the periodontitis patients 
following non-surgical treatment, indicates that salivary uPAR may not be a good 
biomarker for following the clinical course of periodontitis in response to treatment. 
4.3.2 The uPA levels, activity, and relationships with periodontal diseases 
As with uPAR, the present study was the first to investigate the uPA levels in saliva 
of patients with gingivitis, chronic periodontitis, mild/moderate periodontitis and 
advanced periodontitis. The uPA levels in GCF samples of patients with gingivitis and 
chronic periodontitis were also investigated. 
The very first mention of the plasminogen activating system in relation to saliva 
reported the lysis of plasminogen containing bovine-fibrin plates following the 
addition of stimulated mixed human saliva (Albrechtsen and Thaysen 1955). 
Albrechtsen and Thaysen (1955), proposed the presence of an enzyme known as 
fibrinokinase which activates the plasminogen into plasmin in the presence of 
another enzyme lysokinase (or streptokinase). However, this study was not able to 
know what was the exact enzyme that activated the plasminogen, and decades later 
it was found that there were two plasminogen activators: the uPA and tPA enzymes 
and these two enzymes are activated by the plasmin itself and require binding to their 
receptors such as uPAR for the uPA (Ploug and Ellis 1994; Crippa 2007; Blasi and 
Sidenius 2010; Smith and Marshall 2010). Moody (1982b), reported the presence of 
the substrate plasminogen in the human saliva suggesting that it was due to the 
tissue plasminogen content of leucocytes and epithelial cells present in saliva as well 
as due to the fibrinolysis of the surrounding oral mucosa. Nevertheless, the author 
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did not carry out any experimental investigation, Page (1991), was another study to 
suggest that the uPA and the PA system may play a role in the pathogenesis of 
periodontal diseases; that study is consistent with the present study in terms of the 
detection of high levels of uPA, as well as uPAR in saliva and GCF of periodontitis 
and gingivitis patients, and the proposed roles of these PA proteins in the 
pathogenesis of periodontal diseases (Page 1991). 
In their study, Schmid et al. (1991) reported that the PA system proteins in the 
human GCF have 100-fold greater concentration as compared to their levels in 
plasma, this may explain the high uPA levels in the GCF of the periodontitis patients 
found by the present study. Kinnby et al. (1996), investigated PA system proteins in 
GCF samples of females with gingivitis during pregnancy and postpartum. They 
found high levels of the PA system proteins (tPA, uPA, PAI-2 and PAI-1) in the GCF 
samples of 14 pregnant women with gingivitis, and these high GCF levels of PA 
proteins were positively correlated with the periodontal disease indices plaque index 
(PI) and gingival index (GI), as well as with the pregnancy status. The study 
implicated a role for the PA system in gingivitis and in the aggravation of gingival 
inflammatory symptoms during pregnancy. However, in contrast to Kinnby et al. 
(1996), the present study didn’t find high levels of uPA in the GCF samples of the 
gingivitis patients. Though it was carried out on pregnant women with gingivitis, this 
data is consistent with the presence of high levels and the positive correlations of 
uPA in the GCF samples of the periodontitis patients, as well as, in the saliva 
samples of the gingivitis and periodontitis patients found by the present study (Kinnby 
et al. 1996). 
The activator tPA and the inhibitor PAI-2 were investigated in GCF samples of 
gingivitis and periodontitis patients in comparison to healthy subjects (Yin et al. 
2000). The study found that, the tPA and PAI-2 levels were higher in the GCF 
samples of the patients in comparison to the control subjects, and these high levels 
were positively correlated with the periodontal disease indices (PD and GI). Yin et al. 
(2000), suggested that both tPA and PAI-2 may play significant roles in the 
periodontal tissue destruction and remodelling that occur in periodontal diseases, 
and that tPA and PAI-2 in GCF may be useful biomarkers for periodontal diseases. 
Although they did not investigate uPA, the Yin et al. (2000) study can be considered 
to be consistent with the findings of the present study in regard to the high levels of 
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uPA in both the GCF and saliva samples of the periodontitis patients and their 
positive correlations with the periodontal indices, because uPA belongs to the PA 
system same as tPA and PAI-2 which are both more related to the fibrinolytic activity 
of the PA system in the blood and vascular endothelium than to the proteolysis 
activity which is related to uPA (Ogura et al. 1995; Ogura et al. 1999; Sulniute et al. 
2011). 
Buduneli et al. (2004), measured the PA system proteins (tPA, PAI-2, uPA, and PAI-
1) in the gingival sites and total GCF samples of 18 renal transplant patients with 
gingival overgrowth induced by cyclosporine-A, and 16 chronic gingivitis patients in 
comparison to control subjects (16 healthy, and 10 renal transplant patients with no 
signs of gingival inflammation). High levels of tPA and PAI-2 were found in the 
gingival overgrowth sites, whereas uPA and PAI-1 levels showed no significant 
difference between the patients and controls. However, when the total amounts of 
GCF were considered for each patient, uPA levels were significantly higher in both 
the gingival overgrowth and chronic gingivitis patients in comparison to the control 
subjects. Hence, the data of Buduneli et al. (2004) were in contrast with those of the 
present study results which revealed that there was no significant difference in the 
GCF uPA levels between the gingivitis patients and control subjects; however, 
Buduneli et al. (2004) study may support the present study in regard to the 
significantly high levels of uPA found in the GCF of the periodontitis patients and 
saliva of the gingivitis and periodontitis patients in comparison to the control subjects. 
In addition to that, Buduneli et al. (2004) found positive correlations between the GCF 
PA proteins levels and the periodontal indices PI, papillary bleeding index (PBI), 
hyperplastic index (HI), and PD, a finding that may explain the positive correlations 
between the salivary/GCF uPA levels and the periodontal indices found by the 
present study. Thus, Buduneli et al. (2004) is another study that backs up the 
proposed role of the PA system proteins in the pathogenesis of periodontal diseases. 
Another study carried out by Buduneli et al. (2005), measured the same PA system 
proteins (tPA, PAI-2, uPA, and PAI-1) in GCF and serum samples of 20 patients with 
chronic gingivitis, and 20 patients with chronic periodontitis in comparison to 20 
healthy control subjects (all groups were divided into 10 smokers and 10 non-
smoking subjects). The results suggested that all the PA system proteins (tPA, PAI-2, 
uPA, and PAI-1) were significantly elevated in the GCF samples of the patients in 
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comparison to the control subjects, and that smoking had a minor effect on the GCF 
PA system proteins levels with an exception for the PAI-2 protein. In contrary to the 
results of Buduneli et al. (2005), the present study revealed that there was no 
difference in the GCF uPA levels between the gingivitis patients and the healthy 
subjects; however, both the present study and Buduneli et al. (2005) study were in 
agreement in regard to the chronic periodontitis, as the present study results 
revealed that the GCF uPA levels were significantly higher in the chronic periodontitis 
patients than in the healthy control subjects. Buduneli et al. (2005), also found 
positive correlations between the GCF PA proteins levels and the periodontal 
disease indices (PD, GI, and PBI), again this finding was in agreement with the 
present study which also demonstrated positive correlations between the GCF uPA 
levels and the periodontal indices. As whole unstimulated saliva contains traces of 
GCF from all periodontal sites, therefore, the GCF uPA results of Buduneli et al. 
(2005) study are consistent with the high levels of salivary uPA in the gingivitis and 
periodontitis patients and their positive correlations with the periodontal disease 
indices found by present study. Hence, Buduneli et al. (2005) study is a further 
evidence that supports the role of the PA system proteins especially uPA in the 
pathogenesis of periodontal diseases. 
Once again, the present study was the first to measure the salivary uPA levels in 
periodontitis patients following non-surgical treatment. In regard to the GCF uPA, the 
present study was also the first to investigate the uPA levels in the GCF of 
periodontitis patients in response to treatment; however, there were 2 studies that 
measured uPA in the GCF of gingivitis patients before and after treatment (Kinnby et 
al. 1994; Kinnby et al. 1996), and only one study that measured other PA system 
proteins in the GCF of periodontitis patients before and after treatment (Yin et al. 
2000) (discussed below). The investigation of longitudinal changes in biomarkers as 
part of the clinical study A revealed that, the salivary uPA levels were significantly 
reduced in the periodontitis patients following non-surgical treatment. Similar data 
from studies of clinical study B samples showed that, the salivary uPA levels dropped 
significantly in both the mild/moderate and advanced periodontitis patients after 
treatment. In the clinical study C, the GCF uPA levels were significantly reduced in 
the periodontitis patients at the post-treatment visits in comparison to the pre-
treatment visit. This reduction of both the salivary and GCF uPA levels following 
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treatment, may be explained by the improvement in the periodontal health status of 
the periodontitis patients in response to treatment which was evident by the 
improvement in the periodontal disease indices records, for instance the %BOP 
index in the periodontitis patients of the study A dropped from 52% to 18%. In the 
study B, the %BOP index in the mild/moderate periodontitis patients dropped from 
47% to 15%, and in the advanced periodontitis patients the %BOP dropped from 
67% to 24%. In the study C, the %BOP index of the periodontitis patients was 
reduced from 62% at the pre-treatment visit to 30% and 23% respectively at the post-
treatment visits. 
The Kinnby et al. (1994) study, was the first to measure the uPA along with other PA 
system proteins levels in GCF samples of patients with gingivitis before and after 
treatment. Before treatment, they found high levels of the PA system proteins (uPA, 
tPA, and PAI-2) in the GCF of 8 gingivitis patients with positive correlations of these 
GCF PA proteins levels with the periodontal disease indices (PI, GI, and PD), these 
findings were in contrast to the present study which didn’t find significant levels of 
uPA in the GCF of gingivitis patients. However, the Kinnby et al. (1994) pre-treatment 
results may support the present study results which found high levels of uPA in the 
GCF samples of periodontitis patients with their positive correlations with periodontal 
disease indices, as well as, the high levels of salivary uPA in gingivitis and 
periodontitis patients which positively correlated with clinical periodontal indices. The 
post-treatment results of Kinnby et al. (1994) demonstrated reduced levels of tPA 
and PAI-2 in the GCF samples of gingivitis patients, whereas the post-treatment GCF 
uPA levels didn’t show significant difference in comparison to the pre-treatment 
status. The post-treatment results of Kinnby et al. (1994) were in contrast to the 
results of the present study, which showed significantly reduced uPA levels in both 
the GCF and saliva samples of periodontitis patients following non-surgical 
treatment. 
The other study carried out by Kinnby et al. (1996) , in which they followed up women 
with gingivitis during and after pregnancy. The postpartum results revealed that the 
GCF levels of the PA system proteins (tPA, PAI-2, and PAI-1) were reduced in 
comparison to the pregnancy period, whereas the uPA levels didn’t show significant 
difference. Despite the fact that Kinnby et al. (1996) study was carried out on 
pregnant women with gingivitis, their results were in contrast to the present study 
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which found that the uPA levels in both GCF and saliva of periodontitis patients were 
significantly reduced at post-treatment visits in comparison to the pre-treatment visits. 
Yin et al. (2000), measured the PA system proteins (tPA and PAI-2) in patients with 
periodontitis before and after treatment. The results revealed that the PAI-2 levels 
were significantly decreased following treatment, in a similar manner to what 
happened in the present study when the levels of uPA were reduced significantly in 
both saliva and GCF of periodontitis patients following non-surgical treatment. Yin et 
al. (2000), also found that the GCF tPA levels were lower at the post-treatment visit 
but the difference was not statistically significant in comparison to the pre-treatment 
visit, this was consistent with the findings of the present study in which the salivary 
uPAR levels were reduced at the post-treatment visit as compared to the pre-
treatment visit but the difference was not statistically significant.  
The present study was the first to investigate the uPA activity in the whole 
unstimulated and stimulated saliva of untreated periodontitis patients and its 
relationships with both the salivary uPA levels and the periodontal disease indices. 
The results (for both studies A and B) revealed that, the salivary uPA activity was 
significantly higher in the untreated periodontitis patients as compared to both the 
gingivitis patients and healthy control subjects. Furthermore, significant positive 
correlations were found between the high salivary uPA activity in the periodontitis 
patients with both the high salivary uPA levels and the periodontal indices. This high 
activity of salivary uPA may simply reflect the high levels of uPA found in saliva of the 
periodontitis patients as they were positively correlated. The positive correlations of 
salivary uPA activity with the periodontal diseases indices may relate to the proposed 
role of uPA/uPAR in the pathogenesis of periodontitis.  
The Moody (1982a) study, investigated the plasminogen activity in healthy human 
stimulated whole, parotid, and submandibular saliva using human fibrin plates. 
However, the activity that Moody (1982a) found was fibrinolytic activity which was 
only detected in the presence of epithelial cells and epithelial fragments in saliva, and 
this activity totally disappeared when the saliva was centrifuged. Therefore, Moody 
(1982a) related this activity in saliva to its epithelial cells’ content and considered this 
fibrinolytic activity as the only plasminogen activator activity in saliva. In contrast to 
Moody (1982a), the present study proved that the plasminogen activator activity in 
the centrifuged stimulated and unstimulated whole saliva is also related to uPA which 
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is responsible for the proteolytic activity (matrix proteolysis) of the PA system in 
addition to cells migration, signalling and other functions of the PA system whereas 
tPA which also known as blood vessel type PA is responsible for the fibrinolytic 
activity of PA system in the blood and vascular endothelium (Kinnby et al. 1996; 
Ogura et al. 1999; Ogura et al. 2001; Buduneli et al. 2004; Buduneli et al. 2005; 
Virtanen et al. 2006; Blasi and Sidenius 2010; Sulniute et al. 2011; Montuori et al. 
2012; Fleetwood et al. 2014). 
In their study, Watanabe et al. (1987) investigated the PA activity in 3 GCF samples 
obtained from 2 patients representing 3 different periodontal sites. The molecular 
weights of the PA protein tPA was determined by zymography, and the PA activity 
was determined by the digestion of plasminogen in fibrin gels. This PA activity was 
inhibited when anti-tPA antibodies were added to the GCF samples. Though it was a 
fibrinolytic activity related to the tPA activator, the detection of PA activity in GCF by 
Watanabe et al. (1987) supports the role of the PA system in periodontitis and may 
justify the detection of uPA in the saliva and GCF samples of periodontitis patients as 
well as the uPA activity in their saliva found by the present study. 
Another study carried out by Sindet-Pedersen et al. (1987), investigated the 
fibrinolytic activity in human stimulated and unstimulated saliva obtained from 10 
healthy non-smoking subjects, using plasminogen-free and plasminogen-rich fibrin 
plates. They found that the fibrinolytic activity zones generated by saliva were 
inhibited by the addition of anti-tPA antibodies, whereas this fibrinolytic activity 
remained unchanged when anti-uPA antibodies were added. From their results, 
Sindet-Pedersen et al. (1987) assumed that the tPA is the only type of plasminogen 
activator present in normal human saliva, in fact this assumption was not right 
because they neither measured the uPA levels nor investigated its activity. 
Furthermore, the present study detected the presence as well as the activity of uPA 
in healthy subjects’ saliva and in significantly higher levels in periodontitis patients’ 
saliva; hence the tPA is not the only plasminogen activator present in saliva. 
In a similar manner to (Moody 1982a; Sindet-Pedersen et al. 1987; Watanabe et al. 
1987), Schmid and Chambers (1989) investigated the presence and activity of the 
plasminogen activator in the human supra-gingival plaque and saliva. Although they 
detected proteolytic zones on the plasminogen-dependent indicating plates, Schmid 
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and Chambers (1989) did not relate this activity to uPA. Instead of the proteolysis, 
Schmid and Chambers (1989) carried out further investigation on the fibrinolytic 
activity, in which fibrinolytic zones were detected on the fibrin-agar gel, and this 
fibrinolytic activity was higher in the plaque samples than the proteolytic activity. 
Furthermore, Schmid and Chambers (1989), added anti-tPA antibodies to their fibrin-
agar gel which inhibited the fibrinolysis, they also added anti-uPA antibodies which 
didn’t affect the fibrinolytic activity and this is true as uPA is related to the proteolysis 
whereas tPA is related to the fibrinolysis (Moody 1982a; Crippa 2007; Montuori et al. 
2012). Moreover, the incubation of human unstimulated parotid and mixed saliva on 
the fibrin-agar gel demonstrated high tPA related fibrinolytic activity (Schmid and 
Chambers 1989). Schmid and Chambers (1989), suggested that the PA system role 
in periodontal diseases is attributed to its fibrinolytic activity which is related to tPA. 
Despite the fact that they did not carry out any investigation about uPA or its activity 
and role in proteolysis; the Schmid and Chambers (1989) study was a further 
evidence for the PA system involvement in the periodontal diseases pathogenesis. 
Talonpoika et al. (1991), investigated the plasmin activity in 152 GCF samples 
obtained from 12 subjects with different clinical conditions and after periodontal 
treatment. The plasmin activity was measured in plasminogen-free fibrin plates by 
weighing the fibrin liquefied by the GCF samples. Talonpoika et al. (1991), found that 
there was a variation in the total GCF plasmin activity among the subjects and 
among the different periodontal pockets from which the GCF samples were collected 
within the subjects. There was a weak positive correlation between the GCF plasmin 
activity and each of the plaque amount, bleeding tendency, pocket depth, and bone 
loss. The Talonpoika et al. (1991) GCF plasmin activity results were in contrary with 
the present study which found that there was a significantly high salivary uPA activity 
in the periodontitis patients as well as significantly positive correlations between the 
salivary uPA activity and the periodontal disease indices. Furthermore, Talonpoika et 
al. (1991) found that the plasmin levels in the GCF didn’t correlate with the clinical 
parameters, whereas the present study found that the uPA levels in both GCF and 
saliva were positively correlated with the periodontal disease indices. An interesting 
finding by Talonpoika et al. (1991) was the significant reduction in the GCF plasmin 
activity of the patients following periodontal treatment, this finding may explain the 
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significantly reduced levels of GCF uPA in the periodontitis patients following 
treatment found by the present study. 
Brown et al. (1995) investigated the PA proteins (tPA, uPA, PAI-1, and PAI-2) in GCF 
samples obtained from healthy adults. Fibrin zymography was used to determine the 
PA activity in the GCF samples, and the assay detected tPA activity but not uPA 
activity. This finding may explain the lower uPA activity measured in saliva of the 
healthy subjects as compared to the periodontitis patients found by the present 
study. Moreover, Brown et al. (1995) immunoblotting and ELISA assays revealed that 
the tPA and PAI-2 levels were higher than the uPA and PAI-1 levels. The detection of 
low GCF uPA levels by Brown et al. (1995), was in agreement with the present study 
which also detected very low GCF uPA levels in the healthy subjects as compared to 
the periodontitis patients and may explain the lower salivary uPA levels in the healthy 
subjects of the present study as well. 
The Virtanen et al. (2006) was the first study which investigated the uPA activity 
along with the activity and expression of other plasminogen activators and inhibitors 
in human saliva and salivary gland tissues. However, though the study was carried 
out on 34 patients attending the neurological department of Helsinki University 
Central Hospital, the results were not related to any periodontal, oral, or systemic 
disease. The activity of both the tPA and uPA, in addition to the relative inhibition of 
tPA were measured in whole saliva samples obtained from the patients using 
microtiter plate assays. The salivary levels of PAI-1 and PAI-2 were measured using 
ELISA assays. The expression of tPA, uPA, PAI-1 and PAI-2 proteins were 
investigated by the immunohistochemistry of 6 salivary gland tissue specimens (4 
parotid, 1 submandibular, and 1 sublingual samples). The results of Virtanen et al. 
(2006) study, revealed that both the tPA and its inhibition activities were higher in all 
patients in comparison to the uPA activity which was observed in 9 patients only. 
Though it was found in the salivary gland tissue samples, the uPA expression was 
lower than that of tPA, PAI-1, and PAI-2 proteins. Furthermore, Virtanen et al. (2006) 
ELISA assays detected PAI-2 but not PAI-1 in the saliva samples. The present study 
results were in agreement with the Virtanen et al. (2006) results in respect to the low 
uPA activity measured in saliva of the healthy control subjects. However, the 
expression of uPA in salivary gland tissues and the detection of active uPA in human 
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saliva by Virtanen et al. (2006), may justify the detection of active uPA in saliva 
samples of periodontitis patients by the present study. 
4.3.3 Summary of findings 
The investigations carried out on the clinical study A samples revealed that, the 
salivary uPAR levels were significantly elevated in the chronic periodontitis patients 
in comparison to the healthy control subjects. There were positive correlations 
between the high salivary uPAR levels and the periodontal disease indices used for 
the clinical assessment of periodontitis. Therefore, salivary uPAR is suggested as a 
good biomarker for the diagnosis of periodontitis, the indication of the disease 
severity, and the differentiation between periodontitis patients and healthy subjects. 
Though salivary uPAR levels were reduced in the periodontitis patients following 
treatment, the difference was not statistically significant as compared to their pre-
treatment levels. Therefore, salivary uPAR may not be a good biomarker that can 
follow the clinical course of periodontitis in response to treatment. 
The results of the clinical studies A, B and C revealed that, the uPA levels were 
significantly higher in both the saliva and GCF samples of the periodontitis patients in 
comparison to the healthy subjects. Significant positive correlations were found 
between the high salivary/GCF uPA levels and the periodontal disease indices used 
for the clinical assessment of periodontal health status. Therefore, uPA in both saliva 
and GCF is suggested as a good biomarker for the diagnosis of periodontitis, the 
indication of the disease severity, and it is able to discriminate between periodontitis 
patients and healthy subjects. Moreover, the uPA levels were higher in both the 
saliva and GCF samples of the periodontitis patients as compared to the gingivitis 
patients, these findings suggested that uPA is more related to periodontitis than 
gingivitis and supported the proposed role of uPA in the proteolysis and destruction 
of the supporting periodontal tissues in periodontitis. 
Both the salivary and GCF uPA levels were significantly reduced following non-
surgical treatment in the periodontitis patients. Therefore, uPA in both saliva and 
GCF is suggested as a good biomarker that can predict and follow the clinical course 
of periodontitis in response to treatment. The salivary uPA activity was significantly 
higher in the periodontitis patients as compared to both the healthy subjects and the 
gingivitis patients, and the uPA activity was positively correlated with both its levels in 
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saliva and the periodontal disease indices. Consequently, in addition to its levels, the 
salivary uPA activity is also suggested as another useful biomarker for the diagnosis 
of periodontitis, indication of the disease severity, and distinguishing periodontitis 
patients from healthy subjects. Furthermore, the results indicated that the uPA 
activity is more related to periodontitis than gingivitis which may explain the high 
salivary uPA levels and support its proteolytic role during periodontitis. Hence, both 
the salivary uPA levels and activity can differentiate periodontitis patients from 
gingivitis patients. 
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Table 4.1: Recovery and linearity results for the uPAR and uPA ELISAs. 
The results represent the recovery values for the spiked samples and spiked controls 
in the recovery assays for each ELISA assayed in duplicate. As well as, the recovery 
values for the neat sample dilutions, spiked sample dilutions, and spiked control 
dilutions in the linearity assays for each ELISA assayed in duplicate. The undiluted 
neat (unspiked) samples have no recovery or linearity measures. Recovery values 
presented as %, values between 80 and 120% generally acceptable (R & D systems) 
(Jaedicke et al. 2012). NA (not applicable because the sample/control was not 
assayed). Number=n.   
 uPAR DuoSet    (n=1) uPA DuoSet     (n=1) uPA Quantikine (n=1) 
Neat sample NA NA NA 
1:2 neat sample 140.29% NA 94.6% 
1:4 neat sample 141.3% NA 89.1% 
1:8 neat sample 126.62% NA NA 
1:16 neat sample 107.21% NA NA 
Spiked sample 96.67% 26.65% 83.95% 
1:2 spiked sample 112.62% 68.7% 97.81% 
1:4 spiked sample 122.48% 66.45% 95.55% 
1:8 spiked sample 123.13% 88.87% NA 
1:16 spiked sample 107.55% 104.14% NA 
Spiked control 83.26% 98.42% 94.77% 
1:2 spiked control 101.28% 129.44% 94.76% 
1:4 spiked control 100.47% 130.53% NA 
1:8 spiked control 134.05% 192% NA 
1:16 spiked control 193.86% 577.63% NA 
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 Sample 1 Sample 2 Sample 3 
n 3 3 3 
Mean (pg/ml) 135.9 95.7 184.2 
SD 9.8 2.3 9.8 
CV% 7.2 2.4 5.3 
Table 4.2: Intra-assay variation values for the uPAR DuoSet ELISA. 
The intra-assay variation test was carried out on the uPAR DuoSet ELISA, using 
three different saliva samples obtained from three healthy volunteers, assayed in 
triplicates on the same plate. Results presented as CV %, mean and standard 
deviation (SD). Number=n. 
 
 
 
 Sample 1 Sample 2 Sample 3 
n 9 9 9 
Mean (pg/ml) 138 82.4 180.7 
SD 5.4 3.6 5.1 
CV% 3.9 4.4 2.8 
Table 4.3: Inter-assay variation values for the uPAR DuoSet ELISA. 
The inter-assay variation test was carried out on the uPAR DuoSet ELISA, using 
three different saliva samples assayed in triplicates in three different plates on three 
separate days (one plate per day). Results presented as CV %, mean and SD. 
  
153 
 
 
Figure 4.1: Salivary uPAR levels in untreated periodontitis patients of study A. 
ELISA was carried out to measure the salivary uPAR levels in samples obtained at 
the baseline visit of clinical study A from 30 untreated periodontitis patients in 
comparison to 34 healthy subjects. The box plots represent the median and IQR for 
each group. ***=p<0.001 (Mann-Whitney U test).  
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Figure 4.2: The pre-treatment salivary uPAR levels in the periodontitis patients 
of study A. 
Salivary uPAR levels were measured by ELISA in samples obtained from 45 pre-
treatment periodontitis patients in comparison to 40 healthy subjects. The box plots 
represent the median and IQR for each group. ***=p<0.001 (Mann-Whitney U test). 
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Figure 4.3: Relationship of salivary uPAR levels with MGI in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPAR levels in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the MGI index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.4: Relationship of salivary uPAR levels with PD in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPAR levels in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the PD index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.5: Relationship of salivary uPAR levels with %BOP in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPAR levels in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the %BOP index in the clinical 
study A. The trend-line demonstrates the presence of a significant positive 
correlation. 
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 Figure 4.6: Relationship of salivary uPAR levels with CAL in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPAR levels in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the CAL index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.7: The pre-treatment salivary uPA levels in the periodontitis patients of 
study A. 
The uPA levels were measured in saliva of 45 pre-treatment periodontitis patients in 
comparison to 40 healthy control subjects. The box plots represent the median and 
IQR for each group. ***=p<0.001 (Mann-Whitney U test). 
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Figure 4.8: The post-treatment salivary uPA levels in the periodontitis patients 
of study A. 
Salivary uPA levels were measured in 45 periodontitis patients after 6 months of non-
surgical treatment in comparison to their pre-treatment status. Box plots represent 
the median and IQR for each group. *=p<0.05 (Wilcoxon signed rank test). 
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Figure 4.9: Relationship of salivary uPA levels with MGI in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the MGI index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.10: Relationship of salivary uPA levels with PD in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the PD index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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 Figure 4.11: Relationship of salivary uPA levels with %BOP in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the %BOP index in the clinical 
study A. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.12: Relationship of salivary uPA levels with CAL in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the CAL index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.13: The pre-treatment salivary uPA levels in the periodontitis patients 
of study B. 
The uPA levels were measured in saliva obtained from 31 pre-treatment 
mild/moderate periodontitis patients and 27 pre-treatment advanced periodontitis 
patients in comparison to 25 gingivitis patients, 26 edentulous subjects and 29 
dentulous healthy subjects. The box plots represent the medians and IQRs for 4 
groups, and the mean, minimum and maximum levels for the pre-treatment 
mild/moderate periodontitis patients. **=p<0.01, ***=p<0.001, and NS=non-significant 
(Kruskal-Wallis with Mann-Whitney U test and Bonferroni correction). 
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Figure 4.14: The post-treatment salivary uPA levels in the mild/moderate 
periodontitis patients of study B. 
Salivary uPA levels were measured in 31 mild/moderate periodontitis patients in 12±2 
weeks following non-surgical treatment in comparison to their pre-treatment levels. 
Data presented as mean, minimum and maximum levels. **=p<0.01 (Paired samples 
t-test). 
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Figure 4.15: The post-treatment salivary uPA levels in the advanced 
periodontitis patients of study B. 
Salivary uPA levels were measured in 27 advanced periodontitis patients in 12±2 
weeks after treatment in comparison to their pre-treatment levels. The box plots 
represent the median and IQR for each group. **=p<0.01 (Wilcoxon singed rank 
test). 
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Figure 4.16: Relationship of salivary uPA levels with MGI in pre-treatment 
mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 31 pre-treatment 
mild/moderate periodontitis patients and 29 healthy subjects with the MGI index in 
the clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.17: Relationship of salivary uPA levels with PD in pre-treatment 
mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 31 pre-treatment 
mild/moderate periodontitis patients and 29 healthy subjects with the PD index in the 
clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.18: Relationship of salivary uPA levels with %BOP in pre-treatment 
mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 31 pre-treatment 
mild/moderate periodontitis patients and 29 healthy subjects with the %BOP index in 
the clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.19: Relationship of salivary uPA levels with CAL in pre-treatment 
mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 31 pre-treatment 
mild/moderate periodontitis patients and 29 healthy subjects with the CAL index in 
the clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.20: Relationship of salivary uPA levels with MGI in pre-treatment 
advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 27 pre-treatment advanced 
periodontitis patients and 29 healthy subjects with the MGI index in the clinical study 
B. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.21: Relationship of salivary uPA levels with PD in pre-treatment 
advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 27 pre-treatment advanced 
periodontitis patients and 29 healthy subjects with the PD index in the clinical study 
B. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.22: Relationship of salivary uPA levels with %BOP in pre-treatment 
advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 27 pre-treatment advanced 
periodontitis patients and 29 healthy subjects with the %BOP index in the clinical 
study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.23: Relationship of salivary uPA levels with CAL in pre-treatment 
advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA levels in 27 pre-treatment advanced 
periodontitis patients and 29 healthy subjects with the CAL index in the clinical study 
B. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.24: The pre-treatment GCF uPA levels in the periodontitis patients of 
study C. 
The uPA levels were measured in GCF samples obtained from 9 pre-treatment 
periodontitis patients in comparison to 7 healthy control subjects and 13 gingivitis 
patients. Data presented as median and IQR. **=p<0.01, ***=p<0.001, and NS=non-
significant (Kruskal-Wallis test with Mann-Whitney U test and Bonferroni correction). 
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Figure 4.25: The post-treatment GCF uPA levels in the periodontitis patients of 
study C. 
The uPA levels were measured in GCF samples of 9 periodontitis patients in 3 and 6 
months following non-surgical treatment in comparison to their pre-treatment levels. 
The box plots represent the median and IQR for each group. *=p<0.05, and NS=non-
significant (Friedman test with Wilcoxon signed rank test and Bonferroni correction). 
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Figure 4.26: Relationship of GCF uPA levels with MGI in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the GCF uPA levels in 9 pre-treatment periodontitis 
patients and 7 healthy subjects with the MGI index in the clinical study C. The trend-
line demonstrates the presence of a significant positive correlation. 
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Figure 4.27: Relationship of GCF uPA levels with PD in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the GCF uPA levels in 9 pre-treatment periodontitis 
patients and 7 healthy subjects with the PD index in the clinical study C. The trend-
line demonstrates the presence of a significant positive correlation. 
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Figure 4.28: Relationship of GCF uPA levels with %BOP in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the GCF uPA levels in 9 pre-treatment periodontitis 
patients and 7 healthy subjects with the %BOP index in the clinical study C. The 
trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.29: Relationship of GCF uPA levels with CAL in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the GCF uPA levels in 9 pre-treatment periodontitis 
patients and 7 healthy subjects with the CAL index in the clinical study C. The trend-
line demonstrates the presence of a significant positive correlation. 
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Figure 4.30: Salivary uPA activity in the periodontitis patients of study A. 
The uPA activity was assayed in saliva of 45 pre-treatment periodontitis patients in 
comparison to 40 healthy subjects. Data presented as median and IQR for each 
group. ***=p<0.001 (Mann-Whitney U test). 
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Figure 4.31: Relationship of salivary uPA activity with salivary uPA levels in 
pre-treatment periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy with the salivary uPA levels 
in 45 pre-treatment periodontitis patients and 40 healthy subjects in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.32: Relationship of salivary uPA activity with MGI in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the MGI index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.33: Relationship of salivary uPA activity with PD in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the PD index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.34: Relationship of salivary uPA activity with %BOP in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the %BOP index in the clinical 
study A. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.35: Relationship of salivary uPA activity with CAL in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 45 pre-treatment 
periodontitis patients and 40 healthy subjects with the CAL index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 4.36: Salivary uPA activity in the periodontitis patients of study B. 
Salivary uPA activity was assayed in 31 pre-treatment mild/moderate periodontitis 
patients and 27 pre-treatment advanced periodontitis patients in comparison to 25 
gingivitis patients and 29 healthy subjects. The box plots represent the median and 
IQR for each group. *=p<0.05, ***=p<0.001, and NS=non-significant (Kruskal-Wallis 
with Mann-Whitney U test and Bonferroni correction). 
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Figure 4.37: Relationship of salivary uPA activity with salivary uPA levels in 
pre-treatment mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy with the salivary uPA levels 
in 31 pre-treatment mild/moderate periodontitis patients and 29 healthy subjects in 
the clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.38: Relationship of salivary uPA activity with MGI in pre-treatment 
mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 31 pre-treatment 
mild/moderate periodontitis patients and 29 healthy subjects with the MGI index in 
the clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.39: Relationship of salivary uPA activity with PD in pre-treatment 
mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 31 pre-treatment 
mild/moderate periodontitis patients and 29 healthy subjects with the PD index in the 
clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.40: Relationship of salivary uPA activity with %BOP in pre-treatment 
mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 31 pre-treatment 
mild/moderate periodontitis patients and 29 healthy subjects with the %BOP index in 
the clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.41: Relationship of salivary uPA activity with CAL in pre-treatment 
mild/moderate periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 31 pre-treatment 
mild/moderate periodontitis patients and 29 healthy subjects with the CAL index in 
the clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.42: Relationship of salivary uPA activity with salivary uPA levels in 
pre-treatment advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy with the salivary uPA levels 
in 27 pre-treatment advanced periodontitis patients and 29 healthy subjects in the 
clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.43: Relationship of salivary uPA activity with MGI in pre-treatment 
advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 27 pre-treatment 
advanced periodontitis patients and 29 healthy subjects with the MGI index in the 
clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.44: Relationship of salivary uPA activity with PD in pre-treatment 
advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 27 pre-treatment 
advanced periodontitis patients and 29 healthy subjects with the PD index in the 
clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.45: Relationship of salivary uPA activity with %BOP in pre-treatment 
advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 27 pre-treatment 
advanced periodontitis patients and 29 healthy subjects with the %BOP index in the 
clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 4.46: Relationship of salivary uPA activity with CAL in pre-treatment 
advanced periodontitis patients. 
The Spearman’s correlation of the salivary uPA activitiy in 27 pre-treatment 
advanced periodontitis patients and 29 healthy subjects with the CAL index in the 
clinical study B. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Chapter 5 Investigation of the association between salivary VDBP 
and periodontitis 
5.1 Introduction 
Among the proteins which was found to be elevated in saliva of the chronic 
periodontitis patients in the experiments using PPA assays, was the vitamin D 
binding protein (VDBP) (See Chapter 3, section 3.2.2). The main function of VDBP is 
in the transportation of vitamin D (VD) and its metabolites in serum.  Vitamin D plays 
a major role in maintaining normal serum levels of calcium and in electrolyte balance. 
VDBP is synthesized by the hepatocytes, a process regulated by oestrogen and pro-
inflammatory cytokines such as IL-6. In comparison to other carrier proteins, VDBP 
has stable levels throughout life (300-600 µg/ml in plasma of healthy subjects) and 
always higher than its own ligand VD (Guha et al. 1995; White and Cooke 2000; 
Speeckaert et al. 2006; Malik et al. 2013; Zhang et al. 2013b; Bhan 2014). It has 
been reported that VD may have immune-modulating effects and VD has been 
proposed to be associated with periodontal tissue health (Van der Velden et al. 
2011). In addition to VD transport, VDBP is involved in a number of functions such 
actin scavenging, fatty acids transport, macrophage activation and chemotaxis 
(Yamamoto and Kumashiro 1993; Kew et al. 1995; Yamamoto and Naraparaju 1996; 
White and Cooke 2000; Speeckaert et al. 2006; Malik et al. 2013; Bhan 2014; Zhang 
et al. 2014; Fu et al. 2016; Herrmann et al. 2016). The few studies that have been 
carried out to investigate the role of VDBP in the pathogenesis of periodontal 
diseases have investigated VDBP in plasma or in GCF of periodontitis patients (Wu 
et al. 2009; Zhang et al. 2013b; Zhang et al. 2014). One study carried out by Krayer 
et al. (1987) identified VDBP in stimulated saliva of periodontitis patients; however, 
this study did not investigate salivary VDBP levels in periodontitis patients following 
treatment. Therefore, the present study was the first to carry out substantial 
investigations on this candidate salivary biomarker of periodontitis. The research 
presented in this chapter aimed to investigate the VDBP levels in the whole 
unstimulated saliva of patients with chronic periodontitis in an attempt to study the 
relationship between salivary VDBP and periodontitis, and therefore assess the 
validity of salivary VDBP as a candidate biomarker. 
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5.2  Results 
Following the identification of VDBP as a candidate salivary biomarker for 
periodontitis, ELISA assays were carried out to confirm the results from the cytokine 
PPA assays and to thereby quantify the VDBP levels in saliva of periodontitis 
patients. Experiments were carried out using human VDBP Quantikine ELISA kit. 
ELISA validation was carried out on the VDBP ELISA assay prior to use on the study 
samples. The ELISA results were compared between the patients and control 
groups, and in the patients before and after treatment. The results were correlated 
with the periodontal disease indices used for the clinical assessment of periodontitis. 
The results of the ELISA assays (concentrations ng/ml) are presented as median and 
interquartile ranges (IQR) [median (upper quartile-lower quartile)] because data were 
not normally distributed. 
5.2.1 The VDBP Quantikine ELISA validation  
Though the human VDBP Quantikine ELISA was valid for assaying VDBP in saliva 
samples according to the manufacturer (R & D systems); as mentioned before in the 
ELISA validation assays (see Chapter 2, section 2.3.2) and (Jaedicke et al. 2012), it 
is necessary to perform at least one of the validation assays before using a new 
ELISA assay on study samples. Therefore the determination of optimal dilution was 
performed on the VDBP ELISA. The rest of the validation assays values were 
obtained from R & D systems. 
  Determination of optimal dilution 
Though the manufacturer recommendations were to dilute saliva samples in a 1:2 
ratio using the calibrator diluent supplied; two more detailed dilution assays were 
carried out on 3 saliva samples obtained from 3 healthy volunteers for each assay. 
Thus, the samples were assayed in 5 dilutions for each sample (neat, 1:2, 1:3, 1:4 & 
1:8) in duplicates. The assays revealed that 1:4 and 1:8 were the suitable dilution 
factors at which VDBP was detected within the range of the assay standard curve 
(15.6-250 ng/ml), because at the 1:2 dilution factor recommended by the 
manufacturer, the VDBP levels in most of the samples were higher than the range of 
the assay standard curve. The 1:4 dilution factor was used for most of the healthy 
and periodontitis saliva samples, 1:8 dilution factor was used with some of the 
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periodontitis samples in which the VDBP levels were higher than the standard curve 
range at the 1:4 dilution. 
  Recovery and linearity measurements  
The values of the recovery and linearity measurements were obtained from the 
manufacturer. The recovery values for VDBP in saliva were quoted as 90-103%. 
Linearity values were quoted as: 90-103% for the 1:2 dilution in 47 saliva samples, 
and 96-103% for the 1:4 dilution in 47 saliva samples. All recovery and linearity 
values were within the accepted range (80-120%) (R & D systems) and (Jaedicke et 
al. 2012). 
  Intra- and inter-assay variations  
The intra-assay variation (precision) values were obtained from R & D systems. The 
CV% values were (5.7, 5.8, and 6.2) all less than 10-15% (R & D systems) and 
(Hanneman et al. 2011). The inter-assay variation values were also obtained from 
the manufacturer. The CV% values were (5.1, 6, and 7.4) all were within the 
acceptable range. 
  Assay sensitivity 
The assay sensitivity value for the VDBP Quantikine ELISA, was obtained from R & 
D systems. The minimum detectable concentration was 0.65 ng/ml. All periodontitis 
and healthy samples measured by VDBP ELISA in the present research were above 
this minimum concentration (minimum concentration detected was 45.96 ng/ml in 
one of the healthy samples). 
  Summary of ELISA validation  
The optimal dilution assay results together with the values obtained from R & D 
systems, confirmed that the VDBP Quantikine ELISA assay can measure VDBP in 
saliva samples within the standard curve range of the assay. 
5.2.2 Investigation of salivary VDBP levels in periodontitis 
The VDBP Quantikine ELISA kits were used to measure the VDBP levels in whole 
unstimulated saliva samples obtained from the clinical study A. Investigations were 
carried out to study the relationships of VDBP levels in saliva samples with the 
periodontal disease indices used for the clinical assessment of periodontitis. 
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  Salivary VDBP levels in pre- and post-treatment samples of periodontitis 
patients 
The VDBP levels were measured in saliva samples of 40 patients with untreated 
chronic periodontitis (pre-treatment samples) and 40 healthy control subjects (healthy 
samples) (cross-sectional investigation). All samples were obtained at visit 2 of the 
clinical study A (see Chapter 2, section 2.1.3, study A). Salivary VDBP levels were 
higher in the pre-treatment periodontitis patients [682 (331-930) ng/ml] than in the 
healthy subjects [215 (146-392) ng/ml] and the difference was highly significant 
(Mann-Whitney U test, p<0.001), (Figure 5.1). 
The VDBP levels were measured again in saliva samples of the same 40 
periodontitis patients following non-surgical periodontal treatment (longitudinal 
investigation). The post treatment periodontitis samples were obtained at the visit 6 
which was 6 months from the visit 2 of clinical study A (i.e. 6 months after obtaining 
the pre-treatment samples) (see Chapter 2, section 2.1.3, study A). There was no 
statistically significant difference in the salivary VDBP levels between the pre-
treatment visit [682 (331-930) ng/ml] and the post-treatment visit [635 (419-959) 
ng/ml], (Wilcoxon signed rank test, p>0.05). 
  Salivary VDBP correlations with periodontal disease indices 
Determination of the Spearman’s rank correlation coefficient (rho) was used to study 
the relationships of the salivary VDBP levels in 40 pre-treatment periodontitis patients 
and 40 healthy controls with the periodontal disease indices used for the clinical 
assessment of the periodontitis in the clinical study A. These correlations gave 
information about the potential of salivary VDBP as a biomarker that might indicate 
the severity of chronic periodontitis. The statistical analysis of the salivary VDBP 
correlations revealed that there was a significantly positive correlation between the 
salivary VDBP levels and each of the indices: MGI (rho=0.494, p<0.001), PD 
(rho=0.616, p<0.001), %BOP (rho=0.560, p<0.001), and CAL (rho=0.563, p<0.001), 
(Figure 5.2, Figure 5.3, Figure 5.4, & Figure 5.5). 
5.3 Discussion 
5.3.1 Salivary VDBP levels and their relationship with periodontitis 
VDBP was first identified in saliva of periodontitis patients by Krayer et al. (1987), but 
their study was carried out on stimulated saliva and did not investigate salivary VDBP 
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levels in response to treatment. Hence, the present study was the first to investigate 
the VDBP levels in whole unstimulated saliva of chronic periodontitis patients before 
and after non-surgical treatment, and to study the salivary VDBP relationship with 
chronic periodontitis. The results of the ELISA assays carried out on the saliva 
samples obtained from the patients and healthy controls revealed that, the VDBP 
levels were higher in saliva of the pre-treatment chronic periodontitis patients than in 
the healthy subjects and the difference was highly significant. These high levels of 
salivary VDBP in the periodontitis patients were positively correlated with the 
periodontal indices used for the clinical assessment of periodontitis. 
The high levels of VDBP measured in saliva of the periodontitis patients may be 
explained by the roles of this multi-functional protein during inflammation. Aside from 
its main role as a carrier and transporter of vitamin D and its’ metabolites, VDBP play 
vital roles in the inflammatory cells chemotaxis especially neutrophils and 
macrophages, the activation of macrophages, and the synthesis of macrophage 
activating factor (VDBP-MAF) complex which induces bone morphogenesis and 
remodelling via the activation of macrophages and osteoclasts differentiation (Kew 
and Webster 1988; Perez et al. 1988; Yamamoto and Kumashiro 1993; Perez 1994; 
Piquette et al. 1994; Yamamoto et al. 1994; Kew et al. 1995; Schneider et al. 1995; 
Yamamoto and Naraparaju 1996; DiMartino and Kew 1999; White and Cooke 2000; 
Gumireddy et al. 2003; Schneider et al. 2003; Speeckaert et al. 2006; Malik et al. 
2013; Zhang et al. 2013b; Zhang et al. 2014). Such inflammatory events mediated by 
VDBP may take place during the pathogenesis of periodontitis, which may explain 
the significantly elevated levels of VDBP in saliva of the patients. 
The Krayer et al. (1987) study was carried out on 13 patients with periodontitis in 
comparison to control subjects comprised 10 dentulous periodontally healthy 
subjects and 9 edentulous subjects. The patients and subjects were clinically 
assessed using pocket depth, bleeding on probing, radiography of bone loss, and the 
(Loe 1967) gingival index (GI). Whole stimulated saliva and stimulated parotid saliva 
samples were collected from the patients and the control subjects. In their 
investigations for salivary VDBP, Krayer et al. (1987) used a double radial 
immunodiffusion assay and found that the VDBP was detected in the whole 
stimulated saliva of 10 patients, and in the parotid stimulated saliva of one patient 
only. Though the precipitin lines were weaker than those of the periodontitis patients; 
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VDBP was also detected by the double radial immunodiffusion assay in the whole 
stimulated saliva of the dentulous control subjects but not detected in their parotid 
stimulated saliva. VDBP was detected in the whole stimulated saliva of only one 
edentulous subject, and in the parotid stimulated saliva of 2 edentulous subjects only. 
Despite the fact that they used a different technique, the findings of Krayer et al. 
(1987) were in agreement with the findings of the present study in regard to the 
identification of VDBP in whole unstimulated saliva of untreated chronic periodontitis 
patients using the PPA assays. Krayer et al. (1987), also carried out ELISA assays 
on their study samples and reported that, in the stimulated parotid saliva the VDBP 
levels were relatively low and constant (8-80 ng/ml) in all groups and there was no 
distinct relationship between the parotid VDBP levels and any of the periodontal 
diseases measures. In the whole stimulated saliva, Krayer et al. (1987) found that 
there was no statistically significant difference in the VDBP levels between the 
dentulous and the edentulous control subjects, whereas the VDBP levels were higher 
in the periodontitis patients as compared to both the dentulous and edentulous 
control subjects and the difference was statistically significant (p<0.01). In a similar 
manner, the present study detected higher levels of VDBP in the whole unstimulated 
saliva of the pre-treatment periodontitis patients [635 (419-959) ng/ml] as compared 
to the healthy subjects [215 (146-392) ng/ml] and the difference was highly significant 
(p<0.001). Therefore, the present study results were in agreement with (Krayer et al. 
1987). Krayer et al. (1987), reported positive correlations between the VDBP levels in 
the whole stimulated saliva of the periodontitis patients and the periodontal disease 
measures from which the most prominent relationship was with the GI index, a 
finding that was in agreement with the present study which demonstrated significantly 
positive correlations between the salivary VDBP levels and the periodontal disease 
indices. 
In their study carried out on patients with generalized aggressive periodontitis 
(GAgP), Wu et al. (2009) identified VDBP in whole unstimulated saliva of the 
patients. Two-dimensional gel electrophoresis (2DE) was used to investigate the 
proteome profile of whole unstimulated saliva obtained from 5 GAgP patients and 5 
healthy control subjects. The Wu et al. (2009) 2DE proteomic assays revealed that, 
VDBP was among the 11 highly expressed proteins detected in saliva of the GAgP 
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patients in comparison to the control subjects, the findings of the present study are in 
agreement with this. 
Zhang et al. (2014), investigated the VDBP levels in plasma of 59 GAgP patients in 
comparison to 58 healthy control subjects, and in the GCF of 22 GAgP patients in 
comparison to 23 healthy controls. Zhang et al. (2014), found that the patients had 
lower levels of VDBP in the GCF but higher levels in plasma as compared to the 
healthy subjects. The study also reported that the GCF VDBP levels were negatively 
correlated with both the periodontal pocket depth and the attachment loss periodontal 
measures. Zhang et al. (2014), concluded that the GAgP is associated with lower 
levels of GCF VDBP but higher levels of plasma VDBP. However, Zhang et al. (2014) 
suggested that the presence of high VDBP levels in the GCF of healthy subjects 
indicated that this protein might have a role in the periodontal health, and that in 
addition to serum, the periodontal tissues might represent another source for VDBP 
in the human GCF. In addition to their own findings, Zhang et al. (2014) proposed 
that the GCF VDBP might have contributed to the high levels of salivary VDBP 
detected by the Krayer et al. (1987) study, as both the volume and flow rate of GCF 
are increased in periodontal diseases. This may explain the high salivary VDBP 
levels in the periodontitis patients found by the present study. Nevertheless, its GCF 
levels were lower in the GAgP periodontitis patients than in the controls; Zhang et al. 
(2014) proposed that the presence of VDBP in the GCF of the patients might be an 
indication that this protein participates in the inflammatory process of periodontal 
diseases, which may support the present study for the identification and measure of 
VDBP in high levels in saliva of the periodontitis patients. Another study carried out 
by Zhang et al. (2013b), investigated VDBP along with IL-6, procalcitonin, and 
calcidiol (a vitamin D metabolite) in the plasma of 44 patients with GAgP and 32 
healthy control subjects. The Zhang et al. (2013b) ELISA results revealed that, the 
VDBP levels were significantly elevated in plasma of the GAgP patients in 
comparison to the healthy subjects, and the plasma VDBP levels were associated 
with the disease severity as they were significantly positively correlated with the 
periodontal disease measures in the GAgP patients (PD, LOA, and bleeding index). 
Despite the fact that the study was carried out on plasma samples but not saliva or 
GCF, the Zhang et al. (2013b) study was a further evidence for the association of 
VDBP with periodontal diseases. 
206 
 
Zhang et al. (2014), recommended a longitudinal study to investigate the influence of 
periodontal treatment on the local and systemic VDBP levels and to confirm the 
proposed relationship between VDBP and periodontal diseases. The present study 
was the first to carry out such a longitudinal investigation, in which salivary VDBP 
levels were measured in 40 periodontitis patients before and after non-surgical 
treatment. The ELISA results revealed that, there was no statistically significant 
difference in the salivary VDBP levels of the patients between the pre-and post-
treatment visits. As previously explained for the salivary uPAR levels in response to 
treatment (see Chapter 4, section 4.3.1), the persistent levels of salivary VDBP 
following treatment could be explained by the fact that though the periodontal health 
status was improved in the periodontitis patients which was obvious by the 
improvement in the periodontal disease indices (such as %BOP reduced from 52 to 
18, and CAL reduced from 4.5 mm to 3.6 mm); when the periodontal supporting 
tissues are destroyed and pockets formed during periodontitis, they will never return 
back to the ideal healthy status (Pihlstrom et al. 2005), this means that sites of mild 
inflammation may still exist in the periodontal supporting tissues from which VDBP 
may be expressed into the GCF to reach the whole saliva (Zhang et al. 2014). 
Moreover, VDBP possess stable high levels throughout life in the human serum 
which may be increased both locally and systemically during an inflammation (White 
and Cooke 2000; Speeckaert et al. 2006), this may give another explanation for the 
persistent considerable levels of VDBP following treatment, as serum together with 
the local periodontal tissue exudate are sources for the GCF contents which in turn 
flow into saliva (Zhang et al. 2014). Furthermore, as previously mentioned in respect 
to the roles of VDBP during inflammatory events (see section 5.1 Introduction), 
VDBP is involved in the synthesis of the VDBP-MAF factor. Aside from its’ roles in 
the macrophages activation, and in bone morphogenesis and remodelling, the 
VDBP-MAF factor induces macrophage apoptosis via the stimulation of pro-apoptotic 
enzymes such as caspase-3, -8, and -9, which occurs when activated macrophages 
are no longer needed at the site of inflammation (Gumireddy et al. 2003), this may 
also explain the persistent high levels of VDBP in saliva of the periodontitis patients 
following treatment and improvement in their periodontal health status. 
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5.3.2 Summary of findings 
The pre-treatment ELISA results revealed that, the salivary VDBP levels were 
significantly higher in the chronic periodontitis patients as compared to the healthy 
control subjects, and there were significantly positive correlations between these high 
salivary VDBP levels and each of the periodontal disease indices used for the clinical 
assessment of periodontitis. Accordingly, salivary VDBP is suggested as a good 
biomarker for the diagnosis of periodontitis, indication of the disease severity, and 
distinguishing between periodontitis patients and healthy subjects.  
The post-treatment ELISA results revealed that, the salivary VDBP levels were not 
reduced in the patients following non-surgical periodontal treatment. Therefore, 
salivary VDBP may not be a good biomarker for following the clinical course of 
periodontitis in response to treatment. 
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Figure 5.1: The pre-treatment salivary VDBP levels in periodontitis patients as 
compared to salivary VDBP in healthy volunteers.  
Salivary VDBP levels were measured by ELISA in samples obtained from 40 pre-
treatment periodontitis patients in comparison to 40 healthy subjects. The box plots 
represent the median and IQR for each group. ***=p< 0.001 (Mann-Whitney U test). 
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Figure 5.2: Relationship of salivary VDBP levels with MGI in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary VDBP levels in 40 pre-treatment 
periodontitis patients and 40 healthy subjects with the MGI index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 5.3: Relationship of salivary VDBP levels with PD in pre-treatment 
periodontitis patients.  
The Spearman’s correlation of the salivary VDBP levels in 40 pre-treatment 
periodontitis patients and 40 healthy subjects with the PD index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Figure 5.4: Relationship of salivary VDBP levels with %BOP in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary VDBP levels in 40 pre-treatment 
periodontitis patients and 40 healthy subjects with the %BOP index in the clinical 
study A. The trend-line demonstrates the presence of a significant positive 
correlation. 
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Figure 5.5: Relationship of salivary VDBP levels with CAL in pre-treatment 
periodontitis patients. 
The Spearman’s correlation of the salivary VDBP levels in 40 pre-treatment 
periodontitis patients and 40 healthy subjects with the CAL index in the clinical study 
A. The trend-line demonstrates the presence of a significant positive correlation. 
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Chapter 6 Investigation of the in vitro production of uPA and uPAR 
by stimulated hGFs  
6.1 Introduction 
As described in Chapters 3 and 4, uPA and its receptor uPAR were identified by the 
PPA assays as candidate salivary biomarkers for periodontitis, then they were 
investigated for their levels in both saliva and GCF samples of patients with gingivitis 
and periodontitis in comparison to healthy control subjects, and their relationships 
with the periodontal disease indices were determined. Furthermore, the two 
biomarkers were investigated in both saliva and GCF samples of the periodontitis 
patients before and after non-surgical periodontal treatment. Finally, the uPA 
enzymatic activity was assayed in saliva of the periodontitis patients, and its 
relationships with both the salivary uPA levels and the periodontal disease indices 
were investigated. uPA and uPAR are among the most important proteins of the 
plasminogen activating (PA) system, and they act together to initiate the PA system 
activities especially proteolysis. During inflammation and in the presence of a 
stimulus such bacterial toxin or host inflammatory mediator, uPA binds to its receptor 
uPAR which will in turn stimulate and localize the uPA  activity on the cell surface, 
where the active uPA activates the pro-enzyme plasminogen into the active plasmin 
(Crippa 2007; Blasi and Sidenius 2010; Smith and Marshall 2010). A number of cell 
culture studies investigated the production or activity of different PA system proteins 
in gingival epithelium and in gingival fibroblasts. Thus, Tanaka et al. (1997), reported 
the production of uPA by hGFs in response to exogenous oxygen radicals. It has 
been found that uPA along with tPA, PAI-1, and PAI-2 proteins were produced by the 
fibroblasts of healing periodontal wounds generated in rat models (Xiao et al. 2001b). 
Smith and Martinez (2006), reported the production of uPA from hGFs in response to 
stimulation with the transforming growth factor-β1 (TGF-β1).  
Though they were both investigated in a number of cell culture studies, it was 
necessary to carry out cell culture experiments to investigate the local production of 
uPA and uPAR proteins by hGFs in response to an in vitro stimulation to validate 
these mediators as biomarkers for periodontal diseases. Therefore, this chapter 
aimed to: investigate the production of both uPA and uPAR by the hGFs in response 
to the in vitro stimulation with different doses of interleukin -1β (IL-1β), and both the 
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E. coli and P. gingivalis LPS, and to investigate the uPA enzymatic activity in the 
supernatants of the stimulated hGFs. 
6.2 Results 
Experiments were carried out on primary hGF cells previously prepared by Dr Rachel 
Williams from gingival tissues obtained from patients undergoing canine exposure 
surgery (Williams et al. 2016) (see Chapter 2 section 2.2.2). All stimulation 
experiments were carried out independently on cells obtained from 8 donors in total 
(see Chapter 2 section 2.3.3). Before carrying out any stimulating experiment, the 
primary hGF cells were brought out their storage in liquid nitrogen, allowed to thaw, 
cultured in DMEM+ medium in T75 flasks till they reach 80-90% confluent growth. 
The cells were then seeded into plastic-ware including T25 flasks (at density of 2-
4x105 cells/flask) and 6 multi-well plates (at density of 2x105 cells/well), and sub-
cultured to allow the cells to grow till 80-90% confluency. At this point, the hGF cells 
were serum starved by replacing the DMEM+ medium with the SFM medium for 24 
hours. Following serum-starvation, stimulating experiments were carried out on the 
hGF cells including: stimulation with the IL-1β, E. coli LPS, and P. gingivalis LPS for 
24 hours in separate experiments (see Chapter 2 section 2.3.3).  After 24-hour 
stimulation, the hGF cell culture supernatants were aliquoted into cryovials and 
stored at -80°C till use. The levels of uPAR, uPA, and MMP-1 were measured in the 
hGF cell culture supernatants using the human uPAR DuoSet, human uPA DuoSet, 
and human MMP-1 DuoSet ELISA assays (R & D systems), (see Chapter 2 section 
2.3.2). The uPA enzymatic activity in the stimulated hGF cell culture supernatants 
was assayed using the uPA activity fluorometric assay kit (Sigma-Aldrich), (see 
Chapter 2 section 2.3.4). 
The results of the ELISA assays (concentrations pg/ml) and the uPA enzymatic 
activity assays (IU/ml), presented either as median and IQR [median (upper quartile-
lower quartile)] when data were not normally distributed, or as mean and SEM (mean 
±SEM) when data were normally distributed. 
6.2.1 The in vitro stimulation of the hGFs with IL-1β 
Following their primary confluent growth in the T75 flasks, hGFs were stimulated with 
IL-1β in two sets of experiments. The first was a preliminary stimulation experiment 
carried out using T25 flasks in which the hGFs were seeded at density of (2-4x105 
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cells/flask), sub-cultured and allowed to grow till 80-90% confluency then stimulated. 
The second was a set of stimulation experiments carried out using the 6-multi well 
plates in which the cells were seeded at density of (2x105 cells/well), sub-cultured 
and allowed to grow till 80-90% confluency then stimulated. 
  The preliminary IL-1β stimulation experiment 
This preliminary stimulation experiment was carried out using three T25 cell culture 
flasks, in which hGFs from 1 donor were stimulated for 24 hours with 5 ml/flask of 2 
doses of IL-1β in SFM (5 ng/ml and 0.05 ng/ml) as compared to control (0 ng/ml of 
SFM). The aim of this experiment was to investigate if the IL-1β will stimulate the 
hGFs to produce MMP-1, which is a measure of pro-inflammatory response by such 
cells. MMP-1 levels were measured by ELISA, the results revealed that the 5 ng/ml 
stimulated the hGFs to produce an MMP-1 concentration of 55031± 872 pg/ml, and 
the 0.05 ng/ml stimulated the hGFs to produce an MMP-1 concentration of 38326± 
2668 pg/ml, whereas the control (unstimulated) hGFs produced MMP-1 
concentration of 6908±144 pg/ml, no statistical analysis was carried out as the n=1 
for each dose (Figure 6.1). 
  The IL-1β stimulation experiments 
Following the preliminary experiment, three independent IL-1β stimulation 
experiments were carried out, in which the hGFs were cultured in the 6 multi-well 
plates. Once their growth reached 80-90% confluency, the hGFs were stimulated 
with 2 ml/well of 2 doses of IL-1β in SFM (5 ng/ml and 0.05 ng/ml) in comparison to 
control (0 ng/ml of SFM) for 24 hours. The IL-1β stimulation experiments were carried 
out as 10 replicates for each of the stimulating doses and control using hGFs from 3 
donors. The aims of these experiments were to investigate if the hGFs will produce 
the biomarkers uPA and uPAR in response to the IL-1β stimulation, and to 
investigate the uPA activity in the supernatants of the stimulated cells.  
  MMP-1 production by hGFs in response to IL-1β stimulation  
The MMP-1 levels were measured first in the supernatants of the stimulated cells to 
investigate the pro-inflammatory response of the hGFs to the IL-1β stimulation. The 
ELISA results revealed that there was a statistically significant difference among the 
stimulating and control doses (One-Way ANOVA test with Bonferroni correction, 
P<0.001). Both the 5 ng/ml and 0.05 ng/ml of IL-1β stimulated the hGFs to produce 
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higher levels of MMP-1 (33365±3784 pg/ml, and 28024±3196 pg/ml respectively) 
than the control hGFs (5856±402 pg/ml) and the difference was highly significant 
(Independent samples t-test, p<0.001 respectively). There was no statistically 
significant difference in the MMP-1 levels produced by the 5 ng/ml and the 0.05 ng/ml 
stimulated hGFs (Independent samples t-test, p>0.05), (Figure 6.2). 
  uPA production by hGFs in response to IL-1β stimulation  
Following the 24-hour stimulation with IL-1β, uPA DuoSet ELISA experiments were 
carried out on the supernatants of the stimulated cells. The results revealed that 
there was no statistically significant difference among the stimulating and control 
doses (Kruskal-Wallis test, p>0.05). Though the hGFs stimulated with 5 ng/ml and 
0.05 ng/ml of IL-1β produced higher levels of uPA [138 (109-516) pg/ml and 70 (60-
463) pg/ml respectively] in comparison to the hGFs incubated with the control dose 
[48 (42-297) pg/ml], the difference was not statistically significant (Mann-Whitney U 
test, p>0.05). There was no statistically significant difference in the supernatants uPA 
levels between the 5 ng/ml and the 0.05 ng/ml stimulated cells (Mann-Whitney U test, 
p>0.05). 
  uPA activity in supernatants of the IL-1β stimulated hGFs 
The uPA activity fluorometric assay was used to assay the uPA activity in the 
supernatants of the hGFs stimulated with IL-1β. The results revealed that there was 
no statistically significant difference in the uPA activity among the stimulating and 
control doses (0.4647 (0.4628-0.4781) IU/ml, 0.4638 (0.4620-0.4766) IU/ml, and 
0.4626 (0.4604- 0.4751) IU/ml respectively] (Kruskal-Wallis and Mann-Whitney U 
tests, p>0.05).   
  uPAR production by hGFs in response to IL-1β stimulation  
The uPAR levels were measured in the supernatants of the stimulated and control 
hGFs by uPAR ELISA. The results revealed that, there was a statistically significant 
difference among the stimulating and control doses (One-Way ANOVA with 
Bonferroni correction, p<0.01). The hGFs stimulated with the 5 ng/ml of IL-1β 
produced higher levels of uPAR (138±11 pg/ml) than the control cells (85±9 pg/ml) 
and the difference was highly significant (Independent samples t-test, p<0.01). The 
hGFs stimulated with the 0.05 ng/ml of IL-1β also produced higher levels of uPAR 
(116±9 pg/ml) as compared to the control cells (85±9 pg/ml) and the difference was 
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statistically significant (Independent samples t-test, p<0.05). There was no 
statistically significant difference between the 5 ng/ml and 0.05 ng/ml stimulating 
doses (Independent samples t-test, p>0.05), (Figure 6.3). 
  Summary of the IL-1β stimulation experiments 
The 24-hour incubation of the hGFs with 5 ng/ml and 0.05 ng/ml of IL-1β stimulated 
the cells to produce significantly higher levels of MMP-1 and uPAR as compared to 
the control cells. IL-1β stimulated the hGFs to produce uPA in numerically higher 
levels as compared to the control cells; however, the difference was not statistically 
significant. There was no statistically significant difference in the uPA activity 
measured in the supernatants of the IL-1β stimulated and control hGFs. 
6.2.2 The in vitro stimulation of the hGFs with E. coli LPS  
After their primary confluent growth in the T75 flasks, the hGFs were seeded into the 
6-multi well plates at density of (2x105 cells/well), cultured till the cells reached 80-
90% confluent growth. Then stimulated in two independent experiments for 24 hours 
with 2 ml/well of 100 ng/ml of E. coli LPS in SFM as compared to control (0 ng/ml of 
SFM). The E. coli LPS stimulation experiments were carried out as 6 replicates for 
each of the stimulating dose and control using hGFs from 2 donors. The aims of 
these stimulation experiments were to investigate the uPA and uPAR production by 
the hGFs in response to the E. coli LPS stimulation, along with investigating the uPA 
activity in the supernatants of the stimulated hGFs. 
  MMP-1 production by hGFs in response to E. coli LPS stimulation 
The MMP-1 levels were measured first in the supernatants of the stimulated cells to 
investigate the hGFs pro-inflammatory response to the E. coli LPS stimulation. The 
ELISA results revealed that, the hGFs stimulated with 100 ng/ml of E. coli LPS 
produced higher levels of MMP-1(16706±4787 pg/ml) in comparison to the control 
cells (7581±1283 pg/ml); however, the difference was not statistically significant 
(Independent samples t-test, p>0.05). 
  uPA production by hGFs in response to E. coli LPS stimulation  
Following the 24-hour stimulation with E. coli LPS, ELISA assays were carried out to 
measure the uPA in the supernatants of the stimulated hGFs. Results revealed that, 
though the hGFs stimulated with 100 ng/ml of E. coli LPS produced higher levels of 
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uPA [223 (128-320) pg/ml] than the cells incubated with the control dose [110 (88-
162) pg/ml], the difference was not statistically significant (Mann-Whitney U test, 
p>0.05). 
  uPA activity in supernatants of the E. coli LPS stimulated hGFs 
The uPA enzymatic activity was measured in the supernatants of the hGFs 
stimulated with E. coli LPS. Results revealed that, there was no statistically 
significant difference between the stimulated and control hGFs [0.4785 (0.4777- 
0.4796) IU/ml and 0.4779 (0.4748 - 0.4783) IU/ml respectively], (Mann-Whitney U 
test, p>0.05).   
  uPAR production by hGFs in response to E. coli LPS stimulation 
The uPAR levels produced by the hGFs stimulated with E. coli LPS for 24 hours were 
measured by ELISA. Results showed that, though the hGFs stimulated with 100 
ng/ml of E. coli LPS produced higher levels of uPAR (176±25 pg/ml) than the control 
cells (123±10 pg/ml), the difference was not statistically significant (Independent 
samples t-test, p>0.05). 
  Summary of the E. coli LPS stimulation experiments 
The 24-hour incubation of the hGFs with 100 ng/ml of E. coli LPS stimulated the cells 
to produce MMP-1, uPA and uPAR in numerically higher levels than the control cells; 
however, the difference was not statistically significant. Furthermore, no difference 
was found in the supernatants uPA activity between the stimulated and control cells. 
6.2.3 The in vitro stimulation of the hGFs with P. gingivalis LPS  
The P. gingivalis LPS stimulation experiments were carried out by seeding the hGFs 
into the 6-multi well plates at density of (2x105 cells/well) in two independent 
experiments, and cultured till the cells reached 80-90% confluent growth At this point 
the cells were stimulated for 24 hours with 2 ml/well of 100 ng/ml of P. gingivalis LPS 
in SFM in comparison to control (0 ng/ml of SFM). The P. gingivalis LPS stimulation 
experiments were carried out as 6 replicates for each of the stimulating dose and 
control using hGFs from 2 donors. These stimulation experiments aimed to 
investigate the uPA and uPAR production by the hGFs, and to investigate the uPA 
activity in the supernatants of the cells in response to the P. gingivalis LPS 
stimulation. 
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  MMP-1 production by hGFs in response to P. gingivalis LPS stimulation 
Using ELISA, the MMP-1 levels were measured in the supernatants of the stimulated 
cells to investigate their pro-inflammatory response to stimulation with P. gingivalis 
LPS. Results revealed that, the hGFs stimulated with 100 ng/ml of P. gingivalis LPS 
produced higher levels of MMP-1 (8449±1030 pg/ml) in comparison to the control 
cells (5179±1002 pg/ml) and the difference was statistically significant (Independent 
samples t-test, p<0.05), (Figure 6.4). 
  uPA production by hGFs in response to P. gingivalis LPS stimulation  
After the 24-hour stimulation with P. gingivalis LPS, the uPA levels in the 
supernatants of the stimulated hGFs were measured by uPA ELISA. Results 
demonstrated that the cells stimulated with 100 ng/ml of P. gingivalis LPS produced 
higher levels of uPA (112±8 pg/ml) than the hGFs incubated with the control dose 
(33±14 pg/ml), and the difference was highly significant (Independent samples t-test, 
p<0.01), (Figure 6.5). 
  uPA activity in supernatants of the P. gingivalis LPS stimulated hGFs  
The uPA activity was measured in the supernatants of the hGFs stimulated with P. 
gingivalis LPS for 24 hours. Results revealed that, there was a significant difference 
in uPA activity between the stimulated hGFs (0.4871±0.00033 IU/ml) and the control 
cells (0.4861±0.0002 IU/ml) (Independent samples t-test, p<0.05), (Figure 6.6). 
However, the uPA activity levels measured in the supernatants of the stimulated 
hGFs were very low as compared to the uPA activity levels measured in the saliva 
samples of the periodontitis patients and healthy controls (see Chapter 4, section 
4.2.4). 
  uPAR production by hGFs in response to P. gingivalis LPS stimulation 
The uPAR ELISA was used to measure the uPAR levels in the supernatants of the 
hGFs stimulated with P. gingivalis LPS for 24 hours. The stimulated hGFs produced 
higher levels of uPAR (86±3 pg/ml) than the cells incubated with the control dose 
(60±4 pg/ml), and the difference was highly significant (Independent samples t-test, 
p<0.01), (Figure 6.7).  
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  Summary of the P. gingivalis LPS stimulation experiments 
The hGFs incubated with 100 ng/ml of P. gingivalis LPS for 24 hours, were 
stimulated to produce significantly higher levels of MMP-1, uPA and uPAR in 
comparison to the control cells. There was a statistically significant difference in the 
supernatants uPA activity between the stimulated and control cells. 
6.3 Discussion  
6.3.1 Regulation of uPA and uPAR by IL-1β  
IL-1β is a well-known inflammatory cytokine that executes a number of important 
functions that regulate the inflammation, inflammatory response to pathogens such 
as microbial invasion, and healing of injured tissues. As an inflammatory mediator, 
the IL-1β is involved in the pathogenesis of periodontal diseases by its roles in the 
tissue destruction, stimulation of chemokines, recruiting inflammatory cells to the 
inflamed site, and inducing other inflammatory mediators potentiating the 
inflammatory response (Barksby et al. 2007; Buduneli and Kinane 2011; Taylor 2014; 
Jaedicke et al. 2016). Hence, studies have reported higher levels of IL-1β in gingival 
tissues and GCF from inflamed sites, and saliva of periodontitis patients in 
comparison to healthy tissues and healthy subjects (Figueredo et al. 1999; 
Suwatanapongched et al. 2000; Ogura et al. 2001; Dinarello 2009; Salminen et al. 
2014; Javed et al. 2015; de Lima et al. 2016; Gomes et al. 2016; Jaedicke et al. 
2016). IL-1β stimulates the production and activity of the matrix metallo-proteinases 
such as MMP-1 in human gingival fibroblasts, therefore IL-1β is an important 
mediator of connective tissue and matrix degradation associated with periodontal 
diseases (Gogly et al. 1998; Kida et al. 2005; Liu et al. 2010). On this basis, IL-1β 
was used in the stimulation experiments of the primary hGFs by the present study to 
investigate its role as a stimulant for the candidate biomarkers uPA and uPAR 
production, along with investigating the IL-1β stimulatory effects on the uPA activity in 
the hGFs. 
The results of the cell culture experiments carried out by the present study showed 
that, the incubation of the hGFs with 5 ng/ml and 0.05 ng/ml of IL-1β for 24 hours 
stimulated the cells to produce higher levels of MMP-1 in comparison to the controls, 
which was an indication for the pro-inflammatory response by the hGFs to the IL-1β 
stimulation. These results were in agreement with Williams et al. (2016) who also 
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found that the 24-hour incubation of hGFs with 0.05 ng/ml of IL-1β stimulated the 
hGFs to produce higher levels of MMP-1 in comparison to the unstimulated cells. 
Such results may be explained by the ability of IL-1β to stimulate the production of 
other inflammatory mediators, proteins, and pro-enzymes such as MMP-1 and PGE2 
in the hGFs (Kida et al. 2005). Following 3 days incubation of hGFs with 1-20 ng/ml 
of IL-1β, active MMP-1 (collagenase enzyme) was detected in the stimulated hGFs 
by western blotting in comparison to the pro-enzymatic MMP-1 detected in the 
unstimulated cells (Cox et al. 2006). This finding by Cox et al. (2006), may explain 
the high levels of MMP-1 measured in the supernatants of the hGFs stimulated with 
IL-1β found by the present study.  
Though the hGFs incubated with 5 ng/ml and 0.05 ng/ml of IL-1β for 24 hours were 
stimulated to produce numerically higher levels of uPA in comparison to the controls; 
the difference was not statistically significant. This finding was in contrast to the 
results of Ogura et al. (2001) study, which was the only available study (before 
conducting the present project) that investigated the role of IL-1β in the stimulation of 
hGFs to express both uPA and uPAR. Ogura et al. (2001), found that the 24-hour 
incubation with 1 unit/ml of IL-1β stimulated the hGFs to express higher mRNA and 
protein levels of uPA in comparison to the unstimulated cells.  
The present study investigated the uPA activity in the supernatants of hGFs following 
24-hour stimulation with IL-1β using the uPA fluorometric activity assay. The assay 
results indicated that there was no statistically significant difference in the uPA 
activity between the stimulated and control cells, a finding that may contradict the 
Ogura et al. (2001) results. Using a modified activity assay described by Pfeilschifter 
et al. (1990) which measures the release of chromogenic plasmin substrate, Ogura et 
al. (2001), found that IL-1β stimulated the hGFs to demonstrate higher plasminogen 
(PA) activity in their lysates in a time dependent manner (1 unit/ml of IL-1β for 4, 8, 
and 24 hours) which was greater at each time point as compared to the unstimulated 
cells (p<0.01), and in a dose dependent manner ( 0.01, 0.1, 1, and 10 unit/ml of IL-1β 
for 7 hours) with the highest PA activity at 1 and 10 unit/ml (p<0.01) then 0.1 unit/ml 
(p<0.05) and no difference was found with the 0.01 unit/ml of IL-1β as compared to 
the unstimulated cells. Furthermore, the releasable PA activity from the 
phosphatidylinositol-specific phospholipase C (PI-PLC) treated hGFs lysates was 
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higher in the hGFs stimulated with 1 unit/ml of IL-1β for 7 hours in comparison to the 
control cells.  
On the other hand, the present study found that the 24-hour incubation with 5 ng/ml 
and 0.05 ng/ml of IL-1β, stimulated the hGFs to produce significantly higher levels of 
uPAR in comparison to the unstimulated cells, a finding that was in harmony with 
Ogura et al. (2001) study which reported higher protein levels and mRNA expression 
of uPAR by the hGFs in response to 24-hour stimulation with 1 unit/ml of IL-1β. 
Despite the fact that there was no significant difference in the uPA levels and activity 
between the stimulated and control hGFs; the production of uPA and uPAR by the 
stimulated hGFs, indicated that the present study was a further evidence along with 
the Ogura et al. (2001) study for the role of the inflammatory cytokine IL-1β in 
stimulating the local production of both uPA and uPAR by the hGFs. 
Along with the IL-1β, Williams et al. (2016) investigated the effects of IL-1α alone and 
in synergism with the leptin hormone on hGFs. Williams et al. (2016), found that the 
24-hour incubation of hGFs with 0.05 ng/ml of IL-1α or 10 µg/ml of leptin stimulated 
the hGFs to produce higher levels of MMP-1 in comparison to the unstimulated cells, 
and this stimulation was maximized when the hGFs were incubated with the both 
stimulants (i.e. a synergistic effect). As IL-1α and IL-1β both belong to the same 
interleukin-1 superfamily, the production of MMP-1 by hGFs stimulated with IL-1α 
reported by Williams et al. (2016), is consistent with the findings of the present study 
regarding the production of MMP-1 by the IL-1β stimulated hGFs. 
Two previous studies investigated the stimulatory effects of IL-1 on the hGFs 
production of MMP-1 and plasminogen activators (Mochan et al. 1988; Tewari et al. 
1994). Mochan et al. (1988), carried out the first study to investigate the role of IL-1 in 
the stimulation of the plasminogen activator production by the hGFs. The PA activity 
was determined by measuring the hydrolysis of a chromogenic substrate. The 24-
hour incubation of the hGFs with different concentrations of IL-1 (0-10 U/ml), 
stimulated the cells to express higher PA activity with the maximum effect at the 3 
U/ml dose for the cell culture supernatants and at the 5 U/ml dose for the cell lysates. 
In addition to that, the cells were stimulated in a time dependent manner by 10 U/ml 
of IL-1 for (0-24 hours), the maximum stimulation of the PA activity was at the 24-
hour time point for the cell culture supernatants and at the 4-hour time point for the 
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cell lysates. Moreover, the immuno-peroxidase staining of the cells demonstrated 
higher expression of the PA molecules in the stimulated hGFs. Nevertheless, they 
did not specify if the IL-1 they used was IL-1α or IL-1β, the Mochan et al. (1988) 
results were in contrast to the present study results in regard to the uPA activity 
which was not significant in the supernatants of the hGFs stimulated with the IL-1β. 
On the other hand, though they didn’t define which PA protein was highly expressed, 
the Mochan et al. (1988) study may support the present study in respect to the higher 
production of uPAR by the hGFs stimulated with IL-1β for 24 hours.  
The second study was by Tewari et al. (1994), who investigated the relative 
expression of the MMPs (1 and 3) and the plasminogen activator in response to IL-1 
stimulation. The 24-hour incubation of the hGFs with 100 nM of IL-1 significantly 
stimulated the mRNA expression of MMP-1, MMP-3, and PA from the hGFs. 
Furthermore, Tewari et al. (1994) found that the IL-1 stimulated the expression of the 
3 proteins from the hGFs in a time dependent manner by the incubation of the cells 
for (0-24 hours), the maximum stimulation for the MMP-1 was at the 2-hour time point 
and this remained until the 24-hour time point, whereas the maximum stimulation for 
both the MMP-3 and PA was at the 12-hour time point and this remained until the 24-
hour time point. Though they didn’t assign which PA protein production was 
stimulated, the Tewari et al. (1994) study may support the present study for the 
higher production of both the MMP-1 and uPAR by the IL-1β stimulated hGFs in 
comparison to the control cells. 
6.3.2 Regulation of uPA and uPAR by LPS  
Lipopolysaccharides are endotoxins produced by various gram-negative bacteria. 
Bacterial LPS have been implicated in the pathogenesis of periodontal diseases, they 
were detected in the dental plaque of periodontitis patients and positively correlated 
with the clinical measures of the disease. LPS can induce diverse responses in the 
periodontal tissues which will result in inflammation and degradation of these 
supporting tissues, in addition to the alveolar bone resorption leading to periodontitis 
(Gupta 2013; Hasan and Palmer 2014; Kang et al. 2016). LPS may exert direct toxic 
effects on the hGFs and other periodontal tissues, stimulate the release and activity 
of host inflammatory mediators and enzymes such as collagenases, PGE2, and 
interleukins (such as IL-1β), and may stimulate the osteoclasts formation in the 
periodontal tissues (Ogura et al. 1995; Mochizuki et al. 1999; Xiao et al. 2001a; 
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Gupta 2013; Wara-aswapati et al. 2013; Kang et al. 2016). Bacterial LPS have been 
used by numerous in vitro studies to investigate the stimulatory or inhibitory effects of 
these bacterial toxins on different oral cells such as human gingival fibroblasts. 
In the present study, both the E. coli and P. gingivalis LPS were used in the cell 
culture experiments to investigate the stimulatory effects of these two bacterial toxins 
on the hGFs. In a similar manner to the IL-1β experiments, the MMP-1 levels were 
measured first in the supernatants of the stimulated hGFs as an inflammatory 
response to the stimulation with these bacterial LPS. The study results revealed that, 
the P. gingivalis LPS stimulated the hGFs to produce significantly higher levels of 
MMP-1 in comparison to the control cells. In contrast to the P. gingivalis LPS, though 
the E. coli LPS stimulated the hGFs to produce numerically higher levels of MMP-1 
than the control cells, the difference was not statistically significant. Williams et al. 
(2016), found that the E. coli LPS stimulatory effect on the hGFs in respect to the 
MMP-1 production was in a donor-dependent manner (i.e. hGFs obtained from some 
donors demonstrated higher levels of MMP-1 while cells derived from other donors 
did not). Nevertheless, the MMP-1 mRNA expression and protein levels were 
increased in the hGFs stimulated with the E. coli LPS; the difference was only 
significant when the E. coli LPS was synergized with leptin (Williams et al. 2016). 
These findings by Williams et al. (2016) are consistent with the present study findings 
with regard to the MMP-1 production by the E. coli LPS stimulated and control hGFs. 
Moreover, it has been reported that P. gingivalis LPS has the greatest influence on 
the hGFs production of inflammatory cytokines (such as IL-6, IL-8 and PGE2) as 
compared to LPS from A. actinomycetemcomitans, and E. coli (Yamaji et al. 1995; 
Noguchi et al. 1996), this may also explain the difference in the MMP-1 production in 
response to P. gingivalis and E. coli LPS found by the present study. 
The present study was the first to investigate the uPA and uPAR production in 
addition to the uPA activity in hGFs in response to stimulation by E. coli LPS. Results 
demonstrated that, though the uPA and uPAR levels were numerically higher in the 
supernatants of the stimulated cells as compared to the control cells, the difference 
was not statistically significant. Furthermore, no significant difference was found in 
the uPA activity between the stimulated and control cells. hGFs obtained from the 
same donor but from different anatomical locations on the periodontium may have 
different phenotypes therefore they may demonstrate different responses to 
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stimulation (Irwin et al. 1994; Jonsson et al. 2011), this may explain the hGFs 
responses to E. coli LPS found by the present study. In addition to that, inter-
individual variability and differences in the hGFs sensitivity and responses to LPS 
have been reported by a number of studies (Tipton et al. 1991; Michel et al. 2001; 
Wurfel et al. 2005; Sukkar et al. 2007; Uehara and Takada 2007). 
In contrast to E. coli LPS, the P. gingivalis LPS stimulated the hGFs to produce 
significantly higher levels of both uPA and uPAR in comparison to the control cells. 
Though it was in low levels as compared to what was found in saliva of periodontitis 
patients, the P. gingivalis LPS stimulated the hGFs to express higher uPA activity 
than the control cells. As uPAR binds and localizes the activity of uPA (Crippa 2007; 
Smith and Marshall 2010), the higher levels of both uPA and uPAR may explain the 
higher uPA activity measured in the supernatants of the stimulated hGFs. 
Furthermore, the high levels of MMP-1, uPA, uPAR, and uPA activity in the 
supernatants of the stimulated hGFs, might be explained by the fact that P. gingivalis 
is one of the well-known bacteria involved in the pathogenesis of periodontal 
diseases (Nickles et al. 2016; Kakuta et al. 2017), and that the inflamed hGFs 
response to the P. gingivalis LPS differs from that of the healthy cells by the 
expression and production of higher levels of different inflammatory cytokines and 
proteins (Kang et al. 2016). 
Stimulation of receptors known as the toll-like receptors (TLRs) expressed by the 
hGFs induce these cells to demonstrate various responses. The hGFs express these 
surface receptors in order to activate inflammatory responses that may help to kill 
and remove any bacteria or bacterial products in the gingival tissues. The hGFs may 
express up to 10 TLRs, the most common are the TLR2 and TLR4 receptors. These 
receptors recognise bacterial-associated molecular patterns in the gingiva and dental 
plaque such as LPS (Wang et al. 2000; Kiji et al. 2007; Mahanonda et al. 2007; 
Uehara and Takada 2007; Yoshioka et al. 2008; Scheres et al. 2011; Kang et al. 
2016; Williams et al. 2016; Palm et al. 2017). The TLR2 receptors are stimulated by 
TLR2 agonists such as P. gingivalis LPS (Hirschfeld et al. 2001; Darveau 2010; 
Scheres et al. 2011; Andrukhov et al. 2014; Kang et al. 2016). Whereas the TLR4 are 
stimulated by TLR4 agonists such as LPS of A. actinomycetemcomitans and 
enterobacteria such as E. coli (Lee et al. 2006; Andrukhov et al. 2014; Williams et al. 
2016). Studies reported that periodontal pathogens (such as P. gingivalis) mostly 
226 
 
stimulate the destructive inflammatory responses of periodontitis by activating TLR2 
receptors (Burns et al. 2006; Darveau 2010; Wara-aswapati et al. 2013; de Aquino et 
al. 2014). Other studies demonstrated that during inflammation the collagen 
degradation activity is increased after exposure of the hGFs TLR4 receptors to LPS 
such as A. actinomycetemcomitans LPS (Bhide et al. 2005; Takahashi et al. 2008). 
However, in addition to periodontal pathogens, commensal oral bacteria may also 
stimulate TLRs such as TLR2 in an attempt to induce a protective response that may 
prevent the host from developing disease (Darveau 2010). Furthermore, agonists 
and pathogens may stimulate receptors other than those known to be their specific 
targets, for instance a study have shown that P. gingivalis LPS induced hGFs to 
produce IL-1 via stimulating TLR4 receptor, and this IL-1 production was inhibited by 
anti-TLR4 antibody (Wang et al. 2000). Another study reported that in addition to 
TLR2, TLR1 and TLR7 in hGFs obtained from periodontitis patients also 
demonstrated strong affinity for induction by P. gingivalis (Scheres et al. 2011). 
Accordingly, hGFs that express TLR2 receptors are stimulated by P. gingivalis LPS, 
whereas cells that express TLR4 receptors are stimulated by E. coli LPS, this may 
explain the variation in the responses of the hGFs stimulated by these 2 bacterial 
LPS found by the present study. 
A number of studies investigated the effects of LPS derived from P. gingivalis and 
other bacterial species on the hGFs in respect to the PA system proteins production 
and activities. In their research, Ogura et al. (1995) studied the stimulatory effects of 
LPS derived from the periodontal bacteria Campylobacter rectus on the hGFs in a 
time and dose dependent manner. Ogura et al. (1995), also investigated the effects 
of the C. rectus LPS along with LPS derived from other periodontal bacteria including 
the P. gingivalis, Prevotella loescheii, and Porphyromonas endodontalis on the 
production of PA system proteins by hGFs. Using the fluorogenic assay with a 
plasmin substrate, Ogura et al. (1995) found that the 24-hour incubation of hGFs with 
10 µg/ml of the aforementioned LPS stimulated the PA activity determined by uPA 
and the highest activity was observed in the cells stimulated with the C. rectus and P. 
endodontalis LPS. Ogura et al. (1995), investigated the PA activity in a time 
dependent manner, they found that the incubation of hGFs with 10 µg/ml of the C. 
rectus LPS for 10, 24, 48, and 72 hours stimulated the cells to express significantly 
higher PA activity via uPA in comparison to the unstimulated cells. Moreover, the 
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dose dependent course showed that the incubation of hGFs with 0.4, 2 and 10 µg/ml 
of the C. rectus LPS for 72 hours stimulated the cells to demonstrate higher PA 
activity in comparison to the control cells (Ogura et al. 1995). Though they didn’t 
carry out further investigations with the P. gingivalis LPS and focused on the C. 
rectus LPS, the Ogura et al. (1995) results may support the present study in regard 
to the higher production and activity of uPA by hGFs in response to the P. gingivalis 
LPS as both P. gingivalis and C. rectus are among the essential pathogens in 
periodontal diseases (Nickles et al. 2016). Furthermore, the PA activity via the uPA 
action on plasmin substrate measured by Ogura et al. (1995), is consistent with the 
uPA activity measured in the P. gingivalis LPS stimulated hGFs by the present study, 
and the Ogura et al. (1995) study was a further evidence for the role of uPA in the 
pathogenesis of periodontal diseases and may backup the present study for the 
identification of uPA as a biomarker for periodontal diseases. 
Abiko et al. (1998), investigated the PA activity along with the PGE2, IL-1β and IL-6 
production by young and aged hGFs stimulated with C. rectus LPS for 24 hours. 
Abiko et al. (1998), measured the inflammatory mediators and the PA activity in the 
media of the stimulated cells in 3, 9, 12, and 24 hours following stimulation. The 
results showed that all the mediators were higher in both the stimulated aged and 
young cells (higher in the aged cells) in comparison to the controls. The PA activity 
assay using fluorogenic substrate, enabled Abiko et al. (1998) to find that the PA 
activity was higher in the stimulated cells as compared to the control cells. The semi-
quantitative real time-PCR (RT-PCR) analysis showed that the gene expression for 
each of the inflammatory proteins was higher in the stimulated aged and young hGFs 
(more significant in the aged cells) than the control cells. Though they used C. rectus 
LPS, the Abiko et al. (1998) study is consistent with the present study in regard to the 
uPA activity measured in the hGFs stimulated with the P. gingivalis LPS. 
Furthermore, Abiko et al. (1998) found that the tPA gene expression was higher than 
that of the uPA in the stimulated cells, a finding that may explain the non-significant 
difference in the uPA levels produced by the E. coli LPS stimulated hGFs and the 
control cells found by the present study. 
Mochizuki et al. (1999), investigated the effects of the C. rectus LPS on young and 
aged gingival fibroblasts obtained from rats and human donors (rGFs and hGFs) in 
relation to the plasminogen activators production and activity. The cells were 
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incubated with 0.01, 0.1, 1 and 10 µg/ml of C. rectus LPS for 8 hours, and the PA 
activity in the stimulated cells culture media was measured by the plasmin production 
from plasminogen substrate. Mochizuki et al. (1999), found that the PA activity was 
significantly elevated in both the young and aged hGFs and rGFs (more in the aged 
cells) in a dose dependent manner as compared to the control cells. Though they 
measured the PA activity in response to C. rectus LPS, the Mochizuki et al. (1999) 
study is also consistent with the present study in regard to the higher uPA activity 
measured in the P. gingivalis LPS stimulated hGFs as compared to the controls. 
Moreover, Mochizuki et al. (1999) detected high levels of tPA mRNA but not uPA in 
both the aged hGFs and aged rGFs stimulated with C. rectus LPS, a finding that 
might be in harmony with the present study results which revealed non-significant 
difference in the uPA levels produced by both the E. coli LPS stimulated and 
unstimulated hGFs.  
The uPA and uPAR levels along with the PA activity were investigated in hGFs in 
response to stimulation with the P. gingivalis LPS (Ogura et al. 1999). Ogura et al. 
(1999), measured the PA activity using the Pfeilschifter et al. (1990) activity assay 
which measures the release of chromogenic plasmin substrate by the hGFs lysates 
and the releasable PA activity from the PI-PLC treated hGFs. The uPA and uPAR 
levels were measured using the slot blot analysis, the relative mRNA expression for 
the both proteins was measured by the RT-PCR. Ogura et al. (1999), incubated the 
cells with 1 µg/ml of LPS for 24 hours, the PA activity was measured at 4, 8, and 24 
hours following stimulation. The PA activity was higher at all the time points in the 
stimulated cells as compared to the control cells, and the maximum increase in the 
activity was at the 8-hour time point. Ogura et al. (1999), also measured the PA 
activity in the hGFs following stimulation with 0.1, 1, and 10 µg/ml of LPS for 8 hours 
which increased the PA activity in the stimulated cells in a dose dependant manner 
and the maximum stimulation was at the 1 µg/ml of LPS. The 8-hour incubation of the 
hGFs with 1 µg/ml of P. gingivalis LPS increased the PI-PLC releasable PA activity 
by 3 folds in the stimulated cells as compared to the unstimulated cells. Considering 
the incubation time and the stimulating doses used by Ogura et al. (1999) in their 
experiments, the PA activity results of Ogura et al. (1999) are in agreement with the 
increased uPA activity measured in the hGFs supernatants following the 24-hour 
stimulation with P. gingivalis LPS found by the present study. Furthermore, Ogura et 
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al. (1999) found that the incubation of the hGFs with 1 µg/ml of P. gingivalis LPS for 8 
hours increased both the protein levels and the relative mRNA expression for both 
uPA and uPAR in the stimulated cells in comparison to the control cells, these results 
were in congruence with present study results which also revealed that the P. 
gingivalis LPS stimulated the hGFs to produce higher levels of both uPA and uPAR 
in comparison to the unstimulated cells. 
The production of tPA and its inhibitor PAI-2 were investigated in hGFs stimulated 
with LPS derived from A. actinomycetemcomitans, P. gingivalis, and Fusobacterium 
nucleatum periodontal bacteria and LPS from other non-periodontal bacteria 
including E. coli and Salmonella enteritidis (Xiao et al. 2001a). Follwoing a 24-hour 
incubation of the hGFs with 0.6 µg/ml of LPS from the aforementioned bacteria, Xiao 
et al. (2001a) measured the tPA and PAI-2 production using ELISA and RT-PCR 
assays which both revealed that there were significantly higher levels of tPA in the 
stimulated cells as compared to the control cells. The PAI-2 levels were increased in 
response to LPS from all bacteria except the P. gingivalis and the greatest increase 
was in response to the E. coli LPS. Moreover, Xiao et al. (2001a) found that the ratio 
of tPA to its inhibitor PAI-2 was greater following stimulation with LPS from all the 
periodontal bacteria and the highest ratio was in response to the P. gingivalis LPS. 
Xiao et al. (2001a), explained the P. gingivalis LPS stimulation of tPA as compared to 
its inhibior PAI-2, by the high plasminogen activation and inhibition of the 
plasminogen inhibitors (i.e. plasminogens activators production is stimulated and 
plasminogen inhibitors production is inhibited) possessed by P. gingivalis in 
comparison to other bacterial species such as A. actinomycetemcomitans, T. 
forsythus and F. nucleatum (Grenier 1996). Therefore, Xiao et al. (2001a) concluded 
that the periodontal bacteria had the greatest stimulatory effect on the plasminogen 
activators (represented by tPA), and that these bacteria affect the ratio or balance 
between the activators and their inhibitors in the favour of the activators resulting in 
degradation of the supporting periodontal tissues during periodontitis. Although, they 
investigated tPA and its inhibitor PAI-2 but not uPA or uPAR, the Xiao et al. (2001a) 
results are consistent with the increased levels of the PA system proteins (uPA and 
uPAR) produced by the hGFs in response to the P. gingivalis LPS stimulation found 
by the present study. 
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Otsuka et al. (2001), investigated the plasminogen activity in the hGFs of subjects 
with and without Down syndrome (DGFs and NDGFs) in response to the LPS derived 
from A. actinomycetemcomitans. The PA activity was measured by the Pfeilschifter et 
al. (1990) method. The cells were incubated with 0.01, 0.1, 1, and 10 µg/ml of LPS 
for 5 hours. Otsuka et al. (2001), found that the LPS stimulated the PA activity in both 
the DFGs and NDGFs in a dose dependent manner, and this activity was significantly 
higher in the stimulated cells as compared to the unstimulated cells, and was more 
significant in the stimulated DGFs. Otsuka et al. (2001), also assayed the PA activity 
after they incubated the cells for 3, 6, 9, 12 and 24 hours with 1 µg/ml of LPS. The 
results revealed that the PA activity was stimulated in a time dependent manner, and 
it was significantly higher in both the stimulated DGFs and NDGFs at all-time points 
than in the unstimulated cells and again the most significant effect was observed in 
the DGFs. Despite the fact they used other source of bacterial LPS and carried out 
the study on subjects with and without Down syndrome, the Otsuka et al. (2001) 
study may support the present study in regard to the high uPA activity measured in 
the hGFs stimulated with P. gingivalis LPS as compared to the unstimulated cells. 
The production of the MMPs (2, 3, & 9) and tissue inhibitors of MMPs (TIMP-1 & 
TIMP-2) along with the activities of MMP-2 and uPA were investigated in hGFs in 
response to stimulation with LPS obtained from A. actinomycetemcomitans, P. 
gingivalis, and Fusobacterium nucleatum subsp.nucleatum (Bodet et al. 2007). Bodet 
et al. (2007), found that there was an overproduction of MMP-2 more than MMP-3, 
whereas MMP-9 was not expressed, and there was an overproduction of TIMP-1 but 
not TIMP-2 in response to the stimulation with 1 µg/ml of A. actinomycetemcomitans 
LPS for 6, 24, and 48 hours. The 48-hour incubation of the hGFS with 1 µg/ml of P. 
gingivalis, and F. nucleatum LPS also stimulated the cells to produce higher levels of 
MMP-2 and TIMP-1 in comparison to the controls. Bodet et al. (2007), used the 
zymography assay to assay the activity of MMP-2 and uPA. The 24/48-hour 
stimulation of the cells with 1 µg/ml of the 3 bacterial LPS stimulated the MMP-2 
activity. In a similar manner to the MMP-2 activity, the incubation of the hGFs with 1 
µg/ml of LPS obtained from the 3 bacteria for 24-48 hours also stimulated the cells to 
express significantly higher uPA activity in comparison to the control cells, and the 
most potent stimulation was in response to the A. actinomycetemcomitans and P. 
gingivalis LPS. Though they did not measure MMP-1, the Bodet et al. (2007) study is 
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in agreement with the present study in regard to the high levels of MMP-1 produced 
by the hGFs in response to P. gingivalis LPS. Furthermore, the Bodet et al. (2007) 
study was in harmony with the present study which also found high uPA activity in 
the hGFs stimulated with P. gingivalis LPS as compared to control cells. On the other 
hand, Bodet et al. (2007) attributed the higher uPA activity in response to the 
bacterial LPS, to the overproduction of uPA from the stimulated hGFs, which is 
consistent with the higher uPA levels and activity produced by the hGFs stimulated 
with P. gingivalis LPS found by the present study. 
Na et al. (2014), investigated the mRNA expression and production levels of PAI-1 by 
hGFs in response to stimulation with P. gingivalis LPS. First, Na et al. (2014) 
checked the response of the cells to LPS derived from P. gingivalis, E. coli, and F. 
nucleatum by measuring the mRNA expression of both PAI-1 and TNF-α. Na et al. 
(2014), found that the PAI-1 mRNA expression was significantly higher in the cells 
stimulated with the P. gingivalis LPS in comparison to that of other bacteria, whereas 
the TNF-α mRNA expression was higher in response to the E. coli LPS. Na et al. 
(2014), found that the PAI-1 mRNA expression and protein levels were increased in 
both dose and time dependent manner in response to stimulation with P. gingivalis 
LPS (0.1,1, 2, 5 & 10µg of LPS for 2 hours, and 2µg of LPS for 30 minutes -24 
hours). Though they investigated the PA system protein (PAI-1) but not uPA or 
uPAR, Na et al. (2014) study may support the present study which also found that 
the P. gingivalis LPS stimulated the hGFs to produce the PA proteins (uPA and 
uPAR) in higher levels as compared to the unstimulated cells. Therefore, the findings 
of both the present study and the Na et al. (2014) study along with the findings of the 
above-mentioned studies support the role of the periodontal bacteria P. gingivalis 
LPS in stimulating the hGFS to produce different PA system proteins. 
6.3.3 The PA system proteins in other experimental studies 
Though they did not stimulate the cells, Schmid and Chambers (1988) investigated 
the local PA system proteins production and activity in human gingival biopsies 
obtained from 2 healthy sites, 4 inflamed sites, and 10 apparently healthy sites 6 
weeks after periodontal treatment. To differentiate between the specific PA system 
proteins, anti-tPA and anti-uPA antibodies were added to the prepared tissue 
samples. The results revealed that both the PA proteins production and activity were 
related to the tPA protein, and that the tPA activity was limited in both the healthy and 
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treated gingiva while in the inflamed tissues the entire epithelium demonstrated tPA 
activity. Schmid and Chambers (1988), concluded that tPA is the predominant PA 
protein in both the healthy and diseased human gingiva. Despite the fact that the PA 
activity detected was related to tPA, the Schmid and Chambers (1988) study may 
support the present study and the aforementioned studies in section (6.3.2) for the 
detection of PA activity in the hGFs in response to periodontal pathogen stimulus. On 
the other hand, the present study and the studies mentioned in sections (6.3.1, and 
6.3.2) proved that tPA is not the predominant protein produced by the healthy and 
diseased hGFs, as high levels of uPA, uPAR, and PAI-2 were also detected in the 
stimulated and control hGFs by these studies. Furthermore, the uPA activity detected 
by the present study and the studies in sections (6.3.1, and 6.3.2) proved that the PA 
activity in the hGFs is not only related to tPA but uPA also plays a significant role in 
the PA activity especially in the presence of a periodontal pathogen stimulus. 
In a similar manner to Schmid and Chambers (1988), Schmid et al. (1991) examined 
the local PA activity in gingival tissue biopsies obtained from 4 healthy subjects, 11 
treated periodontitis patients (6 weeks after treatment), and 4 untreated periodontitis 
patients. The PA activity observed in the samples was a tPA fibrinolytic activity, which 
was limited to local areas in the healthy and treated samples, and distributed to the 
entire tissue in the diseased samples. Therefore, Schmid et al. (1991) found that the 
PA activity has a different pattern in the healthy and diseased tissues, and that the 
tPA activity was higher in the diseased tissues. Schmid et al. (1991), suggested that 
their findings may support the hypothesis that the PA system plays a role in the 
degradation of the periodontal tissues which is in agreement with the present study 
hypothesis. Though they also suggested that tPA and its activity are both prominent 
in the diseased gingival tissues; in contrary to Schmid and Chambers (1988), Schmid 
et al. (1991) found that adding anti-tPA antibodies to the samples did not totally 
inhibit the PA activity suggesting the possibility that uPA could be found in the tissues 
and exerts its activity during periodontitis. This finding may explain the high uPA 
levels and activity detected in the hGFs stimulated by periodontal bacteria LPS found 
by the present study and the studies in section (6.3.2). 
In their study, Kinnby et al. (1999) investigated the PA system proteins (uPA, uPAR, 
tPA , PAI-1 and PAI-2) in gingival tissue samples obtained from 9 patients 
undergoing periodontal surgery (gingivectomy) preceded by a 6-week period of 
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treatment with scaling and oral hygiene instructions. The localization of the tPA and 
PAI-2 was carried out by the means of in situ hybridization and 
immunohistochemistry, whereas the uPA and PAI-1 were investigated by in situ 
hybridization only. Kinnby et al. (1999), revealed that the tPA protein and its inhibitor 
PAI-2 were found predominantly in the sulcular and junctional gingival epithelium. 
The uPA and its receptor uPAR were also found in single cells within the sulcular and 
junctional epithelium, as well as adjacent to the blood vessels close to the junctional 
epithelium. The PAI-1 was invariably found in the connective tissues associated with 
the blood vessels. The Kinnby et al. (1999) findings indicated the local production of 
PA proteins in gingival tissue which may explain the production of these proteins in 
the LPS stimulated hGFs found by the present study and the studies in section 
(6.3.2). Based on their findings, Kinnby et al. (1999) suggested that tPA and its 
inhibitor PAI-2 to be the most prominent PA proteins in the periodontal tissues 
exposed to bacterial invasion. However, it was found by the present study and the 
studies in section (6.3.2), that uPA and its receptor uPAR were produced in 
significantly high levels by the hGFs in the presence of periodontal bacterial stimulus 
such as LPS.  
Fleetwood et al. (2015), investigated the production and activity of uPA in mice and 
human macrophage matrix culture models, and in mice periodontitis models in 
response to stimulation with the RgpA-Kgp complex of P. gingivalis. The RgpA-Kgp 
is a protease complex produced by P. gingivalis and is among its virulence factors. 
Fleetwood et al. (2015), found that, the RgpA-Kgp complex stimulated the uPA 
production in both the mice and human macrophages, increased the macrophage 
matrix degradation in a uPA dependent manner, and increased the uPA proteolytic 
activity resulting in enhanced alveolar bone loss in the mice periodontitis models. The 
Fleetwood et al. (2015) study indicated that P. gingivalis and its’ RgpA-Kgp complex 
can induce alveolar bone loss via the activation of uPA proteolytic activity, this was 
another evidence for the uPA role in the pathogenesis of periodontitis, and 
successively supports the present study for the detection of uPA in high levels in 
saliva of periodontitis patients and for the uPA production by hGFs stimulated with 
the P. gingivalis LPS. 
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6.3.4 Summary of findings 
IL-1β at doses of 5 and 0.05 ng/ml stimulated the hGFs to produce significantly 
higher levels of MMP-1 than the control cells. Both the 5 and 0.05 ng/ml of IL-1β 
stimulated the hGFs to produce numerically higher levels of uPA; however, there was 
no statistically significant difference as compared to the control cells. IL-1β did not 
stimulate the hGFs to express high uPA activity. IL-1β at doses of 5 and 0.05 ng/ml 
stimulated the hGFs to produce significantly higher levels of uPAR than the control 
cells. Accordingly, the results suggested that IL-1β may be more related to the 
stimulation of uPAR production by hGFs than the uPA. 
Nevertheless, the 24-hour incubation with 100 ng/ml of E. coli LPS stimulated the 
hGFs to produce numerically higher levels of MMP-1, uPA and uPAR in comparison 
to the control cells, the difference was not statistically significant. Moreover, the E. 
coli LPS did not stimulate the hGFs to express high uPA activity. Therefore, the 
results suggested that the E. coli LPS might not be an effectual stimulant for the uPA 
and uPAR production by the hGFs. 
The 24-hour incubation of the hGFs with 100 ng/ml of P. gingivalis LPS, was able to 
stimulate the cells to produce MMP-1, uPA and uPAR in significantly higher levels 
than the unstimulated cells. P. gingivalis LPS also stimulated the hGFs to express 
uPA activity. Hence, the study results suggested that the P. gingivalis LPS might be a 
potent stimulant for the uPA and uPAR production by the hGFs. 
Thus the in vitro investigations of the present study provided evidence that both uPA 
and uPAR are produced locally by the hGFs in response to an inflammatory and 
bacterial stimuli, and that these two biomarkers might have roles in the pathogenesis 
of periodontitis. Therefore, uPA and uPAR are qualified as plausible biomarkers for 
periodontal diseases. 
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Figure 6.1: MMP-1 production by hGFs after stimulation with IL-1β- preliminary 
experiment.  
hGFs obtained from 1 donor were cultured in three T25 flasks at density of (2-4x105 
cell/flask) till the cells reached confluent growth (80-90%), then stimulated for 24 
hours with 5 ml/flask of IL-1β in 2 doses (5 ng/ml and 0.05 ng/ml) as compared to 
control (0 ng/ml), n=1 flask for each dose. MMP-1 levels were measured by ELISA in 
the supernatants of the stimulated cells. Data represent the mean ±SEM of the 
ELISA duplicate measures for each dose. 
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Figure 6.2: MMP-1 production by hGFs after stimulation with IL-1β.  
hGFs were cultured in the 6 multi-well plates at density of (2x105 cell/well) till the cells 
reached confluent growth (80-90%), then stimulated with 2 ml/well of IL-1β in 2 doses 
(5 ng/ml and 0.05 ng/ml) in comparison to control (0 ng/ml) for 24 hours. MMP-1 
levels were measured by ELISA in the supernatants of the stimulated cells. Data 
shown as mean values ±SEM (n=10 per dose) for cells from 3 donors stimulated in 
independent experiments. ***=p<0.001 respectively, and NS= non-significant (One-
way ANOVA test with Bonferroni correction, and the Independent samples t-test). 
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Figure 6.3: uPAR production by hGFs after stimulation with IL-1β.  
hGFs were cultured in the 6-multi-well plates at density of (2x105 cell/well) till the 
cells reached confluent growth (80-90%), then stimulated for 24 hours with 2 ml/well 
of IL-1β in 2 doses (5 ng/ml and 0.05 ng/ml) as compared to control (0 ng/ml). uPAR 
levels were measured by ELISA in the supernatants of the stimulated cells. Data 
presented as mean values ±SEM (n=10 per dose) for hGFs from 3 donors stimulated 
in independent experiments. **=p<0.01, *=p<0.05 respectively, and NS= non-
significant (One-way ANOVA test with Bonferroni correction, and the Independent 
samples t-test). 
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Figure 6.4: MMP-1 production by hGFs after stimulation with P. gingivalis LPS.  
hGFs were cultured in the 6-multi-well plates at density of (2x105 cell/well), allowed to 
grow till (80-90%) confluency, then stimulated for 24 hours with 2 ml/well of 100 ng/ml 
of P. gingivalis LPS in comparison to control (0 ng/ml). MMP-1 levels were measured 
by ELISA in the supernatants of the stimulated cells. Data shown as mean values 
±SEM (n=6 per dose) for cells from 2 donors stimulated in independent experiments. 
*=p<0.05 (Independent samples t-test). 
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Figure 6.5: uPA production by hGFs after stimulation with P. gingivalis LPS.  
hGFs were cultured in the 6-multi-well plates at density of (2x105 cell/well), till the 
cells reached (80-90%) confluent growth, then stimulated for 24 hours with 2 ml/well 
of 100 ng/ml of P. gingivalis LPS as compared to control (0 ng/ml). uPA levels were 
measured by ELISA in the supernatants of the stimulated hGFs. Data presented as 
mean values ±SEM (n=6 per dose) for hGFs from 2 donors stimulated in independent 
experiments. **=p<0.01 (Independent samples t-test). 
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Figure 6.6: uPA activity in supernatants of hGFs stimulated with P. gingivalis 
LPS.  
hGFs were seeded into the 6-multi-well plates at density of (2x105 cell/well), cultured 
till the cells reached (80-90%) confluent growth, then stimulated for 24 hours with 2 
ml/well of 100 ng/ml of P. gingivalis LPS in comparison to control (0 ng/ml). The uPA 
fluorometric activity assay was used to measure the uPA activity in the supernatants 
of the stimulated hGFs. Data shown as mean values ±SEM (n=6 per dose) for cells 
from 2 donors stimulated in independent experiments. *=p<0.05 (Independent 
samples t-test). 
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Figure 6.7: uPAR production by hGFs after stimulation with P. gingivalis LPS.  
hGF cells were cultured in the 6-multi-well plates at density of (2x105 cell/well), 
allowed to grow till (80-90%) confluent, then stimulated for 24 hours with 2 ml/well of 
100 ng/ml of P. gingivalis LPS as compared to control (0 ng/ml). uPAR levels were 
measured by ELISA in the supernatants of the stimulated cells. Data presented as 
mean values ±SEM (n=6 per dose) for hGFs from 2 donors stimulated in independent 
experiments. **=p<0.01 (Independent samples t-test).
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Chapter 7 General discussion, suggestions and summary  
7.1 General discussion  
Periodontitis and gingivitis are the most common oral inflammatory diseases affecting 
adults in the UK and worldwide. The progression of periodontal diseases is slow and 
painless, therefore if not diagnosed and prevented at early stages, can result in loss 
of teeth which requires complicated and expensive restorative treatments that exert a 
huge burden on the dental health care (Petersen and Ogawa 2012; White et al. 
2012). Further to the conventional clinical diagnosis based on the examination of 
teeth and their supporting periodontal tissues, investigations of oral fluids including 
saliva and GCF have been used in the diagnosis and monitoring of periodontal 
diseases (Yin et al. 2000; Buduneli et al. 2005; Sorsa et al. 2010; Rathnayake et al. 
2013; Schafer et al. 2014; Taylor 2014). Despite the fact that there are number of 
well-known salivary biomarkers such as IL-1β and MMP-8 (Kaushik et al. 2011; 
Ebersole et al. 2013; Rathnayake et al. 2013; Miricescu et al. 2014), in order to 
understand the complicated pathogenesis of periodontitis and its progression, in 
addition to the inter-individual variations, smoking, and systemic diseases which may 
confound the identification of the well-known biomarkers, there is always a need for 
new salivary biomarkers that can predict the onset of the disease, reflect its severity, 
follow the disease course and response to treatment. On this basis, the present study 
aimed to identify and characterize novel salivary biomarkers for periodontal diseases. 
Data analysis of the PPA assays, which were used for the first time on saliva 
samples by the present research, revealed that there was a difference in the 
proteome profile of the whole unstimulated saliva obtained from patients with 
untreated chronic periodontitis as compared to healthy subjects. This difference in 
the salivary proteome profile might be attributed to the effects of periodontitis on the 
salivary proteins, a finding that was in agreement with a number of saliva and GCF 
proteomic studies in periodontal diseases (Kojima et al. 2000; Goncalves Lda et al. 
2010; Goncalves Lda et al. 2011; Range et al. 2012; Salazar et al. 2013). Among the 
proteins identified by the PPA assays, were the two PA system proteins (uPA and 
uPAR), and the carrier protein VDBP. The 3 proteins were selected as candidate 
salivary biomarkers for periodontitis. 
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The present study investigated for the first time the relationships of the identified 
biomarkers with periodontitis. Results revealed that the 3 biomarkers were elevated 
in saliva of the periodontitis patients as compared to the healthy controls, and these 
elevated levels were positively correlated with the periodontal disease indices used 
for the clinical assessment of periodontitis. Therefore, the 3 salivary proteins were 
suggested as good biomarkers for the diagnosis of periodontitis and indicating the 
disease severity. Investigating the effects of non-surgical periodontal treatment on 
the biomarkers showed that only the uPA levels were significantly reduced following 
treatment. Thus, the results suggested that salivary uPA was the only useful 
biomarker to follow the clinical course of periodontitis in response to treatment as 
compared to uPAR and VDBP. Moreover, the present study was the first to 
investigate the enzymatic activity of salivary uPA in relation to periodontitis, results 
revealed that the uPA activity was significantly elevated in saliva of the periodontitis 
patients in comparison to the healthy controls and this activity was positively 
correlated with both the salivary uPA levels and the clinical measures of periodontitis. 
These findings suggested that uPA is not only elevated in saliva but it has a high 
activity during periodontitis. 
For further confirmation of the results, the present study investigated the hypothesis 
that during periodontitis and in the presence of an inflammatory or bacterial stimulus, 
the hGFs will produce uPA and uPAR. The in vitro experimental investigations 
revealed that, IL-1β stimulated the hGFs to produce significantly elevated levels of 
uPAR as compared to the unstimulated cells. The P. gingivalis LPS stimulated the 
cells to produce significantly higher levels of both uPA and uPAR in comparison to 
the unstimulated cells.  
As previously mentioned, there are well-known or robust salivary biomarkers for 
periodontitis such as IL-1β and MMP-8. Several cross-sectional studies 
demonstrated a thorough positive association between the high levels of salivary IL-
1β and periodontitis, indicating that salivary IL-1β is a good biomarker for 
distinguishing periodontitis patients from healthy subjects (Miller et al. 2006; Ng et al. 
2007; Scannapieco et al. 2007; Tobon-Arroyave et al. 2008; Fine et al. 2009; Gursoy 
et al. 2009; Mirrielees et al. 2010; Gursoy et al. 2011; Kaushik et al. 2011; Yoon et al. 
2012; Ebersole et al. 2013; Rathnayake et al. 2013; Salminen et al. 2014). However, 
some studies were not able to find the same positive association between salivary IL-
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1β and periodontitis (Christodoulides et al. 2007; Ramseier et al. 2009; Teles et al. 
2009). A number of studies reported that systemic diseases or their treatment may 
confound the identification of robust salivary biomarkers, for instance Mirrielees et al. 
(2010) investigated the effects of rheumatoid arthritis on the levels of selected 
salivary biomarkers for periodontal disease, Mirrielees et al. (2010) found that 
periodontitis patients with rheumatoid arthritis treated with the anti-TNF-α antibody-
based disease modifying therapy had significantly lower levels of salivary IL-1β and 
TNF-α as compared to systemically healthy periodontitis patients. Numerous cross-
sectional studies demonstrated significantly positive association of the high salivary 
MMP-8 levels and/or activity with periodontitis (Iijima et al. 1983; Gangbar et al. 
1990; Uitto et al. 1990; Hayakawa et al. 1994; Makela et al. 1994; Ingman et al. 
1996; Matsuki et al. 1996; Miller et al. 2006; Herr et al. 2007a; Rai et al. 2008; 
Ramseier et al. 2009; Costa et al. 2010; Gursoy et al. 2010; Mirrielees et al. 2010; 
Gursoy et al. 2011; Ebersole et al. 2013; Rathnayake et al. 2013; Miricescu et al. 
2014). On the other hand, in spite of its substantial value as a biomarker for the 
diagnosis of periodontitis, the use of salivary MMP-8 may face some limitations. 
Smoking, which is one of the major risk factors for periodontitis, is considered as one 
of the important limitations for the use salivary MMP-8 as a biomarker (Genco and 
Borgnakke 2013; Sorsa et al. 2016). Lower levels of MMP-8 have been measured in 
saliva of smokers as compared to former smokers or non-smokers (Ding et al. 1994; 
Liede et al. 1999; Heikkinen et al. 2010). Therefore, the low levels of MMP-8 in saliva 
of smokers may confound its use as a diagnostic biomarker for periodontitis in such 
patients (Sorsa et al. 2016).  
In a similar manner to IL-1β and MMP-8, the cross sectional investigations of the 
present study revealed that the 3 candidate biomarkers were significantly higher in 
saliva of the periodontitis patients as compared to the healthy controls, positively 
associated with the clinical measures of periodontitis, able to diagnose periodontitis, 
indicate the disease severity, and distinguish periodontitis patients from healthy 
subjects. In comparison among the 3 candidate biomarkers, the receiver operating 
characteristic curve analysis (ROC) (see Chapter 2, section 2.4) was used to 
investigate which salivary protein among the 3 candidates was the best as a 
biomarker to differentiate between periodontitis and health status. The ROC curve, 
analysed the biomarkers by the means of their sensitivity (true positive rate) and 1-
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specificity (false positive rate) as measures of accuracy for the biomarker ability to 
diagnose the disease. Results were expressed as the area under the curve (AUC) 
values ranging between 0-1, values of 0.5 means that the biomarker is half true 
positive-half false positive, values below 0.5 means that the biomarker is more 
toward the false positive rate indicating that it is not truly able to differentiate between 
health and disease status, whereas values above 0.5 means that the biomarker is 
more toward the true positive rate indicating its ability to differentiate between 
disease and health status (Fawcett 2006; Hajian-Tilaki 2013). The statistical analysis 
revealed that the AUC values for salivary uPA, uPAR and VDBP were: 0.95, 0.75, 
and 0.81 respectively. Salivary uPA possessed the highest AUC value, indicating that 
it was the best among the three biomarkers to discriminate periodontitis patients from 
healthy subjects (Figure 7.1). Thus, the present study cross-sectional results and the 
ROC curve analysis, along with the high salivary uPA activity measured in saliva of 
the periodontitis patients, all suggested salivary uPA as a potentially better biomarker 
for periodontitis when compared to both salivary uPAR and VDBP. 
One of the cross-sectional studies carried out on IL-1β and MMP-8 was the Ebersole 
et al. (2013) study, which investigated the salivary levels of IL-1β, IL-6, MMP-8, IFN-
α, and albumin in 50 periodontitis patients in comparison to 30 healthy adults. 
Results revealed that levels of IL-1β, IL-6, MMP-8, and albumin were significantly 
elevated in saliva of the patients as compared to the healthy controls, while the levels 
of IFN-α were consistently lower in saliva of the patients than in the healthy controls 
(Ebersole et al. 2013). Moreover, Ebersole et al. (2013) performed the ROC curve 
analysis on the biomarkers and found that salivary IL-1β, IL-6 and MMP-8 yielded 
high AUC values (0.963-0.984) for discriminating periodontitis from health. This 
finding might be in agreement with the present study ROC curve analysis which 
demonstrated that the 3 candidate biomarkers were also able to discriminate 
periodontitis from health, and salivary uPA had the highest AUC value. Another 
cross-sectional study was the Ramseier et al. (2009) study. Ramseier et al. (2009), 
used a combination of biomarkers including MMP-8, MMP-9, OPG and calprotectin 
along with quantifying the periodontal bacteria P. gingivalis to differentiate among 4 
groups comprising: 18 healthy subjects, 32 gingivitis patients, 28 mild periodontitis 
patients, and 21 moderate/severe periodontitis patients. Results revealed that the 
biomarkers and bacteria were higher in the patients as compared to the healthy 
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subjects (higher in the periodontitis patients), and the biomarkers were able to 
differentiate between the patients groups with their different periodontal disease 
categories (Ramseier et al. 2009). These findings of Ramseier et al. (2009), were in 
harmony with present study which also found that the 3 candidate biomarkers were 
able to distinguish between periodontitis patients and healthy controls. Furthermore, 
the present study was in agreement with Ramseier et al. (2009) study in regard to the 
potential ability of salivary uPA levels and activity (as well as GCF uPA levels) in 
distinguishing between patients with different periodontal disease categories 
(gingivitis, chronic periodontitis, mild/moderate periodontitis, and advanced 
periodontitis). On the other hand, both the Ramseier et al. (2009) and Ebersole et al. 
(2013) studies adopted the concept of “biomarker signatures” which implies using 
multiple biomarkers rather than depending on one biomarker only for more efficient 
diagnosis of periodontitis and more substantial association with periodontitis. This 
concept was in agreement with the present study which aimed to identify novel 
salivary biomarkers for periodontitis in an attempt to add candidate biomarkers to the 
field of salivary diagnostics especially when the identification of some of the well-
known salivary biomarkers might be compromised in the presence of confounding 
factors such as smoking, systemic diseases and inter-individual variations, or even 
the methods or techniques by which the biomarkers to be identified and quantified 
(Mirrielees et al. 2010; Taylor 2014; Jaedicke et al. 2016; Sorsa et al. 2016). 
As compared to cross-sectional studies, data derived from longitudinal investigations 
of salivary biomarkers might be limited or variable, this may be explained by the fact 
that some longitudinal studies were confined to investigating the changes in the GCF 
levels of some biomarkers (such as MMP-8) and GCF samples are known to be not 
easily collected and time consuming, or there were difficulties to record or archive 
some studies, and other studies only followed the natural course of the disease 
without investigating the effects of treatment (Taylor 2014). Hence, rather robust 
longitudinal clinical studies to investigate the changes in salivary biomarkers in 
response to treatment are still required (Buduneli and Kinane 2011). A 4-year cohort 
longitudinal study followed up the progression of periodontitis by measuring the 
pocket depths of 219 patients who were not offered any dental treatment and 
measured the levels of 9 salivary biomarkers (Kibayashi et al. 2007). Kibayashi et al. 
(2007), found that the disease progression was related to smoking but not to the 
248 
 
salivary levels of any of the 9 biomarkers (IL-1β, MMP-8, MMP-9, lactoferrin, IgA, 
albumin, AST, LDH, and ALP). A longitudinal case control study measured a number 
of biomarkers (osteonectin, HGF, IL-1β, IFN-γ, TNF-α, IL-4, IL-6, IL-8 and ICTP) in 
40 patients with alveolar bone loss in a 5-year follow up period as compared to 
healthy subjects, the study results demonstrated a positive association between the 
progression of alveolar bone loss and each of IL-1β and HGF levels in saliva 
(Scannapieco et al. 2007). Another case control longitudinal study followed the 
changes in the salivary levels of MIP-1α and IL-1β in 41 subjects in relation to 
developing localized aggressive periodontitis in a 2-3 year monitoring period (Fine et 
al. 2009). Fine et al. (2009) found that, though both the MIP-1α and IL-1β levels were 
elevated in 7 subjects who developed LAgP, salivary IL-1β levels were elevated for 
5-fold only as compared to 50-fold increase in MIP-1α salivary levels; however, the 
results indicated an association between salivary IL-1β and the progression of LAgP 
(Fine et al. 2009). 
Other longitudinal studies investigated the effects of periodontal treatment on the 
levels of biomarkers in saliva of periodontitis patients, albeit the treatment regimens 
used were diverse and the data generated were not enough for comparing the effects 
of a precise periodontal treatment on a particular biomarker (Taylor 2014). One of 
these studies investigated the MMP-8 levels along with MMP-9 and TIMP-1 levels 
before and after treatment in 33 periodontitis patients (Gorska and Nedzi-Gora 2006). 
Gorska and Nedzi-Gora (2006), found that the MMP-8 levels but not MMP-9 were 
reduced significantly following non-surgical periodontal treatment without adjunctive 
doxycycline therapy (not if used together), whereas the TIMP-1 levels were increased 
after non-surgical treatment combined with doxycycline but not if non-surgical 
treatment was offered alone. Kinney et al. (2011), carried out a longitudinal study on 
a cohort of 100 patients, they measured a panel of salivary biomarkers during a 6-
month monitoring phase without any periodontal treatment, the results revealed that 
there were no changes in the levels of any of the salivary biomarkers during the 
monitoring phase as compared to their baseline levels. Treatment was offered for the 
patients, followed by a disease-recovery phase for 6 months during which the 
response to treatment was assessed and the biomarkers were measured after 
treatment. The levels of salivary MMP-8, MMP-9, OPG and IL-1β were significantly 
reduced after treatment (Kinney et al. 2011). Another longitudinal study carried out 
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on 68 periodontitis patients in which salivary biomarkers were measured over a 
period of 28 weeks in 33 patients who received only OHI and 35 patients who 
received both OHI and non-surgical periodontal treatment (Sexton et al. 2011). The 
improvement in the periodontal health in the both treated groups was associated with 
significant reduction in the salivary MMP-8 levels. However, the detailed analysis of 
the biomarkers revealed that the salivary levels of both IL-1β and MMP-8 were 
reduced significantly only the group who received both OHI and non-surgical 
periodontal treatment in comparison to the patients treated with OHI only (Sexton et 
al. 2011). Furthermore, Sexton et al. (2011) revealed that the salivary biomarkers 
(MMP-8, OPG, MIP-1α, and IL-1β) were able to discriminate patients who responded 
to treatment from those who did not. Using the ROC analysis, Sexton et al. (2011) 
demonstrated that MMP-8 was the best biomarker to assess the response to 
treatment as compared to the other biomarkers. Though they performed the ROC 
curve analysis on the biomarkers after treatment, this finding by Sexton et al. (2011) 
may be in harmony with present study, which also found that salivary uPA was the 
best among the three candidate biomarkers that distinguished periodontitis patients 
from healthy controls. 
As with the longitudinal studies of salivary IL-1β and MMP-8, longitudinal 
investigations were also carried out by the present research to study the effects of 
non-surgical periodontal treatment on the levels of uPA, uPAR and VDBP in saliva of 
periodontitis patients. The results revealed that among the 3 biomarkers only the uPA 
levels were significantly reduced in the whole unstimulated and whole stimulated 
saliva, as well as in the GCF of periodontitis patients. These findings of salivary uPA 
were in accordance with the previously mentioned longitudinal studies of salivary IL-
1β and MMP-8. It was infeasible to perform the ROC curve analysis on the 3 
candidate biomarkers in the longitudinal investigations because only the salivary uPA 
levels were reduced after treatment of the patients as compared to both salivary 
uPAR and VDBP. Thus, the present study longitudinal investigations results 
suggested salivary uPA as a potential biomarker that can assess the response of 
periodontitis patients to treatment and follow the clinical course of the disease. 
7.2 Concluding remarks and suggestions 
According to the results of the present study, it might be worthy to carry out further 
cross sectional and longitudinal studies on the candidate salivary biomarker uPA 
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along with uPAR as this receptor is biologically related to uPA. Such clinical studies 
might give further information about salivary uPA and its relationship with 
periodontitis. Moreover, clinical studies along with measuring the levels of uPA and 
uPAR in saliva of periodontitis patients may confirm the findings of the present study. 
Furthermore, as uPA and uPAR were both identified and measured in saliva of non-
smokers with periodontitis by the present study, it might be worthy to investigate both 
uPA and uPAR in saliva of smokers with periodontitis to study the effects of smoking 
on these two biomarkers. Though the in vitro production of uPA and uPAR by 
stimulated hGFs has been investigated by the present study and a number of 
previous studies, it might be reasonable to perform further in vitro studies. As 
suggestions for future work, investigating the in vitro production of uPA and uPAR by 
hGFs in response to IL-1β and P. gingivalis LPS stimulation in both a dose and time-
dependent manner, and investigating the presence of uPA and uPAR in periodontal 
tissue biopsies obtained from patients with untreated periodontal diseases, such cell 
culture and histopathological laboratory investigations would be interesting and may 
confirm the results of the clinical studies. Future clinical and laboratory studies should 
validate salivary uPA as a biomarker for periodontitis and provide substantial data 
which might open the door for utilizing salivary uPA and uPAR as diagnostic 
biomarkers in daily clinical practice using chairside devices which could be used 
domestically by patients as well. Examples of chairside devices are the point-of-care 
devices (POC) (see Chapter 1, section 1.4.2) which have been developed and used 
for the identification of a number of biomarkers such as MMP-8 and IL-1β. Such 
devices enabled the clinicians to confirm the diagnosis of periodontitis in their 
practice, helped researchers while carrying out surveys for salivary biomarkers in 
rural areas or areas were highly equipped laboratories might not be available, and 
helped patients to monitor their disease progression and response to treatment as 
well (Wong 2006; Christodoulides et al. 2007; Herr et al. 2007b; Herr et al. 2007a; 
Sorsa et al. 2011; Fuentes et al. 2014). However, as previously mentioned, MMP-8 
and IL-β may not be detected in saliva of some patients, therefore, it might be useful 
to add further biomarkers to the field of POC diagnostics such as salivary uPA 
following the validation of this biomarker. 
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7.3 Limitations of the study 
There were no serious limitations in the design of the study; however, some points 
were noted. The challenges of sensitivity and cross-reactivity of the PPA assays may 
affect the reliability of the data generated. Therefore, as previously mentioned (see 
Chapter 2, section 2.3.1, and Chapter 3, sections 3.2.1 & 3.2.2) to overcome these 
challenges and for data reliability, the assays were repeated 6 times for each array. 
However, the budget of any project should be considered as these arrays are quite 
expensive and each array kit “currently” is supplied with 4 membranes only, which 
are enough for 2 study and 2 control samples. 
As the GCF samples analysed in the present study were obtained from another 
project in the periodontal research group, the volumes were limited. This may explain 
the limited number of GCF samples in comparison to the saliva samples. However, 
the results of the GCF uPA investigations did yield useful data. Moreover, uPA and 
other PA system proteins have been investigated in GCF of periodontal diseases 
patients by previous studies. Therefore, the GCF samples number was not a serious 
issue for the present study, and the GCF uPA results were further support for the 
novel salivary uPA results. 
7.4 Summary of findings 
In conclusion, the study results highlighted the following: 
The proteome profiler arrays can be used to investigate the salivary protein profile 
and to identify candidate salivary biomarkers, an approach that may contribute 
positively to the diagnosis of periodontal diseases. 
Salivary uPAR is a candidate biomarker for the diagnosis of periodontitis, and 
indication of the disease severity. However, further longitudinal investigations are 
suggested to investigate the salivary uPAR ability to follow the clinical course of 
periodontitis in response to treatment. 
Salivary uPA is a candidate biomarker for the diagnosis of periodontitis, has the 
potential to indicate the disease severity and progression, discriminate periodontitis 
from health, and follow its clinical course in response to treatment.  
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Salivary VDBP is a candidate biomarker for the diagnosis of periodontitis and 
indication of the disease severity. As this protein presents in high levels following 
inflammatory diseases, it might not be a useful biomarker to follow the clinical course 
of periodontitis in response to treatment; however, this could be investigated in 
further longitudinal studies.  
Both uPA and uPAR can be locally produced by the human gingival fibroblasts in 
response to an inflammatory and periodontal bacterial stimuli, indicating that these 
two proteins might play roles in the pathogenesis of periodontitis (Figure 7.2). Thus, 
uPA and uPAR are qualified as plausible biomarkers for periodontal diseases. 
Finally, the findings of the present study may contribute positively to the field of 
salivary diagnostics of periodontal diseases. 
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Figure 7.1: The ROC curve analysis of the candidate salivary biomarkers.  
The ROC curve analysis was carried out on the salivary uPA, uPAR and VDBP levels 
in 45 pre-treatment periodontitis patients and 40 healthy control subjects. Salivary 
uPA was the best among the three candidate biomarkers to discriminate periodontitis 
from healthy status.
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Figure 7.2: Potential roles of uPA and uPAR in the initiation of tissue 
destruction in periodontitis. 
Schematic diagram demonstrating the potential roles of uPA and uPAR in the 
pathogenesis of periodontal diseases. During inflammation, uPA binds to uPAR, a 
binding that will activate and localize uPA leading to the conversion of plasminogen 
into active plasmin, thereby initiating the process of proteolysis. In the presence of 
inflammatory stimuli (such as IL-1β from infiltrating neutrophils and local periodontal 
tissues) or bacterial stimuli (such as LPS from P. gingivalis), the uPA/uPAR binding 
might be enhanced leading to more production of plasmin stimulating the proteolysis 
of supporting periodontal tissues associated with periodontitis. In addition to 
proteolysis, active uPA/uPAR complex exert chemotactic activity on inflammatory 
cells such as dendritic cells, macrophages and neutrophils which in turn release 
cytokines, as well as, proteolytic and lysosomal enzymes that also degrade the 
supporting periodontal tissues “collateral damage”. Hence the elevated levels of 
uPA/uPAR in saliva, GCF and local periodontal tissues, may indicate the extent of 
periodontal tissue destruction during periodontitis. After proteolysis, the uPA inhibitor 
PAI-1 inhibits the uPA activity by binding to the active uPA-uPAR complex, in the 
presence of low density lipoprotein receptor family (LDL proteins), uPAR mediates 
the internalization of the uPA-uPAR-PAI-1 complex, ending with uPA degradation by 
PAI-1 and releasing of uPAR to be available for further binding. 
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Salivary proteases Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean values 
±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
ADAM9 1661 ±720 2416 ±508 + 1.45 NS 
ADAMTS1 1302 ±766 1597 ±298 + 1.23 NS 
ADAMTS13 2453 ±1709 1811 ±456 - 1.35 NS 
Cathepsin A 24698 ±6670 22183 ±5984 - 1.11 NS 
Cathepsin B 25108 ±8206 21943 ±7159 - 1.14 NS 
Cathepsin C 9160 ±5511 5789 ±2627 - 1.58 NS 
Cathepsin D 26306 ±9832 20405 ±5998 - 1.29 NS 
Cathepsin E 1625 ±838 2126 ±602 + 1.31 NS 
Cathepsin L 1844 ±1298 1947 ±880 + 1.06 NS 
Cathepsin S 22957 ±7030 21755 ±4889 - 1.06 NS 
Cathepsin V 20114 ±8573 11813 ±3239 - 1.7 NS 
Cathepsin X/Z/P 22371 ±10560 14969 ±5793 - 1.49 NS 
DPPIV/CD26 30794 ±9329 27497 ±7991 - 1.12 NS 
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Salivary proteases Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean values 
±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Kallikrein 3/PSA 3439 ±2655 1828 ±240 - 1.88 NS 
Kallikrein 5 33989 ±10178 21312 ±8702 - 1.59 NS 
Kallikrein 6 18294 ±5639 18771 ±6535 + 1.03 NS 
Kallikrein 7 8674 ±2382 6349 ±2092 - 1.37 NS 
Kallikrein 10 33000 ±10051 26081 ±6185 - 1.27 NS 
Kallikrein 11 29341 ±10132 29875 ±7959 + 1.02 NS 
Kallikrein 13 15622 ±5376 16185 ±6983 + 1.04 NS 
MMP-13 1964 ±1911 1494 ±545 - 1.31 NS 
Presenilin-1 353 ±460 833 ±320 + 2.36 NS 
Proprotein Convertase 9 190 ±229 878 ±352 + 4.61 NS 
Appendix A. Table 1: Relative expression of salivary proteases in periodontitis samples as compared to healthy samples, 
single sample PPA assays. 
The relative expression of 23 salivary proteases identified in 3 single sample protease PPA assays. Data are presented as mean ±SEM 
of the PI values. Proteins compared by the means of fold change and p-value of the logarithm-fold change (Statistics: One sample t-test, 
NS= non-significant).  
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Salivary proteases Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean values 
±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
ADAM9 665 ±112 5290 ±1025 + 7.96 <0.05 
ADAMTS1 697 ±79 2490 ±800 + 3.57 NS 
ADAMTS13 1266 ±136 6316 ±2461 + 4.99 NS 
Cathepsin A 12367 ±1055 17803 ±1612 + 1.44 <0.01 
Cathepsin B 14168 ±1301 16963 ±833 + 1.2 <0.05 
Cathepsin C 7220 ±555 10806 ±1683 + 1.5 NS 
Cathepsin D  14125 ±945 16159 ±2035 + 1.14 NS 
Cathepsin E 1095 ±198 8242 ±3267 + 7.52 NS 
Cathepsin L 682 ±81 2836 ±926 + 4.15 NS 
Cathepsin S 10739 ±702 16401 ±1733 + 1.53 <0.05 
Cathepsin V 10031 ±846 15130 ±1822 + 1.51 <0.05 
Cathepsin X/Z/P 14707 ±954 17998 ±1791 + 1.22 NS 
DPPIV/CD26 16206 ±1733 19476 ±996 + 1.2 NS 
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Salivary proteases Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean values 
±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Kallikrein 3/PSA 871 ±120 2792 ±906 + 3.2 <0.05 
Kallikrein 5 8795 ±1221 14241 ±3648 + 1.62 NS 
Kallikrein 6 8441 ±204 13083 ±778 + 1.55 <0.01 
Kallikrein 7 3935 ±782 9271 ±1892 + 2.36 <0.01 
Kallikrein 10 14103 ±1879 19591 ±2645 + 1.39 NS 
Kallikrein 11 15435 ±612 18274 ±1415 + 1.18 <0.05 
Kallikrein 13 11330 ±328 15104 ±1182 + 1.33 <0.05 
MMP-13 662 ±159 2675 ±923 + 4.04 NS 
Presenilin-1 133 ±44 2550 ±1121 + 19.12 <0.05 
Proprotein Convertase 9 48 ±26 1724 ±685 + 35.87 NS 
Appendix A. Table 2: Relative expression of salivary proteases in periodontitis samples as compared to healthy samples, 
pooled sample PPA assays. 
The relative expression of 23 salivary proteases identified in 3 pooled sample protease PPA assays. Data are presented as mean ±SEM 
of the PI values. Proteins compared by the means of fold change and p-value of the logarithm-fold change (Statistics: One sample t-test, 
NS= non-significant).  
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Aggrecan 545 ±473 2533 ±1731 + 4.64 NS 
Angiogenin 6625 ±4482 7685 ±5484 + 1.16 NS 
Angiopoietin-1 ND 1377 ±1493 NA NA 
Angiopoietin-2 ND ND NA NA 
B-cell activating factor (BAFF) ND 6913 ±6831 NA NA 
Brain-derived neurotrophic factor 
(BDNF) 
ND 242 ±429 NA NA 
Complement component C5/C5a ND 5678 ±4233 NA NA 
Cluster of differentiation 14 
(CD14) 
3556 ±2251 5380 ±4019 + 1.51 NS 
CD30 (TNFRSF8) ND 1183 ±1053 NA NA 
CD40 ligand (CD40L) ND 1696 ±1516 NA NA 
Chitinase 3-like 1 21860 ±11342 24126 ±9258 + 1.1 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Complement Factor D 746 ±424 6058 ±4520 + 8.12 <0.05 
C-reactive protein ND 1190 ±1354 NA NA 
Teratocarcinoma-derived Growth 
Factor (Cripto-1) 
ND ND NA NA 
Dickkopf-1 (Dkk-1) ND 402 ±548 NA NA 
Dipeptidyl-peptidase IV 495 ±25 8124 ±6965 + 16.38 NS 
ENA-78 (CXCL5) 10149 ±7193 4186 ±4217 - 2.42 NS 
Endoglin ND 783 ±773 NA NA 
Fas Ligand ND 128 ±266 NA NA 
Basic fibroblast growth factor 
(FGF basic) 
ND ND NA NA 
 Fibroblast growth factor 7 (FGF-7) ND ND NA NA 
Fibroblast growth factor 19 (FGF-
19) 
ND 417 ±392 NA NA 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
FMS-like tyrosine kinase 3 ligand 
(Flt-3 Ligand) 
ND ND NA NA 
Granulocyte-colony stimulating 
factor (G-CSF) 
ND 125 ±288 NA NA 
Growth/differentiation factor 15 
(GDF-15) 
ND 2575 ±2609 NA NA 
Granulocyte-macrophage colony-
stimulating factor (GM-CSF) 
ND 553 ±638 NA NA 
GRO-α (CXCL1) 1911 ±2155 9244 ±9297 + 4.84 NS 
Growth hormone ND 125 ±246 NA NA 
Hepatocyte growth factor (HGF) ND 184 ±329 NA NA 
Intercellular Adhesion Molecule 1 
(ICAM-1) 
ND 425 ±591 NA NA 
Interferon gamma (IFN-γ) ND ND NA NA 
Insulin like growth factor binding 
protein 2 (IGFBP-2) 
ND 3727 ±3353 NA NA 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
 Insulin like growth factor binding 
protein 3 (IGFBP-3) 
ND ND NA NA 
IL-1α ND 5860 ±4251 NA NA 
IL-1β ND 2471 ±2610 NA NA 
IL-1ra 11374 ±6613 12662 ±7520 + 1.11 NS 
IL-2 ND 349 ±361 NA NA 
IL-3 ND 426 ±413 NA NA 
IL-4 ND 998 ±1046 NA NA 
IL-5 ND 756 ±880 NA NA 
IL-6 ND 897 ±818 NA NA 
IL-10 ND 4188 ±4273 NA NA 
IL-11 ND 292 ±355 NA NA 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
IL-12p70 (IL-12) ND 29 ±171 NA NA 
IL-13 ND 72 ±212 NA NA 
IL-15 ND 76 ±281 NA NA 
IL-16 ND 1882 ±1781 NA NA 
IL-17A (IL-17) 212 ±59 1699 ±1188 + 8 NS 
IL-18 BPa ND 774 ±660 NA NA 
IL-19 ND 4149 ±4121 NA NA 
IL-22 ND 485 ±471 NA NA 
IL-23 6 ±76 1286 ±796 + 200.45 NS 
IL-24 ND 367 ±411 NA NA 
IL-27 ND 64 ±207 NA NA 
IL-31 ND ND NA NA 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
IL-32 α/β/γ   ND 432 ±542 NA NA 
IL-33 ND 41 ±217 NA NA 
IL-34 ND ND NA NA 
IP-10 (CXCL10) ND 763 ±856 NA NA 
ITAC (CXCL11) ND 350 ±334 NA NA 
Kallikrein 3 562 ±69 1938 ±1445 + 3.44 NS 
Leptin ND 340 ±429 NA NA 
Leukemia inhibitory factor (LIF) ND 356 ±315 NA NA 
Lipocalin-2 17346 ±7613 16915 ±6309 - 1.03 NS 
Monocyte chemoattractant protein 
1 (MCP-1) 
4022 ±4163 1726 ±1557 - 2.33 NS 
 Monocyte chemoattractant 
protein 3 (MCP-3) 
ND ND NA NA 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Macrophage colony-stimulating 
factor (M-CSF) 
ND 172 ±264 NA NA 
Migration inhibitory factor (MIF) 4924 ±3758 8948 ±5968 + 1.82 NS 
 MIG (CXCL9) ND 426 ±555 NA NA 
Macrophage inflammatory 
proteins (MIP-1α/MIP-1β) 
ND 53 ±211 NA NA 
Macrophage inflammatory protein 
(MIP-3α) 
ND 1424 ±1538 NA NA 
Macrophage inflammatory protein 
(MIP-3β) 
ND 653 ±573 NA NA 
MMP-9 (Gelatinase B) 14035 ±8909 17003 ±10033 + 1.21 NS 
Osteopontin ND 528 ±466 NA NA 
Platelet-derived growth factor 
(PDGF-AA) 
ND 7162 ±6981 NA NA 
Platelet-derived growth factor 
(PDGF-AB/BB) 
ND 89 ±209 NA NA 
Pentraxin-3 ND 5427 ±5184 NA NA 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Platelet factor 4 (PF4) (CXCL4) 1161 ±2619 73 ±232 - 15.86 NS 
Receptor for advanced glycation 
endproducts (RAGE) 
ND ND NA NA 
RANTES (CCL5) ND 189 ±299 NA NA 
Retinol binding protein 4 (RBP4) 1389 ±1571 10268 ±538 + 7.39 <0.05 
Relaxin-2 ND 662 ±614 NA NA 
Stromal cell-derived factor 1 (SDF-
1α) (CXCL12) 
ND 1284 ±1018 NA NA 
Serpin E1 119 ±190 6452 ±5839 + 53.88 NS 
Sex hormone-binding globulin 
(SHBG) 
ND 1691 ±1681 NA NA 
ST2 (IL-1 R4, IL1RL1) ND 811 ±722 NA NA 
TARC (CCL17) ND 308 ±421 NA NA 
Trefoil factor 3 (TFF3) 16177 ±7436 18636 ±9577 + 1.15 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Transferrin receptor (TfR) ND 346 ±394 NA NA 
Transforming growth factor alpha 
(TGF-α) 
ND ND NA NA 
Thrombospondin-1 ND 1028 ±1245 NA NA 
Tumour necrosis factor-alpha 
(TNFα) 
ND 1206 ±160 NA NA 
Appendix A. Table 3: Relative expression of salivary cytokines in periodontitis samples as compared to healthy samples, single 
sample PPA assays. 
The relative expression of 92 salivary cytokines identified in 3 single sample cytokine PPA assays. Data are presented as mean ±SEM of 
the PI values. Proteins compared by the means of fold change and p-value of the logarithm-fold change (Statistics: One sample t-test, 
NS= non-significant). ND not detected or negatively expressed. NA not applicable. 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Aggrecan 14145 ±13634 11925 ±10291 - 1.19 NS 
Angiogenin 17423 ±13663 23042 ±16514 + 1.32 NS 
Angiopoietin-1 13757 ±13663 12749 ±11092 - 1.08 NS 
Angiopoietin-2 11193 ±11237 12585 ±12205 + 1.12 NS 
B-cell activating factor (BAFF) 11982 ±11863 20827 ±19790 + 1.74 NS 
Brain-derived neurotrophic factor 
(BDNF) 
10757 ±10841 13863 ±13572 + 1.29 NS 
Complement component C5/C5a 12377 ±12229 27546 ±22117 + 2.23 NS 
Cluster of differentiation 14 (CD14) 14737 ±13563 19898 ±16030 + 1.35 NS 
CD30 (TNFRSF8) 14751 ±14725 14213 ±13673 - 1.04 NS 
CD40 ligand (CD40L) 12310 ±12013 13709 ±12604 + 1.11 NS 
Chitinase 3-like 1 16555 ±9198 72061 ±58216 + 4.35 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Complement Factor D 25096 ±23622 17563 ±11876 - 1.43 NS 
C-reactive protein 9570 ±9587 15962 ±13429 + 1.67 NS 
Teratocarcinoma-derived Growth 
Factor (Cripto-1) 
9125 ±9214 11005 ±10733 + 1.21 NS 
Dickkopf-1 (Dkk-1) 10317 ±10367 12072 ±11615 + 1.17 NS 
Dipeptidyl-peptidase IV 12947 ±10982 34267 ±28260 + 2.65 NS 
ENA-78 (CXCL5) 10453 ±8283 30579 ±27756 + 2.93 NS 
Endoglin 43741 ±43580 9279 ±8420 - 4.71 NS 
Fas Ligand 10703 ±10721 6361 ±5854 - 1.68 NS 
Basic fibroblast growth factor 
(FGF basic) 
7655 ±7721 8157 ±7686 + 1.07 NS 
 Fibroblast growth factor 7 (FGF-7) 7623 ±7754 7922 ±7689 + 1.04 NS 
Fibroblast growth factor 19 (FGF-
19) 
19660 ±19623 9877 ±9143 - 1.99 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
FMS-like tyrosine kinase 3 ligand 
(Flt-3 Ligand) 
9167 ±9297 8463 ±8251 - 1.08 NS 
Granulocyte-colony stimulating 
factor (G-CSF) 
17248 ±17379 10889 ±10582 - 1.58 NS 
Growth/differentiation factor 15 
(GDF-15) 
17599 ±17691 11040 ±10105 - 1.59 NS 
Granulocyte-macrophage colony-
stimulating factor (GM-CSF) 
10764 ±10794 9692 ±9059 - 1.11 NS 
GRO-α (CXCL1) 8106 ±8033 13162 ±11879 + 1.62 NS 
Growth hormone 22306 ±22249 5717 ±5253 - 3.9 NS 
Hepatocyte growth factor (HGF) 7372 ±7380 5265 ±4898 - 1.4 NS 
Intercellular Adhesion Molecule 1 
(ICAM-1) 
5929 ±5927 5770 ±5230 - 1.03 NS 
Interferon gamma (IFN-γ) 5768 ±5874 6078 ±5813 + 1.05 NS 
Insulin like growth factor binding 
protein 2 (IGFBP-2) 
6832 ±6677 12148 ±9952 + 1.78 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
 Insulin like growth factor binding 
protein 3 (IGFBP-3) 
7352 ±7472 7453 ±7306 + 1.01 NS 
IL-1ra 8305 ±6311 18741 ±13916 + 2.26 <0.05 
IL-2 5434 ±5584 7799 ±7413 + 1.44 NS 
IL-3 10503 ±10595 9479 ±9273 - 1.11 NS 
IL-4 7398 ±7325 5283 ±4747 - 1.4 NS 
IL-5 4991 ±4968 4243 ±3831 - 1.18 NS 
IL-6 5019 ±4915 4573 ±3836 - 1.1 NS 
IL-10 4391 ±4505 4647 ±4463 + 1.06 NS 
IL-11 3914 ±4048 6121 ±5691 + 1.56 NS 
IL-12p70 (IL-12) 3781 ±3943 6417 ±6221 + 1.7 NS 
IL-13 4730 ±4817 7526 ±7314 + 1.6 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
IL-15 5259 ±5394 4368 ±4182 - 1.2 NS 
IL-16 10609 ±10611 5600 ±5074 - 1.9 NS 
IL-17A (IL-17) 5525 ±5374 9002 ±7334 + 1.63 NS 
IL-18 BPa 8498 ±8593 7860 ±7539 - 1.08 NS 
IL-19 4777 ±4508 4721 ±3333 - 1.01 NS 
IL-22 3432 ±3324 3960 ±3337 + 1.15 NS 
IL-23 2327 ±2124 5202 ±4417 + 2.23 NS 
IL-24 3625 ±3599 5189 ±4577 + 1.43 NS 
IL-27 2754 ±2869 1508 ±1359 - 1.83 NS 
IL-31 2684 ±2786 4249 ±4141 + 1.58 NS 
IL-32 α/β/γ   3049 ±3120 6380 ±5935 + 2.09 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
IL-33 3722 ±3862 3311 ±3149 - 1.12 NS 
IL-34 3871 ±4008 4887 ±4729 + 1.26 NS 
IP-10 (CXCL10) 1944 ±2037 3985 ±3692 + 2.05 NS 
ITAC (CXCL11) 3934 ±4019 5131 ±4885 + 1.3 NS 
Kallikrein 3 6178 ±6045 10165 ±8731 + 1.65 NS 
Leptin 2012 ±1904 437 ±295 - 4.6 NS 
Leukemia inhibitory factor (LIF) 199 ±182 748 ±359 + 3.75 NS 
Lipocalin-2 5780 ±2876 50423 ±41098 + 8.72 NS 
Monocyte chemoattractant protein 
1 (MCP-1) 
372 ±303 5494 ±3223 + 14.74 NS 
 Monocyte chemoattractant protein 
3 (MCP-3) 
566 ±703 609 ±527 + 1.08 NS 
Macrophage colony-stimulating 
factor (M-CSF) 
474 ±613 2311 ±2099 + 4.87 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Migration inhibitory factor (MIF) 156 ±1190 22224 ±18528 + 142.46 NS 
 MIG (CXCL9) 2016 ±2115 2572 ±2270 + 1.28 NS 
Macrophage inflammatory proteins 
(MIP-1α/MIP-1β) 
3464 ±3583 2459 ±2137 - 1.41 NS 
Macrophage inflammatory protein 
(MIP-3α) 
3455 ±3539 3159 ±2961 - 1.09 NS 
Macrophage inflammatory protein 
(MIP-3β) 
2179 ±2268 4136 ±3714 + 1.9 NS 
MMP-9 (Gelatinase B) 4887 ±2606 49397 ±43481 + 10.11 NS 
Myeloperoxidase ND 14650 ±12373 NA NA 
Osteopontin ND ND NA NA 
Platelet-derived growth factor 
(PDGF-AA) 
16636 ±16385 10125 ±7671 - 1.64 NS 
Platelet-derived growth factor 
(PDGF-AB/BB) 
460 ±555 ND NA NA 
Pentraxin-3 ND 4710 ±2997 NA NA 
276 
 
Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Platelet factor 4 (PF4) (CXCL4) ND 1204 ±1028 NA NA 
Receptor for advanced glycation 
endproducts (RAGE) 
2041 ±2187 64 ±151 - 31.81 NS 
RANTES (CCL5) 3414 ±3512 503 ±304 - 6.78 NS 
Retinol binding protein 4 (RBP4) 5986 ±2985 28659 ±15122 + 4.79 NS 
Relaxin-2 2166 ±2227 1937 ±1229 - 1.12 NS 
Stromal cell-derived factor 1 (SDF-
1α) (CXCL12) 
22635 ±22603 3892 ±3035 - 5.82 NS 
Serpin E1 ND 1192 ±889 NA NA 
Sex hormone-binding globulin 
(SHBG) 
ND ND NA NA 
ST2 (IL-1 R4, IL1RL1) ND 672 ±398 NA NA 
TARC (CCL17) 605 ±3065 ND NA NA 
Trefoil factor 3 (TFF3) 2904 ±3349 36414 ±28307 + 12.54 NS 
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Salivary cytokines Healthy samples PI mean values 
±SEM (n=3) 
Periodontitis samples PI mean 
values ±SEM (n=3) 
Fold change 
(periodontitis vs health) 
p-value of the log-fold change 
Transferrin receptor (TfR) ND ND NA NA 
Transforming growth factor alpha 
(TGF-α) 
1698 ±1915 ND NA NA 
Thrombospondin-1 1907 ±1954 ND NA NA 
Tumour necrosis factor-alpha 
(TNFα) 
6589 ±6560 3430 ±654 - 1.92 NS 
Appendix A. Table 4: Relative expression of salivary cytokines in periodontitis samples as compared to healthy samples, 
pooled sample PPA assays. 
The relative expression of 91 salivary cytokines identified in 3 pooled sample cytokine PPA assays. Data are presented as mean ±SEM 
of the PI values. Proteins compared by the means of fold change and p-value of the logarithm-fold change (Statistics: One sample t-test, 
NS= non-significant). ND not detected or negatively expressed. NA not applicable.
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Appendix B. Figure 1: Reproduction permission for the periodontitis 
pathogenesis figure.  
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Appendix B. Figure 2: Reproduction permission for the PPA assay principle 
figure. 
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Appendix C: Presentations and scientific meetings 
1. Identification and Characterisation of Novel Salivary Biomarkers for Oral 
Inflammatory Disease. ICM - ICM Postgraduate Students Research 
Seminar. 18/02/2015. 
2. Three minutes presentation of the study in the COHR research afternoon 
13/05/2015. Runner up in the postgraduate oral presentation competition. 
3. Presentation of the study in the COHR event “It’s OK to ask. Patient and 
Public Event. Dental Clinical Research Facility, School of Dental Sciences” 
20/05/2015. 
4. Presentation of the study in the COHR presentation programme 
08/07/2015. 
5. Identification of novel salivary biomarkers for chronic periodontitis. Abstract 
in the BSODR Annual Meeting - Cardiff 14-16 September 2015. Ahmed 
Khudhur, John Taylor, Philip Preshaw. 
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